
<html lang="en"     class="pb-page"  data-request-id="b070778e-25dc-47df-afa0-1e65c40574b5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.8b01957;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-5;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer" /></meta><meta name="dc.Creator" content="Andrew&#xA;E.  Shouksmith" /></meta><meta name="dc.Creator" content="Fenil  Shah" /></meta><meta name="dc.Creator" content="Michelle L.  Grimard" /></meta><meta name="dc.Creator" content="Justyna M.  Gawel" /></meta><meta name="dc.Creator" content="Yasir S.  Raouf" /></meta><meta name="dc.Creator" content="Mulu  Geletu" /></meta><meta name="dc.Creator" content="Angelika  Berger-Becvar" /></meta><meta name="dc.Creator" content="Elvin D.  de Araujo" /></meta><meta name="dc.Creator" content="H. Artee  Luchman" /></meta><meta name="dc.Creator" content="William L.  Heaton" /></meta><meta name="dc.Creator" content="David  Bakhshinyan" /></meta><meta name="dc.Creator" content="Ashley A.  Adile" /></meta><meta name="dc.Creator" content="Chitra  Venugopal" /></meta><meta name="dc.Creator" content="Thomas  O’Hare" /></meta><meta name="dc.Creator" content="Michael W.  Deininger" /></meta><meta name="dc.Creator" content="Sheila K.  Singh" /></meta><meta name="dc.Creator" content="Stephen F.  Konieczny" /></meta><meta name="dc.Creator" content="Samuel  Weiss" /></meta><meta name="dc.Creator" content="Melissa L.  Fishel" /></meta><meta name="dc.Creator" content="Patrick T.  Gunning" /></meta><meta name="dc.Description" content="Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, incurable cancer with a 20% 1 year survival rate. While standard-of-care therapy can prolong life in a small fraction of cases, PDAC is inh..." /></meta><meta name="Description" content="Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, incurable cancer with a 20% 1 year survival rate. While standard-of-care therapy can prolong life in a small fraction of cases, PDAC is inh..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 18, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01957" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01957" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01957" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01957" /></link>
        
    
    

<title>Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01957" /></meta><meta property="og:title" content="Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0010.jpeg" /></meta><meta property="og:description" content="Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, incurable cancer with a 20% 1 year survival rate. While standard-of-care therapy can prolong life in a small fraction of cases, PDAC is inherently resistant to current treatments, and novel therapies are urgently required. Histone deacetylase (HDAC) inhibitors are effective in killing pancreatic cancer cells in in vitro PDAC studies, and although there are a few clinical studies investigating combination therapy including HDAC inhibitors, no HDAC drug or combination therapy with an HDAC drug has been approved for the treatment of PDAC. We developed an inhibitor of HDACs, AES-135, that exhibits nanomolar inhibitory activity against HDAC3, HDAC6, and HDAC11 in biochemical assays. In a three-dimensional coculture model, AES-135 kills low-passage patient-derived tumor spheroids selectively over surrounding cancer-associated fibroblasts and has excellent pharmacokinetic properties in vivo. In an orthotopic murine model of pancreatic cancer, AES-135 prolongs survival significantly, therefore representing a candidate for further preclinical testing." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01957"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01957">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01957&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01957&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01957&amp;href=/doi/10.1021/acs.jmedchem.8b01957" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2651-2665</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01949" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b02008" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Andrew E. Shouksmith</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew E. Shouksmith</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Road, Mississauga, Ontario L5L 1C6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew%0AE.++Shouksmith">Andrew E. Shouksmith</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fenil Shah</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fenil Shah</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pediatrics, Wells Center for Pediatric Research, IU School of Medicine, 1044 West Walnut Street, R4 321, Indianapolis, Indiana 46202, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fenil++Shah">Fenil Shah</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michelle L. Grimard</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michelle L. Grimard</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pediatrics, Wells Center for Pediatric Research, IU School of Medicine, 1044 West Walnut Street, R4 321, Indianapolis, Indiana 46202, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michelle+L.++Grimard">Michelle L. Grimard</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Justyna M. Gawel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Justyna M. Gawel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Road, Mississauga, Ontario L5L 1C6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Justyna+M.++Gawel">Justyna M. Gawel</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yasir S. Raouf</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yasir S. Raouf</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Road, Mississauga, Ontario L5L 1C6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yasir+S.++Raouf">Yasir S. Raouf</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mulu Geletu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mulu Geletu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Road, Mississauga, Ontario L5L 1C6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mulu++Geletu">Mulu Geletu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Angelika Berger-Becvar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Angelika Berger-Becvar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Road, Mississauga, Ontario L5L 1C6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Angelika++Berger-Becvar">Angelika Berger-Becvar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elvin D. de Araujo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elvin D. de Araujo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Road, Mississauga, Ontario L5L 1C6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elvin+D.++de+Araujo">Elvin D. de Araujo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">H. Artee Luchman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">H. Artee Luchman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Hotchkiss Brain Institute and Department of Cell Biology and Anatomy, University of Calgary, Calgary, Alberta T2N 1N4, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=H.+Artee++Luchman">H. Artee Luchman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">William L. Heaton</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">William L. Heaton</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Huntsman Cancer Institute, Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, Utah 84112, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=William+L.++Heaton">William L. Heaton</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David Bakhshinyan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Bakhshinyan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">McMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, Ontario L8S 4L8, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David++Bakhshinyan">David Bakhshinyan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ashley A. Adile</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ashley A. Adile</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">McMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, Ontario L8S 4L8, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ashley+A.++Adile">Ashley A. Adile</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chitra Venugopal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chitra Venugopal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">McMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, Ontario L8S 4L8, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chitra++Venugopal">Chitra Venugopal</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas O’Hare</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas O’Hare</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Huntsman Cancer Institute, Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, Utah 84112, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas++O%E2%80%99Hare">Thomas O’Hare</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael W. Deininger</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael W. Deininger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Huntsman Cancer Institute, Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, Utah 84112, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+W.++Deininger">Michael W. Deininger</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sheila K. Singh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sheila K. Singh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">McMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, Ontario L8S 4L8, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sheila+K.++Singh">Sheila K. Singh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stephen F. Konieczny</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephen F. Konieczny</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biological Sciences, Purdue University, West Lafayette, Indiana 47907, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephen+F.++Konieczny">Stephen F. Konieczny</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Samuel Weiss</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Samuel Weiss</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Hotchkiss Brain Institute and Department of Cell Biology and Anatomy, University of Calgary, Calgary, Alberta T2N 1N4, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Samuel++Weiss">Samuel Weiss</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Melissa L. Fishel</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Melissa L. Fishel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pediatrics, Wells Center for Pediatric Research,  Department of Pharmacology and Toxicology, IU School of Medicine, 1044 West Walnut Street, R4 321, Indianapolis, Indiana 46202, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#e489828d978c8188a48d91ca818091"><span class="__cf_email__" data-cfemail="e588838c968d8089a58c90cb808190">[email protected]</span></a>. Tel: (317) 274-8810 (M.L.F.).</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Melissa+L.++Fishel">Melissa L. Fishel</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Patrick T. Gunning</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Patrick T. Gunning</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Road, Mississauga, Ontario L5L 1C6, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#42322336302b21296c25372c2c2b2c250237362d302d2c362d6c2123"><span class="__cf_email__" data-cfemail="12627366607b71793c75677c7c7b7c755267667d607d7c667d3c7173">[email protected]</span></a>. Tel: (905) 828-5354 (P.T.G.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Patrick+T.++Gunning">Patrick T. Gunning</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0654-735X" title="Orcid link">http://orcid.org/0000-0003-0654-735X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01957&amp;href=/doi/10.1021%2Facs.jmedchem.8b01957" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2651–2665</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 18, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>13 December 2018</li><li><span class="item_label"><b>Published</b> online</span>18 February 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 March 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01957" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01957</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2651%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAndrew%250AE.%2BShouksmith%252C%2BFenil%2BShah%252C%2BMichelle%2BL.%2BGrimard%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D5%26contentID%3Dacs.jmedchem.8b01957%26title%3DIdentification%2Band%2BCharacterization%2Bof%2BAES-135%252C%2Ba%2BHydroxamic%2BAcid-Based%2BHDAC%2BInhibitor%2BThat%2BProlongs%2BSurvival%2Bin%2Ban%2BOrthotopic%2BMouse%2BModel%2Bof%2BPancreatic%2BCancer%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2665%26publicationDate%3DMarch%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01957"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1840</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">13</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01957" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Andrew\nE.&quot;,&quot;last_name&quot;:&quot;Shouksmith&quot;},{&quot;first_name&quot;:&quot;Fenil&quot;,&quot;last_name&quot;:&quot;Shah&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;L. Grimard&quot;},{&quot;first_name&quot;:&quot;Justyna&quot;,&quot;last_name&quot;:&quot;M. Gawel&quot;},{&quot;first_name&quot;:&quot;Yasir&quot;,&quot;last_name&quot;:&quot;S. Raouf&quot;},{&quot;first_name&quot;:&quot;Mulu&quot;,&quot;last_name&quot;:&quot;Geletu&quot;},{&quot;first_name&quot;:&quot;Angelika&quot;,&quot;last_name&quot;:&quot;Berger-Becvar&quot;},{&quot;first_name&quot;:&quot;Elvin&quot;,&quot;last_name&quot;:&quot;D. de Araujo&quot;},{&quot;first_name&quot;:&quot;H.&quot;,&quot;last_name&quot;:&quot;Artee Luchman&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;L. Heaton&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Bakhshinyan&quot;},{&quot;first_name&quot;:&quot;Ashley&quot;,&quot;last_name&quot;:&quot;A. Adile&quot;},{&quot;first_name&quot;:&quot;Chitra&quot;,&quot;last_name&quot;:&quot;Venugopal&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;O’Hare&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;W. Deininger&quot;},{&quot;first_name&quot;:&quot;Sheila&quot;,&quot;last_name&quot;:&quot;K. Singh&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;F. Konieczny&quot;},{&quot;first_name&quot;:&quot;Samuel&quot;,&quot;last_name&quot;:&quot;Weiss&quot;},{&quot;first_name&quot;:&quot;Melissa&quot;,&quot;last_name&quot;:&quot;L. Fishel&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;T. Gunning&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;18&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;2651-2665&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01957&quot;},&quot;abstract&quot;:&quot;Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, incurable cancer with a 20% 1 year survival rate. While standard-of-care therapy can prolong life in a small fraction of cases, PDAC is inherently resistant to current treatments, and novel therapies are urgently required. Histone deacetylase (HDAC) inhibitors are effective in killing pancreatic cancer cells in in vitro PDAC studies, and although there are a few clinical studies investigating combination therapy including HDAC inhibitors, no HDAC drug or combination therapy with an HDAC drug has been approved for the treatment of PDAC. We developed an inhibitor of HDACs, AES-135, that exhibits nanomolar inhibitory activity against HDAC3, HDAC6, and HDAC11 in biochemical assays. In a three-dimensional coculture model, AES-135 kills low-passage patient-derived tumor spheroids selectively over surrounding cancer-associated fibroblasts and has excellent pharmacokinetic properties in vivo. In an orthotopic murine model of pancreatic cancer, AES-135 prolongs&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01957&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01957" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01957&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01957" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01957&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01957" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01957&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01957&amp;href=/doi/10.1021/acs.jmedchem.8b01957" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01957" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01957" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01957%26sid%3Dliteratum%253Aachs%26pmid%3D30776234%26genre%3Darticle%26aulast%3DShouksmith%26date%3D2019%26atitle%3DIdentification%2Band%2BCharacterization%2Bof%2BAES-135%252C%2Ba%2BHydroxamic%2BAcid-Based%2BHDAC%2BInhibitor%2BThat%2BProlongs%2BSurvival%2Bin%2Ban%2BOrthotopic%2BMouse%2BModel%2Bof%2BPancreatic%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D5%26spage%3D2651%26epage%3D2665%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/jmcmar.2019.62.issue-5/20190314/jmcmar.2019.62.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/medium/jm-2018-019576_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01957&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, incurable cancer with a 20% 1 year survival rate. While standard-of-care therapy can prolong life in a small fraction of cases, PDAC is inherently resistant to current treatments, and novel therapies are urgently required. Histone deacetylase (HDAC) inhibitors are effective in killing pancreatic cancer cells in in vitro PDAC studies, and although there are a few clinical studies investigating combination therapy including HDAC inhibitors, no HDAC drug or combination therapy with an HDAC drug has been approved for the treatment of PDAC. We developed an inhibitor of HDACs, <b>AES-135</b>, that exhibits nanomolar inhibitory activity against HDAC3, HDAC6, and HDAC11 in biochemical assays. In a three-dimensional coculture model, <b>AES-135</b> kills low-passage patient-derived tumor spheroids selectively over surrounding cancer-associated fibroblasts and has excellent pharmacokinetic properties in vivo. In an orthotopic murine model of pancreatic cancer, <b>AES-135</b> prolongs survival significantly, therefore representing a candidate for further preclinical testing.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25018" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25018" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with only a 20% 1 year survival rate and a 7% 5 year survival rate for all stages combined, and is widely considered incurable.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> It is currently the third leading cause of cancer-related mortality in the United States<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> and is characterized by a complex tumor microenvironment that is immunosuppressive and contains myeloid-derived suppressor cells (MDSCs) as well as cancer-associated fibroblasts (CAFs), heterogeneity within the tumor, and an innate capacity for metastasis.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7">(4−7)</a> Therefore, there is an imminent need for therapies in PDAC, inhibiting novel targets.</div><div class="NLM_p">Histone/lysine deacetylases control post-translational protein acetylation,<a onclick="showRef(event, 'ref8 ref9 ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10 ref11 ref12 ref13">(8−13)</a> in conjunction with histone acetyltransferases (HATs), which fulfill an antagonistic role,<a onclick="showRef(event, 'ref9 ref14'); return false;" href="javascript:void(0);" class="ref ref9 ref14">(9,14)</a> for a large number of substrates, most notably histones. By regulating histone acetylation/deacetylation, HATs and histone deacetylases (HDACs) play a key indirect role in gene expression.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Oncogenic HDAC activity has been observed in aggressive human cancers, including pancreatic cancer.<a onclick="showRef(event, 'ref1 ref2 ref15'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref15">(1,2,15)</a> To date, four small-molecule HDAC inhibitors have been approved by the Food and Drug Administration (FDA) for hematological cancer treatment (cutaneous T-cell lymphoma, peripheral T-cell lymphoma and multiple myeloma):<a onclick="showRef(event, 'ref8 ref11 ref13'); return false;" href="javascript:void(0);" class="ref ref8 ref11 ref13">(8,11,13)</a> suberoylanilide hydroxamic acid (SAHA, Vorinostat),<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Romidepsin (depsipeptide-FK228),<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Belinostat (PXD101),<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and Panobinostat (LBH-589).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Current HDAC clinical trials in PDAC consist of adjuvant therapies using Vorinostat or Panobinostat in combination with radiation, surgery, or standard-of-care chemotherapy.<a onclick="showRef(event, 'ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27">(20−27)</a> Three of the four HDAC drugs contain an <i>N</i>-hydroxamic acid, which mimics the hydrogen bonds formed by acetylated lysine substrates, competitively coordinating to the metal ion within the catalytic domain, rendering the HDAC inactive.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The catalytic domain is the most structurally conserved region in the HDAC family primary sequence, and targeting of this domain by small molecules often results in the inhibition of more than one HDAC. Despite this, clinical efficacy with pan-HDAC inhibitors has been observed in select cancer subtypes, but with adverse side effects including diarrhea and bone marrow toxicity observed in patients.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> HDAC inhibitors, with the exception of Romidepsin,<a onclick="showRef(event, 'ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30">(28−30)</a> possess a similar linear structural design, with a metal chelating group (e.g., hydroxamic acid) at one end and a hydrophobic capping group (e.g., a 2-methylindole) at the other, connected by a linear hydrophobic scaffold, for example, a benzene ring or an alkyl chain.<a onclick="showRef(event, 'ref13 ref31'); return false;" href="javascript:void(0);" class="ref ref13 ref31">(13,31)</a> A lack of structural diversity might infer that many of the current clinical candidates are likely to encounter the same pitfalls in clinical trials.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><div class="NLM_p last">Herein, we introduce a small family of novel HDAC inhibitors, including lead compound, <b>AES-135</b>, which biochemically inhibits HDACs 3, 6, 8, and 11 with half-maximal inhibitory concentration (IC<sub>50</sub>) values of 190–1100 nM and exhibits selective in vitro cytotoxicity in low-passage patient-derived pancreatic cancer cells even in the presence of cancer-associated fibroblast (CAF) cells. <b>AES-135</b> has other favorable in vivo properties such as metabolic stability in mouse hepatocytes and bioavailability in micromolar (μM) concentrations in NSG mice for >10 h (intraperitoneal (IP) injection). <b>AES-135</b> combines the proven attributes of an <i>N</i>-hydroxamic acid with a new chemotype for exploration as an HDAC inhibitor.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66130" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66130" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p"><b>AES-135</b> was identified as part of a structure–activity relationship (SAR) study designed to repurpose a class of signal transducer and activator of transcription 3 (STAT3)-targeting compounds, including <b>SH-4-54</b> (<b>1</b>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), toward HDACs.<a onclick="showRef(event, 'ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35">(33−35)</a> Efforts were predominantly focused on replacing the STAT3 SH2 domain-targeting benzoic acid substituent with an isosteric <i>N</i>-hydroxamic acid for HDAC catalytic domain targeting.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> A brief SAR around the general structure of <b>1</b> sought to identify direct-binding nanomolar (nM) IC<sub>50</sub> HDAC inhibitors. A series of analogs were prepared with substitutions made at positions R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. IC<sub>50</sub> Values for <b>AES-135</b> and Its Analogs against HDACs 3, 6, 8, and 11, Evaluated up to 1 μM (Electrophoretic Mobility Shift Assay (EMSA), <i>n</i> = 1)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/medium/jm-2018-019576_0008.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="4" align="center">substituents</th><th class="rowsep1 colsep0" colspan="4" align="center">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound #</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R<sup>3</sup></th><th class="colsep0 rowsep0" align="center">HDAC3</th><th class="colsep0 rowsep0" align="center" char=".">HDAC6</th><th class="colsep0 rowsep0" align="center">HDAC8</th><th class="colsep0 rowsep0" align="center" char=".">HDAC11</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>AES-135</b></td><td class="colsep0 rowsep0" align="left"><i>t</i>-Bu</td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">2,3,4,5,6-F</td><td class="colsep0 rowsep0" align="left">0.654</td><td class="colsep0 rowsep0" align="char" char=".">0.190</td><td class="colsep0 rowsep0" align="left">>1</td><td class="colsep0 rowsep0" align="char" char=".">0.636</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left"><i>t</i>-Bu</td><td class="colsep0 rowsep0" align="left">3,4-F</td><td class="colsep0 rowsep0" align="left">2-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">>1</td><td class="colsep0 rowsep0" align="char" char=".">0.362</td><td class="colsep0 rowsep0" align="left">>1</td><td class="colsep0 rowsep0" align="char" char=".">0.254</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">3,4-F</td><td class="colsep0 rowsep0" align="left">2-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">>1</td><td class="colsep0 rowsep0" align="char" char=".">0.188</td><td class="colsep0 rowsep0" align="left">>1</td><td class="colsep0 rowsep0" align="char" char=".">0.396</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left"><i>t</i>-Bu</td><td class="colsep0 rowsep0" align="left">2,4-F</td><td class="colsep0 rowsep0" align="left">2-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">>1</td><td class="colsep0 rowsep0" align="char" char=".">0.289</td><td class="colsep0 rowsep0" align="left">>1</td><td class="colsep0 rowsep0" align="char" char=".">0.288</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">2,4-F</td><td class="colsep0 rowsep0" align="left">2-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">>1</td><td class="colsep0 rowsep0" align="char" char=".">0.151</td><td class="colsep0 rowsep0" align="left">>1</td><td class="colsep0 rowsep0" align="char" char=".">0.346</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left"><i>t</i>-Bu</td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">2-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">>1</td><td class="colsep0 rowsep0" align="char" char=".">0.230</td><td class="colsep0 rowsep0" align="left">>1</td><td class="colsep0 rowsep0" align="char" char=".">0.253</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">2-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">>1</td><td class="colsep0 rowsep0" align="char" char=".">0.093</td><td class="colsep0 rowsep0" align="left">>1</td><td class="colsep0 rowsep0" align="char" char=".">0.304</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">2,3,4,5,6-F</td><td class="colsep0 rowsep0" align="left">>1</td><td class="colsep0 rowsep0" align="char" char=".">0.086</td><td class="colsep0 rowsep0" align="left">>1</td><td class="colsep0 rowsep0" align="char" char=".">0.191</td></tr></tbody></table></div></div><div class="NLM_p">Compounds were synthesized as outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Briefly, anilines <b>11</b> and <b>12</b> were prepared in good to excellent yields via reductive amination of benzyl 4-aminobenzoate <b>10</b> with different benzaldehydes under standard conditions. Glycine <i>tert</i>-butyl (<i>t-</i>Bu) ester hydrochloride (<b>13</b>) was sulfonylated, and the resulting sulfonamides <b>14</b>–<b>17</b> were benzylated under basic conditions. Removal of the <i>t-</i>Bu protecting group with diluted trifluoroacetic acid (TFA) furnished the carboxylic acids <b>23</b>–<b>27</b> quantitatively. Anilines and carboxylic acids were coupled using dichlorotriphenylphosphorane (PPh<sub>3</sub>Cl<sub>2</sub>) under microwave conditions, and subsequent hydrogenation cleaved the carboxybenzyl group. Chlorination of the benzoic acids using oxalyl chloride, followed by coupling with <i>O</i>-benzylhydroxylamine, generated the hydroxamate esters, and the <i>O</i>-benzyl group was removed by hydrogenation.</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/medium/jm-2018-019576_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <i>N</i>-Hydroxamic Acid-Based HDAC Inhibitors<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01957&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) BnBr, Cs<sub>2</sub>CO<sub>3</sub>, dimethylformamide (DMF), 24 h, room temperature (RT); (b) (i) ArCHO, MgSO<sub>4</sub>, tetrahydrofuran (THF), 16 h, RT; (ii) NaBH<sub>4</sub>, trifluoroethanol (TFE), 16 h, RT; (c) ArSO<sub>2</sub>Cl, <i><sup>i</sup></i>Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 16 h, 0 °C to RT, N<sub>2</sub>; (d) BrCH<sub>2</sub>Ar, Cs<sub>2</sub>CO<sub>3</sub>, MeCN, 16 h, 50 °C to RT; (e) CF<sub>3</sub>CO<sub>2</sub>H/CHCl<sub>3</sub> (1:3), 3 h, RT; (f) PPh<sub>3</sub>Cl<sub>2</sub>, CHCl<sub>3</sub>, 1 h, 100 °C, N<sub>2</sub>, microwave; (g) H<sub>2</sub>, 10% Pd/C, THF/MeOH (2:1), 16 h, RT; (h) (i) (COCl)<sub>2</sub>, THF, DMF, 2 h, 0 °C, N<sub>2</sub>; (ii) H<sub>2</sub>NOBn, <i><sup>i</sup></i>Pr<sub>2</sub>NEt, THF, 16 h, RT, N<sub>2</sub>.</p></p></figure><div class="NLM_p">The R<sup>2</sup> position of <b>1</b>, occupied by a pentafluorobenzenesulfonamide, was substituted with less electron-deficient mono- and difluorinated benzene rings to minimize potential nucleophilic addition in vivo.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The cyclohexyl R<sup>1</sup> group reduced solubility and was susceptible to phase I oxidation,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> so this was replaced with less lipophilic <i>t-</i>Bu and trifluoromethyl (CF<sub>3</sub>) groups.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Finally, the R<sup>3</sup><i>N</i>-methyl group, previously shown to be sensitive to oxidation in mouse hepatocytes, was substituted with either a pentafluorobenzyl (PFB) or 2-(trifluoromethyl)benzyl appendage.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> The prepared library was evaluated for inhibitory activity against select HDAC representatives of groups I (3 and 8), II (6), and IV (11) using an electrophoretic mobility shift assay (EMSA). In this assay, enzymatic deacetylation of a FAM-labeled peptide substrate is measured as a change in the relative fluorescence intensity of the substrate and product following incubation. In the presence of an inhibitor, deacetylation is impeded, altering the fluorescence intensity of the product and substrate (a detailed procedure is provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_001.pdf" class="ext-link">Supporting Information</a>). With the exception of <b>AES-135</b>, compounds in this library demonstrated selective activity for HDAC groups II and IV, with limited activity observed against either HDAC3 or HDAC8 (group I). <b>AES-135</b> exhibited nanomolar (nM) inhibition of HDACs 3, 6, and 11, with low-μM activity against HDAC8 (IC<sub>50</sub> was later confirmed to be 1.10 μM when <b>AES-135</b> was evaluated up to 10 μM against these targets (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_001.pdf" class="ext-link">Figures S22–S25</a>, Supporting Information)).</div><div class="NLM_p">To explain the observed results, compounds were modeled in silico using AutoDock Vina/AutoDockTools (ADT) v4.2.6. Specifically, <b>AES-135</b> and <b>6</b> were chosen as representative ligands due to their differing HDAC selectivity profiles despite being structurally similar, differing only at the R<sup>3</sup> position (pentafluorobenzyl vs 2-(trifluoromethyl)benzyl, respectively). These compounds were docked against eukaryotic, zinc-dependent <i>h</i>HDAC 3, 6, and 8 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4A69">4A69</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EDU">5EDU</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T64">1T64</a>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). <i>h</i>HDAC11 analysis was not possible as no crystal structure has been resolved to date. A detailed description of the experiments performed can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_001.pdf" class="ext-link">Supporting Information</a>.</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/medium/jm-2018-019576_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Computational modeling/docking studies of <b>AES-135</b> against <i>h</i>HDAC 3, 6, and 8 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4A69">4A69</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EDU">5EDU</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T64">1T64</a>, respectively). (Left column) catalytic active site of enzyme, Zn<sup>2+</sup> (yellow sphere), residues within/around the lysine-substrate channel (shown as white ball-and-stick) and catalytic triad residues (shown as colored ball-and-stick). (Centre column) molecular surface view of channel entrance, low hydrophobicity residues (white), and high hydrophobicity residues (red). (Right column) side view of ligands docked within the active site. Panel A: <i>h</i>HDAC6 (blue cartoon), <b>AES-135</b> (magenta), and SAHA (green). Panel B: <i>h</i>HDAC3 (green cartoon), <b>AES-135</b> (magenta), and <b>6</b> (cyan). Panel C: <i>h</i>HDAC8 (red cartoon), <b>AES-135</b> (magenta), and <b>6</b> (cyan).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01957&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">All three enzymes have a largely hydrophobic surface proximal to the lysine-substrate channel. In <i>h</i>HDAC6, the lysine tunnel surroundings are largely featureless and flat, whereas <i>h</i>HDAC3 and 8 contain greater surface topology. While the importance of the metal binding group for HDAC targeting is critical, the contribution of the capping group to binding and selectivity among the HDAC isoforms is significant. Increased hydrophobic interaction between the enzyme surface and the capping group is postulated to greatly increase binding affinity.<a onclick="showRef(event, 'ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40">(38−40)</a> These interactions were of interest when analyzing the in silico binding conformations of <b>AES-135</b> and <b>6</b> to <i>h</i>HDACs 3, 6, and 8 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), relative to the in vitro EMSA data shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. The docking of <b>AES-135</b> to <i>h</i>HDAC3, 6, and 8 returned average free energy of binding values (Δ<i>G</i><sub>B</sub>) of −8.31 ± 0.08, −8.98 ± 0.17, and −8.80 ± 0.13 kcal/mol, whereas <b>6</b> scored −7.31 ± 0.44, −8.64 ± 0.17, and −7.74 ± 0.12 kcal/mol, respectively (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_001.pdf" class="ext-link">Tables S17–S23</a>, Supporting Information). In silico, <b>AES-135</b> binds more favorably to all three isoforms than <b>6</b>, while having greater affinity for <i>h</i>HDAC3/8, yet has more comparable binding to <i>h</i>HDAC6. Comparing binding to <i>h</i>HDAC 3 and 8 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B,C), the perfluorinated ring of <b>AES-135</b> makes significantly more interactions with residues proximal to the channel, with minimal steric clash compared to the 2-(trifluoromethyl) group of <b>6</b>, which appears to occupy poses that unfavorably clash with the HDAC surface.</div><div class="NLM_p">To confirm <b>AES-135</b> as the lead candidate, cytotoxicity profiles were determined against a bank of human cancer cell lines (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_001.pdf" class="ext-link">Tables S1, S2 and Figures S1–S6</a>, Supporting Information). Encouragingly, <b>AES-135</b> was shown to be the most promising candidate, with low μM potency being observed in multiple brain tumor stem cell (BTSC) glioblastoma lines, MV4-11 and MOLM-13 acute myeloid leukemia (AML) cells, and PC-3 prostate cancer cells. In D425 primary medulloblastoma (MDB) and D458 recurrent MDB cells, nM activity was observed. Patient-derived pancreatic cancer cells were sensitive to single-digit μM/high nM concentrations of <b>AES-135</b>. Of the lines tested, only chronic myelogenous leukemia K562 cells were resistant to <b>AES-135</b>. Encouragingly, in MRC-9 lung cells (noncancerous), <b>AES-135</b> demonstrated minimal toxicity, identifying a clear therapeutic window.</div><div class="NLM_p">To assess the stability of the pentafluorobenzyl (PFB) ring to biological nucleophiles, a 10 mM solution of <b>AES-135</b> in dimethyl sulfoxide (DMSO) was mixed with a 100-fold excess of reduced <span class="smallcaps smallerCapital">l</span>-glutathione in (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) buffer, pH 7.4, and monitored by analytical high-performance liquid chromatography (HPLC) at regular intervals. No discernible reaction was observed even after 25 h (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_001.pdf" class="ext-link">Figures S7 and S8</a>, Supporting Information). This was corroborated by <sup>19</sup>F NMR studies, in which no displacement of fluoride was observed after 16 h of immersion in 100-fold excess glutathione (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_001.pdf" class="ext-link">Figure S9</a>, Supporting Information).</div><div class="NLM_p">Given the structural origin of <b>AES-135</b> from <b>1</b>, we confirmed that the cytotoxicity observed with the former was not due to STAT3/5 inhibition. Western blot studies were performed in MDA-MB-231 breast cancer cells (STAT3-overexpressing) and MV4-11 AML cells (STAT5-overexpressing). The results showed that <b>AES-135</b> did not inhibit activation of STAT3 or STAT5 signaling via immunoblotting for Y694 phosphorylation on STAT5b and Y705 phosphorylation on STAT3 (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_001.pdf" class="ext-link">Figure S10</a>, Supporting Information). In MDA-MB-231 cells, <b>AES-135</b> returned an IC<sub>50</sub> of 2.72 ± 0.60 μM (<i>n</i> = 4), yet even at 10-fold of this concentration, neither total STAT3 nor pY705 STAT3 was significantly reduced. Similar results were observed in MV4-11 cells, where <b>AES-135</b> had an IC<sub>50</sub> of 1.88 ± 0.89 μM (<i>n</i> = 4), yet failed to suppress total STAT5b or pY694 STAT5b, even at 10 μM. Evidence from western blots in pancreatic Pa03C cancer cells and multiple BTSC glioblastoma multiforme (GBM) lines was subsequently obtained, further supporting the conclusion that <b>AES-135</b> was not a STAT3/5 inhibitor (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_001.pdf" class="ext-link">Figures S11–S14</a>, Supporting Information).</div><div class="NLM_p">To confirm that the <i>N</i>-hydroxamic acid group in <b>AES-135</b> was responsible for HDAC targeting, the compound was screened against seven metal-dependent HDACs, representing classes I, II, and IV, at a fixed concentration (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). As a negative control, an <i>N</i>-methylhydroxamic acid, <b>60</b>, was prepared and assessed in parallel. The synthetic route is described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Briefly, starting from <i>O</i>-benzylhydroxylamine (<b>55</b>), Boc protection of the amino group was followed by methylation and acid-mediated removal of the Boc group to furnish <i>O</i>-benzyl-<i>N</i>-methylhydroxylamine (<b>58</b>). Coupling of this compound with <b>37</b>, followed by hydrogenation, as previously described, yielded <b>60</b>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/medium/jm-2018-019576_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <i>N</i>-Methylhydroxamic Acid <b>60</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01957&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Boc<sub>2</sub>O, THF, 24 h, RT; (b) MeI, NaH (60%), DMF, 24 h, RT; (c) (i) CF<sub>3</sub>CO<sub>2</sub>H/CHCl<sub>3</sub> (1:3), 22 h, RT; (ii) 1 M NaOH; (d) (i) (COCl)<sub>2</sub>, THF, DMF, 2 h, 0 °C, N<sub>2</sub>; (ii) <b>58</b>, <i><sup>i</sup></i>Pr<sub>2</sub>NEt, THF, 16 h, RT, N<sub>2</sub>; (e) H<sub>2</sub>, 10% Pd/C, THF/MeOH (2:1), 16 h, RT.</p></p></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Percentage Inhibition of HDACs 1, 3, 4, 6, 8, 10, and 11 by <b>AES-135</b> and <b>60</b> at 10 μM (EMSA, <i>n</i> = 2)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" align="center" char=".">% inhibition</th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">HDAC</th><th class="colsep0 rowsep0" align="center" char=".">AES-135</th><th class="colsep0 rowsep0" align="center" char=".">60</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">72</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>3</b></td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>4</b></td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>6</b></td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="char" char=".">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8</b></td><td class="colsep0 rowsep0" align="char" char=".">94</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>10</b></td><td class="colsep0 rowsep0" align="char" char=".">70</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">97</td><td class="colsep0 rowsep0" align="char" char=".">64</td></tr></tbody></table></div></div><div class="NLM_p"><b>AES-135</b> and control compound <b>60</b> were screened against full recombinant human HDACs 1, 3, 4, 6, 8, 10, and 11 using an electrophoretic mobility shift assay (EMSA) at 10 μM. <b>AES-135</b> inhibited HDACs 3, 6, 8, and 11 (>90%) and showed moderate inhibition of HDACs 1 and 10 (≥70%), with HDAC4 not being affected (<20%). HDAC inhibition was highly sensitive to modification of the hydroxamic acid motif, with compound <b>60</b> demonstrating only modest inhibition of HDAC11 (64%) but negligible activity against the remaining HDACs (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_p">To evaluate in vitro stability, <b>AES-135</b> and <b>8</b> were incubated with mouse hepatocytes for 2 h to assess the rate of intrinsic clearance. The calcium channel blocker Verapamil was used as a positive control. <b>AES-135</b> reported an intrinsic clearance rate of 36.0 μL/min per 10<sup>6</sup> cells, almost half the rate of Verapamil (63.3 μL/min per 10<sup>6</sup> cells), and a half-life of 38.5 min, which was almost twice that of Verapamil (21.9 min) (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_001.pdf" class="ext-link">Table S4 and Figures S15–S20</a>, Supporting Information). Derivative <b>8</b>, possessing a CF<sub>3</sub> in the R<sup>1</sup> position, performed similarly to <b>AES-135</b> (R<sup>1</sup> = <i>t</i>-Bu), returning a clearance rate of 37.4 μL/min per 10<sup>6</sup> cells and a half-life of 37.1 min, suggesting that the <i>t-</i>Bu group of <b>AES-135</b> was not being targeted for oxidation in mouse hepatocytes. The observed stability of <b>AES-135</b> supported the in vitro findings that the PFB ring was a relatively stable substituent. A protein binding study using <b>AES-135</b> in mouse plasma found that the compound was 99.6% bound after 6 h of incubation. The low recovery (16–20%) of <b>AES-135</b> after this time indicated the compound to be susceptible to metabolism in plasma (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_001.pdf" class="ext-link">Table S5</a>, Supporting Information). In a separate study, the experimental Log <i>D</i><sub>7.4</sub> for <b>AES-135</b> was calculated using a 1-octanol/phosphate-buffered saline (PBS) system, returning a value of 4.15 (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_001.pdf" class="ext-link">Table S6</a>, Supporting Information).</div><div class="NLM_p">To investigate the permeability profiles of <b>AES-135</b> and <b>8</b> through the blood–brain barrier, the compounds were tested using a parallel artificial membrane permeability assay (PAMPA), which assesses the ability of a compound to cross a lipid-infused artificial membrane and has been shown to correlate well with performance in crossing in vivo barriers. Testosterone and the antimetabolite Methotrexate were used as positive and negative controls, respectively. In this assay, a permeability coefficient (−Log <i>P</i><sub>e</sub>) <6 defined the compound as having high permeability through a lipid membrane, whereas a −Log <i>P</i><sub>e</sub> > 6 meant the compound had low permeability. Results from this assay showed that <b>AES-135</b> and <b>8</b> were poorly permeable compounds, returning −Log <i>P</i><sub>e</sub> values of 7.73 and 7.02, respectively. By comparison, testosterone gave a value of 4.61 and Methotrexate >8.5, where the degree of membrane permeation was below the limit of detection (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_001.pdf" class="ext-link">Tables S7–S11</a>, Supporting Information). The results indicated that <b>AES-135</b> would be poorly efficacious against cancers surrounded by undamaged membranes, for example, GBM, despite impressive in vitro potency.</div><div class="NLM_p"><b>AES-135</b> was also analyzed in a Caco-2 assay to gauge its permeability through a monolayer of tightly packed epithelial cells, an in vitro model of the human small intestinal membrane. The Caco-2 cells also express several transporter proteins, for example, P-glycoprotein, and can thus provide information on the efflux rate of compounds from a cell. Propranolol, Digoxin, and Prazosin were used as controls with low, high, and medium efflux rates, respectively. Results from this assay supported those from the PAMPA, showing <b>AES-135</b> to have poor permeation through the monolayer, with an apparent permeability coefficient, <i>P</i><sub>app</sub> (A-B), of 0.27 × 10<sup>–6</sup> cm/s. Compared to Propranolol and Prazosin, with respective <i>P</i><sub>app</sub> (A-B) values of 15.41 and 19.94 × 10<sup>–6</sup> cm/s, <b>AES-135</b> was significantly less permeable. In addition, the <i>P</i><sub>app</sub> (B-A) for <b>AES-135</b> was 1.02 × 10<sup>–6</sup> cm/s, calculating an efflux ratio of 3.83 (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_001.pdf" class="ext-link">Tables S12 and S13</a>, Supporting Information). This suggested that <b>AES-135</b> was transported out of the cell approximately 4-fold faster than it was being absorbed, meaning that it would struggle to achieve suitable intestinal absorption in vivo if administered orally. The data also indicated that despite potent in vitro activity, <b>AES-135</b> would not be efficacious if used to treat cancers requiring penetration of bone marrow, for example, AML.</div><div class="NLM_p">To assess the pharmacokinetic (PK) properties of <b>AES-135</b> in vivo, NSG mice were dosed with a single 20 mg/kg intraperitoneal (IP) injection, and blood was taken at 0.5, 1, 2, 4, 8, and 24 h. <b>AES-135</b> achieved μM concentrations in the blood, reaching <i>C</i><sub>max</sub> 7452 ng/mL (10.74 μM) within 30 min, which was sustained for 8 h, with significant clearance observed only after 24 h (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). In these mice, <b>AES-135</b> had a calculated half-life of 5.0 h, with a clearance rate of 0.004 L/h, assuming bioavailability to be 100% (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_001.pdf" class="ext-link">Tables S14 and S15</a>, Supporting Information).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Serum Concentrations of <b>AES-135</b> Following One Dose at 20 mg/kg, IP (<i>n</i> = 2)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/medium/jm-2018-019576_0009.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">time (h)</th><th class="colsep0 rowsep0" align="center" char="±">[<b>AES-135</b>] (ng/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>0.5</b></td><td class="colsep0 rowsep0" align="char" char="±">7452 ± 1354</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char="±">5397 ± 1079</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char="±">5391 ± 2418</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char="±">3655 ± 400</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="char" char="±">6392 ± 222</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="char" char="±">265 ± 29</td></tr></tbody></table></div></div><div class="NLM_p">In a follow-up study, <b>AES-135</b> was administered at 10 and 40 mg/kg once a day for 5 days. Blood was collected from each mouse 5 h following the final injection (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). Encouragingly, the results showed that the blood concentration of <b>AES-135</b> was dose dependent, achieving an average of 323 ng/mL (0.47 μM) with 10 mg/kg dosing and 1829 ng/mL (2.64 μM) with 40 mg/kg. No visible toxicity associated with either dose, based on percentage weight loss compared to vehicle control, was observed. This represents an approximate 5.7-fold increase in blood concentration from quadrupling the dose.</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/medium/jm-2018-019576_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Serum concentrations of <b>AES-135</b> in NSG mice following 10 and 40 mg/kg injections daily for 5 days, IP (<i>n</i> = 6, ±standard deviation (SD)). (B) Toxicity study with <b>AES-135</b> in NSG mice administered over 5 days, IP (<i>n</i> = 6, ±SD).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01957&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To evaluate <b>AES-135</b> toxicity in vivo, NSG mice were dosed by IP daily with a range of concentrations for 4–5 days (<i>n</i> = 6). Mice were weighed prior to, and following, administration of the compound and toxicity assessed via weight loss (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). At 60 mg/kg, the mice showed no significant weight loss, indicating <b>AES-135</b> to be nontoxic at the highest concentration.</div><div class="NLM_p"><b>AES-135</b> was consistently cytotoxic in multiple low-passage patient-derived pancreatic cancer cell lines, namely, Pa03C, Pa02C, and Panc10.05 cells (the latter hereto referred to as 10.05). IC<sub>50</sub> values were in the low μM range (1–4 μM) in monolayer proliferation-based assays of these tumor lines. The efficacy of <b>AES-135</b> was also assessed in KPC tumor cells, which are derived from the “gold standard” genetically engineered mouse model of PDAC (Kras<sup>LSL.G12D/+</sup>; Trp53<sup>R172H/+</sup>; <i>Pdx1-Cre</i><sup><i>ER</i></sup>).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Interestingly, the tumor cells generated from the KPC<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> genetically engineered PDAC mouse model were extremely sensitive to <b>AES-135</b> and had an IC<sub>50</sub> of 1.3 μM in the monolayer, compared to 8.5 μM for the pan-HDAC inhibitor Panobinostat, which was used as a positive control (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). KPC mice develop premalignant lesions called pancreatic intraepithelial neoplasia (PanIN), which progress to visible carcinomas with 100% penetrance and display a morphology similar to that observed in human PDAC. Metastases arise in 80% of KPC mice, primarily in the liver and lungs, the most common metastatic sites in humans. The KPC tumors possess intricate genomic rearrangements, a sign of genomic instability, making this one of the most aggressive PDAC models used in preclinical research. They are notoriously resistant to standard-of-care therapy; only 12% of tumors demonstrate sensitivity toward gemcitabine.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/medium/jm-2018-019576_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Dose-dependent reduction by (A) <b>AES-135</b> and (B) Panobinostat in cell proliferation in pancreatic cancer cells in the monolayer. Average of at least three experiments ± standard error (SE).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01957&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, we evaluated the efficacy of <b>AES-135</b> in preclinical predictive three-dimensional (3D) tumor models of pancreatic cancer using patient-derived tumor cells as well as CAFs. Pancreatic cancers are difficult to treat effectively in part because of the CAFs that surround the tumor and impede access by chemotherapeutics. Additionally, CAFs facilitate tumor growth through the secretion of growth factors, for example, vascular endothelial growth factor, interleukin 6, and transforming growth factor β, promoting invasion and metastasis.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a><b>AES-135</b> reduced pancreatic tumor spheroids, even with a protective CAF microenvironment, and showed 5- to 6-fold greater selectivity for the tumor cells over the CAFs (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Single-digit μM to high nM potencies were demonstrated in the analogous 3D tumor models, in reducing both tumor area and intensity (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/medium/jm-2018-019576_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Dose-dependent reduction in tumor spheroid intensity in patient-derived pancreatic cancer cells Pa03C (red, <i>n</i> = 3, ±SE) and 10.05 (blue, <i>n</i> = 3, ±SE); fold change compares the treated tumor only spheroids to media control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01957&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. IC<sub>50</sub> Values for <b>AES-135</b> in Several Monolayer and 3D Human-Derived PDAC Cell Lines (<i>n</i> = 3–5)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="2" align="center">monolayer PDAC cells</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pa02C</td><td class="colsep0 rowsep0" align="char" char=".">4.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pa03C</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10.05</td><td class="colsep0 rowsep0" align="char" char=".">3.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KPC</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="3" align="center">3D PDAC cells</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">scan type</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pa03C</td><td class="colsep0 rowsep0" align="left">area<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">1.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pa03C + CAFs</td><td class="colsep0 rowsep0" align="left">area</td><td class="colsep0 rowsep0" align="char" char=".">1.41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CAF coculture</td><td class="colsep0 rowsep0" align="left">area</td><td class="colsep0 rowsep0" align="char" char=".">7.80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pa03C</td><td class="colsep0 rowsep0" align="left">intensity<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">1.33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pa03C + CAFs</td><td class="colsep0 rowsep0" align="left">intensity</td><td class="colsep0 rowsep0" align="char" char=".">1.56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CAF coculture</td><td class="colsep0 rowsep0" align="left">intensity</td><td class="colsep0 rowsep0" align="char" char=".">4.50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10.05</td><td class="colsep0 rowsep0" align="left">area</td><td class="colsep0 rowsep0" align="char" char=".">0.97</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10.05 + CAFs</td><td class="colsep0 rowsep0" align="left">area</td><td class="colsep0 rowsep0" align="char" char=".">0.94</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CAF coculture</td><td class="colsep0 rowsep0" align="left">area</td><td class="colsep0 rowsep0" align="char" char=".">4.70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10.05</td><td class="colsep0 rowsep0" align="left">intensity</td><td class="colsep0 rowsep0" align="char" char=".">0.60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10.05 + CAFs</td><td class="colsep0 rowsep0" align="left">intensity</td><td class="colsep0 rowsep0" align="char" char=".">0.50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CAF coculture</td><td class="colsep0 rowsep0" align="left">intensity</td><td class="colsep0 rowsep0" align="char" char=".">3.40</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Area: the μ<sup>2</sup> of objects that exceed a minimum tomato red intensity threshold in the well.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">The sum of all intensity values for pixels marked as χ<sup>2</sup> objects (i.e., total red OR green fluorescence in the well, after background removal).</p></div></div></div><div class="NLM_p">Due to the high sensitivity of the KPC cells to <b>AES-135</b> treatment, we tested the in vivo potency of <b>AES-135</b> in a syngeneic orthotopic model. KPC cells were orthotopically implanted in the pancreas of C57Bl/6 mice, which were subsequently treated with either 50 mg/kg <b>AES-135</b> or vehicle control. A murine mouse model was utilized in the in vivo studies due to the role of HDACs in the modulation of immune cell function.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> Furthermore, in lung and renal cell carcinoma mouse models, the HDAC inhibitor Entinostat (SNDX-275; MS-275) potentiated the effects of PD-1 inhibition, and this effect was partially mediated by functional inhibition of MDSCs.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> HDAC inhibitors would be effective in blockading tumor cell proliferation and cell-cycle progression and also have immunomodulatory effects.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a> Mice treated with <b>AES-135</b> showed significantly increased survival, with a median survival rate of 36.5 days compared to 29.5 days for the vehicle mice (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, <i>p</i> = 0.0146). The ability to provide a survival advantage in this aggressive PDAC model illustrates the potential of <b>AES-135</b> as a hit-to-lead compound. This effect was only observed in immunocompetent mice; the equivalent immunodeficient mice showed no obvious survival advantage (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_001.pdf" class="ext-link">Figure S21</a>, Supporting Information).</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/medium/jm-2018-019576_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Increased survival of C57Bl/6 mice implanted with KPC tumor cells following <b>AES-135</b> treatment. Mice treated with 50 mg/kg <b>AES-135</b>, IP daily (blue, <i>n</i> = 10) exhibited a statistically significant survival advantage compared to mice treated with vehicle (green, <i>n</i> = 10), <i>p</i> = 0.0146 (log-rank test). Treatment started on day 7 with a cycle of 5 days on, 2 days off and continued until day 36.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01957&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13080" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13080" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Several reviews have described the potential of HDAC inhibitors to effectively treat PDAC,<a onclick="showRef(event, 'ref48 ref49 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref48 ref49 ref50 ref51">(48−51)</a> but to date, no compound has been published demonstrating suitable potency and druglike properties against this aggressive disease. We have presented a set of structurally novel hydroxamic acid-containing molecules displaying nM inhibition of HDACs in a target-based assay. The lead compound, <b>AES-135</b>, demonstrated potent inhibition of HDACs 3, 6, 8, and 11 and high cytotoxicity in a variety of cancer cell lines, most notably in pancreatic tumor lines. <b>AES-135</b> was consistently more active in PDAC tumor models, both monolayer and 3D, than STAT inhibitor <b>1</b>, even showing single-digit μM IC<sub>50</sub> values in the highly aggressive KPC model, which was superior to the FDA-approved HDAC inhibitor Panobinostat. <b>AES-135</b> showed an impressive PK profile in mice, with an in vivo half-life of 5.0 h, prolonged blood concentration above its IC<sub>50</sub> value, and unremarkable toxicity, as assessed by a brief study. Subsequent in vivo evaluation in immunocompetent mice found that <b>AES-135</b> extended the life of the mice significantly. To effectively treat pancreatic cancer, single agent therapy has not been effective; therefore, individualized combinations of targeted therapies will be necessary for making therapeutic advances in this devastating disease. Combination studies including <b>AES-135</b> in animal models are crucial in order to determine whether the addition of HDAC inhibitors to standard-of-care agents or a new combination, such as immune checkpoint inhibitors, will dramatically extend survival. NMR and X-ray crystallographic studies are ongoing to determine the exact binding mechanism of <b>AES-135</b> with HDACs to identify more potent and selective binding agents for preclinical evaluation.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55068" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55068" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Materials and Methods</h3><div class="NLM_p">A 400 MHz Bruker NMR was utilized to obtain <sup>1</sup>H, <sup>13</sup>C, and <sup>19</sup>F NMR spectra in CDCl<sub>3</sub> (99.8 atom % D), CD<sub>3</sub>CN (99.8 atom % D), or MeOH-<i>d</i><sub>4</sub> (99.8 atom % D), as indicated (<sup>1</sup>H at 400 MHz, <sup>13</sup>C at 100 MHz, and <sup>19</sup>F at 54 MHz). Chemical shifts (δ) are reported in parts per million (ppm), after calibration to the residual isotopic solvent, and coupling constants (<i>J</i>) are reported in hertz (Hz). Low-resolution mass spectrometry (LRMS) was carried out using Waters LC–MS in electrospray ionization (ESI) mode, fitted with Micromass ZQ MS and Alliance 2690 LC. High-resolution mass spectrometry (HRMS) was carried out using an Agilent 6538 UHD quadrupole-time-of-flight mass spectrometry in ESI mode with a mass accuracy of ±1 mDa. Thin-layer chromatography was conducted on Merck silica gel 60F<sub>254</sub> on aluminum sheets. All sheets were dried after use and visualized using short-wave (254 nm) and long-wave (365 nm) UV light and/or staining with KMnO<sub>4</sub>. Column chromatography was carried out at room temperature using Biotage Isolera One and Isolera Prime purification systems, with industry-standard SNAP cartridges loaded with 40–60 μm silica gel (average pore size 60 Å). Semipreparative HPLC was conducted using a Waters 2487 Dual λ absorbance detector, equipped with a Symmetry C18 4.6 mm × 150 mm cartridge. Inhibitor purity was evaluated at room temperature by a Hewlett Packard Series 1100 analytical HPLC system fitted with a Phenomenex Luna 5.0 μm C18 4.6 mm × 150 mm cartridge using gradient mixtures of (A) Milli-Q water with 0.1% (v/v) TFA and (B) HPLC-grade acetonitrile. Biologically evaluated compounds are ≥95% chemically pure, as measured by HPLC. Chemicals and solvents were purchased from Sigma-Aldrich (MilliporeSigma), VWR International, Alfa Aesar, Combi-Blocks, Caledon Laboratory Chemicals, and Promega and were used as supplied.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> General Procedure for the Synthesis of Compounds AES-135, 2–8, 36–43, and 60</h4><div class="NLM_p">The benzyl or hydroxamate ester (1.0 equiv) was dissolved in THF/methanol (2:1) (0.1 M) and purged with nitrogen. Then, 10% Pd/C (0.04 equiv) was added after 15 min, and the flask was purged with hydrogen for 10 min. The reaction was allowed to stir at RT under hydrogen. After 16 h, the reaction was filtered through celite, washed with EtOAc, and concentrated in vacuo. Semipreparative HPLC, followed by lyophilization at −50 °C, isolated the target compound.</div><div id="sec4_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i14" class="anchor-spacer"></div><h5 class="article-section__title" id="_i14"> 4-(<i>N</i>-(4-(<i>tert</i>-Butyl)benzyl)-2-((4-fluoro-<i>N</i>-((perfluorophenyl)methyl)phenyl)sulfonamido)acetamido)-<i>N</i>-hydroxybenzamide (<b>AES-135</b>)</h5><div class="NLM_p last">Semipreparative HPLC using acetonitrile/0.1% (v/v) TFA in Milli-Q water (0:1 → 1:0, 50 min → 10 min) eluted the target compound at 42.8–44.0 min. The product was suspended in acetonitrile/Milli-Q water (1:3, 4 mL) and lyophilized overnight at −50 °C to give <b>AES-135</b> as a white solid (52.2 mg, 56%); <sup>1</sup>H δ/ppm (400 MHz, CDCl<sub>3</sub>) 1.29 (s, 9H, <i>t-</i>Bu), 3.86 (s, 2H, CH<sub>2</sub>), 4.61 (s, 2H, CH<sub>2</sub>), 4.73 (s, 2H, CH<sub>2</sub>), 6.97 (d, <i>J</i> = 7.8 Hz, 2H, 2 CH), 7.08 (d, <i>J</i> = 7.3 Hz, 2H, 2 CH), 7.14 (t, <i>J</i> = 8.5 Hz, 2H, 2 CH), 7.27 (d, <i>J</i> = 7.9 Hz, 2H, 2 CH), 7.75 (d, <i>J</i> = 7.1 Hz, 2H, 2 CH), 7.83–7.87 (m, 2H, 2 CH), hydroxamic acid NH and OH protons were not observed; <sup>13</sup>C δ/ppm (100 MHz, CDCl<sub>3</sub>) 31.1, 34.4, 39.6, 49.2, 53.0, 101.4, 115.9, 116.1, 124.4, 125.4, 128.3, 128.7, 130.3, 130.4, 132.8, 134.87, 134.91, 143.8, 144.2, 146.8, 150.9, 163.9, 164.8, 166.2, 166.5; <sup>19</sup>F δ/ppm (54 MHz, CDCl<sub>3</sub>) −162.3 (td, <i>J</i> = 6.1 and 20.9 Hz, 2F), −153.9 (t, <i>J</i> = 20.5 Hz, 1F), −142.2 (dd, <i>J</i> = 7.0 and 22.5 Hz, 2F), −105.4 to −105.3 (m, 1F); LRMS (ESI+) <i>m</i>/<i>z</i> calcd for [C<sub>33</sub>H<sub>30</sub>F<sub>6</sub>N<sub>3</sub>O<sub>5</sub>S]<sup>+</sup>: 694.67, found: 694.36; calcd for [C<sub>33</sub>H<sub>29</sub>F<sub>6</sub>N<sub>3</sub>O<sub>5</sub>SNa]<sup>+</sup>: 716.65, found: 716.34; HRMS (ESI+) <i>m</i>/<i>z</i> calcd for [C<sub>33</sub>H<sub>30</sub>F<sub>6</sub>N<sub>3</sub>O<sub>5</sub>S]<sup>+</sup>: 694.1798, found: 694.1805; HPLC (I) <i>t</i><sub>R</sub> = 23.55 min (97.9%); HPLC (II) <i>t</i><sub>R</sub> = 38.44 min (99.9%).</div></div><div id="sec4_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i15" class="anchor-spacer"></div><h5 class="article-section__title" id="_i15"> 4-(<i>N</i>-(4-(<i>tert</i>-Butyl)benzyl)-2-((3,4-difluoro-<i>N</i>-(2-(trifluoromethyl)benzyl)phenyl)sulfonamido)acetamido)-<i>N</i>-hydroxybenzamide (<b>2</b>)</h5><div class="NLM_p last">Semipreparative HPLC using acetonitrile/0.1% (v/v) TFA in Milli-Q water (0:1 → 1:0, 50 min → 10 min) eluted the target compound at 42.1–43.6 min. The product was suspended in acetonitrile/Milli-Q water (1:3, 4 mL) and lyophilized overnight at −50 °C to give <b>2</b> as a white solid (83.9 mg, 68%); <sup>1</sup>H δ/ppm (400 MHz, CDCl<sub>3</sub>) 1.29 (s, 9H, <i>t-</i>Bu), 3.68 (s, br, 2H, CH<sub>2</sub>), 4.70 (s, 2H, CH<sub>2</sub>), 4.74 (s, 2H, CH<sub>2</sub>), 6.90 (d, <i>J</i> = 7.3 Hz, 2H, 2 CH), 6.94 (d, <i>J</i> = 8.1 Hz, 2H, 2 CH), 7.26 (d, <i>J</i> = 8.2 Hz, 2H, 2 CH), 7.30 (d, <i>J</i> = 8.3 Hz, 1H, CH), 7.36 (t, <i>J</i> = 8.3 Hz, 1H, CH), 7.46 (t, <i>J</i> = 7.4 Hz, 1H, CH), 7.61–7.77 (m, 6H, 6 CH), hydroxamic acid NH and OH protons were not observed; <sup>13</sup>C δ/ppm (100 MHz, CDCl<sub>3</sub>) 31.3, 34.5, 47.4, 48.0, 53.1, 117.7, 117.87, 117.90, 118.0, 122.7, 124.87, 124.91, 124.94, 125.0, 125.4, 125.5, 125.75, 125.81, 125.86, 125.92, 128.0, 128.4, 128.5, 128.65, 128.74, 130.1, 132.5, 132.9, 134.1, 136.5, 143.9, 148.8, 151.0, 151.9, 165.8, 166.0; <sup>19</sup>F δ/ppm (54 MHz, CDCl<sub>3</sub>) −134.0 (dt, <i>J</i> = 8.5 and 20.7 Hz, 1F), −129.3 to −129.1 (m, 1F), −59.1 (s, 3F); LRMS (ESI+) <i>m</i>/<i>z</i> calcd for [C<sub>34</sub>H<sub>33</sub>F<sub>5</sub>N<sub>3</sub>O<sub>5</sub>S]<sup>+</sup>: 690.71, found: 690.45; calcd for [C<sub>34</sub>H<sub>32</sub>F<sub>5</sub>N<sub>3</sub>O<sub>5</sub>SNa]<sup>+</sup>: 712.69, found: 712.43; HRMS (ESI+) <i>m</i>/<i>z</i> calcd for [C<sub>34</sub>H<sub>33</sub>F<sub>5</sub>N<sub>3</sub>O<sub>5</sub>S]<sup>+</sup>: 690.2064, found: 690.2056; HPLC (I) <i>t</i><sub>R</sub> = 24.65 min (99.9%); HPLC (II) <i>t</i><sub>R</sub> = 40.23 min (99.9%).</div></div><div id="sec4_1_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i16" class="anchor-spacer"></div><h5 class="article-section__title" id="_i16"> 4-(2-((3,4-Difluoro-<i>N</i>-(2-(trifluoromethyl)benzyl)phenyl)sulfonamido)-<i>N</i>-(4-(trifluoromethyl)benzyl)acetamido)-<i>N</i>-hydroxybenzamide (<b>3</b>)</h5><div class="NLM_p last">Semipreparative HPLC using acetonitrile/0.1% (v/v) TFA in Milli-Q water (0:1 → 1:0, 50 min → 10 min) eluted the target compound at 37.9–39.4 min. The product was suspended in acetonitrile/Milli-Q water (1:3, 4 mL) and lyophilized overnight at −50 °C to give <b>3</b> as a white solid (82.2 mg, 71%); <sup>1</sup>H δ/ppm (400 MHz, CDCl<sub>3</sub>) 3.70 (s, 2H, CH<sub>2</sub>), 4.71 (s, 2H, CH<sub>2</sub>), 4.79 (s, 2H, CH<sub>2</sub>), 6.91 (d, <i>J</i> = 7.6 Hz, 2H, 2 CH), 7.17 (d, <i>J</i> = 7.9 Hz, 2H, 2 CH), 7.29–7.33 (m, 1H, CH), 7.37 (t, <i>J</i> = 7.7 Hz, 1H, CH), 7.47 (t, <i>J</i> = 7.7 Hz, 1H, CH), 7.51 (d, <i>J</i> = 8.1 Hz, 2H, 2 CH), 7.61–7.76 (m, 6H, 6 CH), 9.19 (s, br, 1H, NH), hydroxamic acid OH proton was not observed; <sup>13</sup>C δ/ppm (100 MHz, CDCl<sub>3</sub>) 47.4, 48.0, 52.9, 117.6, 117.8, 117.9, 118.1, 122.6, 122.7, 124.8, 124.87, 124.91, 125.0, 125.3, 125.4, 125.57, 125.59, 125.63, 125.7, 125.8, 125.9, 128.2, 128.3, 128.5, 128.6, 128.9, 129.0, 130.2, 130.4, 131.2, 132.6, 133.9, 136.5, 140.0, 143.5, 151.2, 165.2, 166.4; <sup>19</sup>F δ/ppm (54 MHz, CDCl<sub>3</sub>) −133.9 (dt, <i>J</i> = 8.7 and 20.6 Hz, 1F), −129.0 to −128.9 (m, 1F), −62.6 (s, 3F), −59.0 (s, 3F); LRMS (ESI+) <i>m</i>/<i>z</i> calcd for [C<sub>31</sub>H<sub>24</sub>F<sub>8</sub>N<sub>3</sub>O<sub>5</sub>S]<sup>+</sup>: 702.60, found: 702.36; calcd for [C<sub>31</sub>H<sub>23</sub>F<sub>8</sub>N<sub>3</sub>O<sub>5</sub>SNa]<sup>+</sup>: 724.58, found: 724.34; HRMS (ESI+) <i>m</i>/<i>z</i> calcd for [C<sub>31</sub>H<sub>24</sub>F<sub>8</sub>N<sub>3</sub>O<sub>5</sub>S]<sup>+</sup>: 702.1308, found: 702.1303; HPLC (I) <i>t</i><sub>R</sub> = 23.11 min (99.9%); HPLC (II) <i>t</i><sub>R</sub> = 37.67 min (99.9%).</div></div><div id="sec4_1_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i17" class="anchor-spacer"></div><h5 class="article-section__title" id="_i17"> 4-(<i>N</i>-(4-(<i>tert</i>-Butyl)benzyl)-2-((2,4-difluoro-<i>N</i>-(2-(trifluoromethyl)benzyl)phenyl)sulfonamido)acetamido)-<i>N</i>-hydroxybenzamide (<b>4</b>)</h5><div class="NLM_p last">Semipreparative HPLC using acetonitrile/0.1% (v/v) TFA in Milli-Q water (0:1 → 1:0, 50 min → 10 min) eluted the target compound at 42.0–43.7 min. The product was suspended in acetonitrile/Milli-Q water (1:3, 4 mL) and lyophilized overnight at −50 °C to give <b>4</b> as a white solid (57.4 mg, 69%); <sup>1</sup>H δ/ppm (400 MHz, CDCl<sub>3</sub>) 1.29 (s, 9H, <i>t-</i>Bu), 3.72 (s, 2H, CH<sub>2</sub>), 4.68 (s, 2H, CH<sub>2</sub>), 4.88 (s, 2H, CH<sub>2</sub>), 6.91–6.98 (m, 6H, 6 CH), 7.24 (d, <i>J</i> = 8.2 Hz, 2H, 2 CH), 7.34 (t, <i>J</i> = 7.6 Hz, 1H, CH), 7.46 (t, <i>J</i> = 7.5 Hz, 1H, CH), 7.60–7.66 (m, 4H, 4 CH), 7.85–7.91 (m, 1H, CH), 9.14 (s, br, 1H, NH), hydroxamic acid OH proton was not observed; <sup>13</sup>C δ/ppm (100 MHz, CDCl<sub>3</sub>) 31.3, 34.5, 47.7, 48.0, 53.0, 105.5, 105.7, 106.0, 111.4, 111.6, 124.7, 125.4, 125.5, 125.7, 125.75, 125.81, 125.9, 127.9, 128.4, 128.5, 128.6, 128.7, 128.75, 128.77, 128.84, 130.1, 131.8, 131.9, 132.5, 133.1, 134.7, 144.0, 150.9, 164.1, 164.6, 165.4; <sup>19</sup>F δ/ppm (54 MHz, CDCl<sub>3</sub>) −101.3 to −101.2 (m, 1F), −100.7 to −100.6 (m, 1F), −59.1 (s, 3F); LRMS (ESI+) <i>m</i>/<i>z</i> calcd for [C<sub>34</sub>H<sub>32</sub>F<sub>5</sub>N<sub>3</sub>O<sub>5</sub>SNa]<sup>+</sup>: 712.69, found: 712.56; HRMS (ESI+) <i>m</i>/<i>z</i> calcd for [C<sub>34</sub>H<sub>33</sub>F<sub>5</sub>N<sub>3</sub>O<sub>5</sub>S]<sup>+</sup>: 690.2063, found: 690.2056; HPLC (I) <i>t</i><sub>R</sub> = 24.11 min (95.3%); HPLC (II) <i>t</i><sub>R</sub> = 39.18 min (98.8%).</div></div><div id="sec4_1_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i18" class="anchor-spacer"></div><h5 class="article-section__title" id="_i18"> 4-(2-((2,4-Difluoro-<i>N</i>-(2-(trifluoromethyl)benzyl)phenyl)sulfonamido)-<i>N</i>-(4-(trifluoromethyl)benzyl)acetamido)-<i>N</i>-hydroxybenzamide (<b>5</b>)</h5><div class="NLM_p last">Semipreparative HPLC using acetonitrile/0.1% (v/v) TFA in Milli-Q water (0:1 → 1:0, 50 min → 10 min) eluted the target compound at 38.3–40.1 min. The product was suspended in acetonitrile/Milli-Q water (1:3, 4 mL) and lyophilized overnight at −50 °C to give <b>5</b> as a white solid (95.2 mg, 80%); <sup>1</sup>H δ/ppm (400 MHz, CDCl<sub>3</sub>) 3.74 (s, 2H, CH<sub>2</sub>), 4.77 (s, 2H, CH<sub>2</sub>), 4.85 (s, 2H, CH<sub>2</sub>), 6.92–6.99 (m, 4H, 4 CH), 7.14 (d, <i>J</i> = 8.0 Hz, 2H, 2 CH), 7.35 (t, <i>J</i> = 7.6 Hz, 1H, CH), 7.46 (t, <i>J</i> = 7.6 Hz, 1H, CH), 7.49 (d, <i>J</i> = 8.2 Hz, 2H, 2 CH), 7.59–7.66 (m, 4H, 4 CH), 7.86–7.91 (m, 1H, CH), hydroxamic acid NH and OH protons were not observed; <sup>13</sup>C δ/ppm (100 MHz, CDCl<sub>3</sub>) 47.6, 48.0, 52.9, 105.4, 105.7, 105.9, 111.45, 111.49, 111.68, 111.71, 122.8, 124.58, 124.62, 124.7, 124.8, 125.3, 125.5, 125.7, 125.78, 125.83, 125.9, 127.3, 128.0, 128.6, 128.7, 128.97, 129.00, 130.2, 131.8, 131.9, 132.0, 132.5, 134.4, 140.1, 143.6, 161.6, 164.5, 166.3, 167.1; <sup>19</sup>F δ/ppm (54 MHz, CDCl<sub>3</sub>) −101.6 to −101.5 (m, 1F), −100.3 to −100.2 (m, 1F), −62.6 (s, 3F), −59.0 (s, 3F); LRMS (ESI+) <i>m</i>/<i>z</i> calcd for [C<sub>31</sub>H<sub>24</sub>F<sub>8</sub>N<sub>3</sub>O<sub>5</sub>S]<sup>+</sup>: 702.60, found: 702.48; calcd for [C<sub>31</sub>H<sub>23</sub>F<sub>8</sub>N<sub>3</sub>O<sub>5</sub>SNa]<sup>+</sup>: 724.58, found: 724.40; HRMS (ESI+) <i>m</i>/<i>z</i> calcd for [C<sub>31</sub>H<sub>24</sub>F<sub>8</sub>N<sub>3</sub>O<sub>5</sub>S]<sup>+</sup>: 702.1307, found: 702.1303; HPLC (I) <i>t</i><sub>R</sub> = 22.62 min (99.9%); HPLC (II) <i>t</i><sub>R</sub> = 36.62 min (97.2%).</div></div><div id="sec4_1_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i19" class="anchor-spacer"></div><h5 class="article-section__title" id="_i19"> 4-(<i>N</i>-(4-(<i>tert</i>-Butyl)benzyl)-2-((4-fluoro-<i>N</i>-(2-(trifluoromethyl)benzyl)phenyl)sulfonamido)acetamido)-<i>N</i>-hydroxybenzamide (<b>6</b>)</h5><div class="NLM_p last">Semipreparative HPLC using acetonitrile/0.1% (v/v) TFA in Milli-Q water (0:1 → 1:0, 50 min → 10 min) eluted the target compound at 41.0–42.5 min. The product was suspended in acetonitrile/Milli-Q water (1:3, 4 mL) and lyophilized overnight at −50 °C to give <b>6</b> as a white solid (90.4 mg, 68%); <sup>1</sup>H δ/ppm (400 MHz, CDCl<sub>3</sub>) 1.29 (s, 9H, <i>t-</i>Bu), 3.69 (s, 2H, CH<sub>2</sub>), 4.69 (s, 2H, CH<sub>2</sub>), 4.75 (s, 2H, CH<sub>2</sub>), 6.91 (d, <i>J</i> = 8.0 Hz, 2H, 2 CH), 6.94 (d, <i>J</i> = 8.2 Hz, 2H, 2 CH), 7.18 (t, <i>J</i> = 8.5 Hz, 2H, 2 CH), 7.25 (d, <i>J</i> = 8.2 Hz, 2H, 2 CH), 7.34 (t, <i>J</i> = 7.6 Hz, 1H, CH), 7.45 (t, <i>J</i> = 7.6 Hz, 1H, CH), 7.62 (t, <i>J</i> = 7.8 Hz, 2H, 2 CH), 7.66 (d, <i>J</i> = 8.0 Hz, 2H, 2 CH), 7.90–7.94 (m, 2H, 2 CH), 9.14 (s, br, 1H, NH), hydroxamic acid OH proton was not observed; <sup>13</sup>C δ/ppm (100 MHz, CDCl<sub>3</sub>) 31.3, 34.5, 47.5, 47.9, 53.0, 116.0, 116.2, 125.5, 125.7, 125.76, 125.81, 125.9, 127.9, 128.0, 128.3, 128.5, 128.6, 128.7, 130.0, 130.5, 130.6, 130.7, 132.5, 133.0, 134.45, 134.47, 135.7, 135.8, 150.9, 164.0, 166.13, 166.16, 166.5; <sup>19</sup>F δ/ppm (54 MHz, CDCl<sub>3</sub>) −104.84 to −104.77 (m, 1F), −59.2 (s, 3F); LRMS (ESI+) <i>m</i>/<i>z</i> calcd for [C<sub>34</sub>H<sub>34</sub>F<sub>4</sub>N<sub>3</sub>O<sub>5</sub>S]<sup>+</sup>: 672.72, found: 672.50; calcd for [C<sub>34</sub>H<sub>33</sub>F<sub>4</sub>N<sub>3</sub>O<sub>5</sub>SNa]<sup>+</sup>: 694.70, found: 694.42; HRMS (ESI+) <i>m</i>/<i>z</i> calcd for [C<sub>34</sub>H<sub>34</sub>F<sub>4</sub>N<sub>3</sub>O<sub>5</sub>S]<sup>+</sup>: 672.2157, found: 672.2150; HPLC (I) <i>t</i><sub>R</sub> = 23.66 min (99.9%); HPLC (II) <i>t</i><sub>R</sub> = 38.58 min (99.9%).</div></div><div id="sec4_1_1_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i20" class="anchor-spacer"></div><h5 class="article-section__title" id="_i20"> 4-(2-((4-Fluoro-<i>N</i>-(2-(trifluoromethyl)benzyl)phenyl)sulfonamido)-<i>N</i>-(4-(trifluoromethyl)benzyl)acetamido)-<i>N</i>-hydroxybenzamide (<b>7</b>)</h5><div class="NLM_p last">Semipreparative HPLC using acetonitrile/0.1% (v/v) TFA in Milli-Q water (0:1 → 1:0, 50 min → 10 min) eluted the target compound at 37.1–38.6 min. The product was suspended in acetonitrile/Milli-Q water (1:3, 4 mL) and lyophilized overnight at −50 °C to give <b>7</b> as a white solid (87.9 mg, 77%); <sup>1</sup>H δ/ppm (400 MHz, CDCl<sub>3</sub>) 3.70 (s, 2H, CH<sub>2</sub>), 4.73 (s, 2H, CH<sub>2</sub>), 4.79 (s, 2H, CH<sub>2</sub>), 6.91 (d, <i>J</i> = 7.6 Hz, 2H, 2 CH), 7.15 (d, <i>J</i> = 8.5 Hz, 2H, 2 CH), 7.19 (t, <i>J</i> = 8.5 Hz, 2H, 2 CH), 7.35 (t, <i>J</i> = 7.6 Hz, 1H, CH), 7.45 (t, <i>J</i> = 7.6 Hz, 1H, CH), 7.49 (d, <i>J</i> = 8.1 Hz, 2H, 2 CH), 7.61 (d, <i>J</i> = 8.5 Hz, 2H, 2 CH), 7.65 (d, <i>J</i> = 8.2 Hz, 2H, 2 CH), 7.90–7.94 (m, 2H, 2 CH), hydroxamic acid NH and OH protons were not observed; <sup>13</sup>C δ/ppm (100 MHz, CDCl<sub>3</sub>) 47.4, 47.9, 52.9, 116.1, 116.3, 122.7, 125.3, 125.47, 125.53, 125.57, 125.64, 125.8, 125.85, 125.88, 128.0, 128.3, 128.5, 128.6, 128.9, 128.97, 129.00, 130.1, 130.4, 130.5, 132.5, 134.2, 135.66, 135.69, 140.1, 143.7, 164.0, 166.55, 166.64; <sup>19</sup>F δ/ppm (54 MHz, CDCl<sub>3</sub>) −104.6 to −104.5 (m, 1F), −62.6 (s, 3F), −59.0 (s, 3F); LRMS (ESI+) <i>m</i>/<i>z</i> calcd for [C<sub>31</sub>H<sub>24</sub>F<sub>7</sub>N<sub>3</sub>O<sub>5</sub>SNa]<sup>+</sup>: 706.59, found: 706.33; HRMS (ESI+) <i>m</i>/<i>z</i> calcd for [C<sub>31</sub>H<sub>25</sub>F<sub>7</sub>N<sub>3</sub>O<sub>5</sub>S]<sup>+</sup>: 684.1399, found: 684.1398; HPLC (I) <i>t</i><sub>R</sub> = 22.20 min (99.9%); HPLC (II) <i>t</i><sub>R</sub> = 36.13 min (97.1%).</div></div><div id="sec4_1_1_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i21" class="anchor-spacer"></div><h5 class="article-section__title" id="_i21"> 4-(2-((4-Fluoro-<i>N</i>-((perfluorophenyl)methyl)phenyl)sulfonamido)-<i>N</i>-(4-(trifluoromethyl)benzyl)acetamido)-<i>N</i>-hydroxybenzamide (<b>8</b>)</h5><div class="NLM_p last">Semipreparative HPLC using acetonitrile/0.1% (v/v) TFA in Milli-Q water (0:1 → 1:0, 50 min → 10 min) eluted the target compound at 37.3–37.9 min. The product was suspended in acetonitrile/Milli-Q water (1:3, 4 mL) and lyophilized overnight at −50 °C to give <b>8</b> as a white solid (14.0 mg, 46%); <sup>1</sup>H δ/ppm (400 MHz, CDCl<sub>3</sub>) 3.85 (s, 2H, CH<sub>2</sub>), 4.60 (s, 2H, CH<sub>2</sub>), 4.84 (s, 2H, CH<sub>2</sub>), 7.10 (d, <i>J</i> = 7.8 Hz, 2H, 2 CH), 7.16 (t, <i>J</i> = 8.5 Hz, 2H, 2 CH), 7.21 (d, <i>J</i> = 7.8 Hz, 2H, 2 CH), 7.52 (d, <i>J</i> = 8.0 Hz, 2H, 2 CH), 7.77 (d, <i>J</i> = 7.7 Hz, 2H, 2 CH), 7.84 (dd, <i>J =</i> 5.1 and 8.6 Hz, 2H, 2 CH), hydroxamic acid NH and OH protons were not observed; <sup>13</sup>C δ/ppm (100 MHz, CDCl<sub>3</sub>) 39.7, 49.3, 53.0, 109.7, 116.1, 116.3, 125.6, 125.65, 125.71, 125.74, 128.6, 128.7, 129.00, 129.04, 129.07, 129.09, 130.1, 130.4, 130.5, 131.1, 133.6, 135.0, 135.1, 140.0, 143.6, 164.1, 165.1, 166.7, 166.8; <sup>19</sup>F δ/ppm (54 MHz, CDCl<sub>3</sub>) −161.1 (td, <i>J</i> = 7.4 and 21.5 Hz, 2F), −152.5 (t, <i>J</i> = 20.9 Hz, 1F), −141.3 (dd, <i>J</i> = 8.0 and 22.2 Hz, 2F), −104.1 to −104.0 (m, 1F), −62.6 (s, 3F); LRMS (ESI-) <i>m</i>/<i>z</i> calcd for [C<sub>30</sub>H<sub>19</sub>F<sub>9</sub>N<sub>3</sub>O<sub>5</sub>S]<sup>−</sup>: 704.54, found: 704.35; HRMS (ESI+) <i>m</i>/<i>z</i> calcd for [C<sub>30</sub>H<sub>21</sub>F<sub>9</sub>N<sub>3</sub>O<sub>5</sub>S]<sup>+</sup>: 706.1053, found: 706.1044; HPLC (I) <i>t</i><sub>R</sub> = 21.96 min (99.9%); HPLC (II) <i>t</i><sub>R</sub> = 35.74 min (99.9%).</div></div><div id="sec4_1_1_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i22" class="anchor-spacer"></div><h5 class="article-section__title" id="_i22"> 4-(<i>N</i>-(4-(<i>tert</i>-Butyl)benzyl)-2-((4-fluoro-<i>N</i>-((perfluorophenyl)methyl)phenyl)sulfonamido)acetamido)-<i>N</i>-hydroxy-<i>N</i>-methylbenzamide (<b>60</b>)</h5><div class="NLM_p last">Semipreparative HPLC using acetonitrile/0.1% (v/v) TFA in Milli-Q water (0:1 → 1:0, 50 min → 10 min) eluted the target compound at 47.2–48.4 min. The product was suspended in acetonitrile/Milli-Q water (1:3, 2 mL) and lyophilized overnight at −50 °C to give <b>60</b> as a white solid (19.1 mg, 77%); <sup>1</sup>H δ/ppm (400 MHz, CDCl<sub>3</sub>) 1.31 (s, 9H, <i>t-</i>Bu), 3.42 (s, 3H, CH<sub>3</sub>), 3.87 (s, 2H, CH<sub>2</sub>), 4.61 (s, 2H, CH<sub>2</sub>), 4.75 (s, 2H, CH<sub>2</sub>), 6.99 (d, <i>J</i> = 8.0 Hz, 2H, 2 CH), 7.09 (d, <i>J</i> = 7.8 Hz, 2H, 2 CH), 7.17 (t, <i>J</i> = 8.6 Hz, 2H, 2 CH), 7.29 (d, <i>J</i> = 8.0 Hz, 2H, 2 CH), 7.57 (d, <i>J</i> = 8.2 Hz, 2H, 2 CH), 7.85–7.89 (m, 2H, 2 CH), hydroxamic acid OH proton was not observed; <sup>13</sup>C δ/ppm (100 MHz, CDCl<sub>3</sub>) 31.3, 34.6, 38.0, 39.7, 49.5, 53.2, 116.0, 116.2, 125.5, 127.9, 128.5, 128.56, 128.61, 129.9, 130.5, 130.6, 132.5, 133.0, 135.2, 151.0, 161.1, 164.1, 166.4, 167.2; <sup>19</sup>F δ/ppm (54 MHz, CDCl<sub>3</sub>) −161.3 (td, <i>J =</i> 7.4 and 21.7 Hz, 2F), −151.9 (t, <i>J</i> = 21.0 Hz, 1F), −141.1 (dd, <i>J</i> = 7.7 and 22.4 Hz, 2F), −104.5 to −104.4 (m, 1F); LRMS (ESI+) <i>m</i>/<i>z</i> calcd for [C<sub>34</sub>H<sub>32</sub>F<sub>6</sub>N<sub>3</sub>O<sub>5</sub>S]<sup>+</sup>: 708.70, found: 708.25; calcd for [C<sub>34</sub>H<sub>31</sub>F<sub>6</sub>N<sub>3</sub>O<sub>5</sub>SNa]<sup>+</sup>: 730.68, found: 730.25; (ESI−) <i>m</i>/<i>z</i> calcd for [C<sub>34</sub>H<sub>30</sub>F<sub>6</sub>N<sub>3</sub>O<sub>5</sub>S]<sup>−</sup>: 706.68, found: 706.36; HRMS (ESI+) <i>m</i>/<i>z</i> calcd for [C<sub>34</sub>H<sub>32</sub>F<sub>6</sub>N<sub>3</sub>O<sub>5</sub>S]<sup>+</sup>: 708.1969, found: 708.1961; HPLC (I) <i>t</i><sub>R</sub> = 24.49 min (99.9%); HPLC (II) <i>t</i><sub>R</sub> = 40.09 min (99.9%).</div></div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> General Procedure for the Synthesis of Compound 10</h4><div class="NLM_p last">The appropriate benzoic acid (1.0 equiv) and cesium carbonate (1.2 equiv) were suspended in DMF (0.7 M) and stirred at RT for 20 min in air, before addition of benzyl bromide (1.0 equiv) in one go, and the reaction was stirred at RT. After 24 h, the solvent was removed in vacuo at 80 °C, and the resulting solid was partitioned using EtOAc with saturated aqueous NaHCO<sub>3</sub> and distilled water (1:1). The layers were separated, and the organic layer was washed with saturated aqueous NaHCO<sub>3</sub> and distilled water (1:1) before drying (MgSO<sub>4</sub>), filtering, and concentrating in vacuo. Column chromatography isolated the target compound.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> General Procedure for the Synthesis of Compounds 11 and 12</h4><div class="NLM_p last">The appropriate aniline (1.0 equiv) and anhydrous MgSO<sub>4</sub> (excess) were suspended in THF (0.5 M) in air at RT and charged with the appropriate benzaldehyde in one go. After 16 h, the mixture was filtered in vacuo, washed with EtOAc, and concentrated in vacuo, before suspending in TFE or methanol (0.2 M) and mixing with sodium borohydride (4.0 equiv) portionwise at RT in air. After 16 h, the reaction was concentrated to a low volume in vacuo and partitioned using EtOAc with saturated aqueous NaHCO<sub>3</sub> and distilled water (1:1). The layers were separated, and the aqueous layer was extracted with EtOAc. The combined organic layers were dried (MgSO<sub>4</sub>), filtered, and concentrated in vacuo. Column chromatography isolated the target compound.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> General Procedure for the Synthesis of Compounds 14–17</h4><div class="NLM_p last">The amine salt (1.0 equiv) and the sulfonyl chloride (1.1 equiv) were dissolved in dichloromethane (DCM) (0.2 M) under nitrogen and cooled to 0 °C, before adding anhydrous diisopropylethylamine (3.0 equiv) dropwise. The solution was stirred at 0 °C for 10 min before being allowed to reach RT. After 16 h, the reaction was quenched with 1 M HCl, and the layers were partitioned and separated. The aqueous layer was extracted with DCM, and the combined organic layers were dried (MgSO<sub>4</sub>), filtered, and concentrated in vacuo. Column chromatography isolated the target compound.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> General Procedure for the Synthesis of Compounds 18–22</h4><div class="NLM_p last">The sulfonamide (1.0 equiv) was charged with cesium carbonate (2.0 equiv) and dissolved in acetonitrile (0.2 M) in air before stirring at RT to 50 °C for 20 min. The benzyl or alkyl bromide (1.1–1.5 equiv) was added in one go, and the reaction was stirred at RT. After 16 h, the reaction was concentrated in vacuo and partitioned between EtOAc and distilled water. The layers were separated, and the organic layer was washed with distilled water. The combined aqueous layer was extracted with EtOAc, and the combined organic layer was dried (MgSO<sub>4</sub>), filtered, and concentrated in vacuo. Column chromatography isolated the target compound.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> General Procedure for the Synthesis of Compounds 23–27</h4><div class="NLM_p last">The <i>tert</i>-butyl ester (1.0 equiv) was dissolved in DCM or chloroform in air at RT before mixing with trifluoroacetic acid (3:1, 2:1, or 1:1) (final concentration, 0.2 M). After 3 h, the reaction was concentrated in vacuo, azeotroping with DCM, to isolate the target compound without further purification.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> General Procedure for the Synthesis of Compounds 28–35</h4><div class="NLM_p last">The carboxylic acid (1.2 equiv) and dichlorotriphenylphosphorane (2.4 equiv) were dissolved in chloroform (0.15–0.2 M) under nitrogen and stirred vigorously at RT for 15 min, prior to addition of the aniline (1.0 equiv), neat or as a solution in chloroform (0.3 M), and the vial was irradiated at 100 °C for 1 h (high absorbance). The solution was concentrated in vacuo, and column chromatography isolated the target compound.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> General Procedure for the Synthesis of Compounds 44–51 and 59</h4><div class="NLM_p last">The benzoic acid (1.0 equiv) was dissolved in THF (0.05 M) under nitrogen and cooled to 0 °C before mixing with oxalyl chloride (5.0 equiv) and DMF (one to two drops). After 2 h, the reaction was concentrated in vacuo, repurged with nitrogen, and dissolved in THF (0.05 M). Diisopropylethylamine (4.0 equiv) and <i>O</i>-benzylhydroxylamine (2.0 equiv) were added, and the reaction was stirred at RT. After 16 h, the reaction was quenched with 1 M HCl and partitioned with EtOAc. The layers were separated, and the organic layer was washed with 1 M HCl. The combined aqueous layer was extracted with EtOAc, and the combined organic layer was dried (MgSO<sub>4</sub>), filtered, and concentrated in vacuo. Column chromatography isolated the target compound.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> General Procedure for the Synthesis of Compound 56</h4><div class="NLM_p last">Di-<i>tert</i>-butyl dicarbonate (1.0 equiv) was added, as a solution in THF (7.0 M), to the amine (2.0 equiv) in THF (0.5 M) in air at RT. After 24 h, the reaction was partitioned between EtOAc and 0.5 M HCl. The layers were separated, and the organic layer was washed with 0.5 M HCl. The combined aqueous layer was extracted with EtOAc, and the organic layer was dried (MgSO<sub>4</sub>), filtered, and concentrated in vacuo to give the target compound without further purification.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> General Procedure for the Synthesis of Compound 57</h4><div class="NLM_p last">Sodium hydride (60% in mineral oil) (3.0 equiv) was added, in one go, to the carbamate (1.0 equiv) in DMF (0.40 M) at RT, followed by iodomethane (1.5 equiv) after 15 min. After 24 h, the reaction was quenched with distilled water and extracted with diethyl ether. The organic layer was dried (MgSO<sub>4</sub>), filtered, and concentrated in vacuo. Column chromatography isolated the target compound.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> General Procedure for the Synthesis of Compound 58</h4><div class="NLM_p last">The carbamate (1.0 equiv) was dissolved in chloroform in air at RT and mixed with trifluoroacetic acid (3:1) (final concentration, 0.2 M). After 22 h, the reaction was concentrated in vacuo and partitioned between EtOAc and 1 M NaOH. The layers were separated, and the aqueous layer was extracted with EtOAc. The organic layer was dried (MgSO<sub>4</sub>), filtered, and concentrated in vacuo to give the target compound without further purification.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Cytotoxicity Assays in MDA-MB-231 and MDA-MB-468 Breast Cancer Cells, MV4-11 and MOLM-13 Acute Myeloid Leukemia (AML) Cells, K562 Chronic Myeloid Leukemia (CML) Cells, and MRC-9 Human Lung Fibroblasts</h4><div class="NLM_p last">MDA-MB-231 and MDA-MB-468 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich). MV4-11, MOLM-13, K562, and MRC-9 cells were maintained in Iscove’s modified Dulbecco’s media and Roswell Park Memorial Institute (RPMI)-1640 media, separately, and supplemented with 10% FBS (Sigma-Aldrich). Next, 10 000 cells were plated per well in 96-well flat-bottom sterile culture plates with low-evaporation lids (Costar #3997). After 24 h, inhibitors and a vehicle control (0.5% DMSO) were added (final concentration 100 μM), and the cells were incubated for 72 h at 37 °C in 5% CO<sub>2</sub>. Inhibitors were examined in triplicate at a maximal concentration of 50.0 μM, followed by 50% dilutions in subsequent wells (25.0, 12.5, 6.25, 3.125, 1.5625, 0.78125, 0.390625, 0.195313, and 0.097656 μM). After 72 h, wells were treated with CellTiter-Blue (Promega #G808A) (20 μL/well), and the plates were incubated using standard cell culture conditions for 1–4 h. Plates were shaken for 10 s, and fluorescence was recorded at 560/590 nm using a Cytation 3 spectrophotometer. IC<sub>50</sub> values were determined using nonlinear regression analysis with GraphPad Prism 6.0 (GraphPad Software Inc.).</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Cytotoxicity Assays in AR230 and AR230<sup>R</sup> CML Cells</h4><div class="NLM_p last">Cells were maintained in RPMI-1640 culture media with <span class="smallcaps smallerCapital">l</span>-glutamine (Gibco #11875) supplemented with 10% FBS. In addition, AR230<sup>R</sup> cells were cultured in the presence of 5.0 μM imatinib. Inhibitors were diluted 1000-fold in 100% DMSO into 96-well flat-bottom polystyrene tissue culture (TC)-treated culture plates (Falcon #353072). AR230 cells were plated at 5000 cells/well, and AR230<sup>R</sup> cells were plated at 15 000 cells/well in culture media (100 μL) and incubated with inhibitors at 37 °C and 5% CO<sub>2</sub> for 48 h. Inhibitors were tested in duplicate at a maximum concentration of 31.6 μM, followed by half-logarithmic dilutions between wells (10.0, 3.16, 1.00, 0.316, 0.100, 0.032, 0.010, 0.0032, and 0.001 μM). A vehicle lane (0.1% DMSO) was also included. Following incubation, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2<i>H</i>-tetrazolium reagent (CellTiter96, Promega) (20 μL) was added to each well, followed by incubation at 37 °C and 5% CO<sub>2</sub> for 3–4 h. Absorbance for each well was measured using an Epoch spectrophotometer (Biotek) at 490 nm, and IC<sub>50</sub> values were determined using nonlinear regression analysis with GraphPad Prism 6.0 (GraphPad Software Inc.).</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Cytotoxicity Assays in Glioblastoma Brain Tumor Stem Cells (GBM BTSCs)</h4><div class="NLM_p">Cells were cultured from tumor surgical specimens obtained following consent from adult GBM patients during operative procedures and approved by the University of Calgary Ethics Review Board. BTSC cultures were initiated in serum-free culture media (SFM), containing tissue culture water (150 mL), 10× DMEM (Gibco #12100-046) and F12 (Gibco #21700-075) (20 mL), Hormone Mix (20 mL), 30% glucose (Sigma-Aldrich #G7528) (4 mL), 7.5% NaHCO<sub>3</sub> (Sigma-Aldrich #S5761) (3 mL), and 1 M HEPES (Sigma-Aldrich #H4034) (1 mL). Nonadherent spheres were formed after 7–21 days in culture. BTSC cultures were passaged until they stabilized (5–10 passages) before being cryopreserved in 10% DMSO (Sigma-Aldrich) in SFM until required. All cultures were used within 15 passages after thawing.</div><div class="NLM_p last">BTSC spheres were dissociated to single cells by incubating with Accumax (Innovative Technologies) (1 mL per T25 flask of cells, 5 min, 37 °C), seeded at 2500 cells/well in TC-grade low-adherence 96-well culture plates (Nalgene), and treated with either vehicle (DMSO) or inhibitor (stock concentration 10 mM in DMSO) 1 day after plating. Inhibitors were administered in logarithmic or half-logarithmic serial dilutions, with eight concentrations measured between 100 nM and 20 μM, and cell viability was assessed after 48 h using the alamarBlue assay according to the manufacturer’s instructions. Experiments were performed in triplicate with a minimum of three wells per condition. IC<sub>50</sub> values were determined using nonlinear regression analysis with GraphPad Prism 6.0 (GraphPad Software Inc.).</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Cytotoxicity Assays in D425 (Primary) and D458 (Recurrent) Medulloblastoma Cells</h4><div class="NLM_p last">Cells were cultured in DMEM high glucose (Life Technologies #11965-118) supplemented with 1% penicillin–streptomycin and 20% FBS. To evaluate the IC<sub>50</sub> concentration of each inhibitor, 1000 cells were plated into each well of a tissue-culture-treated 96-well flat-bottom plate (Falcon) with 150 μL of DMEM high glucose with 1% FBS and 50 μL of serially diluted inhibitor. The inhibitor was plated at a concentration of 20 μM, following twofold dilutions, resulting in a final tested concentration of 39 nM. The cells were allowed to proliferate for 3 days at 37 °C in the presence of the inhibitor or DMSO before 20 μL of Presto Blue (Life Technologies), a fluorescent cell metabolism indicator, was added to each well approximately 4 h prior to the readout time point. Fluorescence was measured using a FLUOstar Omega Fluorescence 556 Microplate reader (BMG LABTECH) at excitation and emission wavelengths of 540 and 570 nm, respectively. Readings were analyzed by Omega software by plotting percent cell viability versus log dilutions of the inhibitors to determine the IC<sub>50</sub> value.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Cytotoxicity Assays in Pancreatic Cancer Pa03C, Pa02C, 10.05, and KPC Cells</h4><div class="NLM_p last">Patient-derived tumor cells and CAF19 cells were a kind gift from Dr. Anirban Maitra (The Johns Hopkins University), and KPC cells (TB32043 male) were a kind gift from Drs. David Tuveson and Christopher Frese. All cell lines were authenticated via short tandem repeat analysis (IDEXX BioResearch) and checked routinely for mycoplasma contamination. The proliferative capacities of Pa03C, 10.05, Pa02C, and KPC cells in monolayer were assessed using alamarBlue. For alamarBlue assays, PDAC cells were plated at 2000 cells/well in 96-well plates and treated with <b>AES-135</b> for 72 h. Assays were performed in at least triplicate.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Glutathione Stability Assay Using HPLC</h4><div class="NLM_p last">Assays were run using a Hewlett Packard Series 1100 analytical HPLC system fitted with an Agilent ZORBAX 3.5 μm Eclipse XDB-C18 4.6 mm × 75 mm column at room temperature. Eluent flow was set to 1.200 mL/min using gradient mixtures of (A) Milli-Q water with 0.1% (v/v) TFA and (B) HPLC-grade acetonitrile. Glutathione conjugation was measured by performing a linear elution gradient—A/B (1:0 → 0:1, 8.0 min → 2.0 min)—with UV detection set to 254 nm. Changes in the absorbance profile of the inhibitor were measured across time, with reductions in the HPLC peak area corresponding to a decay in the concentration of the parent compound.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Glutathione Stability Assay Using <sup>19</sup>F NMR</h4><div class="NLM_p last">One-dimensional <sup>19</sup>F NMR experiments were recorded at 37 °C on a 600 MHz spectrometer with an H(F)CN room-temperature probe (number of transients, 800) (scan width, 150 ppm). Compounds were prepared at a final concentration of 100 μM in a solution comprising 100 mM HEPES, pH 7.4, 100 μM 5-fluorotryptophan, 1 mM reduced <span class="smallcaps smallerCapital">l</span>-glutathione (in blank samples, an equivalent volume of HEPES solution was added), 40% DMSO, and 10% D<sub>2</sub>O. All samples were incubated at 37 °C for 16 h, and the data was processed and analyzed using MestreNova 10.0.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Western Blotting in MDA-MB-231 Breast Cancer Cells and MV4-11 AML Cells</h4><div class="NLM_p">All cells were lysed with radioimmunoprecipitation assay (RIPA) buffer: 20 mM Tris, pH 7.4, 150 mM NaCl, 0.5% deoxycholate, 1% Triton X-100, and 0.1% sodium dodecyl sulfate (SDS). Total protein was measured using a bicinchoninic acid assay (Sigma-Aldrich). In each assay, clarified protein was resolved on a 4–15% polyacrylamide–SDS gel and transferred to a poly(vinylidene difluoride) (PVDF) membrane (Bio-Rad). The membranes were blocked with a 5% solution of skimmed milk powder in TBST and incubated for ≥1 h followed by an overnight incubation at 4 °C in primary antibody 1:1000 dilution. Blots were probed with antibodies against pSTAT5, total STAT5, c-myc, Bcl2, and cleaved PARP. β actin (Santa Cruz Biotechnology, #SC-835) was used as a loading control. The PVDF membrane was washed with TBST (three times, 5 min each).</div><div class="NLM_p last">A horseradish peroxidase (HRP)-conjugated goat antimouse immunoglobulin G (IgG) secondary antibody (Cell Signaling, #7076S), a fluorescently labeled secondary antibody antimouse IgG (H+L), F(ab′)<sub>2</sub> fragment (Alexa Fluor 488 Conjugate, #4408), or an antirabbit IgG (H+L), F(ab′)<sub>2</sub> fragment (Alexa Fluor 647 Conjugate, #4414) was applied to the membrane at a 1:5000 dilution and incubated for 1 h at room temperature. The blots were then rinsed again three times in TBST for 10 min each. Bands were visualized using clarity western enhanced chemilumescent (ECL) substrate luminol/enhancer solution and peroxide solution (1:1) for HRP secondary antibody according to the manufacturer’s instructions (Bio-Rad) and analyzed using Image Lab software (Bio-Rad).</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Western Blotting in Glioblastoma Brain Tumor Stem Cells (GBM BTSCs)</h4><div class="NLM_p last">For protein analysis following drug treatment, BTSCs were dissociated to single cells and treated with drug or vehicle (DMSO) for 24 h. Cell pellets were lysed in RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% Na deoxycholate, and 1% NP40) and cOmplete Protease Inhibitor Cocktail Tablets (Roche); 20 μg of protein lysate was separated by SDS-polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane according to standard protocols. Membranes were blocked in Tris-buffered saline with 5% nonfat dry milk and incubated overnight with a primary antibody at 4 °C followed by a 1 h incubation with the appropriate horseradish peroxidase-conjugated secondary antibody. Images were acquired on an Amersham imager 600 using Amersham ECL Select Western Blotting Detection Reagent. Primary antibodies: pSTAT3 (anti-phosphotyrosine 705 STAT3 antibody, Cell Signaling #9145S); STAT3 (1:1000, Santa Cruz Biotechnology, SC-8019); actin (1:2000; Santa Cruz Biotechnology, SC-1615). Secondary antibodies: donkey antimouse (1:5000, Millipore); donkey antirabbit (1:5000, Millipore); donkey antigoat (1:5000, Millipore).</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Determination of Half-Life and Intrinsic Clearance in Mouse Hepatocytes</h4><div class="NLM_p last">Bioanalytical evaluation of in vitro half-lives and rates of intrinsic clearance in mouse hepatocytes was performed at Pharmaron using a liquid chromatography system (Shimadzu) and an API 5500 mass spectrometer (AB Inc., Canada) with an electrospray ionization (ESI) interface. The LC system was equipped with a Phenomenex Synergi 4 μm Hydro-PR 80A (2.0 × 30 mm<sup>2</sup>) column, through which 5 μL injections were made, eluting at 0.65 mL/min at 25 °C, with a mobile phase consisting of (A) Milli-Q water with 0.1% (v/v) formic acid and (B) acetonitrile with 0.1% (v/v) formic acid. Gradients were run over 2.0 min as follows: (A/B, 95:5, 0.0–0.3 min → 0:100, 0.3–0.8 min → 95:5, 1.2–1.5 min → 2.0 min). The MS was equipped with a turbo spray ion source, detecting samples with ionspray voltages of +5500 V (positive MRM) and −4500 V (negative MRM), and using the additional instrument parameters of temperature 500 °C, collision gas 6.0 L/min, curtain gas 30 L/min, nebulize gas 50 L/min, and auxiliary gas 50 L/min. Hepatocytes were sourced from male ICR/CD-1 mice (BioreclamationIVT #M00505, Lot no. XNN) and cryopreserved until used. Calculations were carried out using Excel (Microsoft), and peak areas were determined using the extracted ion chromatograms. The in vitro half-lives of each compound were calculated using regression analysis of the %parent disappearance versus time curve and the following equation: <i>t</i><sub>1/2</sub> = 0.693/<i>k</i>, where <i>t</i><sub>1/2</sub> is the half-life (min) and <i>k</i> is the rate constant (min<sup>–1</sup>). Conversion of the half-life to the in vitro intrinsic clearance (CL<sub>int</sub>, μL/min per 10<sup>6</sup> cells) was done using the following equation: CL<sub>int</sub> = <i>kV</i>/<i>N</i>, where <i>V</i> is the incubation volume (200 μL) and <i>N</i> is the number of hepatocytes per well (0.5 × 10<sup>6</sup>).</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Mouse Plasma Protein Binding Assay</h4><div class="NLM_p last">Determination of protein binding in mouse plasma was performed at Pharmaron using a liquid chromatography system (Shimadzu) and an API 4000 mass spectrometer (AB Inc., Canada) with an electrospray ionization (ESI) interface. The LC system was equipped with a Phenomenex Synergi 4.0 μm Hydro-RP 80A (2.0 × 30 mm<sup>2</sup>) new column, through which 10 μL injections were made, eluting at 0.65 mL/min at room temperature. The mobile phase consisted of (A) Milli-Q water with 0.1% (v/v) formic acid and (B) acetonitrile with 0.1% (v/v) formic acid. Gradients were run over 1.4 min and proceeded as follows: (A/B, 95:5 → 0:100, 0.0–0.8 min, 0:100, 0.8–1.1 min, 0:100 → 95:5, 1.1–1.2 min, 95:5, 1.2–1.4 min). The MS was equipped with a turbo spray ion source, detecting samples with an ionspray voltage of −4500 V (negative MRM), and using the additional instrument parameters of temperature 500 °C, collision gas 6.0 L/min, curtain gas 30 L/min, nebulize gas 50 L/min, and auxiliary gas 50 L/min. Plasma from male and female CD-1 mice (BioreclamationIVT) was stored at −80 °C until required. Ketoconazole was used as a control. Experiments were run in duplicate, and calculations were carried out using Microsoft Excel. Concentrations of the test compound in the buffer and plasma chambers were determined from peak area ratios.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Determination of Experimental Log <i>D</i><sub>7.4</sub></h4><div class="NLM_p last">Determination of experimental Log <i>D</i><sub>7.4</sub> was performed at Pharmaron using a liquid chromatography system (Shimadzu) and an API 4000 mass spectrometer (AB Inc., Canada) with an electrospray ionization (ESI) interface. The LC system was equipped with a Phenomenex Synergi 4.0 μm Hydro-RP 80A (2.0 × 30 mm<sup>2</sup>) new column coupled with a preguard, through which 10 μL injections were made, eluting at 0.65 mL/min at room temperature. The mobile phase consisted of (A) Milli-Q water with 0.1% (v/v) formic acid and (B) acetonitrile with 0.1% (v/v) formic acid. Gradients were run over 1.4 min and proceeded as follows: (A/B, 95:5 → 0:100, 0.0–0.8 min, 0:100, 0.8–1.1 min, 0:100 → 95:5, 1.1–1.2 min, 95:5, 1.2–1.4 min). The MS was equipped with a turbo spray ion source, detecting samples with an ionspray voltage of +5500 V (positive MRM), and using the additional instrument parameters of temperature 500 °C, collision gas 10 L/min, curtain gas 30 L/min, nebulize gas 55 L/min, and auxiliary gas 55 L/min. Progesterone was used as a control, and experiments were performed in duplicate.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Permeability Determination Using a Lipid-PAMPA</h4><div class="NLM_p last">Determination of compound cell permeability using a parallel artificial membrane permeability assay (PAMPA) was performed at Pharmaron using a liquid chromatography system (Shimadzu) and an API 4000 mass spectrometer (AB Inc., Canada) with an electrospray ionization (ESI) interface. The LC system was equipped with a Phenomenex Synergi 4 μm Hydro-PR 80A (2.0 × 30 mm<sup>2</sup>) column, through which 10 μL injections were made, eluting at 0.65 mL/min at 25 °C, with a mobile phase consisting of (A) Milli-Q water with 0.1% (v/v) formic acid and (B) acetonitrile with 0.1% (v/v) formic acid. Two gradients were run over 1.4 min (run 1) and 2.0 min (run 2). Run 1 proceeded as follows: (A/B, 95:5 → 0:100, 0.0–0.3 min, 0:100 → 95:5, 0.8–1.1 min, 95:5, 1.1–1.4 min). Run 2 proceeded as follows: (A/B, 95:5, 0.0–0.3 min, 95:5 → 0:100, 0.3–0.8 min, 0:100 → 95:5, 1.2–1.5 min, 95:5, 1.5–2.0 min). The MS was equipped with a turbo spray ion source, detecting samples with ionspray voltages of +5500 V (positive MRM) and −4500 V (negative MRM), and using the additional instrument parameters of temperature 500 °C, collision gas 6.0 L/min, curtain gas 30 L/min, nebulize gas 50 L/min, and auxiliary gas 50 L/min. Experiments were conducted in triplicate, and methotrexate and testosterone were used as positive controls.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Permeability Determination Using a Caco-2 Assay</h4><div class="NLM_p last">Determination of compound cell permeability using a Caco-2 cell line was performed at Pharmaron using a liquid chromatography system (Shimadzu) and API 5500 and API 4000 mass spectrometers (AB Inc., Canada) with an electrospray ionization (ESI) interface. The LC systems were equipped with a Phenomenex Kinetex 1.7 μm C8 100A (2.1 × 30 mm<sup>2</sup>) column and a Phenomenex Kinetex 1.7 μm C18 100A (2.1 × 30 mm<sup>2</sup>) column, through which 10 and 3.0 μL injections were made, eluting at 0.65 mL/min at 40 and 25 °C. The mobile phase consisted of (A) Milli-Q water with 0.1% (v/v) formic acid and (B) acetonitrile with 0.1% (v/v) formic acid. Two gradients were run over 2.0 min (run 1) and 1.4 min (run 2). Run 1 (10 μL injection) proceeded as follows: (A/B, 95:5, 0.0–0.3 min, 95:5 → 0:100, 0.3–0.8 min, 0:100 → 95:5, 1.2–1.5 min, 95:5, 1.5–2.0 min). Run 2 (3.0 μL injection) proceeded as follows: (A/B, 95:5 → 0:100, 0.0–0.8 min, 0:100 → 95:5, 1.1–1.2 min, 95:5, 1.2–1.4 min). The MS was equipped with a turbo spray ion source, detecting samples with ionspray voltages of +5500 V (positive MRM) and −4500 V (negative MRM), and using the additional instrument parameters of temperature 500 °C, collision gas 6.0 L/min, curtain gas 30 L/min, nebulize gas 50 L/min, and auxiliary gas 50 L/min. Transepithelial electrical resistance (TEER) was measured across the monolayer using a Millicell Epithelial Volt-Ohm measuring system (Millipore), and the plate was returned to the incubator. TEER values were calculated using the following equation: TEER (Ω cm<sup>2</sup>) = TEER measurement (Ω) × membrane area (cm<sup>2</sup>). Studies were run in duplicate, and Digoxin, Prazosin, and Propranolol were used as control compounds. Internal standards consisted of 100 nM alprazolam with 200 nM labetalol (positive mode) and 2.0 μM ketoprofen with 200 nM labetalol (negative mode). Lucifer Yellow fluorescence to monitor monolayer integrity was measured in a fluorescence plate reader at 485 nm excitation and 530 nm emission.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Inhibition of Histone Deacetylases (HDACs)</h4><div class="NLM_p last">Biochemical HDAC assays were performed at Nanosyn using microfluidic detection technology (electrophoretic mobility shift assay). Full-length recombinant human HDACs 3, 6, 8, and 11 were produced in an SF9 baculoviral system. Reactions were assembled in 384-well plates (total volume 20 μL), and the test compounds were serially prediluted in DMSO and added by an acoustic dispenser (Labcyte550) directly to the reaction buffer comprising 100 mM HEPES (pH 7.5), 25 mM KCl, 0.1% bovine serum albumin, 0.01% Triton X-100, and enzyme. Final concentrations of HDACs 3, 6, 8, and 11 were 0.5, 60, 5.0, and 10 nM, respectively. Concentration of DMSO was equalized at 1% in all samples. Reactions were initiated by addition of the fluorescently FAM-labeled acetylated peptide substrate to a final concentration of 1 μM with HDACs 3, 6, and 8 and 100 μM with HDAC11. Change in the relative fluorescence intensity of the substrate and product peaks is the parameter measured, reflecting the enzyme activity. Activity in each test sample was determined as the product sum ratio (PSR): <i>P</i>/(<i>S</i> + <i>P</i>), where <i>P</i> is the peak height of the product and <i>S</i> is the peak height of the substrate. For each compound, enzyme activity was measured at 12 concentrations spaced by 3× dilution intervals, ranging from 30.0 to 0.0001694 μM. Reference compound <b>JNJ-26481585</b> (Quisinostat) was tested in an identical manner. Negative control samples (0% inhibition in the absence of inhibitor, DMSO only) and positive control samples (100% inhibition in the absence of enzyme) were assembled in replicates of four and were used to calculate % inhibition values in the presence of compounds. Percent inhibition (<i>P</i><sub>inh</sub>) was determined using the following equation: <i>P</i><sub>inh</sub> = (PSR<sub>0%</sub> – PSR<sub>inh</sub>)/(PSR<sub>0%</sub> – PSR<sub>100%</sub>) × 100, where PSR<sub>inh</sub> is the product sum ratio in the presence of inhibitor, PSR<sub>0%</sub> is the product sum ratio in the absence of inhibitor, and PSR<sub>100%</sub> is the product sum ratio in 100% inhibition control samples. To determine IC<sub>50</sub> values, the inhibition curves (<i>P</i><sub>inh</sub> vs inhibitor concentration) were fitted by a four-parameter sigmoid dose-response model using XLfit software (IDBS).</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Molecular Modeling</h4><div class="NLM_p last">Receptor and ligand preparation protocols utilized molecular visualization software PyMOL v.1.7.4.5, advanced cross-platform molecular editing software Avagadro v.1.2.0, as well as graphical user interface software AutoDockTools (ADT) v.4.2.6. The docking simulations were performed by AutoDock Vina v.1.1.2. Analyses of the docking results were also visualized by PyMOL v.1.7.4.5. Three-dimensional crystal structures of the human HDAC isoforms were retrieved from the RCSB protein data bank (<a href="http://www.rcsb.org" class="extLink">www.rcsb.org</a>): <i>h</i>HDAC3 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4A69">4A69</a>), <i>h</i>HDAC6 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EDU">5EDU</a>), and <i>h</i>HDAC8 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T64">1T64</a>). ADT was used to remove water molecules, assign polar hydrogens, unite atom Kollman charges, and assign Gasteiger charges and solvation parameters. ADT does not naturally recognize charged inorganic heteroatoms; hence, the charges on zinc in all three enzymes were manually modeled to +2. These studies utilized three distinct ligands: <b>AES-135</b>, <b>6</b>, and SAHA (Vorinostat). Energy minimization calculations utilizing molecular mechanics and the steepest descent algorithm were used to produce low-energy conformers of each ligand. The grid size was set to 40 × 40 × 40 <i>xyz</i> points, with a grid spacing of 0.497 Å. Binding poses with the most favorable free energy of binding values were visualized using PyMOL.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Pharmacokinetic (PK) Studies</h4><div class="NLM_p">All animal studies were conducted under the guidelines of the National Institute of Health and were approved by the Institutional Animal Care and Use Committee of Indiana University School of Medicine. Animals were maintained under pathogen-free conditions and a 12 h light–dark cycle. NOD SCID γ (NOD.Cg-<i>Prkdc</i><sup><i>scid</i></sup><i>Il2rg</i><sup><i>tm1Wjl</i></sup>/SzJ) or NSG mice were administered 20 mg/kg <b>AES-135</b> IP in Cremophor EL/EtOH (1:1, 4% final volume)/sterile saline, and blood was collected via the tail vein at multiple timepoints between 0.5 and 24 h following administration. <b>AES-135</b> was quantified in plasma using an internal standard (sorafenib), liquid–liquid extraction with ethyl acetate, and HPLC–MS/MS (Agilent HPLC, Applied Biosystems API 4000). The HPLC was run in isocratic mode using acetonitrile/5 mM ammonium acetate (20:80, v/v). The API 4000 was run in negative mode for <b>AES-135</b> (Q1/Q3: 692/192) and positive mode for sorafenib (Q1/Q3, 465/270). The lower limit of quantification was 1 ng/mL using 20 μL of blood or plasma.</div><div class="NLM_p last">Pharmacokinetic parameters for <b>AES-135</b>, including area under the curve (AUC), area under the moment curve (AUMC), and <i>t</i><sub>1/2</sub>, were estimated using noncompartmental methods with Excel. The maximum plasma concentration (<i>C</i><sub>max</sub>) and time of <i>C</i><sub>max</sub> (<i>t</i><sub>max</sub>) were obtained from the data. The AUC from zero to infinity (AUC<sub>0-∞</sub>) was estimated from the AUC<sub>0–<i>t</i></sub> (time zero to the last quantifiable concentration <i>C</i><sub>last</sub>) and the AUC from <i>C</i><sub>last</sub> to infinity, <i>C</i><sub>last</sub>/<i>k</i><sub>el</sub>, where <i>k</i><sub>el</sub> is the rate constant of elimination. The AUMC<sub>0–∞</sub> was estimated in an analogous manner. The systemic clearance (Cl/F, where F = bioavailability) of <b>AES-135</b> was calculated from the dose and AUC<sub>0–∞</sub>. The apparent volume of distribution (Vd<sub>ss</sub>) was estimated by the following equation: (dosage/AUC<sub>0–∞</sub>) × (AUMC<sub>0–∞</sub>/AUC<sub>0–∞</sub>).</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Tumor and Cancer-Associated Fibroblast (CAF) 3D Cocultures</h4><div class="NLM_p last">Patient-derived tumor cells and CAF19 cells were a kind gift from Dr. Anirban Maitra (The Johns Hopkins University). TdTomato-labeled PDAC cells and EGFP-labeled CAFs were resuspended in DMEM media containing 3% Reduced Growth Factor Matrigel (BD Biosciences) and 5% FBS at a cell ratio of 1:4 (tumor/CAF) and fed or treated with <b>AES-135</b> on days 4 and 8 following plating. Both cell populations were quantitated for intensity and area via Thermo ArrayScan at day 12 of coculture.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Orthotopic Tumor Treatment</h4><div class="NLM_p last">All animal studies were conducted under the guidelines of the National Institute of Health and were approved by the Institutional Animal Care and Use Committee of Indiana University School of Medicine. Animals were maintained under pathogen-free conditions and a 12 h light–dark cycle. C57Bl/6 mice (Jackson Laboratory) were orthotopically implanted with 5 × 10<sup>4</sup> KPC2 cells. The mice were randomized into two groups of 10 mice each just before commencing treatment (7 days post implantation). The treatment regime consisted of 50 mg/kg <b>AES-135</b> IP prepared in Cremophor EL/EtOH (1:1, 8% final volume) in sterile PBS. The vehicle mice received Cremophor EL/EtOH (1:1, 8% final volume) in sterile PBS. Both groups were treated 5 days a week for 1 month. Mice were euthanized when they exhibited signs of deterioration such as lack of grooming and appetite, loss of weight and activity, etc. Data was analyzed using Kaplan–Meier curves (GraphPad Prism 6), statistical significance was determined using the log-rank test, and <i>p</i> values <0.05 were considered statistically significant.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52"><a href="/doi/suppl/10.1021/acs.jmedchem.8b01957" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37402" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37402" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b01957" class="ext-link">10.1021/acs.jmedchem.8b01957</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Chemicals and solvents, analytical techniques and chromatography methods; cytotoxicity results of top compounds in breast, AML, CML, MDB, and pancreatic cancer cell lines, GBM BTSCs, and noncancerous human lung fibroblasts; glutathione stability data by HPLC and <sup>19</sup>F NMR; western blots in breast cancer cells, AML cells, and GBM BTSCs; in vitro half-life and intrinsic clearance rates of top compounds in mouse hepatocytes; mouse plasma protein binding assay data; determination of experimental Log <i>D</i><sub>7.4</sub>; PAMPA and Caco-2 permeability data; in vivo PK data and orthotopic tumor treatment data; HDAC inhibition assay data; in silico modeling/docking data; chemical synthesis procedures for all compounds with NMR, LRMS, HRMS, and HPLC data; <sup>1</sup>H NMR spectra for all final compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings for final compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_001.pdf">jm8b01957_si_001.pdf (2.75 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_002.csv">jm8b01957_si_002.csv (1.92 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b01957" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22856" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22856" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melissa L. Fishel</span> - <span class="hlFld-Affiliation affiliation">Department of Pediatrics, Wells
Center for Pediatric Research, 
    Department of Pharmacology
and Toxicology, 
     and , IU School of Medicine, 1044 West Walnut Street, R4 321, Indianapolis, Indiana 46202, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#127f747b617a777e527b673c777667"><span class="__cf_email__" data-cfemail="caa7aca3b9a2afa68aa3bfe4afaebf">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick T. Gunning</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Road, Mississauga, Ontario L5L 1C6, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0654-735X" title="Orcid link">http://orcid.org/0000-0003-0654-735X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9aeafbeee8f3f9f1b4fdeff4f4f3f4fddaefeef5e8f5f4eef5b4f9fb"><span class="__cf_email__" data-cfemail="6c1c0d181e050f07420b19020205020b2c1918031e03021803420f0d">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew
E. Shouksmith</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Road, Mississauga, Ontario L5L 1C6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fenil Shah</span> - <span class="hlFld-Affiliation affiliation">Department of Pediatrics, Wells
Center for Pediatric Research and , IU School of Medicine, 1044 West Walnut Street, R4 321, Indianapolis, Indiana 46202, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle L. Grimard</span> - <span class="hlFld-Affiliation affiliation">Department of Pediatrics, Wells
Center for Pediatric Research and , IU School of Medicine, 1044 West Walnut Street, R4 321, Indianapolis, Indiana 46202, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Justyna M. Gawel</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Road, Mississauga, Ontario L5L 1C6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yasir S. Raouf</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Road, Mississauga, Ontario L5L 1C6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mulu Geletu</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Road, Mississauga, Ontario L5L 1C6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Angelika Berger-Becvar</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Road, Mississauga, Ontario L5L 1C6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elvin D. de Araujo</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Road, Mississauga, Ontario L5L 1C6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">H. Artee Luchman</span> - <span class="hlFld-Affiliation affiliation">Hotchkiss
Brain Institute and Department of Cell Biology and Anatomy, University of Calgary, Calgary, Alberta T2N 1N4, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William L. Heaton</span> - <span class="hlFld-Affiliation affiliation">Huntsman
Cancer Institute, Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, Utah 84112, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Bakhshinyan</span> - <span class="hlFld-Affiliation affiliation">McMaster
Stem Cell and Cancer Research Institute, McMaster University, Hamilton, Ontario L8S 4L8, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ashley A. Adile</span> - <span class="hlFld-Affiliation affiliation">McMaster
Stem Cell and Cancer Research Institute, McMaster University, Hamilton, Ontario L8S 4L8, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chitra Venugopal</span> - <span class="hlFld-Affiliation affiliation">McMaster
Stem Cell and Cancer Research Institute, McMaster University, Hamilton, Ontario L8S 4L8, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas O’Hare</span> - <span class="hlFld-Affiliation affiliation">Huntsman
Cancer Institute, Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, Utah 84112, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael W. Deininger</span> - <span class="hlFld-Affiliation affiliation">Huntsman
Cancer Institute, Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, Utah 84112, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sheila K. Singh</span> - <span class="hlFld-Affiliation affiliation">McMaster
Stem Cell and Cancer Research Institute, McMaster University, Hamilton, Ontario L8S 4L8, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen F. Konieczny</span> - <span class="hlFld-Affiliation affiliation">Department
of Biological Sciences, Purdue University, West Lafayette, Indiana 47907, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Samuel Weiss</span> - <span class="hlFld-Affiliation affiliation">Hotchkiss
Brain Institute and Department of Cell Biology and Anatomy, University of Calgary, Calgary, Alberta T2N 1N4, Canada</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>A.E.S. synthesized and characterized the compounds, provided glutathione stability data by HPLC, and summarized all data. F.S., M.L.G., S.F.K., and M.L.F. conducted the in vivo PK experiments and tumor treatment studies and conducted cytotoxicity assays in pancreatic cancer cells. J.M.G., M.G., and A.B.-B. conducted cytotoxicity assays and western blot studies in breast, AML, and CML cell lines and human lung fibroblasts. Y.S.R. conducted in silico docking analysis of top compounds. E.D.d.A. provided glutathione stability data by 19F NMR. H.A.L. and S.W. conducted cytotoxicity assays and western blot studies in GBM BTSCs. W.L.H., T.O., and M.W.D. conducted cytotoxicity assays in CML cell lines. D.B., A.A.A., C.V., and S.K.S. conducted cytotoxicity assays in MDB cell lines. A.E.S. and P.T.G. wrote the manuscript with input from all authors.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e4158-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i54">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05746" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05746" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the Leukemia and Lymphoma Society of Canada (LLSC) and a Mitacs Accelerate grant from the University of Toronto (A.E.S and P.T.G.), as well as support from the Indiana Clinical and Translational Sciences Institute funded, in part, by Award Number UL1TR001108 from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award (M.L.F.), by the National Cancer Institute CA122298 (M.L.F.), CA167291, to M.L.F., and Jeff Gordon Children’s Foundation (M.L.F.). H.A.L., S.W., and P.T.G. shared grants from the Stem Cell Network and Alberta Innovates Health Solutions. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors also would like to thank Lubna Abu-Jazar from the University of Toronto for technical assistance, Nanosyn (Santa Clara, CA) for EMSA data, and Pharmaron (Beijing, China) for various PK analyses.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">HAT</td><td class="NLM_def"><p class="first last">histone acetyltransferase</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">BTSC</td><td class="NLM_def"><p class="first last">brain tumor stem cell</p></td></tr><tr><td class="NLM_term">PFB</td><td class="NLM_def"><p class="first last">pentafluorobenzyl/perfluorobenzyl</p></td></tr><tr><td class="NLM_term">GBM</td><td class="NLM_def"><p class="first last">glioblastoma multiforme</p></td></tr><tr><td class="NLM_term">MDB</td><td class="NLM_def"><p class="first last">medulloblastoma</p></td></tr><tr><td class="NLM_term">EMSA</td><td class="NLM_def"><p class="first last">electrophoretic mobility shift assay</p></td></tr><tr><td class="NLM_term">HEPES</td><td class="NLM_def"><p class="first last">(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)</p></td></tr><tr><td class="NLM_term">CAF</td><td class="NLM_def"><p class="first last">cancer-associated fibroblast</p></td></tr><tr><td class="NLM_term">KPC</td><td class="NLM_def"><p class="first last">KrasLSL.G12D/+, p53R172H/+, PdxCretg/+</p></td></tr><tr><td class="NLM_term">PDAC</td><td class="NLM_def"><p class="first last">pancreatic ductal adenocarcinoma</p></td></tr><tr><td class="NLM_term">PanIN</td><td class="NLM_def"><p class="first last">pancreatic intraepithelial neoplasia</p></td></tr><tr><td class="NLM_term">LRMS</td><td class="NLM_def"><p class="first last">low-resolution mass spectrometry</p></td></tr><tr><td class="NLM_term">HRMS</td><td class="NLM_def"><p class="first last">high-resolution mass spectrometry</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i56">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41762" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41762" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 51 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manji, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olive, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saenger, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberstein, P.</span></span> <span> </span><span class="NLM_article-title">Current and Emerging Therapies in Metastatic Pancreatic Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1670</span>– <span class="NLM_lpage">1678</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-2319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1158%2F1078-0432.CCR-16-2319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=28373365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A280%3ADC%252BC1cvkt1aisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=1670-1678&author=G.+A.+Manjiauthor=K.+P.+Oliveauthor=Y.+M.+Saengerauthor=P.+Oberstein&title=Current+and+Emerging+Therapies+in+Metastatic+Pancreatic+Cancer&doi=10.1158%2F1078-0432.CCR-16-2319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Current and Emerging Therapies in Metastatic Pancreatic Cancer</span></div><div class="casAuthors">Manji Gulam Abbas; Saenger Yvonne M; Oberstein Paul; Olive Kenneth P</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1670-1678</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">Targeted therapies and immunotherapy have changed the face of multiple solid malignancies, including metastatic melanoma and lung cancer, but no such therapies exist for pancreatic ductal adenocarcinoma (PDAC) despite the knowledge of key mutations and an increasing understanding of the tumor microenvironment.  Until now, most clinical studies have not been biomarker driven in this highly immunosuppressive and heterogeneous cancer.  Ongoing basic and translational studies are better classifying the disease in hopes of identifying critical pathways that distinguish the unique PDAC subtypes, which will lead to personalized therapies.  In this review, we discuss the current treatment options for metastatic pancreatic cancer and highlight current ongoing clinical trials, which aim to target the stroma and the immune microenvironment either alone or in combination with standard chemotherapy.  Identifying biomarkers and key resistance pathways and targeting these pathways in a personalized manner in combination with chemotherapy are likely to yield a more immediate and durable clinical benefit.  Clin Cancer Res; 23(7); 1670-8. ©2017 AACRSee all articles in this CCR Focus section, "Pancreatic Cancer: Challenge and Inspiration."</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRS3gZgDC0xqLGbPKh4T9eAfW6udTcc2eaYjkW2xvSR27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvkt1aisA%253D%253D&md5=eeee384ae0ab37ff2afc92d33684869a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2319%26sid%3Dliteratum%253Aachs%26aulast%3DManji%26aufirst%3DG.%2BA.%26aulast%3DOlive%26aufirst%3DK.%2BP.%26aulast%3DSaenger%26aufirst%3DY.%2BM.%26aulast%3DOberstein%26aufirst%3DP.%26atitle%3DCurrent%2520and%2520Emerging%2520Therapies%2520in%2520Metastatic%2520Pancreatic%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D1670%26epage%3D1678%26doi%3D10.1158%2F1078-0432.CCR-16-2319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rahib, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aizenberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleshman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matrisian, L. M.</span></span> <span> </span><span class="NLM_article-title">Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">2913</span>– <span class="NLM_lpage">2921</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-0155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1158%2F0008-5472.CAN-14-0155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=24840647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovFalur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=2913-2921&author=L.+Rahibauthor=B.+D.+Smithauthor=R.+Aizenbergauthor=A.+B.+Rosenzweigauthor=J.+M.+Fleshmanauthor=L.+M.+Matrisian&title=Projecting+Cancer+Incidence+and+Deaths+to+2030%3A+The+Unexpected+Burden+of+Thyroid%2C+Liver%2C+and+Pancreas+Cancers+in+the+United+States&doi=10.1158%2F0008-5472.CAN-14-0155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States</span></div><div class="casAuthors">Rahib, Lola; Smith, Benjamin D.; Aizenberg, Rhonda; Rosenzweig, Allison B.; Fleshman, Julie M.; Matrisian, Lynn M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2913-2921</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cancer incidence and deaths in the United States were projected for the most common cancer types for the years 2020 and 2030 based on changing demographics and the av. annual percentage changes in incidence and death rates.  Breast, prostate, and lung cancers will remain the top cancer diagnoses throughout this time, but thyroid cancer will replace colorectal cancer as the fourth leading cancer diagnosis by 2030, and melanoma and uterine cancer will become the fifth and sixth most common cancers, resp.  Lung cancer is projected to remain the top cancer killer throughout this time period.  However, pancreas and liver cancers are projected to surpass breast, prostate, and colorectal cancers to become the second and third leading causes of cancer-related death by 2030, resp.  Advances in screening, prevention, and treatment can change cancer incidence and/or death rates, but it will require a concerted effort by the research and healthcare communities now to effect a substantial change for the future.  Cancer Res; 74(11); 2913-21. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHGt66quENkbVg90H21EOLACvtfcHk0liBHnANISzTAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovFalur0%253D&md5=893d688f1ccba88ee094b743f7e4f152</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-0155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-0155%26sid%3Dliteratum%253Aachs%26aulast%3DRahib%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DAizenberg%26aufirst%3DR.%26aulast%3DRosenzweig%26aufirst%3DA.%2BB.%26aulast%3DFleshman%26aufirst%3DJ.%2BM.%26aulast%3DMatrisian%26aufirst%3DL.%2BM.%26atitle%3DProjecting%2520Cancer%2520Incidence%2520and%2520Deaths%2520to%25202030%253A%2520The%2520Unexpected%2520Burden%2520of%2520Thyroid%252C%2520Liver%252C%2520and%2520Pancreas%2520Cancers%2520in%2520the%2520United%2520States%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D2913%26epage%3D2921%26doi%3D10.1158%2F0008-5472.CAN-14-0155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Cancer Statistics, 2016</span>. <i>CA—Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.3322/caac.21332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.3322%2Fcaac.21332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=26742998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A280%3ADC%252BC28rot1Kjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2016&pages=7-30&author=R.+L.+Siegelauthor=K.+D.+Millerauthor=A.+Jemal&title=Cancer+Statistics%2C+2016&doi=10.3322%2Fcaac.21332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2016</span></div><div class="casAuthors">Siegel Rebecca L; Miller Kimberly D; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival.  Incidence data were collected by the National Cancer Institute (Surveillance, Epidemiology, and End Results [SEER] Program), the Centers for Disease Control and Prevention (National Program of Cancer Registries), and the North American Association of Central Cancer Registries.  Mortality data were collected by the National Center for Health Statistics.  In 2016, 1,685,210 new cancer cases and 595,690 cancer deaths are projected to occur in the United States.  Overall cancer incidence trends (13 oldest SEER registries) are stable in women, but declining by 3.1% per year in men (from 2009-2012), much of which is because of recent rapid declines in prostate cancer diagnoses.  The cancer death rate has dropped by 23% since 1991, translating to more than 1.7 million deaths averted through 2012.  Despite this progress, death rates are increasing for cancers of the liver, pancreas, and uterine corpus, and cancer is now the leading cause of death in 21 states, primarily due to exceptionally large reductions in death from heart disease.  Among children and adolescents (aged birth-19 years), brain cancer has surpassed leukemia as the leading cause of cancer death because of the dramatic therapeutic advances against leukemia.  Accelerating progress against cancer requires both increased national investment in cancer research and the application of existing cancer control knowledge across all segments of the population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKAn5ROFAaRS86Js-BCLiifW6udTcc2eYekDorDxH7s7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rot1Kjug%253D%253D&md5=2d4030a531945c5ebaaab181bfd80457</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21332%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520Statistics%252C%25202016%26jtitle%3DCA%25E2%2580%2594Cancer%2520J.%2520Clin.%26date%3D2016%26volume%3D66%26spage%3D7%26epage%3D30%26doi%3D10.3322%2Fcaac.21332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leary, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angenendt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mankoo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamiyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calhoun, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolskaya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolsky, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartigan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffee, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goggins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobuzio-Donahue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eshleman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruban, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karchin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmigiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velculescu, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzler, K. W.</span></span> <span> </span><span class="NLM_article-title">Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>321</i></span>,  <span class="NLM_fpage">1801</span>– <span class="NLM_lpage">1806</span>, <span class="refDoi"> DOI: 10.1126/science.1164368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1126%2Fscience.1164368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=18772397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFCrtLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2008&pages=1801-1806&author=S.+Jonesauthor=X.+Zhangauthor=D.+W.+Parsonsauthor=J.+C.+Linauthor=R.+J.+Learyauthor=P.+Angenendtauthor=P.+Mankooauthor=H.+Carterauthor=H.+Kamiyamaauthor=A.+Jimenoauthor=S.+M.+Hongauthor=B.+Fuauthor=M.+T.+Linauthor=E.+S.+Calhounauthor=M.+Kamiyamaauthor=K.+Walterauthor=T.+Nikolskayaauthor=Y.+Nikolskyauthor=J.+Hartiganauthor=D.+R.+Smithauthor=M.+Hidalgoauthor=S.+D.+Leachauthor=A.+P.+Kleinauthor=E.+M.+Jaffeeauthor=M.+Gogginsauthor=A.+Maitraauthor=C.+Iacobuzio-Donahueauthor=J.+R.+Eshlemanauthor=S.+E.+Kernauthor=R.+H.+Hrubanauthor=R.+Karchinauthor=N.+Papadopoulosauthor=G.+Parmigianiauthor=B.+Vogelsteinauthor=V.+E.+Velculescuauthor=K.+W.+Kinzler&title=Core+Signaling+Pathways+in+Human+Pancreatic+Cancers+Revealed+by+Global+Genomic+Analyses&doi=10.1126%2Fscience.1164368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses</span></div><div class="casAuthors">Jones, Sian; Zhang, Xiaosong; Parsons, D. Williams; Lin, Jimmy Cheng-Ho; Leary, Rebecca J.; Angenendt, Philipp; Mankoo, Parminder; Carter, Hannah; Kamiyama, Hirohiko; Jimeno, Antonio; Hong, Seung-Mo; Fu, Baojin; Lin, Ming-Tseh; Calhoun, Eric S.; Kamiyama, Mihoko; Walter, Kimberly; Nikolskaya, Tatiana; Nikolsky, Yuri; Hartigan, James; Smith, Douglas R.; Hidalgo, Manuel; Leach, Steven D.; Klein, Alison P.; Jaffee, Elizabeth M.; Goggins, Michael; Maitra, Anirban; Iacobuzio-Donahue, Christine; Eshleman, James R.; Kern, Scott E.; Hruban, Ralph H.; Karchin, Rachel; Papadopoulos, Nickolas; Parmigiani, Giovanni; Vogelstein, Bert; Velculescu, Victor E.; Kinzler, Kenneth W.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">5897</span>),
    <span class="NLM_cas:pages">1801-1806</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">There are currently few therapeutic options for patients with pancreatic cancer, and new insights into the pathogenesis of this lethal disease are urgently needed.  Toward this end, the authors performed a comprehensive genetic anal. of 24 pancreatic cancers.  The authors first detd. the sequences of 23,219 transcripts, representing 20,661 protein-coding genes, in these samples.  Then, the authors searched for homozygous deletions and amplifications in the tumor DNA by using microarrays contg. probes for ~106 single-nucleotide polymorphisms.  It was found that pancreatic cancers contain an av. of 63 genetic alterations, the majority of which are point mutations.  These alterations defined a core set of 12 cellular signaling pathways and processes that were each genetically altered in 67 to 100% of the tumors.  Anal. of these tumors' transcriptomes with next-generation sequencing-by-synthesis technologies provided independent evidence for the importance of these pathways and processes.  These data indicate that genetically altered core pathways and regulatory processes only become evident once the coding regions of the genome are analyzed in depth.  Dysregulation of these core pathways and processes through mutation can explain the major features of pancreatic tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopWEan4wZjSLVg90H21EOLACvtfcHk0liBHnANISzTAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFCrtLrL&md5=62aa344f0bd3ba335cf6a8263ebbf29a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.1164368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1164368%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DParsons%26aufirst%3DD.%2BW.%26aulast%3DLin%26aufirst%3DJ.%2BC.%26aulast%3DLeary%26aufirst%3DR.%2BJ.%26aulast%3DAngenendt%26aufirst%3DP.%26aulast%3DMankoo%26aufirst%3DP.%26aulast%3DCarter%26aufirst%3DH.%26aulast%3DKamiyama%26aufirst%3DH.%26aulast%3DJimeno%26aufirst%3DA.%26aulast%3DHong%26aufirst%3DS.%2BM.%26aulast%3DFu%26aufirst%3DB.%26aulast%3DLin%26aufirst%3DM.%2BT.%26aulast%3DCalhoun%26aufirst%3DE.%2BS.%26aulast%3DKamiyama%26aufirst%3DM.%26aulast%3DWalter%26aufirst%3DK.%26aulast%3DNikolskaya%26aufirst%3DT.%26aulast%3DNikolsky%26aufirst%3DY.%26aulast%3DHartigan%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DD.%2BR.%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DLeach%26aufirst%3DS.%2BD.%26aulast%3DKlein%26aufirst%3DA.%2BP.%26aulast%3DJaffee%26aufirst%3DE.%2BM.%26aulast%3DGoggins%26aufirst%3DM.%26aulast%3DMaitra%26aufirst%3DA.%26aulast%3DIacobuzio-Donahue%26aufirst%3DC.%26aulast%3DEshleman%26aufirst%3DJ.%2BR.%26aulast%3DKern%26aufirst%3DS.%2BE.%26aulast%3DHruban%26aufirst%3DR.%2BH.%26aulast%3DKarchin%26aufirst%3DR.%26aulast%3DPapadopoulos%26aufirst%3DN.%26aulast%3DParmigiani%26aufirst%3DG.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26atitle%3DCore%2520Signaling%2520Pathways%2520in%2520Human%2520Pancreatic%2520Cancers%2520Revealed%2520by%2520Global%2520Genomic%2520Analyses%26jtitle%3DScience%26date%3D2008%26volume%3D321%26spage%3D1801%26epage%3D1806%26doi%3D10.1126%2Fscience.1164368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biankin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waddell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassahn, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingras, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthuswamy, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patch, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardiner, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harliwong, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idrisoglu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nourse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nourbakhsh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gongora, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pajic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarlett, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinho, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nones, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christ, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruxner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloonan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolle, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mead, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colvin, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagrial, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chantrill, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mawson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samra, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kench, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrett, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, N. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeps, N.</span></span>; <span class="NLM_contrib-group">Australian Pancreatic Cancer Genome Initiative</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakkar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzny, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunicardi, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhay, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timms, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Borja, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denroche, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yung, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onetto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhopadhyay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, M.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruban, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobuzio-Donahue, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulick, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfgang, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawlor, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scardoni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortora, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempero, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Mancera, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Largaespada, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessels, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rust, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuveson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musgrove, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eshleman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPherson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimmond, S. M.</span></span> <span> </span><span class="NLM_article-title">Pancreatic Cancer Genomes Reveal Aberrations in Axon Guidance Pathway Genes</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>491</i></span>,  <span class="NLM_fpage">399</span>– <span class="NLM_lpage">405</span>, <span class="refDoi"> DOI: 10.1038/nature11547</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1038%2Fnature11547" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=23103869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOmt7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=491&publication_year=2012&pages=399-405&author=A.+V.+Biankinauthor=N.+Waddellauthor=K.+S.+Kassahnauthor=M.-C.+Gingrasauthor=L.+B.+Muthuswamyauthor=A.+L.+Johnsauthor=D.+K.+Millerauthor=P.+J.+Wilsonauthor=A.-M.+Patchauthor=J.+Wuauthor=D.+K.+Changauthor=M.+J.+Cowleyauthor=B.+B.+Gardinerauthor=S.+Songauthor=I.+Harliwongauthor=S.+Idrisogluauthor=C.+Nourseauthor=E.+Nourbakhshauthor=S.+Manningauthor=S.+Waniauthor=M.+Gongoraauthor=M.+Pajicauthor=C.+J.+Scarlettauthor=A.+J.+Gillauthor=A.+V.+Pinhoauthor=I.+Roomanauthor=M.+Andersonauthor=O.+Holmesauthor=C.+Leonardauthor=D.+Taylorauthor=S.+Woodauthor=Q.+Xuauthor=K.+Nonesauthor=J.+L.+Finkauthor=A.+Christauthor=T.+Bruxnerauthor=N.+Cloonanauthor=G.+Kolleauthor=F.+Newellauthor=M.+Pineseauthor=R.+S.+Meadauthor=J.+L.+Humphrisauthor=W.+Kaplanauthor=M.+D.+Jonesauthor=E.+K.+Colvinauthor=A.+M.+Nagrialauthor=E.+S.+Humphreyauthor=A.+Chouauthor=V.+T.+Chinauthor=L.+A.+Chantrillauthor=A.+Mawsonauthor=J.+S.+Samraauthor=J.+G.+Kenchauthor=J.+A.+Lovellauthor=R.+J.+Dalyauthor=N.+D.+Merrettauthor=C.+Toonauthor=K.+Epariauthor=N.+Q.+Nguyenauthor=A.+Barbourauthor=N.+Zepsauthor=Australian+Pancreatic+Cancer+Genome+Initiativeauthor=N.+Kakkarauthor=F.+Zhaoauthor=Y.+Q.+Wuauthor=M.+Wangauthor=D.+M.+Muznyauthor=W.+E.+Fisherauthor=F.+C.+Brunicardiauthor=S.+E.+Hodgesauthor=J.+G.+Reidauthor=J.+Drummondauthor=K.+Changauthor=Y.+Hanauthor=L.+R.+Lewisauthor=H.+Dinhauthor=C.+J.+Buhayauthor=T.+Beckauthor=L.+Timmsauthor=M.+Samauthor=K.+Begleyauthor=A.+Brownauthor=D.+Paiauthor=A.+Panchalauthor=N.+Buchnerauthor=R.+De+Borjaauthor=R.+E.+Denrocheauthor=C.+K.+Yungauthor=S.+Serraauthor=N.+Onettoauthor=D.+Mukhopadhyayauthor=M.-S.+Tsaoauthor=P.+A.+Shawauthor=G.+M.+Petersenauthor=S.+Gallingerauthor=R.+H.+Hrubanauthor=A.+Maitraauthor=C.+A.+Iacobuzio-Donahueauthor=R.+D.+Schulickauthor=C.+L.+Wolfgangauthor=R.+A.+Morganauthor=R.+T.+Lawlorauthor=P.+Capelliauthor=V.+Corboauthor=M.+Scardoniauthor=G.+Tortoraauthor=M.+A.+Temperoauthor=K.+M.+Mannauthor=N.+A.+Jenkinsauthor=P.+A.+Perez-Manceraauthor=D.+J.+Adamsauthor=D.+A.+Largaespadaauthor=L.+F.+Wesselsauthor=A.+G.+Rustauthor=L.+D.+Steinauthor=D.+A.+Tuvesonauthor=N.+G.+Copelandauthor=E.+A.+Musgroveauthor=A.+Scarpaauthor=J.+R.+Eshlemanauthor=T.+J.+Hudsonauthor=R.+L.+Sutherlandauthor=D.+A.+Wheelerauthor=J.+V.+Pearsonauthor=J.+D.+McPhersonauthor=R.+A.+Gibbsauthor=S.+M.+Grimmond&title=Pancreatic+Cancer+Genomes+Reveal+Aberrations+in+Axon+Guidance+Pathway+Genes&doi=10.1038%2Fnature11547"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes</span></div><div class="casAuthors">Biankin, Andrew V.; Waddell, Nicola; Kassahn, Karin S.; Gingras, Marie-Claude; Muthuswamy, Lakshmi B.; Johns, Amber L.; Miller, David K.; Wilson, Peter J.; Patch, Ann-Marie; Wu, Jianmin; Chang, David K.; Cowley, Mark J.; Gardiner, Brooke B.; Song, Sarah; Harliwong, Ivon; Idrisoglu, Senel; Nourse, Craig; Nourbakhsh, Ehsan; Manning, Suzanne; Wani, Shivangi; Gongora, Milena; Pajic, Marina; Scarlett, Christopher J.; Gill, Anthony J.; Pinho, Andreia V.; Rooman, Ilse; Anderson, Matthew; Holmes, Oliver; Leonard, Conrad; Taylor, Darrin; Wood, Scott; Xu, Christina; Nones, Katia; Lynn Fink, J.; Christ, Angelika; Bruxner, Tim; Cloonan, Nicole; Kolle, Gabriel; Newell, Felicity; Pinese, Mark; Scott Mead, R.; Humphris, Jeremy L.; Kaplan, Warren; Jones, Marc D.; Colvin, Emily K.; Nagrial, Adnan M.; Humphrey, Emily S.; Chou, Angela; Chin, Venessa T.; Chantrill, Lorraine A.; Mawson, Amanda; Samra, Jaswinder S.; Kench, James G.; Lovell, Jessica A.; Daly, Roger J.; Merrett, Neil D.; Toon, Christopher; Epari, Krishna P.; Nguyen, Nam Q.; Barbour, Andrew P.; Zeps, Nikolajs; Brancato, Mary-Anne L.; Rowe, Sarah J.; Simpson, Skye L.; Martyn-Smith, Mona; Thomas, Michelle T.; Pettit, Jessica; Tao, Jiang; DiPietro, Renee; Watson, Clare; Wong, Rachel; Giry-Laterriere, Marc; Musgrove, Elizabeth A.; Sutherland, Robert L.; Grimmond, Sean M.; Patch, Ann-Marie; Nourse, Craig; Anderson, Matthew; Pavlakis, Nick; Guminski, Alex; Asghari, Ray; Pavey, Darren A.; Das, Amitabha; Cosman, Peter H.; Ismail, Kasim; O'Connor, Chelsie; Lam, Vincent W.; McLeod, Duncan; Pleass, Henry C.; Richardson, Arthur; James, Virginia; Cooper, Caroline L.; Joseph, David; Sandroussi, Charbel; Crawford, Michael; Gallagher, James; Texler, Michael; Forrest, Cindy; Laycock, Andrew; Ballal, Mo; Fletcher, David R.; Mukhedkar, Sanjay; Spry, Nigel A.; DeBoer, Bastiaan; Chai, Ming; Beilin, Maria; Feeney, Kynan; Ruszkiewicz, Andrew R.; Worthley, Chris; Tan, Chuan P.; Debrencini, Tamara; Chen, John; Brooke-Smith, Mark E.; Papangelis, Virginia; Tang, Henry; Clouston, Andrew D.; Martin, Patrick; O'Rourke, Thomas J.; Chiang, Amy; Fawcett, Jonathan W.; Slater, Kellee; Yeung, Shinn; Hatzifotis, Michael; Hodgkinson, Peter; Christophi, Christopher; Nikfarjam, Mehrdad; Eshleman, James R.; Hruban, Ralph H.; Maitra, Anirban; Iacobuzio-Donahue, Christine A.; Schulick, Richard D.; Wolfgang, Christopher L.; Morgan, Richard A.; Hodgin, Mary B.; Scarpa, Aldo; Lawlor, Rita T.; Capelli, Paola; Beghelli, Stefania; Corbo, Vincenzo; Scardoni, Maria; Pederzoli, Paolo; Tortora, Giampaolo; Bassi, Claudio; Tempero, Margaret A.; Kakkar, Nipun; Zhao, Fengmei; Wu, Yuan Qing; Wang, Min; Muzny, Donna M.; Fisher, William E.; Charles Brunicardi, F.; Hodges, Sally E.; Reid, Jeffrey G.; Drummond, Jennifer; Chang, Kyle; Han, Yi; Lewis, Lora R.; Dinh, Huyen; Buhay, Christian J.; Beck, Timothy; Timms, Lee; Sam, Michelle; Begley, Kimberly; Brown, Andrew; Pai, Deepa; Panchal, Ami; Buchner, Nicholas; De Borja, Richard; Denroche, Robert E.; Yung, Christina K.; Serra, Stefano; Onetto, Nicole; Mukhopadhyay, Debabrata; Tsao, Ming-Sound; Shaw, Patricia A.; Petersen, Gloria M.; Gallinger, Steven; Iacobuzio-Donahue, Christine A.; Mann, Karen M.; Jenkins, Nancy A.; Perez-Mancera, Pedro A.; Adams, David J.; Largaespada, David A.; Wessels, Lodewyk F. A.; Rust, Alistair G.; Stein, Lincoln D.; Tuveson, David A.; Copeland, Neal G.; Hudson, Thomas J.; Wheeler, David A.; McPherson, John D.; Gibbs, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">491</span>
        (<span class="NLM_cas:issue">7424</span>),
    <span class="NLM_cas:pages">399-405</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pancreatic cancer is a highly lethal malignancy with few effective therapies.  We performed exome sequencing and copy no. anal. to define genomic aberrations in a prospectively accrued clin. cohort (n = 142) of early (stage I and II) sporadic pancreatic ductal adenocarcinoma.  Detailed anal. of 99 informative tumors identified substantial heterogeneity with 2,016 non-silent mutations and 1,628 copy-no. variations.  We define 16 significantly mutated genes, reaffirming known mutations (KRAS, TP53, CDKN2A, SMAD4, MLL3, TGFBR2, ARID1A and SF3B1), and uncover novel mutated genes including addnl. genes involved in chromatin modification (EPC1 and ARID2), DNA damage repair (ATM) and other mechanisms (ZIM2, MAP2K4, NALCN, SLC16A4 and MAGEA6).  Integrative anal. with in vitro functional data and animal models provided supportive evidence for potential roles for these genetic aberrations in carcinogenesis.  Pathway-based anal. of recurrently mutated genes recapitulated clustering in core signalling pathways in pancreatic ductal adenocarcinoma, and identified new mutated genes in each pathway.  We also identified frequent and diverse somatic aberrations in genes described traditionally as embryonic regulators of axon guidance, particularly SLIT/ROBO signalling, which was also evident in murine Sleeping Beauty transposon-mediated somatic mutagenesis models of pancreatic cancer, providing further supportive evidence for the potential involvement of axon guidance genes in pancreatic carcinogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6I8TIAplbi7Vg90H21EOLACvtfcHk0liB1dQIedvvFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOmt7jN&md5=482b61e2d2caec25b5b68aa955f2fb74</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature11547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11547%26sid%3Dliteratum%253Aachs%26aulast%3DBiankin%26aufirst%3DA.%2BV.%26aulast%3DWaddell%26aufirst%3DN.%26aulast%3DKassahn%26aufirst%3DK.%2BS.%26aulast%3DGingras%26aufirst%3DM.-C.%26aulast%3DMuthuswamy%26aufirst%3DL.%2BB.%26aulast%3DJohns%26aufirst%3DA.%2BL.%26aulast%3DMiller%26aufirst%3DD.%2BK.%26aulast%3DWilson%26aufirst%3DP.%2BJ.%26aulast%3DPatch%26aufirst%3DA.-M.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DD.%2BK.%26aulast%3DCowley%26aufirst%3DM.%2BJ.%26aulast%3DGardiner%26aufirst%3DB.%2BB.%26aulast%3DSong%26aufirst%3DS.%26aulast%3DHarliwong%26aufirst%3DI.%26aulast%3DIdrisoglu%26aufirst%3DS.%26aulast%3DNourse%26aufirst%3DC.%26aulast%3DNourbakhsh%26aufirst%3DE.%26aulast%3DManning%26aufirst%3DS.%26aulast%3DWani%26aufirst%3DS.%26aulast%3DGongora%26aufirst%3DM.%26aulast%3DPajic%26aufirst%3DM.%26aulast%3DScarlett%26aufirst%3DC.%2BJ.%26aulast%3DGill%26aufirst%3DA.%2BJ.%26aulast%3DPinho%26aufirst%3DA.%2BV.%26aulast%3DRooman%26aufirst%3DI.%26aulast%3DAnderson%26aufirst%3DM.%26aulast%3DHolmes%26aufirst%3DO.%26aulast%3DLeonard%26aufirst%3DC.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DNones%26aufirst%3DK.%26aulast%3DFink%26aufirst%3DJ.%2BL.%26aulast%3DChrist%26aufirst%3DA.%26aulast%3DBruxner%26aufirst%3DT.%26aulast%3DCloonan%26aufirst%3DN.%26aulast%3DKolle%26aufirst%3DG.%26aulast%3DNewell%26aufirst%3DF.%26aulast%3DPinese%26aufirst%3DM.%26aulast%3DMead%26aufirst%3DR.%2BS.%26aulast%3DHumphris%26aufirst%3DJ.%2BL.%26aulast%3DKaplan%26aufirst%3DW.%26aulast%3DJones%26aufirst%3DM.%2BD.%26aulast%3DColvin%26aufirst%3DE.%2BK.%26aulast%3DNagrial%26aufirst%3DA.%2BM.%26aulast%3DHumphrey%26aufirst%3DE.%2BS.%26aulast%3DChou%26aufirst%3DA.%26aulast%3DChin%26aufirst%3DV.%2BT.%26aulast%3DChantrill%26aufirst%3DL.%2BA.%26aulast%3DMawson%26aufirst%3DA.%26aulast%3DSamra%26aufirst%3DJ.%2BS.%26aulast%3DKench%26aufirst%3DJ.%2BG.%26aulast%3DLovell%26aufirst%3DJ.%2BA.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26aulast%3DMerrett%26aufirst%3DN.%2BD.%26aulast%3DToon%26aufirst%3DC.%26aulast%3DEpari%26aufirst%3DK.%26aulast%3DNguyen%26aufirst%3DN.%2BQ.%26aulast%3DBarbour%26aufirst%3DA.%26aulast%3DZeps%26aufirst%3DN.%26aulast%3D%26aulast%3DKakkar%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DY.%2BQ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DMuzny%26aufirst%3DD.%2BM.%26aulast%3DFisher%26aufirst%3DW.%2BE.%26aulast%3DBrunicardi%26aufirst%3DF.%2BC.%26aulast%3DHodges%26aufirst%3DS.%2BE.%26aulast%3DReid%26aufirst%3DJ.%2BG.%26aulast%3DDrummond%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DK.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DLewis%26aufirst%3DL.%2BR.%26aulast%3DDinh%26aufirst%3DH.%26aulast%3DBuhay%26aufirst%3DC.%2BJ.%26aulast%3DBeck%26aufirst%3DT.%26aulast%3DTimms%26aufirst%3DL.%26aulast%3DSam%26aufirst%3DM.%26aulast%3DBegley%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DPai%26aufirst%3DD.%26aulast%3DPanchal%26aufirst%3DA.%26aulast%3DBuchner%26aufirst%3DN.%26aulast%3DDe%2BBorja%26aufirst%3DR.%26aulast%3DDenroche%26aufirst%3DR.%2BE.%26aulast%3DYung%26aufirst%3DC.%2BK.%26aulast%3DSerra%26aufirst%3DS.%26aulast%3DOnetto%26aufirst%3DN.%26aulast%3DMukhopadhyay%26aufirst%3DD.%26aulast%3DTsao%26aufirst%3DM.-S.%26aulast%3DShaw%26aufirst%3DP.%2BA.%26aulast%3DPetersen%26aufirst%3DG.%2BM.%26aulast%3DGallinger%26aufirst%3DS.%26aulast%3DHruban%26aufirst%3DR.%2BH.%26aulast%3DMaitra%26aufirst%3DA.%26aulast%3DIacobuzio-Donahue%26aufirst%3DC.%2BA.%26aulast%3DSchulick%26aufirst%3DR.%2BD.%26aulast%3DWolfgang%26aufirst%3DC.%2BL.%26aulast%3DMorgan%26aufirst%3DR.%2BA.%26aulast%3DLawlor%26aufirst%3DR.%2BT.%26aulast%3DCapelli%26aufirst%3DP.%26aulast%3DCorbo%26aufirst%3DV.%26aulast%3DScardoni%26aufirst%3DM.%26aulast%3DTortora%26aufirst%3DG.%26aulast%3DTempero%26aufirst%3DM.%2BA.%26aulast%3DMann%26aufirst%3DK.%2BM.%26aulast%3DJenkins%26aufirst%3DN.%2BA.%26aulast%3DPerez-Mancera%26aufirst%3DP.%2BA.%26aulast%3DAdams%26aufirst%3DD.%2BJ.%26aulast%3DLargaespada%26aufirst%3DD.%2BA.%26aulast%3DWessels%26aufirst%3DL.%2BF.%26aulast%3DRust%26aufirst%3DA.%2BG.%26aulast%3DStein%26aufirst%3DL.%2BD.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DCopeland%26aufirst%3DN.%2BG.%26aulast%3DMusgrove%26aufirst%3DE.%2BA.%26aulast%3DScarpa%26aufirst%3DA.%26aulast%3DEshleman%26aufirst%3DJ.%2BR.%26aulast%3DHudson%26aufirst%3DT.%2BJ.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26aulast%3DWheeler%26aufirst%3DD.%2BA.%26aulast%3DPearson%26aufirst%3DJ.%2BV.%26aulast%3DMcPherson%26aufirst%3DJ.%2BD.%26aulast%3DGibbs%26aufirst%3DR.%2BA.%26aulast%3DGrimmond%26aufirst%3DS.%2BM.%26atitle%3DPancreatic%2520Cancer%2520Genomes%2520Reveal%2520Aberrations%2520in%2520Axon%2520Guidance%2520Pathway%2520Genes%26jtitle%3DNature%26date%3D2012%26volume%3D491%26spage%3D399%26epage%3D405%26doi%3D10.1038%2Fnature11547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rucki, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleponis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eyk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffee, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span> <span> </span><span class="NLM_article-title">Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-1383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1158%2F0008-5472.CAN-16-1383" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=41-52&author=A.+A.+Ruckiauthor=K.+Foleyauthor=P.+Zhangauthor=Q.+Xiaoauthor=J.+Kleponisauthor=A.+A.+Wuauthor=R.+Sharmaauthor=G.+Moauthor=A.+Liuauthor=J.+Van+Eykauthor=E.+M.+Jaffeeauthor=L.+Zheng&title=Heterogeneous+Stromal+Signaling+within+the+Tumor+Microenvironment+Controls+the+Metastasis+of+Pancreatic+Cancer&doi=10.1158%2F0008-5472.CAN-16-1383"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-1383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-1383%26sid%3Dliteratum%253Aachs%26aulast%3DRucki%26aufirst%3DA.%2BA.%26aulast%3DFoley%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DXiao%26aufirst%3DQ.%26aulast%3DKleponis%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DA.%2BA.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DMo%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DVan%2BEyk%26aufirst%3DJ.%26aulast%3DJaffee%26aufirst%3DE.%2BM.%26aulast%3DZheng%26aufirst%3DL.%26atitle%3DHeterogeneous%2520Stromal%2520Signaling%2520within%2520the%2520Tumor%2520Microenvironment%2520Controls%2520the%2520Metastasis%2520of%2520Pancreatic%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D41%26epage%3D52%26doi%3D10.1158%2F0008-5472.CAN-16-1383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurisica, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedley, D. W.</span></span> <span> </span><span class="NLM_article-title">Hypoxia Predicts Aggressive Growth and Spontaneous Metastasis Formation from Orthotopically Grown Primary Xenografts of Human Pancreatic Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">3110</span>– <span class="NLM_lpage">3120</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-4049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1158%2F0008-5472.CAN-10-4049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=21343390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslWjsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=3110-3120&author=Q.+Changauthor=I.+Jurisicaauthor=T.+Doauthor=D.+W.+Hedley&title=Hypoxia+Predicts+Aggressive+Growth+and+Spontaneous+Metastasis+Formation+from+Orthotopically+Grown+Primary+Xenografts+of+Human+Pancreatic+Cancer&doi=10.1158%2F0008-5472.CAN-10-4049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Hypoxia Predicts Aggressive Growth and Spontaneous Metastasis Formation from Orthotopically Grown Primary Xenografts of Human Pancreatic Cancer</span></div><div class="casAuthors">Chang, Qing; Jurisica, Igor; Do, Trevor; Hedley, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3110-3120</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Hypoxia in solid tumors is assocd. with treatment resistance and increased metastatic potential.  Although hypoxia has been reported in pancreatic cancer patients, there is little direct evidence that this contributes to their overall poor prognosis.  To address this, we examd. the assocns. between hypoxia and biol. aggression in a series of patient-derived xenografts grown orthotopically.  Early passage xenografts were established from 16 patients undergoing surgery for pancreatic cancer and maintained in the pancreas of immune-deprived mice.  Hypoxic cells were labeled using the 2-nitroimidazole probe EF5 and stained for immunofluorescence microscopy of tissue sections or as cell suspensions for flow cytometry.  Bromodeoxyuridine (BrdUrd) uptake, microvessel d., cleaved caspase-3, and the differentiation markers E-cadherin, cytokeratin 19, and vimentin were analyzed in relation to hypoxia.  Orthotopic implants closely resembled the histol. of the original surgical samples.  The 16 primary xenografts showed a wide range in their growth rates and metastatic potential, reminiscent of the spectrum of behavior seen in the clinic.  EF5 labeling, tumor growth rates, and metastatic patterns were highly consistent within replicates, indicating a significant transmissible (genetic or epigenetic) component.  Hypoxia was highly correlated with rapid tumor growth, increased BrdUrd uptake, and with spontaneous metastasis formation. mRNA expression anal. showed increased expression of genes involved in cell survival and proliferation in the hypoxic models.  The results suggest that hypoxia is a major adverse prognostic factor in pancreatic cancer patients and support the introduction of techniques to measure hypoxia directly in patients and the development of treatment protocols to target hypoxia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps-ZtGnk6qlbVg90H21EOLACvtfcHk0lhhxSFvVYz9iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslWjsb8%253D&md5=0be38da5f5489bc0b4501241f791c3ea</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-4049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-4049%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DQ.%26aulast%3DJurisica%26aufirst%3DI.%26aulast%3DDo%26aufirst%3DT.%26aulast%3DHedley%26aufirst%3DD.%2BW.%26atitle%3DHypoxia%2520Predicts%2520Aggressive%2520Growth%2520and%2520Spontaneous%2520Metastasis%2520Formation%2520from%2520Orthotopically%2520Grown%2520Primary%2520Xenografts%2520of%2520Human%2520Pancreatic%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D3110%26epage%3D3120%26doi%3D10.1158%2F0008-5472.CAN-10-4049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ceccacci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minucci, S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Histone Deacetylases in Cancer Therapy: Lessons from Leukaemia</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">611</span>, <span class="refDoi"> DOI: 10.1038/bjc.2016.36</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1038%2Fbjc.2016.36" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=26908329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsFehsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2016&pages=605-611&author=E.+Ceccacciauthor=S.+Minucci&title=Inhibition+of+Histone+Deacetylases+in+Cancer+Therapy%3A+Lessons+from+Leukaemia&doi=10.1038%2Fbjc.2016.36"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia</span></div><div class="casAuthors">Ceccacci, Elena; Minucci, Saverio</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">605-611</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are a key component of the epigenetic machinery regulating gene expression, and behave as oncogenes in several cancer types, spurring the development of HDAC inhibitors (HDACi) as anticancer drugs.  This review discusses new results regarding the role of HDACs in cancer and the effect of HDACi on tumor cells, focusing on haematol. malignancies, particularly acute myeloid leukemia.  Histone deacetylases may have opposite roles at different stages of tumor progression and in different tumor cell sub-populations (cancer stem cells), highlighting the importance of investigating these aspects for further improving the clin. use of HDACi in treating cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAMwt4F3whRbVg90H21EOLACvtfcHk0lhhxSFvVYz9iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsFehsLg%253D&md5=ed5746bf4f87e8047aff7db3c747ebd6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2016.36&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2016.36%26sid%3Dliteratum%253Aachs%26aulast%3DCeccacci%26aufirst%3DE.%26aulast%3DMinucci%26aufirst%3DS.%26atitle%3DInhibition%2520of%2520Histone%2520Deacetylases%2520in%2520Cancer%2520Therapy%253A%2520Lessons%2520from%2520Leukaemia%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2016%26volume%3D114%26spage%3D605%26epage%3D611%26doi%3D10.1038%2Fbjc.2016.36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barneda-Zahonero, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parra, M.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases and Cancer</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">579</span>– <span class="NLM_lpage">589</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2012.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1016%2Fj.molonc.2012.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=22963873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs12gt7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=579-589&author=B.+Barneda-Zahoneroauthor=M.+Parra&title=Histone+Deacetylases+and+Cancer&doi=10.1016%2Fj.molonc.2012.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and cancer</span></div><div class="casAuthors">Barneda-Zahonero, Bruna; Parra, Maribel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">579-589</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Reversible acetylation of histone and non-histone proteins is one of the most abundant post-translational modifications in eukaryotic cells.  Protein acetylation and deacetylation are achieved by the antagonistic actions of two families of enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs).  Aberrant protein acetylation, particularly on histones, has been related to cancer while abnormal expression of HDACs has been found in a broad range of cancer types.  Therefore, HDACs have emerged as promising targets in cancer therapeutics, and the development of HDAC inhibitors (HDIs), a rapidly evolving area of clin. research.  However, the contributions of specific HDACs to a given cancer type remain incompletely understood.  The aim of this review is to summarize the current knowledge concerning the role of HDACs in cancer with special emphasis on what we have learned from the anal. of patient samples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOl-qXEsP2IrVg90H21EOLACvtfcHk0lhhxSFvVYz9iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs12gt7%252FK&md5=7c294b40669bf079b1319391ee456642</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2012.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2012.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DBarneda-Zahonero%26aufirst%3DB.%26aulast%3DParra%26aufirst%3DM.%26atitle%3DHistone%2520Deacetylases%2520and%2520Cancer%26jtitle%3DMol.%2520Oncol.%26date%3D2012%26volume%3D6%26spage%3D579%26epage%3D589%26doi%3D10.1016%2Fj.molonc.2012.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structure, Mechanism, and Inhibition of Histone Deacetylases and Related Metalloenzymes</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">743</span>, <span class="refDoi"> DOI: 10.1016/j.sbi.2011.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1016%2Fj.sbi.2011.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=21872466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFOhurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=735-743&author=P.+M.+Lombardiauthor=K.+E.+Coleauthor=D.+P.+Dowlingauthor=D.+W.+Christianson&title=Structure%2C+Mechanism%2C+and+Inhibition+of+Histone+Deacetylases+and+Related+Metalloenzymes&doi=10.1016%2Fj.sbi.2011.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes</span></div><div class="casAuthors">Lombardi, Patrick M.; Cole, Kathryn E.; Dowling, Daniel P.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">735-743</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Metal-dependent histone deacetylases (HDACs) catalyze the hydrolysis of acetyl-L-lysine side-chains in histone and nonhistone proteins to yield L-lysine and acetate.  This chem. plays a crit. role in the regulation of numerous biol. processes.  Aberrant HDAC activity is implicated in various diseases, and HDACs are validated targets for drug design.  Two HDAC inhibitors are currently approved for cancer chemotherapy, and other inhibitors are in clin. trials.  To date, x-ray crystal structures are available for 4 human HDACs (2, 4, 7, and 8) and 3 HDAC-related deacetylases from bacteria [histone deacetylase-like protein (HDLP), histone deacetylase-like amidohydrolase (HDAH), and acetylpolyamine amidohydrolase (APAH)].  Structural comparisons among these enzymes reveal a conserved constellation of active site residues, suggesting a common mechanism for the metal-dependent hydrolysis of acetylated substrates.  Structural analyses of HDACs and HDAC-related deacetylases guide the design of tight-binding inhibitors, and future prospects for developing isoenzyme-specific inhibitors are quite promising.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2SnZUQ2FtTrVg90H21EOLACvtfcHk0ljOK5TFhiIguA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFOhurrJ&md5=edab41900a9f233d7ff30c507cfcce66</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2011.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2011.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DLombardi%26aufirst%3DP.%2BM.%26aulast%3DCole%26aufirst%3DK.%2BE.%26aulast%3DDowling%26aufirst%3DD.%2BP.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructure%252C%2520Mechanism%252C%2520and%2520Inhibition%2520of%2520Histone%2520Deacetylases%2520and%2520Related%2520Metalloenzymes%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2011%26volume%3D21%26spage%3D735%26epage%3D743%26doi%3D10.1016%2Fj.sbi.2011.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verdin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span> <span> </span><span class="NLM_article-title">50 Years of Protein Acetylation: from Gene Regulation to Epigenetics, Metabolism and Beyond</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">258</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1038/nrm3931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1038%2Fnrm3931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=25549891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC2MXks1alsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=258-264&author=E.+Verdinauthor=M.+Ott&title=50+Years+of+Protein+Acetylation%3A+from+Gene+Regulation+to+Epigenetics%2C+Metabolism+and+Beyond&doi=10.1038%2Fnrm3931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond</span></div><div class="casAuthors">Verdin, Eric; Ott, Melanie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">258-264</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In 1964, Vincent Allfrey and colleagues reported the identification of histone acetylation and with deep insight proposed a regulatory role for this protein modification in transcription regulation.  Subsequently, histone acetyltransferases (HATs), histone deacetylases (HDACs) and acetyl-Lys-binding proteins were identified as transcription regulators, thereby providing compelling evidence for his daring hypothesis.  During the past 15 years, reversible protein acetylation and its modifying enzymes have been implicated in many cellular functions beyond transcription regulation.  Here, we review the progress accomplished during the past 50 years and discuss the future of protein acetylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCxnSTZh7_tLVg90H21EOLACvtfcHk0ljOK5TFhiIguA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXks1alsLc%253D&md5=87196dc230d495b5e8fed093acf5254b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrm3931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3931%26sid%3Dliteratum%253Aachs%26aulast%3DVerdin%26aufirst%3DE.%26aulast%3DOtt%26aufirst%3DM.%26atitle%3D50%2520Years%2520of%2520Protein%2520Acetylation%253A%2520from%2520Gene%2520Regulation%2520to%2520Epigenetics%252C%2520Metabolism%2520and%2520Beyond%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2015%26volume%3D16%26spage%3D258%26epage%3D264%26doi%3D10.1038%2Fnrm3931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Ruijter, A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gennip, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kuilenburg, B. P.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases (HDACs): Characterization of the Classical HDAC Family</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1042/bj20021321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1042%2Fbj20021321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=12429021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvFKiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2003&pages=737-749&author=A.+J.+M.+de%0ARuijterauthor=A.+H.+van+Gennipauthor=H.+N.+Caronauthor=S.+Kempauthor=B.+P.+van+Kuilenburg&title=Histone+Deacetylases+%28HDACs%29%3A+Characterization+of+the+Classical+HDAC+Family&doi=10.1042%2Fbj20021321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases (HDACs): characterization of the classical HDAC family</span></div><div class="casAuthors">de Ruijter, Annemieke J. M.; van Gennip, Albert H.; Caron, Huib N.; Kemp, Stephan; van Kuilenburg, Andre B. P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">737-749</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review, with refs.  Transcriptional regulation in eukaryotes occurs within a chromatin setting, and is strongly influenced by the post-translational modification of histones, the building blocks of chromatin, such as methylation, phosphorylation and acetylation.  Acetylation is probably the best understood of these modifications: hyperacetylation leads to an increase in the expression of particular genes, and hypoacetylation has the opposite effect.  Many studies have identified several large, multisubunit enzyme complexes that are responsible for the targeted deacetylation of histones.  The aim of this review is to give a comprehensive overview of the structure, function and tissue distribution of members of the classical histone deacetylase (HDAC) family, in order to gain insight into the regulation of gene expression through HDAC activity.  SAGE (serial anal. of gene expression) data show that HDACs are generally expressed in almost all tissues investigated.  Surprisingly, no major differences were obsd. between the expression pattern in normal and malignant tissues.  However, significant variation in HDAC expression was obsd. within tissue types.  HDAC inhibitors have been shown to induce specific changes in gene expression and to influence a variety of other processes, including growth arrest, differentiation, cytotoxicity and induction of apoptosis.  This challenging field has generated many fascinating results which will ultimately lead to a better understanding of the mechanism of gene transcription as a whole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN1-6ct5EQtrVg90H21EOLACvtfcHk0ljOK5TFhiIguA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvFKiu7o%253D&md5=8a521cd3ddcf046b4b806ebf9f1476b4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1042%2Fbj20021321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj20021321%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BRuijter%26aufirst%3DA.%2BJ.%2BM.%26aulast%3Dvan%2BGennip%26aufirst%3DA.%2BH.%26aulast%3DCaron%26aufirst%3DH.%2BN.%26aulast%3DKemp%26aufirst%3DS.%26aulast%3Dvan%2BKuilenburg%26aufirst%3DB.%2BP.%26atitle%3DHistone%2520Deacetylases%2520%2528HDACs%2529%253A%2520Characterization%2520of%2520the%2520Classical%2520HDAC%2520Family%26jtitle%3DBiochem.%2520J.%26date%3D2003%26volume%3D370%26spage%3D737%26epage%3D749%26doi%3D10.1042%2Fbj20021321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falkenberg, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases and their Inhibitors in Cancer, Neurological Diseases and Immune Disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1038/nrd4360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1038%2Fnrd4360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=25131830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=673-691&author=K.+J.+Falkenbergauthor=R.+W.+Johnstone&title=Histone+Deacetylases+and+their+Inhibitors+in+Cancer%2C+Neurological+Diseases+and+Immune+Disorders&doi=10.1038%2Fnrd4360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</span></div><div class="casAuthors">Falkenberg, Katrina J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">673-691</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters.  Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small mols.  This Review discusses the role of altered expression and/or function of one class of epigenetic regulators - histone deacetylases (HDACs) - and their role in cancer, neurol. diseases and immune disorders.  We highlight the development of small-mol. HDAC inhibitors and their use in the lab., in preclin. models and in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXiWEG49LhebVg90H21EOLACvtfcHk0liay28Or9DEiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI&md5=ccfb68fa3fd4685e2305cdf8a6a9c81a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrd4360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4360%26sid%3Dliteratum%253Aachs%26aulast%3DFalkenberg%26aufirst%3DK.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DHistone%2520Deacetylases%2520and%2520their%2520Inhibitors%2520in%2520Cancer%252C%2520Neurological%2520Diseases%2520and%2520Immune%2520Disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D673%26epage%3D691%26doi%3D10.1038%2Fnrd4360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furdas, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kannan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Inhibitors of Histone Acetyltransferases as Epigenetic Tools and Drug Candidates</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>345</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1002/ardp.201100209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1002%2Fardp.201100209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=22234972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlOnu7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2012&pages=7-21&author=S.+D.+Furdasauthor=S.+Kannanauthor=W.+Sipplauthor=M.+Jung&title=Small+Molecule+Inhibitors+of+Histone+Acetyltransferases+as+Epigenetic+Tools+and+Drug+Candidates&doi=10.1002%2Fardp.201100209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors of Histone Acetyltransferases as Epigenetic Tools and Drug Candidates</span></div><div class="casAuthors">Furdas, Silviya D.; Kannan, Srinivasaraghavan; Sippl, Wolfgang; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-21</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Alteration of the acetylation state of histone proteins contributes to transcriptional regulation and epigenetic inheritance.  Dysregulation of these processes may lead to human diseases, esp. cancer.  One of the major chromatin modifications is histone acetylation and this review gives an overview of the role of histone acetyltransferases, their structural aspects, as well as of chem. modulators targeting their enzymic activities.  Inhibitors and activators of histone acetyltransferases are presented and their capability to influence histone and non-histone protein acetylation levels is discussed.  Development of small mols. as epigenetic tools that alter histone acetyltransferase activity will be helpful to better understand the consequences of histone and generally protein acetylation and potentially offer novel therapeutic approaches for the treatment of cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphwDWjySoJrrVg90H21EOLACvtfcHk0liay28Or9DEiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlOnu7%252FK&md5=6a71f3f6cfcfb6e1a84b2761e0d61b11</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fardp.201100209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201100209%26sid%3Dliteratum%253Aachs%26aulast%3DFurdas%26aufirst%3DS.%2BD.%26aulast%3DKannan%26aufirst%3DS.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DSmall%2520Molecule%2520Inhibitors%2520of%2520Histone%2520Acetyltransferases%2520as%2520Epigenetic%2520Tools%2520and%2520Drug%2520Candidates%26jtitle%3DArch.%2520Pharm.%26date%3D2012%26volume%3D345%26spage%3D7%26epage%3D21%26doi%3D10.1002%2Fardp.201100209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mariño-Ramírez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kann, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landsman, D.</span></span> <span> </span><span class="NLM_article-title">Histone Structure and Nucleosome Stability</span>. <i>Expert Rev. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">729</span>, <span class="refDoi"> DOI: 10.1586/14789450.2.5.719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1586%2F14789450.2.5.719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=16209651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1SlsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=719-729&author=L.+Mari%C3%B1o-Ram%C3%ADrezauthor=M.+G.+Kannauthor=B.+A.+Shoemakerauthor=D.+Landsman&title=Histone+Structure+and+Nucleosome+Stability&doi=10.1586%2F14789450.2.5.719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Histone structure and nucleosome stability</span></div><div class="casAuthors">Marino-Ramirez, Leonardo; Kann, Maricel G.; Shoemaker, Benjamin A.; Landsman, David</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Proteomics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">719-729</span>CODEN:
                <span class="NLM_cas:coden">ERPXA3</span>;
        ISSN:<span class="NLM_cas:issn">1478-9450</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone proteins play essential structural and functional roles in the transition between active and inactive chromatin states.  Although histones have a high degree of conservation due to constraints to maintain the overall structure of the nucleosomal octameric core, variants have evolved to assume diverse roles in gene regulation and epigenetic silencing.  Histone variants, post-translational modifications and interactions with chromatin remodeling complexes influence DNA replication, transcription, repair and recombination.  The authors review recent findings on the structure of chromatin that confirm previous interparticle interactions obsd. in crystal structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopDcjUqe2LZrVg90H21EOLACvtfcHk0liay28Or9DEiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1SlsrbF&md5=949ac0323e0d4b05c8f2fe5b951ae829</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1586%2F14789450.2.5.719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14789450.2.5.719%26sid%3Dliteratum%253Aachs%26aulast%3DMari%25C3%25B1o-Ram%25C3%25ADrez%26aufirst%3DL.%26aulast%3DKann%26aufirst%3DM.%2BG.%26aulast%3DShoemaker%26aufirst%3DB.%2BA.%26aulast%3DLandsman%26aufirst%3DD.%26atitle%3DHistone%2520Structure%2520and%2520Nucleosome%2520Stability%26jtitle%3DExpert%2520Rev.%2520Proteomics%26date%3D2005%26volume%3D2%26spage%3D719%26epage%3D729%26doi%3D10.1586%2F14789450.2.5.719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumagai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakimoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gery, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chumakov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeffler, H. P.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid (Vorinostat, SAHA) Profoundly Inhibits the Growth of Human Pancreatic Cancer Cells</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">656</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1002/ijc.22558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1002%2Fijc.22558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=17417771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnt1Crsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2007&pages=656-665&author=T.+Kumagaiauthor=N.+Wakimotoauthor=D.+Yinauthor=S.+Geryauthor=N.+Kawamataauthor=N.+Takaiauthor=N.+Komatsuauthor=A.+Chumakovauthor=Y.+Imaiauthor=H.+P.+Koeffler&title=Histone+Deacetylase+Inhibitor%2C+Suberoylanilide+Hydroxamic+Acid+%28Vorinostat%2C+SAHA%29+Profoundly+Inhibits+the+Growth+of+Human+Pancreatic+Cancer+Cells&doi=10.1002%2Fijc.22558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells</span></div><div class="casAuthors">Kumagai, Takashi; Wakimoto, Naoki; Yin, Dong; Gery, Sigal; Kawamata, Norihiko; Takai, Noriyuki; Komatsu, Naoki; Chumakov, Alexy; Imai, Yasufumi; Koeffler, H. Phillip</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">656-665</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Tumor suppressor genes are often silenced in human cancer; this can occur by transcriptional repression by deacetylation in the promoter regions, mediated by histone deacetylase (HDAC).  HDAC inhibitors can block cancer cell growth by restoring expression of tumor suppressor genes.  In this study, we investigated the effects of a HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA) on pancreatic cancer cells.  SAHA inhibited the growth of 6 pancreatic cancer cell lines in a dose-dependent manner as measured by MTT and clonogenic assays (ED50 ≈10-6 M) assocd. with induction of apoptosis, G2 cell cycle arrest and also induced differentiation as indicated by morphol. and increased expression of cytokeratin 7.  It increased expression of p21WAF1 (independent of the mutational status of p53), C/EBPα, RARα and E-cadherin; these genes have been assocd. with decreased proliferation in other cancers.  SAHA decreased cyclin B1 expression; this cyclin normally promotes progression through G2 of the cell cycle.  SAHA mediated acetylation of histone H3 globally, as well as, assocd. with the p21WAF1 promoter, as measured by chromatin immunopptn.  SAHA also decreased levels of c-myc and cyclin D1, independent of an active β-catenin pathway.  In further studies, the combination of SAHA and an inhibitor of DNA methylation, 5-Aza-2'-deoxycytidine, had an enhanced antiproliferative effect on pancreatic cancer cells.  In summary, SAHA inhibited the growth of human pancreatic cancer cells by inducing apoptosis, differentiation and cell cycle arrest, as well as increase in the expression of several tumor suppressor genes.  SAHA is a novel, promising therapeutic agent for human pancreatic cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVgeJjEzQr77Vg90H21EOLACvtfcHk0lj64ZU6bX0gXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnt1Crsrs%253D&md5=4c7224c82f75d160b934fb0560f73eb5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fijc.22558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.22558%26sid%3Dliteratum%253Aachs%26aulast%3DKumagai%26aufirst%3DT.%26aulast%3DWakimoto%26aufirst%3DN.%26aulast%3DYin%26aufirst%3DD.%26aulast%3DGery%26aufirst%3DS.%26aulast%3DKawamata%26aufirst%3DN.%26aulast%3DTakai%26aufirst%3DN.%26aulast%3DKomatsu%26aufirst%3DN.%26aulast%3DChumakov%26aufirst%3DA.%26aulast%3DImai%26aufirst%3DY.%26aulast%3DKoeffler%26aufirst%3DH.%2BP.%26atitle%3DHistone%2520Deacetylase%2520Inhibitor%252C%2520Suberoylanilide%2520Hydroxamic%2520Acid%2520%2528Vorinostat%252C%2520SAHA%2529%2520Profoundly%2520Inhibits%2520the%2520Growth%2520of%2520Human%2520Pancreatic%2520Cancer%2520Cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2007%26volume%3D121%26spage%3D656%26epage%3D665%26doi%3D10.1002%2Fijc.22558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piekarz, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschbaum, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prince, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geskin, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joske, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figg, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffe, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetler-Stevenson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lade, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span> <span> </span><span class="NLM_article-title">Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">5410</span>– <span class="NLM_lpage">5417</span>, <span class="refDoi"> DOI: 10.1200/JCO.2008.21.6150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1200%2FJCO.2008.21.6150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=19826128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFKkt7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=5410-5417&author=R.+L.+Piekarzauthor=R.+Fryeauthor=M.+Turnerauthor=J.+J.+Wrightauthor=S.+L.+Allenauthor=M.+H.+Kirschbaumauthor=J.+Zainauthor=H.+M.+Princeauthor=J.+P.+Leonardauthor=L.+J.+Geskinauthor=C.+Reederauthor=D.+Joskeauthor=W.+D.+Figgauthor=E.+R.+Gardnerauthor=S.+M.+Steinbergauthor=E.+S.+Jaffeauthor=M.+Stetler-Stevensonauthor=S.+Ladeauthor=A.+T.+Fojoauthor=S.+E.+Bates&title=Phase+II+Multi-Institutional+Trial+of+the+Histone+Deacetylase+Inhibitor+Romidepsin+As+Monotherapy+for+Patients+With+Cutaneous+T-Cell+Lymphoma&doi=10.1200%2FJCO.2008.21.6150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma</span></div><div class="casAuthors">Piekarz, Richard L.; Frye, Robin; Turner, Maria; Wright, John J.; Allen, Steven L.; Kirschbaum, Mark H.; Zain, Jasmine; Prince, H. Miles; Leonard, John P.; Geskin, Larisa J.; Reeder, Craig; Joske, David; Figg, William D.; Gardner, Erin R.; Steinberg, Seth M.; Jaffe, Elaine S.; Stetler-Stevenson, Maryalice; Lade, Stephen; Fojo, A. Tito; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">5410-5417</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Romidepsin (depsipeptide or FK228) is a member of a new class of antineoplastic agents active in T-cell lymphoma, the histone deacetylase inhibitors.  On the basis of obsd. responses in a phase I trial, a phase II trial of romidepsin in patients with T-cell lymphoma was initiated.  The initial cohort was limited to patients with cutaneous T-cell lymphoma (CTCL), or subtypes mycosis fungoides or Sezary syndrome, who had received no more than two prior cytotoxic regimens.  There were no limits on other types of therapy.  Subsequently, the protocol was expanded to enroll patients who had received more than two prior cytotoxic regimens.  Twenty-seven patients were enrolled onto the first cohort, and a total of 71 patients are included in this anal.  These patients had undergone a median of four prior treatments, and 62 patients (87%) had advanced-stage disease (stage IIB, n = 15; stage III, n= 6; or stage IV, n = 41).  Toxicities included nausea, vomiting, fatigue, and transient thrombocytopenia and granulocytopenia.  Pharmacokinetics were evaluated with the first administration of romidepsin.  Complete responses were obsd. in four patients, and partial responses were obsd. in 20 patients for an overall response rate of 34% (95% CI, 23% to 46%).  The median duration of response was 13.7 mo.  The histone deacetylase inhibitor romidepsin has single-agent clin. activity with significant and durable responses in patients with CTCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUzt-4ptTta7Vg90H21EOLACvtfcHk0lj64ZU6bX0gXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFKkt7vO&md5=e99b3bf6b987b6cb5ed3d2cbefcbd259</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.21.6150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.21.6150%26sid%3Dliteratum%253Aachs%26aulast%3DPiekarz%26aufirst%3DR.%2BL.%26aulast%3DFrye%26aufirst%3DR.%26aulast%3DTurner%26aufirst%3DM.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DAllen%26aufirst%3DS.%2BL.%26aulast%3DKirschbaum%26aufirst%3DM.%2BH.%26aulast%3DZain%26aufirst%3DJ.%26aulast%3DPrince%26aufirst%3DH.%2BM.%26aulast%3DLeonard%26aufirst%3DJ.%2BP.%26aulast%3DGeskin%26aufirst%3DL.%2BJ.%26aulast%3DReeder%26aufirst%3DC.%26aulast%3DJoske%26aufirst%3DD.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DGardner%26aufirst%3DE.%2BR.%26aulast%3DSteinberg%26aufirst%3DS.%2BM.%26aulast%3DJaffe%26aufirst%3DE.%2BS.%26aulast%3DStetler-Stevenson%26aufirst%3DM.%26aulast%3DLade%26aufirst%3DS.%26aulast%3DFojo%26aufirst%3DA.%2BT.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DPhase%2520II%2520Multi-Institutional%2520Trial%2520of%2520the%2520Histone%2520Deacetylase%2520Inhibitor%2520Romidepsin%2520As%2520Monotherapy%2520for%2520Patients%2520With%2520Cutaneous%2520T-Cell%2520Lymphoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D5410%26epage%3D5417%26doi%3D10.1200%2FJCO.2008.21.6150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ara, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaRochelle, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichenstein, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffers, M.</span></span> <span> </span><span class="NLM_article-title">Activity of the Histone Deacetylase Inhibitor Belinostat (PXD101) in Preclinical Models of Prostate Cancer</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">1400</span>– <span class="NLM_lpage">1410</span>, <span class="refDoi"> DOI: 10.1002/ijc.23243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1002%2Fijc.23243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=18027850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BD1cXit1yht7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2008&pages=1400-1410&author=X.+Qianauthor=G.+Araauthor=E.+Millsauthor=W.+J.+LaRochelleauthor=H.+S.+Lichensteinauthor=M.+Jeffers&title=Activity+of+the+Histone+Deacetylase+Inhibitor+Belinostat+%28PXD101%29+in+Preclinical+Models+of+Prostate+Cancer&doi=10.1002%2Fijc.23243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer</span></div><div class="casAuthors">Qian, Xiaozhong; Ara, Gulshan; Mills, Evan; La Rochelle, William J.; Lichenstein, Henri S.; Jeffers, Michael</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1400-1410</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACi) represent a promising new class of anticancer agents.  In the current investigation, we examd. the activity of the HDACi belinostat in preclin. models of prostate cancer.  In vitro proliferation assays demonstrated that belinostat potently inhibited the growth of prostate cancer cell lines (IC50 < 1.0 μM) and was cytotoxic to these cells.  Washout expts. indicated that exposure to belinostat for relatively short periods of time (<12 h) induced suboptimal growth-inhibition and that cells exposed to 1.0 μM belinostat for 48 h retained the capacity for regrowth following drug withdrawal, while cells exposed to 4.0 μM belinostat were irreversibly growth-inhibited.  Cell cycle analyses demonstrated that belinostat induced G2/M arrest and increased the percentage of cells with subG1 DNA content, thus confirming the growth-inhibitory and cytotoxic effects of this compd.  Normal prostate epithelial cells were generally less susceptible to the effects of belinostat than were prostate cancer cells.  In an orthotopic prostate cancer tumor model, belinostat inhibited tumor growth by up to 43%.  Moreover, metastatic lung lesions were present in 47% of vehicle-treated animals but in none of the animals administered belinostat.  Consistent with its obsd. antimetastatic activity, belinostat inhibited the migration of prostate tumor cells and increased the prodn. of tissue inhibitor of metalloproteinase-1 (TIMP-1) by these cells, the latter effect being replicated by siRNA knockdown of HDAC3.  Belinostat also increased the expression of p21 and decreased the expression of potentially oncogenic proteins (mutant p53 and ERG).  These results support the clin. evaluation of belinostat for the treatment of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHxA5gtazFvLVg90H21EOLACvtfcHk0liP6hLmffgxqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXit1yht7w%253D&md5=7db206329bf3ad0655a420b33243a3c2</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fijc.23243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.23243%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DX.%26aulast%3DAra%26aufirst%3DG.%26aulast%3DMills%26aufirst%3DE.%26aulast%3DLaRochelle%26aufirst%3DW.%2BJ.%26aulast%3DLichenstein%26aufirst%3DH.%2BS.%26aulast%3DJeffers%26aufirst%3DM.%26atitle%3DActivity%2520of%2520the%2520Histone%2520Deacetylase%2520Inhibitor%2520Belinostat%2520%2528PXD101%2529%2520in%2520Preclinical%2520Models%2520of%2520Prostate%2520Cancer%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2008%26volume%3D122%26spage%3D1400%26epage%3D1410%26doi%3D10.1002%2Fijc.23243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams-Truax, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterfoss, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culver, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prince, H. M.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">4500</span>– <span class="NLM_lpage">4510</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-4262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1158%2F1078-0432.CCR-07-4262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=18628465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFGitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=4500-4510&author=L.+Ellisauthor=Y.+Panauthor=G.+K.+Smythauthor=D.+J.+Georgeauthor=C.+McCormackauthor=R.+Williams-Truaxauthor=M.+Mitaauthor=J.+Beckauthor=H.+Burrisauthor=G.+Ryanauthor=P.+Atadjaauthor=D.+Butterfossauthor=M.+Duganauthor=K.+Culverauthor=R.+W.+Johnstoneauthor=H.+M.+Prince&title=Histone+Deacetylase+Inhibitor+Panobinostat+Induces+Clinical+Responses+with+Associated+Alterations+in+Gene+Expression+Profiles+in+Cutaneous+T-Cell+Lymphoma&doi=10.1158%2F1078-0432.CCR-07-4262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma</span></div><div class="casAuthors">Ellis, Leigh; Pan, Yan; Smyth, Gordon K.; George, Daniel J.; McCormack, Chris; Williams-Truax, Roxanne; Mita, Monica; Beck, Joachim; Burris, Howard; Ryan, Gail; Atadja, Peter; Butterfoss, Dale; Dugan, Margaret; Culver, Kenneth; Johnstone, Ricky W.; Prince, H. Miles</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4500-4510</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors can alter gene expression and mediate diverse antitumor activities.  Herein, we report the safety and activity of the histone deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma (CTCL) and identify genes commonly regulated by panobinostat.  Panobinostat was administered orally to patients with CTCL on Monday, Wednesday, and Friday of each week on a 28-day cycle.  A dose of 30 mg was considered excessively toxic, and subsequent patients were treated at the expanded max. tolerated dose of 20 mg.  Biopsies from six patients taken 0, 4, 8, and 24 h after administration were subjected to microarray gene expression profiling and real-time quant. PCR of selected genes.  Patients attained a complete response (n = 2), attained a partial response (n = 4), achieved stable disease with ongoing improvement (n = 1), and progressed on treatment (n = 2).  Microarray data showed distinct gene expression response profiles over time following panobinostat treatment, with the majority of genes being repressed.  Twenty-three genes were commonly regulated by panobinostat in all patients tested.  Panobinostat is well tolerated and induces clin. responses in CTCL patients.  Microarray analyses of tumor samples indicate that panobinostat induces rapid changes in gene expression, and surprisingly more genes are repressed than are activated.  A unique set of genes that can mediate biol. responses such as apoptosis, immune regulation, and angiogenesis were commonly regulated in response to panobinostat.  These genes are potential mol. biomarkers for panobinostat activity and are strong candidates for the future assessment of their functional role(s) in mediating the antitumor responses of panobinostat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKdLh4qldQ37Vg90H21EOLACvtfcHk0liP6hLmffgxqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFGitL0%253D&md5=0b53d3b837c0f89a700287855ffcc961</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-4262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-4262%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DL.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DSmyth%26aufirst%3DG.%2BK.%26aulast%3DGeorge%26aufirst%3DD.%2BJ.%26aulast%3DMcCormack%26aufirst%3DC.%26aulast%3DWilliams-Truax%26aufirst%3DR.%26aulast%3DMita%26aufirst%3DM.%26aulast%3DBeck%26aufirst%3DJ.%26aulast%3DBurris%26aufirst%3DH.%26aulast%3DRyan%26aufirst%3DG.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DButterfoss%26aufirst%3DD.%26aulast%3DDugan%26aufirst%3DM.%26aulast%3DCulver%26aufirst%3DK.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DPrince%26aufirst%3DH.%2BM.%26atitle%3DHistone%2520Deacetylase%2520Inhibitor%2520Panobinostat%2520Induces%2520Clinical%2520Responses%2520with%2520Associated%2520Alterations%2520in%2520Gene%2520Expression%2520Profiles%2520in%2520Cutaneous%2520T-Cell%2520Lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D4500%26epage%3D4510%26doi%3D10.1158%2F1078-0432.CCR-07-4262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span>NPI-0052 and
Vorinostat in Patients
with Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma.
ClinicalTrials.gov; Identifier NCT00667082, <span class="NLM_year">2016</span> (accessed
Aug 16, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NPI-0052+and%0AVorinostat+in+Patients%0Awith+Non-small+Cell+Lung+Cancer%2C+Pancreatic+Cancer%2C+Melanoma+or+Lymphoma.%0AClinicalTrials.gov%3B+Identifier+NCT00667082%2C+2016+%28accessed%0AAug+16%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span>Vorinostat Plus Radiation Therapy
in Pancreatic Cancer. ClinicalTrials.gov; Identifier NCT00831493, <span class="NLM_year">2012</span> (accessed Aug 16, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Vorinostat+Plus+Radiation+Therapy%0Ain+Pancreatic+Cancer.+ClinicalTrials.gov%3B+Identifier+NCT00831493%2C+2012+%28accessed+Aug+16%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span>Vorinostat With XRT and 5-FU
for Locally Advanced Adenocarcinoma of the Pancreas. ClinicalTrials.gov;
Identifier NCT00948688, <span class="NLM_year">2017</span> (accessed Aug 16, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Vorinostat+With+XRT+and+5-FU%0Afor+Locally+Advanced+Adenocarcinoma+of+the+Pancreas.+ClinicalTrials.gov%3B%0AIdentifier+NCT00948688%2C+2017+%28accessed+Aug+16%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span>Capecitabine, Vorinostat,
and
Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic
Cancer. ClinicalTrials.gov; Identifier NCT00983268, <span class="NLM_year">2015</span> (accessed Aug 16, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Capecitabine%2C+Vorinostat%2C%0Aand%0ARadiation+Therapy+in+Treating+Patients+With+Nonmetastatic+Pancreatic%0ACancer.+ClinicalTrials.gov%3B+Identifier+NCT00983268%2C+2015+%28accessed+Aug+16%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span>Neoadjuvant Chemotherapy Followed
by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic
Cancer. ClinicalTrials.gov; Identifier NCT02349867, <span class="NLM_year">2017</span> (accessed Aug 16, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Neoadjuvant+Chemotherapy+Followed%0Aby+Radiation+Therapy+and+Gemcitabine%2FSorafenib%2FVorinostat+in+Pancreatic%0ACancer.+ClinicalTrials.gov%3B+Identifier+NCT02349867%2C+2017+%28accessed+Aug+16%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span>MS-275 in Treating Patients With
Advanced Solid Tumors or Lymphoma. ClinicalTrials.gov; Identifier
NCT00020579, <span class="NLM_year">2012</span> (accessed Aug 16, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=MS-275+in+Treating+Patients+With%0AAdvanced+Solid+Tumors+or+Lymphoma.+ClinicalTrials.gov%3B+Identifier%0ANCT00020579%2C+2012+%28accessed+Aug+16%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span>Panobinostat & Bortezomib
in Pancreatic Cancer Progressing on Gemcitabine Therapy. ClinicalTrials.gov;
Identifier NCT01056601, <span class="NLM_year">2012</span> (accessed Aug 16, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Panobinostat+%26+Bortezomib%0Ain+Pancreatic+Cancer+Progressing+on+Gemcitabine+Therapy.+ClinicalTrials.gov%3B%0AIdentifier+NCT01056601%2C+2012+%28accessed+Aug+16%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdelfatah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerner, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, N.</span></span> <span> </span><span class="NLM_article-title">Epigenetic Therapy in Gastrointestinal Cancer: the Right Combination</span>. <i>Ther. Adv. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">579</span>, <span class="refDoi"> DOI: 10.1177/1756283X16644247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1177%2F1756283X16644247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=27366224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFOrsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=560-579&author=E.+Abdelfatahauthor=Z.+Kernerauthor=N.+Nandaauthor=N.+Ahuja&title=Epigenetic+Therapy+in+Gastrointestinal+Cancer%3A+the+Right+Combination&doi=10.1177%2F1756283X16644247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic therapy in gastrointestinal cancer: the right combination</span></div><div class="casAuthors">Abdelfatah, Eihab; Kerner, Zachary; Nanda, Nainika; Ahuja, Nita</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Gastroenterology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">560-579</span>CODEN:
                <span class="NLM_cas:coden">TAGHAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-283X</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Epigenetics is a relatively recent field of mol. biol. that has arisen over the past 25 years.  Cancer is now understood to be a disease of widespread epigenetic dysregulation that interacts extensively with underlying genetic mutations.  The development of drugs targeting these processes has rapidly progressed; with several drugs already FDA approved as first-line therapy in hematol. malignancies.  Gastrointestinal (GI) cancers possess high degrees of epigenetic dysregulation, exemplified by subtypes such as CpG island methylator phenotype (CIMP), and the potential benefit of epigenetic therapy in these cancers is evident.  The application of epigenetic drugs in solid tumors, including GI cancers, is just emerging, with increased understanding of the cancer epigenome.  In this review, we provide a brief overview of cancer epigenetics and the epigenetic targets of therapy including DNA (DNA) methylation, histone modifications, and chromatin remodeling.  We discuss the epigenetic drugs currently in use, with a focus on DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibitors, and explain the pharmacokinetic and mechanistic challenges in their application.  We present the strategies employed in incorporating these drugs into the treatment of GI cancers, and explain the concept of the cancer stem cell in epigenetic reprogramming and reversal of chemo resistance.  We discuss the most promising combination strategies in GI cancers including: (1) epigenetic sensitization to radiotherapy, (2) epigenetic sensitization to cytotoxic chemotherapy, and (3) epigenetic immune modulation and priming for immune therapy.  Finally, we present preclin. and clin. trial data employing these strategies thus far in various GI cancers including colorectal, esophageal, gastric, and pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkime7zHEKY7Vg90H21EOLACvtfcHk0ljFSEOyTgmx1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFOrsLw%253D&md5=864e758f0ac272f12cc5669630aac928</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1177%2F1756283X16644247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1756283X16644247%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelfatah%26aufirst%3DE.%26aulast%3DKerner%26aufirst%3DZ.%26aulast%3DNanda%26aufirst%3DN.%26aulast%3DAhuja%26aufirst%3DN.%26atitle%3DEpigenetic%2520Therapy%2520in%2520Gastrointestinal%2520Cancer%253A%2520the%2520Right%2520Combination%26jtitle%3DTher.%2520Adv.%2520Gastroenterol.%26date%3D2016%26volume%3D9%26spage%3D560%26epage%3D579%26doi%3D10.1177%2F1756283X16644247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentze, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">The Oral HDAC Inhibitor Pracinostat (SB939) is Efficacious and Synergistic with the JAK2 Inhibitor Pacritinib (SB1518) in Preclinical Models of AML</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e69</span> <span class="refDoi"> DOI: 10.1038/bcj.2012.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1038%2Fbcj.2012.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=22829971" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&author=V.+Novotny-Diermayrauthor=S.+Hartauthor=K.+C.+Gohauthor=A.+Cheongauthor=L.-C.+Ongauthor=H.+Hentzeauthor=M.+K.+Pashaauthor=R.+Jayaramanauthor=K.+Ethirajuluauthor=J.+M.+Wood&title=The+Oral+HDAC+Inhibitor+Pracinostat+%28SB939%29+is+Efficacious+and+Synergistic+with+the+JAK2+Inhibitor+Pacritinib+%28SB1518%29+in+Preclinical+Models+of+AML&doi=10.1038%2Fbcj.2012.14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2012.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2012.14%26sid%3Dliteratum%253Aachs%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DOng%26aufirst%3DL.-C.%26aulast%3DHentze%26aufirst%3DH.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520Oral%2520HDAC%2520Inhibitor%2520Pracinostat%2520%2528SB939%2529%2520is%2520Efficacious%2520and%2520Synergistic%2520with%2520the%2520JAK2%2520Inhibitor%2520Pacritinib%2520%2528SB1518%2529%2520in%2520Preclinical%2520Models%2520of%2520AML%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2012%26volume%3D2%26doi%3D10.1038%2Fbcj.2012.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venugopal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristeleit, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourneau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellemans, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsayed, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcclue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forslund, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelps, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, T. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de
Bono, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span> <span> </span><span class="NLM_article-title">A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4262</span>– <span class="NLM_lpage">4272</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1158%2F1078-0432.CCR-13-0312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=23741066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4262-4272&author=B.+Venugopalauthor=R.+Bairdauthor=R.+S.+Kristeleitauthor=R.+Plummerauthor=R.+Cowanauthor=A.+Stewartauthor=N.+Fourneauauthor=P.+Hellemansauthor=Y.+Elsayedauthor=S.+Mcclueauthor=J.+W.+Smitauthor=A.+Forslundauthor=C.+Phelpsauthor=J.+Cammauthor=T.+R.+J.+Evansauthor=J.+S.+de%0ABonoauthor=U.+Banerji&title=A+Phase+I+Study+of+Quisinostat+%28JNJ-26481585%29%2C+an+Oral+Hydroxamate+Histone+Deacetylase+Inhibitor+with+Evidence+of+Target+Modulation+and+Antitumor+Activity%2C+in+Patients+with+Advanced+Solid+Tumors&doi=10.1158%2F1078-0432.CCR-13-0312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Venugopal, Balaji; Baird, Richard; Kristeleit, Rebecca S.; Plummer, Ruth; Cowan, Richard; Stewart, Adam; Fourneau, Nele; Hellemans, Peter; Elsayed, Yusri; McClue, Steve; Smit, Johan W.; Forslund, Ann; Phelps, Charles; Camm, John; Evans, T. R. Jeffry; de Bono, Johann S.; Banerji, Udai</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4262-4272</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To det. the max.-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic and pharmacodynamic profile of quisinostat, a novel hydroxamate, pan-histone deacetylase inhibitor (HDACi).  Exptl. Design: In this first-in-human phase I study, quisinostat was administered orally, once daily in three weekly cycles to patients with advanced malignancies, using a two-stage accelerated titrn. design.  Three intermittent schedules were subsequently explored: four days on/three days off; every Monday, Wednesday, Friday (MWF); and every Monday and Thursday (M-Th).  Toxicity, pharmacokinetics, pharmacodynamics, and clin. efficacy were evaluated at each schedule.  Results: Ninety-two patients were treated in continuous daily (2-12 mg) and three intermittent dosing schedules (6-19 mg).  Treatment-emergent adverse events included: fatigue, nausea, decreased appetite, lethargy, and vomiting.  DLTs obsd. were predominantly cardiovascular, including nonsustained ventricular tachycardia, ST/T-wave abnormalities, and other tachyarhythmias.  Noncardiac DLTs were fatigue and abnormal liver function tests.  The max. plasma concn. (Cmax) and area under the plasma concn.-time curve (AUC) of quisinostat increased proportionally with dose.  Pharmacodynamic evaluation showed increased acetylated histone 3 in hair follicles, skin and tumor biopsies, and in peripheral blood mononuclear cells as well as decreased Ki67 in skin and tumor biopsies.  A partial response lasting five months was seen in one patient with melanoma.  Stable disease was seen in eight patients (duration 4-10.5 mo).  Conclusions: The adverse event profile of quisinostat was comparable with that of other HDACi.  Intermittent schedules were better tolerated than continuous schedules.  On the basis of tolerability, pharmacokinetic predictions, and pharmacodynamic effects, the recommended dose for phase II studies is 12 mg on the MWF schedule.  Clin Cancer Res; 19(15); 4262-72. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZhELE0VMCPbVg90H21EOLACvtfcHk0liargzOczT3vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zP&md5=f4db895a7878fddce61ea9640e427d4d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0312%26sid%3Dliteratum%253Aachs%26aulast%3DVenugopal%26aufirst%3DB.%26aulast%3DBaird%26aufirst%3DR.%26aulast%3DKristeleit%26aufirst%3DR.%2BS.%26aulast%3DPlummer%26aufirst%3DR.%26aulast%3DCowan%26aufirst%3DR.%26aulast%3DStewart%26aufirst%3DA.%26aulast%3DFourneau%26aufirst%3DN.%26aulast%3DHellemans%26aufirst%3DP.%26aulast%3DElsayed%26aufirst%3DY.%26aulast%3DMcclue%26aufirst%3DS.%26aulast%3DSmit%26aufirst%3DJ.%2BW.%26aulast%3DForslund%26aufirst%3DA.%26aulast%3DPhelps%26aufirst%3DC.%26aulast%3DCamm%26aufirst%3DJ.%26aulast%3DEvans%26aufirst%3DT.%2BR.%2BJ.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DBanerji%26aufirst%3DU.%26atitle%3DA%2520Phase%2520I%2520Study%2520of%2520Quisinostat%2520%2528JNJ-26481585%2529%252C%2520an%2520Oral%2520Hydroxamate%2520Histone%2520Deacetylase%2520Inhibitor%2520with%2520Evidence%2520of%2520Target%2520Modulation%2520and%2520Antitumor%2520Activity%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D4262%26epage%3D4272%26doi%3D10.1158%2F1078-0432.CCR-13-0312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knipstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gore, L.</span></span> <span> </span><span class="NLM_article-title">Entinostat for Treatment of Solid Tumors and Hematologic Malignancies</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1455</span>– <span class="NLM_lpage">1467</span>, <span class="refDoi"> DOI: 10.1517/13543784.2011.613822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1517%2F13543784.2011.613822" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=1455-1467&author=J.+Knipsteinauthor=L.+Gore&title=Entinostat+for+Treatment+of+Solid+Tumors+and+Hematologic+Malignancies&doi=10.1517%2F13543784.2011.613822"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1517%2F13543784.2011.613822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2011.613822%26sid%3Dliteratum%253Aachs%26aulast%3DKnipstein%26aufirst%3DJ.%26aulast%3DGore%26aufirst%3DL.%26atitle%3DEntinostat%2520for%2520Treatment%2520of%2520Solid%2520Tumors%2520and%2520Hematologic%2520Malignancies%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D1455%26epage%3D1467%26doi%3D10.1517%2F13543784.2011.613822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, O. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahboobi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellmer, A.</span></span> <span> </span><span class="NLM_article-title">Drugging the HDAC6–HSP90 Interplay in Malignant Cells</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2014.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1016%2Fj.tips.2014.08.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=501-509&author=O.+H.+Kr%C3%A4merauthor=S.+Mahboobiauthor=A.+Sellmer&title=Drugging+the+HDAC6%E2%80%93HSP90+Interplay+in+Malignant+Cells&doi=10.1016%2Fj.tips.2014.08.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2014.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2014.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DKr%25C3%25A4mer%26aufirst%3DO.%2BH.%26aulast%3DMahboobi%26aufirst%3DS.%26aulast%3DSellmer%26aufirst%3DA.%26atitle%3DDrugging%2520the%2520HDAC6%25E2%2580%2593HSP90%2520Interplay%2520in%2520Malignant%2520Cells%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2014%26volume%3D35%26spage%3D501%26epage%3D509%26doi%3D10.1016%2Fj.tips.2014.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kroesen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gielen, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brok, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armandari, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoogerbrugge, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adema, G. J.</span></span> <span> </span><span class="NLM_article-title">HDAC Inhibitors and Immunotherapy; a Double Edged Sword?</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">6558</span>– <span class="NLM_lpage">6572</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.18632%2Foncotarget.2289" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=6558-6572&author=M.+Kroesenauthor=P.+R.+Gielenauthor=I.+C.+Brokauthor=I.+Armandariauthor=P.+M.+Hoogerbruggeauthor=G.+J.+Adema&title=HDAC+Inhibitors+and+Immunotherapy%3B+a+Double+Edged+Sword%3F&doi=10.18632%2Foncotarget.2289"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2289%26sid%3Dliteratum%253Aachs%26aulast%3DKroesen%26aufirst%3DM.%26aulast%3DGielen%26aufirst%3DP.%2BR.%26aulast%3DBrok%26aufirst%3DI.%2BC.%26aulast%3DArmandari%26aufirst%3DI.%26aulast%3DHoogerbrugge%26aufirst%3DP.%2BM.%26aulast%3DAdema%26aufirst%3DG.%2BJ.%26atitle%3DHDAC%2520Inhibitors%2520and%2520Immunotherapy%253B%2520a%2520Double%2520Edged%2520Sword%253F%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D6558%26epage%3D6572%26doi%3D10.18632%2Foncotarget.2289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haftchenary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luchman, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouk, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veloso, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, B. D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinshtein, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahani, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-awar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span> <span> </span><span class="NLM_article-title">Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1102</span>– <span class="NLM_lpage">1107</span>, <span class="refDoi"> DOI: 10.1021/ml4003138</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4003138" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSls7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1102-1107&author=S.+Haftchenaryauthor=H.+A.+Luchmanauthor=A.+O.+Joukauthor=A.+J.+Velosoauthor=B.+D.+G.+Pageauthor=X.+R.+Chengauthor=S.+S.+Dawsonauthor=N.+Grinshteinauthor=V.+M.+Shahaniauthor=K.+Kermanauthor=D.+R.+Kaplanauthor=C.+Griffinauthor=A.+M.+Amanauthor=R.+Al-awarauthor=S.+Weissauthor=P.+T.+Gunning&title=Potent+Targeting+of+the+STAT3+Protein+in+Brain+Cancer+Stem+Cells%3A+A+Promising+Route+for+Treating+Glioblastoma&doi=10.1021%2Fml4003138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma</span></div><div class="casAuthors">Haftchenary, Sina; Luchman, H. Artee; Jouk, Andriana O.; Veloso, Anthony J.; Page, Brent D. G.; Cheng, Xin Ran; Dawson, Sean S.; Grinshtein, Natalie; Shahani, Vijay M.; Kerman, Kagan; Kaplan, David R.; Griffin, Carly; Aman, Ahmed M.; Al-awar, Rima; Weiss, Samuel; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1102-1107</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The STAT3 gene is abnormally active in glioblastoma (GBM) and is a critically important mediator of tumor growth and therapeutic resistance in GBM.  Thus, for poorly treated brain cancers such as gliomas, astrocytomas, and glioblastomas, which harbor constitutively activated STAT3, a STAT3-targeting therapeutic will be of significant importance.  Herein, we report a most potent, small mol., nonphosphorylated STAT3 inhibitor, I (SH-4-54) that strongly binds to STAT3 protein (KD = 300 nM).  Inhibitor I potently kills glioblastoma brain cancer stem cells (BTSCs) and effectively suppresses STAT3 phosphorylation and its downstream transcriptional targets at low nM concns.  Moreover, in vivo, I exhibited blood-brain barrier permeability, potently controlled glioma tumor growth, and inhibited pSTAT3 in vivo.  This work, for the first time, demonstrates the power of STAT3 inhibitors for the treatment of BTSCs and validates the therapeutic efficacy of a STAT3 inhibitor for GBM clin. application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8sxT0MMrOY7Vg90H21EOLACvtfcHk0lgR0gUEnJwT8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSls7rK&md5=34a07baae61cd1b90eef1d9eae3d2ea9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fml4003138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4003138%26sid%3Dliteratum%253Aachs%26aulast%3DHaftchenary%26aufirst%3DS.%26aulast%3DLuchman%26aufirst%3DH.%2BA.%26aulast%3DJouk%26aufirst%3DA.%2BO.%26aulast%3DVeloso%26aufirst%3DA.%2BJ.%26aulast%3DPage%26aufirst%3DB.%2BD.%2BG.%26aulast%3DCheng%26aufirst%3DX.%2BR.%26aulast%3DDawson%26aufirst%3DS.%2BS.%26aulast%3DGrinshtein%26aufirst%3DN.%26aulast%3DShahani%26aufirst%3DV.%2BM.%26aulast%3DKerman%26aufirst%3DK.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DGriffin%26aufirst%3DC.%26aulast%3DAman%26aufirst%3DA.%2BM.%26aulast%3DAl-awar%26aufirst%3DR.%26aulast%3DWeiss%26aufirst%3DS.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DPotent%2520Targeting%2520of%2520the%2520STAT3%2520Protein%2520in%2520Brain%2520Cancer%2520Stem%2520Cells%253A%2520A%2520Promising%2520Route%2520for%2520Treating%2520Glioblastoma%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D1102%26epage%3D1107%26doi%3D10.1021%2Fml4003138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haftchenary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croucher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudel, S.</span></span> <span> </span><span class="NLM_article-title">Abstract C246: SH-4-54, a Novel Small-Molecule Inhibitor of STAT3, Demonstrates Significant Anti-Tumor Activity Against Multiple Myeloma</span>. <i>Mol. Cancer. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">C246</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.TARG-13-C246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1158%2F1535-7163.TARG-13-C246" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=C246&author=Z.+H.+Liauthor=S.+Haftchenaryauthor=D.+Croucherauthor=P.+T.+Gunningauthor=S.+Trudel&title=Abstract+C246%3A+SH-4-54%2C+a+Novel+Small-Molecule+Inhibitor+of+STAT3%2C+Demonstrates+Significant+Anti-Tumor+Activity+Against+Multiple+Myeloma&doi=10.1158%2F1535-7163.TARG-13-C246"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.TARG-13-C246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.TARG-13-C246%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%2BH.%26aulast%3DHaftchenary%26aufirst%3DS.%26aulast%3DCroucher%26aufirst%3DD.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26aulast%3DTrudel%26aufirst%3DS.%26atitle%3DAbstract%2520C246%253A%2520SH-4-54%252C%2520a%2520Novel%2520Small-Molecule%2520Inhibitor%2520of%2520STAT3%252C%2520Demonstrates%2520Significant%2520Anti-Tumor%2520Activity%2520Against%2520Multiple%2520Myeloma%26jtitle%3DMol.%2520Cancer.%2520Ther.%26date%3D2013%26volume%3D12%26spage%3DC246%26doi%3D10.1158%2F1535-7163.TARG-13-C246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ali, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Biagi, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, P.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaton, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiring, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellore, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Araujo, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shouksmith, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span> <span> </span><span class="NLM_article-title">Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">850</span>– <span class="NLM_lpage">861</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1002%2Fcmdc.201600021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=27028877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC28XltVOitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=850-861&author=A.+M.+Aliauthor=R.+F.+Gomez-Biagiauthor=D.+A.+Rosaauthor=P.-S.+Laiauthor=W.+L.+Heatonauthor=J.+S.+Parkauthor=A.+M.+Eiringauthor=N.+A.+Velloreauthor=E.+D.+de+Araujoauthor=D.+P.+Ballauthor=A.+E.+Shouksmithauthor=A.+B.+Patelauthor=M.+W.+Deiningerauthor=T.+O%E2%80%99Hareauthor=P.+T.+Gunning&title=Disarming+an+Electrophilic+Warhead%3A+Retaining+Potency+in+Tyrosine+Kinase+Inhibitor+%28TKI%29-Resistant+CML+Lines+While+Circumventing+Pharmacokinetic+Liabilities&doi=10.1002%2Fcmdc.201600021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities</span></div><div class="casAuthors">Ali, Ahmed M.; Gomez-Biagi, Rodolfo F.; Rosa, David A.; Lai, Ping-Shan; Heaton, William L.; Park, Ji Sung; Eiring, Anna M.; Vellore, Nadeem A.; de Araujo, Elvin D.; Ball, Dan P.; Shouksmith, Andrew E.; Patel, Ami B.; Deininger, Michael W.; O'Hare, Thomas; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">850-861</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Pharmacol. blockade of the activation of signal transducer and activator of transcription 3 (STAT3) in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia (CML) cell lines characterized by kinase-independent resistance was shown to re-sensitize CML cells to TKI therapy, suggesting that STAT3 inhibitors in combination with TKIs are an effective combinatorial therapeutic for the treatment of CML.  Benzoic acid- and hydroxamic acid-based STAT3 inhibitors SH-4-054 and SH-5-007, developed previously in our lab., demonstrated promising activity against these resistant CML cell lines.  However, pharmacokinetic studies in murine models (CD-1 mice) revealed that both SH-4-054 and SH-5-007 are susceptible to glutathione conjugation at the para position of the pentafluorophenyl group via nucleophilic arom. substitution (SNAr).  To det. whether the electrophilicity of the pentafluorophenyl sulfonamide could be tempered, an in-depth structure-activity relationship (SAR) study of the SH-4-054 scaffold was conducted.  These studies revealed that AM-1-124, possessing a 2,3,5,6-tetrafluorophenylsulfonamide group, retained STAT3 protein affinity (Ki=15 μm), as well as selectivity over STAT1 (Ki>250 μm).  Moreover, in both hepatocytes and in in vivo pharmacokinetic studies (CD-1 mice), AM-1-124 was found to be dramatically more stable than SH-4-054 (t1/2=1.42 h cf. 10 min, resp.).  AM-1-124 is a promising STAT3-targeting inhibitor with demonstrated bioavailability, suitable for evaluation in preclin. cancer models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS38duOD8NmLVg90H21EOLACvtfcHk0lgR0gUEnJwT8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltVOitL4%253D&md5=f356ee9c2078e878e2756c885f099d55</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600021%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DA.%2BM.%26aulast%3DGomez-Biagi%26aufirst%3DR.%2BF.%26aulast%3DRosa%26aufirst%3DD.%2BA.%26aulast%3DLai%26aufirst%3DP.-S.%26aulast%3DHeaton%26aufirst%3DW.%2BL.%26aulast%3DPark%26aufirst%3DJ.%2BS.%26aulast%3DEiring%26aufirst%3DA.%2BM.%26aulast%3DVellore%26aufirst%3DN.%2BA.%26aulast%3Dde%2BAraujo%26aufirst%3DE.%2BD.%26aulast%3DBall%26aufirst%3DD.%2BP.%26aulast%3DShouksmith%26aufirst%3DA.%2BE.%26aulast%3DPatel%26aufirst%3DA.%2BB.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DDisarming%2520an%2520Electrophilic%2520Warhead%253A%2520Retaining%2520Potency%2520in%2520Tyrosine%2520Kinase%2520Inhibitor%2520%2528TKI%2529-Resistant%2520CML%2520Lines%2520While%2520Circumventing%2520Pharmacokinetic%2520Liabilities%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D850%26epage%3D861%26doi%3D10.1002%2Fcmdc.201600021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cumaraswamy, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geletu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laister, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muench, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimes, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minden, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span> <span> </span><span class="NLM_article-title">Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1202</span>– <span class="NLM_lpage">1206</span>, <span class="refDoi"> DOI: 10.1021/ml500165r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500165r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1202-1206&author=A.+A.+Cumaraswamyauthor=A.+M.+Lewisauthor=M.+Geletuauthor=A.+Todicauthor=D.+B.+Diazauthor=X.+R.+Chengauthor=C.+E.+Brownauthor=R.+C.+Laisterauthor=D.+Muenchauthor=K.+Kermanauthor=H.+L.+Grimesauthor=M.+D.+Mindenauthor=P.+T.+Gunning&title=Nanomolar-Potency+Small+Molecule+Inhibitor+of+STAT5+Protein&doi=10.1021%2Fml500165r"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fml500165r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500165r%26sid%3Dliteratum%253Aachs%26aulast%3DCumaraswamy%26aufirst%3DA.%2BA.%26aulast%3DLewis%26aufirst%3DA.%2BM.%26aulast%3DGeletu%26aufirst%3DM.%26aulast%3DTodic%26aufirst%3DA.%26aulast%3DDiaz%26aufirst%3DD.%2BB.%26aulast%3DCheng%26aufirst%3DX.%2BR.%26aulast%3DBrown%26aufirst%3DC.%2BE.%26aulast%3DLaister%26aufirst%3DR.%2BC.%26aulast%3DMuench%26aufirst%3DD.%26aulast%3DKerman%26aufirst%3DK.%26aulast%3DGrimes%26aufirst%3DH.%2BL.%26aulast%3DMinden%26aufirst%3DM.%2BD.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DNanomolar-Potency%2520Small%2520Molecule%2520Inhibitor%2520of%2520STAT5%2520Protein%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D1202%26epage%3D1206%26doi%3D10.1021%2Fml500165r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Page, B. D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croucher, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haftchenary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Zepeda, V. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spagnuolo, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colaguori, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span> <span> </span><span class="NLM_article-title">Inhibiting Aberrant Signal Transducer and Activator of Transcription Protein Activation with Tetrapodal, Small Molecule Src Homology 2 Domain Binders: Promising Agents Against Multiple Myeloma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7190</span>– <span class="NLM_lpage">7200</span>, <span class="refDoi"> DOI: 10.1021/jm3017255</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3017255" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlWltbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7190-7200&author=B.+D.+G.+Pageauthor=D.+C.+Croucherauthor=Z.+H.+Liauthor=S.+Haftchenaryauthor=V.+H.+Jimenez-Zepedaauthor=J.+Atkinsonauthor=P.+A.+Spagnuoloauthor=Y.+L.+Wongauthor=R.+Colaguoriauthor=A.+M.+Lewisauthor=A.+D.+Schimmerauthor=S.+Trudelauthor=P.+T.+Gunning&title=Inhibiting+Aberrant+Signal+Transducer+and+Activator+of+Transcription+Protein+Activation+with+Tetrapodal%2C+Small+Molecule+Src+Homology+2+Domain+Binders%3A+Promising+Agents+Against+Multiple+Myeloma&doi=10.1021%2Fjm3017255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting Aberrant Signal Transducer and Activator of Transcription Protein Activation with Tetrapodal, Small Molecule Src Homology 2 Domain Binders: Promising Agents against Multiple Myeloma</span></div><div class="casAuthors">Page, Brent D. G.; Croucher, Danielle C.; Li, Zhi Hua; Haftchenary, Sina; Jimenez-Zepeda, Victor H.; Atkinson, Jennifer; Spagnuolo, Paul A.; Wong, Yoong Lim; Colaguori, Robert; Lewis, Andrew M.; Schimmer, Aaron D.; Trudel, Suzanne; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7190-7200</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">[(Arylsulfonyl)glycinyl](cyclohexylbenzyl)aminosalicylic acids such as I (R = 4-MeC6H4, F5C6; R1 = 2-F3CC6H4) were prepd. as inhibitors of the signal transducer and activator of transcription (STAT) protein Stat3 for potential use as treatments for multiple myeloma.  The hydrophobicities of I and their inhibition of Stat3 were detd.; mol. docking of selected compds. to the SH2 domain of Stat3 and inhibition of Stat3 phosphorylation under various conditions were detd. for selected compds., and the activity of I (R = 4-MeC6H4; R1 = 2-F3CC6H4) against human multiple myeloma cells and human hematopoietic cells and its induction of apoptosis in multiple myeloma cells was detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9RTVwhgsvE7Vg90H21EOLACvtfcHk0liBJriElhfS7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlWltbrL&md5=9cce9797681eccfcf43b0f8b1a813914</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm3017255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3017255%26sid%3Dliteratum%253Aachs%26aulast%3DPage%26aufirst%3DB.%2BD.%2BG.%26aulast%3DCroucher%26aufirst%3DD.%2BC.%26aulast%3DLi%26aufirst%3DZ.%2BH.%26aulast%3DHaftchenary%26aufirst%3DS.%26aulast%3DJimenez-Zepeda%26aufirst%3DV.%2BH.%26aulast%3DAtkinson%26aufirst%3DJ.%26aulast%3DSpagnuolo%26aufirst%3DP.%2BA.%26aulast%3DWong%26aufirst%3DY.%2BL.%26aulast%3DColaguori%26aufirst%3DR.%26aulast%3DLewis%26aufirst%3DA.%2BM.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DTrudel%26aufirst%3DS.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DInhibiting%2520Aberrant%2520Signal%2520Transducer%2520and%2520Activator%2520of%2520Transcription%2520Protein%2520Activation%2520with%2520Tetrapodal%252C%2520Small%2520Molecule%2520Src%2520Homology%25202%2520Domain%2520Binders%253A%2520Promising%2520Agents%2520Against%2520Multiple%2520Myeloma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7190%26epage%3D7200%26doi%3D10.1021%2Fjm3017255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helquist, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiech, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiest, O.</span></span> <span> </span><span class="NLM_article-title">Toward Selective Histone Deacetylase Inhibitor Design: Homology Modeling, Docking Studies, and Molecular Dynamics Simulations of Human Class I Histone Deacetylases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6936</span>– <span class="NLM_lpage">6947</span>, <span class="refDoi"> DOI: 10.1021/jm0505011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0505011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtV2jsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6936-6947&author=D.-F.+Wangauthor=P.+Helquistauthor=N.+L.+Wiechauthor=O.+Wiest&title=Toward+Selective+Histone+Deacetylase+Inhibitor+Design%3A+Homology+Modeling%2C+Docking+Studies%2C+and+Molecular+Dynamics+Simulations+of+Human+Class+I+Histone+Deacetylases&doi=10.1021%2Fjm0505011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Selective Histone Deacetylase Inhibitor Design: Homology Modeling, Docking Studies, and Molecular Dynamics Simulations of Human Class I Histone Deacetylases</span></div><div class="casAuthors">Wang, Di-Fei; Helquist, Paul; Wiech, Norbert L.; Wiest, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6936-6947</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) play an important role in gene transcription.  Inhibitors of HDACs induce cell differentiation and suppress cell proliferation in tumor cells.  Although many HDAC inhibitors have been designed and synthesized, selective inhibition for class I HDAC isoforms is a goal that has yet to be achieved.  To understand the difference between class I HDAC isoforms that could be exploited for the design of isoform-specific HDAC inhibitors, the authors have built three-dimensional models of four class I histone deacetylases, HDAC1, HDAC2, HDAC3, and HDAC8.  Comparison of the homol. model of HDAC8 with the recently published x-ray structure shows excellent agreement and validates the approach.  A series of HDAC inhibitors were docked to the homol. models to understand the similarities and differences between the binding modes.  Mol. dynamic simulations of these HDAC-inhibitor complexes indicate that the interaction between the protein surface and inhibitor is playing an important role; also some active site residues show some flexibility, which is usually not included in routine docking protocols.  The implications of these results for the design of isoform-selective HDAC inhibitors are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb6SYJC1ObVLVg90H21EOLACvtfcHk0liBJriElhfS7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtV2jsLnL&md5=0b59815173df7f16feb9ba66c8b4da83</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm0505011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0505011%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.-F.%26aulast%3DHelquist%26aufirst%3DP.%26aulast%3DWiech%26aufirst%3DN.%2BL.%26aulast%3DWiest%26aufirst%3DO.%26atitle%3DToward%2520Selective%2520Histone%2520Deacetylase%2520Inhibitor%2520Design%253A%2520Homology%2520Modeling%252C%2520Docking%2520Studies%252C%2520and%2520Molecular%2520Dynamics%2520Simulations%2520of%2520Human%2520Class%2520I%2520Histone%2520Deacetylases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6936%26epage%3D6947%26doi%3D10.1021%2Fjm0505011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giannini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battistuzzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunetti, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabri, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vesci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisano, C.</span></span> <span> </span><span class="NLM_article-title">Exploring Bis-(Indolyl)Methane Moiety as an Alternative and Innovative CAP Group in the Design of Histone Deacetylase (HDAC) Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2840</span>– <span class="NLM_lpage">2843</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.03.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1016%2Fj.bmcl.2009.03.101" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2840-2843&author=G.+Gianniniauthor=M.+Marziauthor=M.+D.+Marzoauthor=G.+Battistuzziauthor=R.+Pezziauthor=T.+Brunettiauthor=W.+Cabriauthor=L.+Vesciauthor=C.+Pisano&title=Exploring+Bis-%28Indolyl%29Methane+Moiety+as+an+Alternative+and+Innovative+CAP+Group+in+the+Design+of+Histone+Deacetylase+%28HDAC%29+Inhibitors&doi=10.1016%2Fj.bmcl.2009.03.101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.03.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.03.101%26sid%3Dliteratum%253Aachs%26aulast%3DGiannini%26aufirst%3DG.%26aulast%3DMarzi%26aufirst%3DM.%26aulast%3DMarzo%26aufirst%3DM.%2BD.%26aulast%3DBattistuzzi%26aufirst%3DG.%26aulast%3DPezzi%26aufirst%3DR.%26aulast%3DBrunetti%26aufirst%3DT.%26aulast%3DCabri%26aufirst%3DW.%26aulast%3DVesci%26aufirst%3DL.%26aulast%3DPisano%26aufirst%3DC.%26atitle%3DExploring%2520Bis-%2528Indolyl%2529Methane%2520Moiety%2520as%2520an%2520Alternative%2520and%2520Innovative%2520CAP%2520Group%2520in%2520the%2520Design%2520of%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2840%26epage%3D2843%26doi%3D10.1016%2Fj.bmcl.2009.03.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salmi-Smail, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dequiedt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Restouin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morelli, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collette, Y.</span></span> <span> </span><span class="NLM_article-title">Modified Cap Group Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitor Derivatives Reveal Improved Selective Antileukemic Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3038</span>– <span class="NLM_lpage">3047</span>, <span class="refDoi"> DOI: 10.1021/jm901358y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901358y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtVOqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3038-3047&author=C.+Salmi-Smailauthor=A.+Fabreauthor=F.+Dequiedtauthor=A.+Restouinauthor=R.+Castellanoauthor=S.+Garbitauthor=P.+Rocheauthor=X.+Morelliauthor=J.+M.+Brunelauthor=Y.+Collette&title=Modified+Cap+Group+Suberoylanilide+Hydroxamic+Acid+Histone+Deacetylase+Inhibitor+Derivatives+Reveal+Improved+Selective+Antileukemic+Activity&doi=10.1021%2Fjm901358y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Modified Cap Group Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitor Derivatives Reveal Improved Selective Antileukemic Activity</span></div><div class="casAuthors">Salmi-Smail, Chanaz; Fabre, Aurelie; Dequiedt, Franck; Restouin, Audrey; Castellano, Remy; Garbit, Slaveia; Roche, Philippe; Morelli, Xavier; Brunel, Jean Michel; Collette, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3038-3047</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of SAHA cap derivs. RNHCO(CH2)6CONHOH (R = Ph, 4-H2NC6H4, 2-BrC6H4, 2-naphthyl, 8-quinolinyl, etc.) was designed and prepd. in good-to-excellent yields that varied from 49% to 95%.  These derivs. were evaluated for their antiproliferative activity in several human cancer cell lines.  Antiproliferative activity was obsd. for concns. varying from 0.12 to >100 μM, and a mol. modeling approach of selected SAHA derivs., based on available structural information of human HDAC8 in complex with SAHA, was performed.  Strikingly, two compds. displayed up to 10-fold improved antileukemic activity with respect to SAHA; however, these compds. displayed antiproliferative activity similar to SAHA when assayed against solid tumor-derived cell lines.  A 10-fold improvement in the leukemic vs peripheral blood mononuclear cell therapeutic ratio, with no evident in vivo toxicity toward blood cells, was also obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjnbACulcCkrVg90H21EOLACvtfcHk0lg6FzKWgFL8cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtVOqtrY%253D&md5=70cf706e641add7d1ee6d410b501e075</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm901358y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901358y%26sid%3Dliteratum%253Aachs%26aulast%3DSalmi-Smail%26aufirst%3DC.%26aulast%3DFabre%26aufirst%3DA.%26aulast%3DDequiedt%26aufirst%3DF.%26aulast%3DRestouin%26aufirst%3DA.%26aulast%3DCastellano%26aufirst%3DR.%26aulast%3DGarbit%26aufirst%3DS.%26aulast%3DRoche%26aufirst%3DP.%26aulast%3DMorelli%26aufirst%3DX.%26aulast%3DBrunel%26aufirst%3DJ.%2BM.%26aulast%3DCollette%26aufirst%3DY.%26atitle%3DModified%2520Cap%2520Group%2520Suberoylanilide%2520Hydroxamic%2520Acid%2520Histone%2520Deacetylase%2520Inhibitor%2520Derivatives%2520Reveal%2520Improved%2520Selective%2520Antileukemic%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3038%26epage%3D3047%26doi%3D10.1021%2Fjm901358y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitarresi, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuitino, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kladney, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woelke, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sizemore, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egriboz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweickert, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trela, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schilling, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halloran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosol, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesinski, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konieczny, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrowski, M. C.</span></span> <span> </span><span class="NLM_article-title">Genetic Ablation of Smoothened in Pancreatic Fibroblasts Increases Acinar-Ductal Metaplasia</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1943</span>– <span class="NLM_lpage">1955</span>, <span class="refDoi"> DOI: 10.1101/gad.283499.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1101%2Fgad.283499.116" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=1943-1955&author=X.+Liuauthor=J.+R.+Pitarresiauthor=M.+C.+Cuitinoauthor=R.+D.+Kladneyauthor=S.+A.+Woelkeauthor=G.+M.+Sizemoreauthor=S.+G.+Nayakauthor=O.+Egribozauthor=P.+G.+Schweickertauthor=L.+Yuauthor=S.+Trelaauthor=D.+J.+Schillingauthor=S.+K.+Halloranauthor=M.+Liauthor=S.+Duttaauthor=S.+A.+Fernandezauthor=T.+J.+Rosolauthor=G.+B.+Lesinskiauthor=R.+Shakyaauthor=T.+Ludwigauthor=S.+F.+Koniecznyauthor=G.+Leoneauthor=J.+Wuauthor=M.+C.+Ostrowski&title=Genetic+Ablation+of+Smoothened+in+Pancreatic+Fibroblasts+Increases+Acinar-Ductal+Metaplasia&doi=10.1101%2Fgad.283499.116"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1101%2Fgad.283499.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.283499.116%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DPitarresi%26aufirst%3DJ.%2BR.%26aulast%3DCuitino%26aufirst%3DM.%2BC.%26aulast%3DKladney%26aufirst%3DR.%2BD.%26aulast%3DWoelke%26aufirst%3DS.%2BA.%26aulast%3DSizemore%26aufirst%3DG.%2BM.%26aulast%3DNayak%26aufirst%3DS.%2BG.%26aulast%3DEgriboz%26aufirst%3DO.%26aulast%3DSchweickert%26aufirst%3DP.%2BG.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DTrela%26aufirst%3DS.%26aulast%3DSchilling%26aufirst%3DD.%2BJ.%26aulast%3DHalloran%26aufirst%3DS.%2BK.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DDutta%26aufirst%3DS.%26aulast%3DFernandez%26aufirst%3DS.%2BA.%26aulast%3DRosol%26aufirst%3DT.%2BJ.%26aulast%3DLesinski%26aufirst%3DG.%2BB.%26aulast%3DShakya%26aufirst%3DR.%26aulast%3DLudwig%26aufirst%3DT.%26aulast%3DKonieczny%26aufirst%3DS.%2BF.%26aulast%3DLeone%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DOstrowski%26aufirst%3DM.%2BC.%26atitle%3DGenetic%2520Ablation%2520of%2520Smoothened%2520in%2520Pancreatic%2520Fibroblasts%2520Increases%2520Acinar-Ductal%2520Metaplasia%26jtitle%3DGenes%2520Dev.%26date%3D2016%26volume%3D30%26spage%3D1943%26epage%3D1955%26doi%3D10.1101%2Fgad.283499.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hingorani, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multani, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deramaudt, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruban, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustgi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuveson, D. A.</span></span> <span> </span><span class="NLM_article-title">Trp53R172H and KrasG12D Cooperate to Promote Chromosomal Instability and Widely Metastatic Pancreatic Ductal Adenocarcinoma in Mice</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">483</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2005.04.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1016%2Fj.ccr.2005.04.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=15894267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslyitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=469-483&author=S.+R.+Hingoraniauthor=L.+Wangauthor=A.+S.+Multaniauthor=C.+Combsauthor=T.+B.+Deramaudtauthor=R.+H.+Hrubanauthor=A.+K.+Rustgiauthor=S.+Changauthor=D.+A.+Tuveson&title=Trp53R172H+and+KrasG12D+Cooperate+to+Promote+Chromosomal+Instability+and+Widely+Metastatic+Pancreatic+Ductal+Adenocarcinoma+in+Mice&doi=10.1016%2Fj.ccr.2005.04.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice</span></div><div class="casAuthors">Hingorani, Sunil R.; Wang, Lifu; Multani, Asha S.; Combs, Chelsea; Deramaudt, Therese B.; Hruban, Ralph H.; Rustgi, Anil K.; Chang, Sandy; Tuveson, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">469-483</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To define the genetic requirements for pancreatic ductal adenocarcinoma (PDA), we have targeted concomitant endogenous expression of Trp53R172H and KrasG12D to the mouse pancreas, revealing the cooperative development of invasive and widely metastatic carcinoma that recapitulates the human disease.  The primary carcinomas and metastases demonstrate a high degree of genomic instability manifested by nonreciprocal translocations without obvious telomere erosion-hallmarks of human carcinomas not typically obsd. in mice.  No mutations were discovered in other cardinal tumor suppressor gene pathways, which, together with previous results, suggests that there are distinct genetic pathways to PDA with different biol. behaviors.  These findings have clear implications for understanding mechanisms of disease pathogenesis, and for the development of detection and targeted treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUqdYCBqe-vrVg90H21EOLACvtfcHk0lg6FzKWgFL8cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslyitLk%253D&md5=fef745f04506e9e64bbc760a1d6f8cf6</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.04.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.04.023%26sid%3Dliteratum%253Aachs%26aulast%3DHingorani%26aufirst%3DS.%2BR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMultani%26aufirst%3DA.%2BS.%26aulast%3DCombs%26aufirst%3DC.%26aulast%3DDeramaudt%26aufirst%3DT.%2BB.%26aulast%3DHruban%26aufirst%3DR.%2BH.%26aulast%3DRustgi%26aufirst%3DA.%2BK.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26atitle%3DTrp53R172H%2520and%2520KrasG12D%2520Cooperate%2520to%2520Promote%2520Chromosomal%2520Instability%2520and%2520Widely%2520Metastatic%2520Pancreatic%2520Ductal%2520Adenocarcinoma%2520in%2520Mice%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D469%26epage%3D483%26doi%3D10.1016%2Fj.ccr.2005.04.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olive, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobetz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopinathan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldgraben, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frese, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeNicola, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ireland-Zecchini, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichelt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howat, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruckert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grutzmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilarsky, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izeradjene, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hingorani, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plunkett, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egorin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruban, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGovern, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobuzio-Donahue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuveson, D. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">1457</span>– <span class="NLM_lpage">1461</span>, <span class="refDoi"> DOI: 10.1126/science.1171362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1126%2Fscience.1171362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=19460966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVSiu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2009&pages=1457-1461&author=K.+P.+Oliveauthor=M.+A.+Jacobetzauthor=C.+J.+Davidsonauthor=A.+Gopinathanauthor=D.+McIntyreauthor=D.+Honessauthor=B.+Madhuauthor=M.+A.+Goldgrabenauthor=M.+E.+Caldwellauthor=D.+Allardauthor=K.+K.+Freseauthor=G.+DeNicolaauthor=C.+Feigauthor=C.+Combsauthor=S.+P.+Winterauthor=H.+Ireland-Zecchiniauthor=S.+Reicheltauthor=W.+J.+Howatauthor=A.+Changauthor=M.+Dharaauthor=L.+F.+Wangauthor=F.+Ruckertauthor=R.+Grutzmannauthor=C.+Pilarskyauthor=K.+Izeradjeneauthor=S.+R.+Hingoraniauthor=P.+Huangauthor=S.+E.+Daviesauthor=W.+Plunkettauthor=M.+Egorinauthor=R.+H.+Hrubanauthor=N.+Whitebreadauthor=K.+McGovernauthor=J.+Adamsauthor=C.+Iacobuzio-Donahueauthor=J.+Griffithsauthor=D.+A.+Tuveson&title=Inhibition+of+Hedgehog+Signaling+Enhances+Delivery+of+Chemotherapy+in+a+Mouse+Model+of+Pancreatic+Cancer&doi=10.1126%2Fscience.1171362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer</span></div><div class="casAuthors">Olive, Kenneth P.; Jacobetz, Michael A.; Davidson, Christian J.; Gopinathan, Aarthi; McIntyre, Dominick; Honess, Davina; Madhu, Basetti; Goldgraben, Mae A.; Caldwell, Meredith E.; Allard, David; Frese, Kristopher K.; DeNicola, Gina; Feig, Christine; Combs, Chelsea; Winter, Stephen P.; Ireland-Zecchini, Heather; Reichelt, Stefanie; Howat, William J.; Chang, Alex; Dhara, Mousumi; Wang, Lifu; Rueckert, Felix; Gruetzmann, Robert; Pilarsky, Christian; Izeradjene, Kamel; Hingorani, Sunil R.; Huang, Pearl; Davies, Susan E.; Plunkett, William; Egorin, Merrill; Hruban, Ralph H.; Whitebread, Nigel; McGovern, Karen; Adams, Julian; Iacobuzio-Donahue, Christine; Griffiths, John; Tuveson, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">5933</span>),
    <span class="NLM_cas:pages">1457-1461</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDA) is among the most lethal human cancers in part because it is insensitive to many chemotherapeutic drugs.  Studying a mouse model of PDA that is refractory to the clin. used drug gemcitabine, we found that the tumors in this model were poorly perfused and poorly vascularized, properties that are shared with human PDA.  We tested whether the delivery and efficacy of gemcitabine in the mice could be improved by coadministration of IPI-926, a drug that depletes tumor-assocd. stromal tissue by inhibition of the Hedgehog cellular signaling pathway.  The combination therapy produced a transient increase in intratumoral vascular d. and intratumoral concn. of gemcitabine, leading to transient stabilization of disease.  Thus, inefficient drug delivery may be an important contributor to chemoresistance in pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_XYqveCF3BLVg90H21EOLACvtfcHk0lgYSAUPeKSl8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVSiu7Y%253D&md5=930e5843af03a3b1bb15cab8dcb4e3fe</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1126%2Fscience.1171362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1171362%26sid%3Dliteratum%253Aachs%26aulast%3DOlive%26aufirst%3DK.%2BP.%26aulast%3DJacobetz%26aufirst%3DM.%2BA.%26aulast%3DDavidson%26aufirst%3DC.%2BJ.%26aulast%3DGopinathan%26aufirst%3DA.%26aulast%3DMcIntyre%26aufirst%3DD.%26aulast%3DHoness%26aufirst%3DD.%26aulast%3DMadhu%26aufirst%3DB.%26aulast%3DGoldgraben%26aufirst%3DM.%2BA.%26aulast%3DCaldwell%26aufirst%3DM.%2BE.%26aulast%3DAllard%26aufirst%3DD.%26aulast%3DFrese%26aufirst%3DK.%2BK.%26aulast%3DDeNicola%26aufirst%3DG.%26aulast%3DFeig%26aufirst%3DC.%26aulast%3DCombs%26aufirst%3DC.%26aulast%3DWinter%26aufirst%3DS.%2BP.%26aulast%3DIreland-Zecchini%26aufirst%3DH.%26aulast%3DReichelt%26aufirst%3DS.%26aulast%3DHowat%26aufirst%3DW.%2BJ.%26aulast%3DChang%26aufirst%3DA.%26aulast%3DDhara%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%2BF.%26aulast%3DRuckert%26aufirst%3DF.%26aulast%3DGrutzmann%26aufirst%3DR.%26aulast%3DPilarsky%26aufirst%3DC.%26aulast%3DIzeradjene%26aufirst%3DK.%26aulast%3DHingorani%26aufirst%3DS.%2BR.%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DDavies%26aufirst%3DS.%2BE.%26aulast%3DPlunkett%26aufirst%3DW.%26aulast%3DEgorin%26aufirst%3DM.%26aulast%3DHruban%26aufirst%3DR.%2BH.%26aulast%3DWhitebread%26aufirst%3DN.%26aulast%3DMcGovern%26aufirst%3DK.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DIacobuzio-Donahue%26aufirst%3DC.%26aulast%3DGriffiths%26aufirst%3DJ.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26atitle%3DInhibition%2520of%2520Hedgehog%2520Signaling%2520Enhances%2520Delivery%2520of%2520Chemotherapy%2520in%2520a%2520Mouse%2520Model%2520of%2520Pancreatic%2520Cancer%26jtitle%3DScience%26date%3D2009%26volume%3D324%26spage%3D1457%26epage%3D1461%26doi%3D10.1126%2Fscience.1171362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Licciardi, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ververis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Osta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karagiannis, T. C.</span></span> <span> </span><span class="NLM_article-title">Immunomodulatory Effects of Histone Deacetylase Inhibitors</span>. <i>Curr. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">640</span>– <span class="NLM_lpage">647</span>, <span class="refDoi"> DOI: 10.2174/1566524011313040013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.2174%2F1566524011313040013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=23061676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFahtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=640-647&author=P.+V.+Licciardiauthor=K.+Ververisauthor=M.+L.+Tangauthor=A.+El-Ostaauthor=T.+C.+Karagiannis&title=Immunomodulatory+Effects+of+Histone+Deacetylase+Inhibitors&doi=10.2174%2F1566524011313040013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Immunomodulatory effects of histone deacetylase inhibitors</span></div><div class="casAuthors">Licciardi, P. V.; Ververis, K.; Tang, M. L.; El-Osta, A.; Karagiannis, T. C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Molecular Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">640-647</span>CODEN:
                <span class="NLM_cas:coden">CMMUBP</span>;
        ISSN:<span class="NLM_cas:issn">1566-5240</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors (HDACi) have emerged as a new generation of anticancer therapeutics.  The classical broad-spectrum HDACi typically alter the cell cycle distribution and induce cell-death, apoptosis and differentiation in malignant and transformed cells.  This provides the basis for the clin. potential of HDACi in cancer therapy.  Currently two compds., suberoylanilide hydroxamic acid (SAHA, Vorinostat, Zolinza) and depsipeptide (Romidepsin, Istodax) have been approved for by the US Food and Drug Administration for the treatment of refractory cutaneous T-cell lymphoma.  Apart from clin. application in oncol., HDACi have also been investigated as potential therapeutics for various pathologies including those of the central nervous system (such as Huntington's disease and multiple sclerosis), cardiac conditions (particularly hypertrophy), arthritis and malaria.  Further, evidence is accumulating for potent immunomodulatory effects of classical HDACi which is the focus of this review.  We review the anti-inflammatory effects of HDACi and in particular findings implicating regulation of the innate and adaptive immune systems by HDAC enzymes.  The recent findings highlighting the immunomodulatory function of HDAC11 which relates to balancing immune activation vs. tolerance are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCwr7rAQ9baLVg90H21EOLACvtfcHk0lgYSAUPeKSl8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFahtLw%253D&md5=feabae7b0d27b18f38da335e6da10804</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.2174%2F1566524011313040013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1566524011313040013%26sid%3Dliteratum%253Aachs%26aulast%3DLicciardi%26aufirst%3DP.%2BV.%26aulast%3DVerveris%26aufirst%3DK.%26aulast%3DTang%26aufirst%3DM.%2BL.%26aulast%3DEl-Osta%26aufirst%3DA.%26aulast%3DKaragiannis%26aufirst%3DT.%2BC.%26atitle%3DImmunomodulatory%2520Effects%2520of%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DCurr.%2520Mol.%2520Med.%26date%3D2013%26volume%3D13%26spage%3D640%26epage%3D647%26doi%3D10.2174%2F1566524011313040013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orillion, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damayanti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adelaiye-Ogala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arisa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chintala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ordentlich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elzey, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrilovich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pili, R.</span></span> <span> </span><span class="NLM_article-title">Entinostat Neutralizes Myeloid Derived Suppressor Cells and Enhances the Anti-Tumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5187</span>– <span class="NLM_lpage">5201</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-0741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1158%2F1078-0432.CCR-17-0741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=28698201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVCit7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=5187-5201&author=A.+Orillionauthor=A.+Hashimotoauthor=N.+Damayantiauthor=L.+Shenauthor=R.+Adelaiye-Ogalaauthor=S.+Arisaauthor=S.+Chintalaauthor=P.+Ordentlichauthor=C.+Kaoauthor=B.+Elzeyauthor=D.+Gabrilovichauthor=R.+Pili&title=Entinostat+Neutralizes+Myeloid+Derived+Suppressor+Cells+and+Enhances+the+Anti-Tumor+Effect+of+PD-1+Inhibition+in+Murine+Models+of+Lung+and+Renal+Cell+Carcinoma&doi=10.1158%2F1078-0432.CCR-17-0741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma</span></div><div class="casAuthors">Orillion, Ashley; Hashimoto, Ayumi; Damayanti, Nur; Shen, Li; Adelaiye-Ogala, Remi; Arisa, Sreevani; Chintala, Sreenivasulu; Ordentlich, Peter; Kao, Chingai; Elzey, Bennett; Gabrilovich, Dmitry; Pili, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5187-5201</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Recent advances in immunotherapy highlight the antitumor effects of immune checkpoint inhibition despite a relatively limited subset of patients receiving clin. benefit.  The selective class I histone deacetylase inhibitor entinostat has been reported to have immunomodulatory activity including targeting of immune suppressor cells in the tumor microenvironment.  Thus, we decided to assess whether entinostat could enhance anti-PD-1 treatment and investigate those alterations in the immunosuppressive tumor microenvironment that contribute to the combined antitumor activity.  Exptl. Design: We utilized syngeneic mouse models of lung (LLC) and renal cell (RENCA) carcinoma and assessed immune correlates, tumor growth, and survival following treatment with entinostat (5 or 10 mg/kg, p.o.) and a PD-1 inhibitor (10 and 20 mg/kg, s.c.).  Results: Entinostat enhanced the antitumor effect of PD-1 inhibition in two syngeneic mouse tumor models by reducing tumor growth and increasing survival.  Entinostat inhibited the immunosuppressive function of both polymorphonuclear (PMN)- and monocytic-myeloid derived suppressor cell (M-MDSC) populations.  Anal. of MDSC response to entinostat revealed significantly reduced arginase-1, iNOS, and COX-2 levels, suggesting potential mechanisms for the altered function.  We also obsd. significant alterations in cytokine/chemokine release in vivo with a shift toward a tumor-suppressive microenvironment.  Conclusions: Our results demonstrate that entinostat enhances the antitumor effect of PD-1 targeting through functional inhibition of MDSCs and a transition away from an immune-suppressive tumor microenvironment.  These data provide a mechanistic rationale for the clin. testing and potential markers of response of this novel combination in solid tumor patients.  Clin Cancer Res; 23(17); 5187-201. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfjJgfVBKo5rVg90H21EOLACvtfcHk0lgYSAUPeKSl8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVCit7jM&md5=b4461a1641c69b820bc7f6c5f1fcbba8</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-0741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-0741%26sid%3Dliteratum%253Aachs%26aulast%3DOrillion%26aufirst%3DA.%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DDamayanti%26aufirst%3DN.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DAdelaiye-Ogala%26aufirst%3DR.%26aulast%3DArisa%26aufirst%3DS.%26aulast%3DChintala%26aufirst%3DS.%26aulast%3DOrdentlich%26aufirst%3DP.%26aulast%3DKao%26aufirst%3DC.%26aulast%3DElzey%26aufirst%3DB.%26aulast%3DGabrilovich%26aufirst%3DD.%26aulast%3DPili%26aufirst%3DR.%26atitle%3DEntinostat%2520Neutralizes%2520Myeloid%2520Derived%2520Suppressor%2520Cells%2520and%2520Enhances%2520the%2520Anti-Tumor%2520Effect%2520of%2520PD-1%2520Inhibition%2520in%2520Murine%2520Models%2520of%2520Lung%2520and%2520Renal%2520Cell%2520Carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D5187%26epage%3D5201%26doi%3D10.1158%2F1078-0432.CCR-17-0741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markowitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedke, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesinski, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundy-Bosse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekaii-Saab, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, W. E.</span></span> <span> </span><span class="NLM_article-title">Patients with Pancreatic Adenocarcinoma Exhibit Elevated Levels of Myeloid-Derived Suppressor Cells upon Progression of Disease</span>. <i>Cancer Immunol. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1007/s00262-014-1618-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1007%2Fs00262-014-1618-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=25305035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslCisLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=149-159&author=J.+Markowitzauthor=T.+R.+Brooksauthor=M.+C.+Dugganauthor=B.+K.+Paulauthor=X.+Panauthor=L.+Weiauthor=Z.+Abramsauthor=E.+Luedkeauthor=G.+B.+Lesinskiauthor=B.+Mundy-Bosseauthor=T.+Bekaii-Saabauthor=W.+E.+Carson&title=Patients+with+Pancreatic+Adenocarcinoma+Exhibit+Elevated+Levels+of+Myeloid-Derived+Suppressor+Cells+upon+Progression+of+Disease&doi=10.1007%2Fs00262-014-1618-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease</span></div><div class="casAuthors">Markowitz, Joseph; Brooks, Taylor R.; Duggan, Megan C.; Paul, Bonnie K.; Pan, Xueliang; Wei, Lai; Abrams, Zachary; Luedke, Eric; Lesinski, Gregory B.; Mundy-Bosse, Bethany; Bekaii-Saab, Tanios; Carson, William E., III</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">149-159</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Elevated levels of myeloid-derived suppressor cells (MDSCs) induced by tumor-derived factors are assocd. with inhibition of immune responses in patients with gastrointestinal malignancies.  We hypothesized that pro-MDSC cytokines and levels of MDSC in the peripheral blood would be elevated in pancreatic adenocarcinoma patients with progressive disease.  Peripheral blood mononuclear cells (PBMCs) were isolated from 16 pancreatic cancer patients undergoing chemotherapy and phenotyped for MDSC using a five antigen panel (CD33, HLA-DR, CD11b, CD14, CD15).  Patients with stable disease had significantly lower MDSC levels in the peripheral blood than those with progressive disease (1.41 ± 1.12 vs. 5.14 ± 4.58 %, p = 0.013, Wilcoxon test).  A cutoff of 2.5 % MDSC identified patients with progressive disease.  Patients with ECOG performance status ≥2 had a weaker assocn. with increased levels of MDSC.  Plasma was obtained from 15 chemonaive patients, 13 patients undergoing chemotherapy and 9 normal donors.  Increases in the levels of pro-MDSC cytokines were obsd. for pancreatic cancer patients vs. controls, and the pro-MDSC cytokine IL-6 was increased in those patients undergoing chemotherapy.  This study suggests that MDSC in peripheral blood may be a predictive biomarker of chemotherapy failure in pancreatic cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqllxDB5kBbBrVg90H21EOLACvtfcHk0lhFXd2L7BAW3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslCisLfJ&md5=4eef6d9ee81dc20b52de58bc19c11384</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1007%2Fs00262-014-1618-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00262-014-1618-8%26sid%3Dliteratum%253Aachs%26aulast%3DMarkowitz%26aufirst%3DJ.%26aulast%3DBrooks%26aufirst%3DT.%2BR.%26aulast%3DDuggan%26aufirst%3DM.%2BC.%26aulast%3DPaul%26aufirst%3DB.%2BK.%26aulast%3DPan%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DAbrams%26aufirst%3DZ.%26aulast%3DLuedke%26aufirst%3DE.%26aulast%3DLesinski%26aufirst%3DG.%2BB.%26aulast%3DMundy-Bosse%26aufirst%3DB.%26aulast%3DBekaii-Saab%26aufirst%3DT.%26aulast%3DCarson%26aufirst%3DW.%2BE.%26atitle%3DPatients%2520with%2520Pancreatic%2520Adenocarcinoma%2520Exhibit%2520Elevated%2520Levels%2520of%2520Myeloid-Derived%2520Suppressor%2520Cells%2520upon%2520Progression%2520of%2520Disease%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D2015%26volume%3D64%26spage%3D149%26epage%3D159%26doi%3D10.1007%2Fs00262-014-1618-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W. W.</span></span> <span> </span><span class="NLM_article-title">Targeting Stromal Microenvironment in Pancreatic Ductal Adenocarcinoma: Controversies and Promises</span>. <i>J. Gastrointest. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">494</span>, <span class="refDoi"> DOI: 10.21037/jgo.2016.03.03</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.21037%2Fjgo.2016.03.03" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=27284483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FovVSrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=487-494&author=L.+Meiauthor=W.+Duauthor=W.+W.+Ma&title=Targeting+Stromal+Microenvironment+in+Pancreatic+Ductal+Adenocarcinoma%3A+Controversies+and+Promises&doi=10.21037%2Fjgo.2016.03.03"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises</span></div><div class="casAuthors">Mei Lin; Du Wei; Ma Wen Wee</div><div class="citationInfo"><span class="NLM_cas:title">Journal of gastrointestinal oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">487-94</span>
        ISSN:<span class="NLM_cas:issn">2078-6891</span>.
    </div><div class="casAbstract">Pancreatic cancer is a highly lethal disease.  Conventional therapeutics targeting pancreas cancer cell compartment using cytotoxics improved patient survival but at the expense of significant toxicity.  Microscopically, the tumor is characterized by thick desmoplastic stroma that surrounds islands of pancreatic cancer cells.  The tumor microenvironment has been found to play important roles in carcinogenesis, the development of drug resistance, and mediating immunosuppression.  The understanding the tumor-stromal interaction has led to the development of novel therapeutic approaches.  Here, we review the strategies that are currently in (or, near to) clinical evaluation and the underlying preclinical rationales.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQqR636AWNzbgwxfk_AGB-EfW6udTcc2eaHZu1JZgVg7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FovVSrug%253D%253D&md5=a4cde6407249c5c8e5277291c456f39f</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.21037%2Fjgo.2016.03.03&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Fjgo.2016.03.03%26sid%3Dliteratum%253Aachs%26aulast%3DMei%26aufirst%3DL.%26aulast%3DDu%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DW.%2BW.%26atitle%3DTargeting%2520Stromal%2520Microenvironment%2520in%2520Pancreatic%2520Ductal%2520Adenocarcinoma%253A%2520Controversies%2520and%2520Promises%26jtitle%3DJ.%2520Gastrointest.%2520Oncol.%26date%3D2016%26volume%3D7%26spage%3D487%26epage%3D494%26doi%3D10.21037%2Fjgo.2016.03.03" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, O. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsche, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saur, D.</span></span> <span> </span><span class="NLM_article-title">Targeting Histone Deacetylases in Pancreatic Ductal Adenocarcinoma</span>. <i>J. Cell. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1255</span>– <span class="NLM_lpage">1263</span>, <span class="refDoi"> DOI: 10.1111/j.1582-4934.2009.00974.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1111%2Fj.1582-4934.2009.00974.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=19929947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGksLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=1255-1263&author=G.+Schneiderauthor=O.+H.+Kramerauthor=P.+Fritscheauthor=S.+Schulerauthor=R.+M.+Schmidauthor=D.+Saur&title=Targeting+Histone+Deacetylases+in+Pancreatic+Ductal+Adenocarcinoma&doi=10.1111%2Fj.1582-4934.2009.00974.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting histone deacetylases in pancreatic ductal adenocarcinoma</span></div><div class="casAuthors">Schneider, Guenter; Kraemer, Oliver H.; Fritsche, Petra; Schueler, Susanne; Schmid, Roland M.; Saur, Dieter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6A</span>),
    <span class="NLM_cas:pages">1255-1263</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-1838</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease with a median survival below 6 mo and a 5-yr survival rate below 1%.  Effective therapies for locally advanced or metastatic tumors are missing and curatively resected patients relapse in over 80% of the cases.  Although histone deacetylases (HDACs) are involved in the control of proliferation, apoptosis, differentiation, migration and angiogenesis of cancer cells, knowledge about the expression patterns and functions of individual HDAC isoenzymes in pancreatic cancer is sparse.  This review summarizes the roles of HDACs as novel therapeutic targets and the mol. mode of action of HDAC-inhibitors (HDACI) in PDACs.  Success of HDACI in clin. settings will depend on an increased knowledge of HDAC functions as well as on a better understanding of the mode of action of HDACI.  Pre-clin. exptl. data that constitute the basis for rational therapeutic strategies to treat PDAC are described here.  Translating these rational-based therapies into the clinic will finally increase our chance to establish an effective HDACI-contg. combination therapy effective against PDAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs7iIdLdruy7Vg90H21EOLACvtfcHk0lhFXd2L7BAW3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGksLvM&md5=ba3952fdf36be24a94657aedf82d7c05</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1111%2Fj.1582-4934.2009.00974.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1582-4934.2009.00974.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DG.%26aulast%3DKramer%26aufirst%3DO.%2BH.%26aulast%3DFritsche%26aufirst%3DP.%26aulast%3DSchuler%26aufirst%3DS.%26aulast%3DSchmid%26aufirst%3DR.%2BM.%26aulast%3DSaur%26aufirst%3DD.%26atitle%3DTargeting%2520Histone%2520Deacetylases%2520in%2520Pancreatic%2520Ductal%2520Adenocarcinoma%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2010%26volume%3D14%26spage%3D1255%26epage%3D1263%26doi%3D10.1111%2Fj.1582-4934.2009.00974.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koutsounas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaginis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patsouris, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theocharis, S.</span></span> <span> </span><span class="NLM_article-title">Current Evidence for Histone Deacetylase Inhibitors in Pancreatic Cancer</span>. <i>World J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">813</span>– <span class="NLM_lpage">828</span>, <span class="refDoi"> DOI: 10.3748/wjg.v19.i6.813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.3748%2Fwjg.v19.i6.813" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=23430136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFKhsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=813-828&author=I.+Koutsounasauthor=C.+Giaginisauthor=E.+Patsourisauthor=S.+Theocharis&title=Current+Evidence+for+Histone+Deacetylase+Inhibitors+in+Pancreatic+Cancer&doi=10.3748%2Fwjg.v19.i6.813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Current evidence for histone deacetylase inhibitors in pancreatic cancer</span></div><div class="casAuthors">Koutsounas, Ioannis; Giaginis, Constantinos; Patsouris, Efstratios; Theocharis, Stamatios</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">813-828</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">Baishideng Publishing Group Co., Ltd.</span>)
        </div><div class="casAbstract">A review.  Pancreatic cancer is one of the most aggressive human cancers, with more than 200 000 deaths worldwide every year.  Despite recent efforts, conventional treatment approaches, such as surgery and classic chemotherapy, have only slightly improved patient outcomes.  More effective and well-tolerated therapies are required to reverse the current poor prognosis of this type of neoplasm.  Among new agents, histone deacetylase inhibitors (HDACIs) are now being tested.  HDACIs have multiple biol. effects related to acetylation of histones and many non-histone proteins that are involved in regulation of gene expression, apoptosis, cell cycle progression and angiogenesis.  HDACIs induce cell cycle arrest and can activate the extrinsic and intrinsic pathways of apoptosis in different cancer cell lines.  In the present review, the main mechanisms by which HDACIs act in pancreatic cancer cells in vitro, as well as their antiproliferative effects in animal models are presented.  HDACIs constitute a promising treatment for pancreatic cancer with encouraging anti-tumor effects, at well-tolerated doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5vOqCZoSOYbVg90H21EOLACvtfcHk0lidbTsv_8DZhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFKhsbY%253D&md5=9356d261d3a3d684e1b4997236383485</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v19.i6.813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v19.i6.813%26sid%3Dliteratum%253Aachs%26aulast%3DKoutsounas%26aufirst%3DI.%26aulast%3DGiaginis%26aufirst%3DC.%26aulast%3DPatsouris%26aufirst%3DE.%26aulast%3DTheocharis%26aufirst%3DS.%26atitle%3DCurrent%2520Evidence%2520for%2520Histone%2520Deacetylase%2520Inhibitors%2520in%2520Pancreatic%2520Cancer%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2013%26volume%3D19%26spage%3D813%26epage%3D828%26doi%3D10.3748%2Fwjg.v19.i6.813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, X.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of Histone Deacetylase Inhibitors in Pancreatic Cancer</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2014.02.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1016%2Fj.canlet.2014.02.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=24534202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjsVWkurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2014&pages=183-190&author=W.+Fengauthor=B.+Zhangauthor=D.+Caiauthor=X.+Zou&title=Therapeutic+Potential+of+Histone+Deacetylase+Inhibitors+in+Pancreatic+Cancer&doi=10.1016%2Fj.canlet.2014.02.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer</span></div><div class="casAuthors">Feng, Wan; Zhang, Bin; Cai, Dawei; Zou, Xiaoping</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">183-190</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Pancreatic cancer is a devastating disease with a dismal prognosis.  Surgical resection is the only curative option but is heavily hampered by delayed diagnosis.  Due to few therapeutic treatments available, novel and efficacious therapy is urgently needed.  Histone deacetylase inhibitors (HDACIs) are emerging as a prominent class of therapeutic agents for pancreatic cancer and have exhibited significant anticancer potential with negligible toxicity in preclin. studies.  Clin. evaluations of HDACIs are currently underway.  HDACIs as monotherapy in solid tumors have proven less effective than hematol. malignancies, the combination of HDACIs with other anticancer agents have been assessed for advanced pancreatic cancer.  In this review, we describe the mol. mechanism underpin the anticancer effect of HDACIs in pancreatic cancer and summarize the recent advances in the rationale for the combination strategies incorporating HDACIs.  In addn., we discuss the importance of identifying predictors of response to HDACI-based therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEYTC6UbSLT7Vg90H21EOLACvtfcHk0lidbTsv_8DZhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjsVWkurw%253D&md5=a2c52370fdf987aa6f565f459562292d</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2014.02.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2014.02.012%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DCai%26aufirst%3DD.%26aulast%3DZou%26aufirst%3DX.%26atitle%3DTherapeutic%2520Potential%2520of%2520Histone%2520Deacetylase%2520Inhibitors%2520in%2520Pancreatic%2520Cancer%26jtitle%3DCancer%2520Lett.%26date%3D2014%26volume%3D347%26spage%3D183%26epage%3D190%26doi%3D10.1016%2Fj.canlet.2014.02.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, Y.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases Function as Novel Potential Therapeutic Targets for Cancer</span>. <i>Hepatol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1111/hepr.12757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1111%2Fhepr.12757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=27457249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFWmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2017&pages=149-159&author=H.+Zhangauthor=Y.-P.+Shangauthor=H.-Y.+Chenauthor=J.+Li&title=Histone+Deacetylases+Function+as+Novel+Potential+Therapeutic+Targets+for+Cancer&doi=10.1111%2Fhepr.12757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases function as novel potential therapeutic targets for cancer</span></div><div class="casAuthors">Zhang, Hui; Shang, Yu-Ping; Chen, Hong-ying; Li, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">149-159</span>CODEN:
                <span class="NLM_cas:coden">HPRSFM</span>;
        ISSN:<span class="NLM_cas:issn">1386-6346</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Diverse cellular functions, including tumor suppressor gene expression, DNA repair, cell proliferation and apoptosis, are regulated by histone acetylation and deacetylation.  Histone deacetylases (HDACs) are enzymes involved in remodeling of chromatin by deacetylating the lysine residues.  They play a pivotal role in epigenetic regulation of gene expression.  Dysregulation of HDACs and aberrant chromatin acetylation and deacetylation have been implicated in the pathogenesis of various diseases, including cancer.  Histone deacetylases have become a target for the development of drugs for treating cancer because of their major contribution to oncogenic cell transformation.  Overexpression of HDACs correlates with tumorigenesis.  Previous work showed that inhibition of HDACs results in apoptosis and the inhibition of cell proliferation in multiple cells.  A significant no. of HDAC inhibitors have been developed in the past decade.  These inhibitors have strong anticancer effects in vitro and in vivo, inducing growth arrest, differentiation, and programmed cell death, inhibiting cell migration, invasion, and metastasis, and suppressing angiogenesis.  In addn., HDAC-mediated deacetylation alters the transcriptional activity of nuclear transcription factors, including p53, E2F, c-Myc, and nuclear factor-κB, as well as the extracellular signal-regulated kinase1/2, phosphatidylinositol 3-kinase, Notch, and Wnt signaling pathways.  This review highlights the role of HDACs in cancer pathogenesis and, more importantly, that HDACs are potential novel therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJSNAFKpT4ErVg90H21EOLACvtfcHk0lidbTsv_8DZhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFWmtbg%253D&md5=c39207521f57c2c8b48dc3f8924bebf2</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1111%2Fhepr.12757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fhepr.12757%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DShang%26aufirst%3DY.-P.%26aulast%3DChen%26aufirst%3DH.-Y.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DHistone%2520Deacetylases%2520Function%2520as%2520Novel%2520Potential%2520Therapeutic%2520Targets%2520for%2520Cancer%26jtitle%3DHepatol.%2520Res.%26date%3D2017%26volume%3D47%26spage%3D149%26epage%3D159%26doi%3D10.1111%2Fhepr.12757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 13 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Krimo Toutah, Nabanita Nawar, Sanna Timonen, Helena Sorger, Yasir S. Raouf, Shazreh Bukhari, Jana von Jan, Aleksandr Ianevski, Justyna M. Gawel, Olasunkanmi O. Olaoye, Mulu Geletu, Ayah Abdeldayem, Johan Israelian, Tudor B. Radu, Abootaleb Sedighi, Muzaffar N. Bhatti, Muhammad Murtaza Hassan, Pimyupa Manaswiyoungkul, Andrew E. Shouksmith, Heidi A. Neubauer, Elvin D. de Araujo, Tero Aittokallio, Oliver H. Krämer, Richard Moriggl, Satu Mustjoki, Marco Herling, <span class="NLM_string-name hlFld-ContribAuthor">Patrick T. Gunning</span>. </span><span class="cited-content_cbyCitation_article-title">Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8486-8509. <a href="https://doi.org/10.1021/acs.jmedchem.1c00420" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00420</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00420%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BHDAC%252BInhibitors%252BExhibiting%252BTherapeutic%252BPotential%252Bin%252BT-Cell%252BProlymphocytic%252BLeukemia%26aulast%3DToutah%26aufirst%3DKrimo%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08032021%26date%3D08062021%26volume%3D64%26issue%3D12%26spage%3D8486%26epage%3D8509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Olasunkanmi O. Olaoye, Paris R. Watson, Nabanita Nawar, Mulu Geletu, Abootaleb Sedighi, Shazreh Bukhari, Yasir S. Raouf, Pimyupa Manaswiyoungkul, Fettah Erdogan, Ayah Abdeldayem, Aaron D. Cabral, Muhammad Murtaza Hassan, Krimo Toutah, Andrew E. Shouksmith, Justyna M. Gawel, Johan Israelian, Tudor B. Radu, Niyati Kachhiyapatel, Elvin D. de Araujo, David W. Christianson, <span class="NLM_string-name hlFld-ContribAuthor">Patrick T. Gunning</span>. </span><span class="cited-content_cbyCitation_article-title">Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (5)
                                     , 2691-2704. <a href="https://doi.org/10.1021/acs.jmedchem.0c01922" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01922</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01922%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DUnique%252BMolecular%252BInteraction%252Bwith%252Bthe%252BHistone%252BDeacetylase%252B6%252BCatalytic%252BTunnel%25253A%252BCrystallographic%252Band%252BBiological%252BCharacterization%252Bof%252Ba%252BModel%252BChemotype%26aulast%3DOlaoye%26aufirst%3DOlasunkanmi%2BO.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D06112020%26date%3D12022021%26volume%3D64%26issue%3D5%26spage%3D2691%26epage%3D2704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Muhammad Murtaza Hassan, Johan Israelian, Nabanita Nawar, Giovanni Ganda, Pimyupa Manaswiyoungkul, Yasir S. Raouf, David Armstrong, Abootaleb Sedighi, Olasunkanmi O. Olaoye, Fettah Erdogan, Aaron D. Cabral, Fabrizio Angeles, Rabia Altintas, Elvin D. de Araujo, <span class="NLM_string-name hlFld-ContribAuthor">Patrick T. Gunning</span>. </span><span class="cited-content_cbyCitation_article-title">Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 Targeting. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (15)
                                     , 8634-8648. <a href="https://doi.org/10.1021/acs.jmedchem.0c01025" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01025%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCharacterization%252Bof%252BConformationally%252BConstrained%252BBenzanilide%252BScaffolds%252Bfor%252BPotent%252Band%252BSelective%252BHDAC8%252BTargeting%26aulast%3DHassan%26aufirst%3DMuhammad%2BMurtaza%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15062020%26date%3D31072020%26date%3D16072020%26volume%3D63%26issue%3D15%26spage%3D8634%26epage%3D8648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andrew E. Shouksmith, Justyna M. Gawel, Nabanita Nawar, Diana Sina, Yasir S. Raouf, Shazreh Bukhari, Liying He, Alexandra E. Johns, Pimyupa Manaswiyoungkul, Olasunkanmi O. Olaoye, Aaron D. Cabral, Abootaleb Sedighi, Elvin D. de Araujo, <span class="NLM_string-name hlFld-ContribAuthor">Patrick T. Gunning</span>. </span><span class="cited-content_cbyCitation_article-title">Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (1)
                                     , 56-64. <a href="https://doi.org/10.1021/acsmedchemlett.9b00471" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00471</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00471%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DClass%252BI%25252FIIb-Selective%252BHDAC%252BInhibitor%252BExhibits%252BOral%252BBioavailability%252Band%252BTherapeutic%252BEfficacy%252Bin%252BAcute%252BMyeloid%252BLeukemia%26aulast%3DShouksmith%26aufirst%3DAndrew%2BE.%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D13102019%26date%3D13122019%26date%3D30122019%26date%3D13122019%26volume%3D11%26issue%3D1%26spage%3D56%26epage%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ma  Su</span>, <span class="hlFld-ContribAuthor ">Xingyu  Gong</span>, <span class="hlFld-ContribAuthor ">Feng  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>16 </em>
                                    (7)
                                     , 745-761. <a href="https://doi.org/10.1080/17460441.2021.1877656" title="DOI URL">https://doi.org/10.1080/17460441.2021.1877656</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1877656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1877656%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DAn%252Bupdate%252Bon%252Bthe%252Bemerging%252Bapproaches%252Bfor%252Bhistone%252Bdeacetylase%252B%252528HDAC%252529%252Binhibitor%252Bdrug%252Bdiscovery%252Band%252Bfuture%252Bperspectives%26aulast%3DSu%26aufirst%3DMa%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D7%26spage%3D745%26epage%3D761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi  Wang</span>, <span class="hlFld-ContribAuthor ">Qiang  Xie</span>, <span class="hlFld-ContribAuthor ">Huidan  Tan</span>, <span class="hlFld-ContribAuthor ">Minru  Liao</span>, <span class="hlFld-ContribAuthor ">Shiou  Zhu</span>, <span class="hlFld-ContribAuthor ">Ling-Li  Zheng</span>, <span class="hlFld-ContribAuthor ">Haixia  Huang</span>, <span class="hlFld-ContribAuthor ">Bo  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting cancer epigenetic pathways with small-molecule compounds: Therapeutic efficacy and combination therapies. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2021,</strong> <em>13 </em>, 105702. <a href="https://doi.org/10.1016/j.phrs.2021.105702" title="DOI URL">https://doi.org/10.1016/j.phrs.2021.105702</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2021.105702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2021.105702%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DTargeting%252Bcancer%252Bepigenetic%252Bpathways%252Bwith%252Bsmall-molecule%252Bcompounds%25253A%252BTherapeutic%252Befficacy%252Band%252Bcombination%252Btherapies%26aulast%3DWang%26aufirst%3DYi%26date%3D2021%26volume%3D13%26spage%3D105702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qinghua  Ren</span>, <span class="hlFld-ContribAuthor ">Wenqian  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Current status in the discovery of dual BET/HDAC inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>38 </em>, 127829. <a href="https://doi.org/10.1016/j.bmcl.2021.127829" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127829</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127829%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DCurrent%252Bstatus%252Bin%252Bthe%252Bdiscovery%252Bof%252Bdual%252BBET%25252FHDAC%252Binhibitors%26aulast%3DRen%26aufirst%3DQinghua%26date%3D2021%26volume%3D38%26spage%3D127829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qinghua  Ren</span>, <span class="hlFld-ContribAuthor ">Wenqian  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Current status in the discovery of dual BET/HDAC inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>31 </em>, 127671. <a href="https://doi.org/10.1016/j.bmcl.2020.127671" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127671</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127671%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DCurrent%252Bstatus%252Bin%252Bthe%252Bdiscovery%252Bof%252Bdual%252BBET%25252FHDAC%252Binhibitors%26aulast%3DRen%26aufirst%3DQinghua%26date%3D2021%26volume%3D31%26spage%3D127671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Colleen E.  Quaas</span>, <span class="hlFld-ContribAuthor ">David T.  Long</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting (de)acetylation: A Diversity of Mechanism and Disease. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-820472-6.00076-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-820472-6.00076-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820472-6.00076-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820472-6.00076-1%26sid%3Dliteratum%253Aachs%26atitle%3DTargeting%252B%252528de%252529acetylation%25253A%252BA%252BDiversity%252Bof%252BMechanism%252Band%252BDisease%26aulast%3DQuaas%26aufirst%3DColleen%2BE.%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BBiomedical%252BSciences%26date%3D2021%26volume%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shan-Shan  Liu</span>, <span class="hlFld-ContribAuthor ">Fei  Wu</span>, <span class="hlFld-ContribAuthor ">Yue-Mei  Jin</span>, <span class="hlFld-ContribAuthor ">Wei- Qin  Chang</span>, <span class="hlFld-ContribAuthor ">Tian-Min  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">HDAC11: a rising star in epigenetics. </span><span class="cited-content_cbyCitation_journal-name">Biomedicine & Pharmacotherapy</span><span> <strong>2020,</strong> <em>131 </em>, 110607. <a href="https://doi.org/10.1016/j.biopha.2020.110607" title="DOI URL">https://doi.org/10.1016/j.biopha.2020.110607</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biopha.2020.110607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biopha.2020.110607%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicine%2520%2526%2520Pharmacotherapy%26atitle%3DHDAC11%25253A%252Ba%252Brising%252Bstar%252Bin%252Bepigenetics%26aulast%3DLiu%26aufirst%3DShan-Shan%26date%3D2020%26volume%3D131%26spage%3D110607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenhua  Liu</span>, <span class="hlFld-ContribAuthor ">Yuchen  Liang</span>, <span class="hlFld-ContribAuthor ">Xiaoyong  Si</span>. </span><span class="cited-content_cbyCitation_article-title">Hydroxamic acid hybrids as the potential anticancer agents: An Overview. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>205 </em>, 112679. <a href="https://doi.org/10.1016/j.ejmech.2020.112679" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112679</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112679%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHydroxamic%252Bacid%252Bhybrids%252Bas%252Bthe%252Bpotential%252Banticancer%252Bagents%25253A%252BAn%252BOverview%26aulast%3DLiu%26aufirst%3DWenhua%26date%3D2020%26volume%3D205%26spage%3D112679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ziran  Wang</span>, <span class="hlFld-ContribAuthor ">Wenwei  Yu</span>, <span class="hlFld-ContribAuthor ">Yawen  Qiang</span>, <span class="hlFld-ContribAuthor ">Liangfei  Xu</span>, <span class="hlFld-ContribAuthor ">Fan  Ma</span>, <span class="hlFld-ContribAuthor ">Pengsheng  Ding</span>, <span class="hlFld-ContribAuthor ">Lan  Shi</span>, <span class="hlFld-ContribAuthor ">Wenjiao  Chang</span>, <span class="hlFld-ContribAuthor ">Yide  Mei</span>, <span class="hlFld-ContribAuthor ">Xiaoling  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">LukS-PV Inhibits Hepatocellular Carcinoma Progression by Downregulating HDAC2 Expression. </span><span class="cited-content_cbyCitation_journal-name">Molecular Therapy - Oncolytics</span><span> <strong>2020,</strong> <em>17 </em>, 547-561. <a href="https://doi.org/10.1016/j.omto.2020.05.006" title="DOI URL">https://doi.org/10.1016/j.omto.2020.05.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.omto.2020.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.omto.2020.05.006%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Therapy%2520-%2520Oncolytics%26atitle%3DLukS-PV%252BInhibits%252BHepatocellular%252BCarcinoma%252BProgression%252Bby%252BDownregulating%252BHDAC2%252BExpression%26aulast%3DWang%26aufirst%3DZiran%26date%3D2020%26volume%3D17%26spage%3D547%26epage%3D561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dong-Jun  Fu</span>, <span class="hlFld-ContribAuthor ">Jian  Song</span>, <span class="hlFld-ContribAuthor ">Ting  Zhu</span>, <span class="hlFld-ContribAuthor ">Xiao-Jing  Pang</span>, <span class="hlFld-ContribAuthor ">Sheng-Hui  Wang</span>, <span class="hlFld-ContribAuthor ">Yan-Bing  Zhang</span>, <span class="hlFld-ContribAuthor ">Bo-Wen  Wu</span>, <span class="hlFld-ContribAuthor ">Jun-Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaolin  Zi</span>, <span class="hlFld-ContribAuthor ">Sai-Yang  Zhang</span>, <span class="hlFld-ContribAuthor ">Hong-Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel tertiary amide derivatives as NEDDylation pathway activators to inhibit the tumor progression in vitro and in vivo. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>192 </em>, 112153. <a href="https://doi.org/10.1016/j.ejmech.2020.112153" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112153</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112153%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Btertiary%252Bamide%252Bderivatives%252Bas%252BNEDDylation%252Bpathway%252Bactivators%252Bto%252Binhibit%252Bthe%252Btumor%252Bprogression%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%26aulast%3DFu%26aufirst%3DDong-Jun%26date%3D2020%26volume%3D192%26spage%3D112153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/medium/jm-2018-019576_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01957&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/medium/jm-2018-019576_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <i>N</i>-Hydroxamic Acid-Based HDAC Inhibitors<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01957&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) BnBr, Cs<sub>2</sub>CO<sub>3</sub>, dimethylformamide (DMF), 24 h, room temperature (RT); (b) (i) ArCHO, MgSO<sub>4</sub>, tetrahydrofuran (THF), 16 h, RT; (ii) NaBH<sub>4</sub>, trifluoroethanol (TFE), 16 h, RT; (c) ArSO<sub>2</sub>Cl, <i><sup>i</sup></i>Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 16 h, 0 °C to RT, N<sub>2</sub>; (d) BrCH<sub>2</sub>Ar, Cs<sub>2</sub>CO<sub>3</sub>, MeCN, 16 h, 50 °C to RT; (e) CF<sub>3</sub>CO<sub>2</sub>H/CHCl<sub>3</sub> (1:3), 3 h, RT; (f) PPh<sub>3</sub>Cl<sub>2</sub>, CHCl<sub>3</sub>, 1 h, 100 °C, N<sub>2</sub>, microwave; (g) H<sub>2</sub>, 10% Pd/C, THF/MeOH (2:1), 16 h, RT; (h) (i) (COCl)<sub>2</sub>, THF, DMF, 2 h, 0 °C, N<sub>2</sub>; (ii) H<sub>2</sub>NOBn, <i><sup>i</sup></i>Pr<sub>2</sub>NEt, THF, 16 h, RT, N<sub>2</sub>.</p></p></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/medium/jm-2018-019576_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Computational modeling/docking studies of <b>AES-135</b> against <i>h</i>HDAC 3, 6, and 8 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4A69">4A69</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EDU">5EDU</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T64">1T64</a>, respectively). (Left column) catalytic active site of enzyme, Zn<sup>2+</sup> (yellow sphere), residues within/around the lysine-substrate channel (shown as white ball-and-stick) and catalytic triad residues (shown as colored ball-and-stick). (Centre column) molecular surface view of channel entrance, low hydrophobicity residues (white), and high hydrophobicity residues (red). (Right column) side view of ligands docked within the active site. Panel A: <i>h</i>HDAC6 (blue cartoon), <b>AES-135</b> (magenta), and SAHA (green). Panel B: <i>h</i>HDAC3 (green cartoon), <b>AES-135</b> (magenta), and <b>6</b> (cyan). Panel C: <i>h</i>HDAC8 (red cartoon), <b>AES-135</b> (magenta), and <b>6</b> (cyan).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01957&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/medium/jm-2018-019576_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <i>N</i>-Methylhydroxamic Acid <b>60</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01957&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Boc<sub>2</sub>O, THF, 24 h, RT; (b) MeI, NaH (60%), DMF, 24 h, RT; (c) (i) CF<sub>3</sub>CO<sub>2</sub>H/CHCl<sub>3</sub> (1:3), 22 h, RT; (ii) 1 M NaOH; (d) (i) (COCl)<sub>2</sub>, THF, DMF, 2 h, 0 °C, N<sub>2</sub>; (ii) <b>58</b>, <i><sup>i</sup></i>Pr<sub>2</sub>NEt, THF, 16 h, RT, N<sub>2</sub>; (e) H<sub>2</sub>, 10% Pd/C, THF/MeOH (2:1), 16 h, RT.</p></p></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/medium/jm-2018-019576_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Serum concentrations of <b>AES-135</b> in NSG mice following 10 and 40 mg/kg injections daily for 5 days, IP (<i>n</i> = 6, ±standard deviation (SD)). (B) Toxicity study with <b>AES-135</b> in NSG mice administered over 5 days, IP (<i>n</i> = 6, ±SD).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01957&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/medium/jm-2018-019576_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Dose-dependent reduction by (A) <b>AES-135</b> and (B) Panobinostat in cell proliferation in pancreatic cancer cells in the monolayer. Average of at least three experiments ± standard error (SE).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01957&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/medium/jm-2018-019576_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Dose-dependent reduction in tumor spheroid intensity in patient-derived pancreatic cancer cells Pa03C (red, <i>n</i> = 3, ±SE) and 10.05 (blue, <i>n</i> = 3, ±SE); fold change compares the treated tumor only spheroids to media control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01957&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/medium/jm-2018-019576_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Increased survival of C57Bl/6 mice implanted with KPC tumor cells following <b>AES-135</b> treatment. Mice treated with 50 mg/kg <b>AES-135</b>, IP daily (blue, <i>n</i> = 10) exhibited a statistically significant survival advantage compared to mice treated with vehicle (green, <i>n</i> = 10), <i>p</i> = 0.0146 (log-rank test). Treatment started on day 7 with a cycle of 5 days on, 2 days off and continued until day 36.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01957/20190308/images/large/jm-2018-019576_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01957&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i56">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81167" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81167" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 51 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manji, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olive, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saenger, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberstein, P.</span></span> <span> </span><span class="NLM_article-title">Current and Emerging Therapies in Metastatic Pancreatic Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1670</span>– <span class="NLM_lpage">1678</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-2319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1158%2F1078-0432.CCR-16-2319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=28373365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A280%3ADC%252BC1cvkt1aisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=1670-1678&author=G.+A.+Manjiauthor=K.+P.+Oliveauthor=Y.+M.+Saengerauthor=P.+Oberstein&title=Current+and+Emerging+Therapies+in+Metastatic+Pancreatic+Cancer&doi=10.1158%2F1078-0432.CCR-16-2319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Current and Emerging Therapies in Metastatic Pancreatic Cancer</span></div><div class="casAuthors">Manji Gulam Abbas; Saenger Yvonne M; Oberstein Paul; Olive Kenneth P</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1670-1678</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">Targeted therapies and immunotherapy have changed the face of multiple solid malignancies, including metastatic melanoma and lung cancer, but no such therapies exist for pancreatic ductal adenocarcinoma (PDAC) despite the knowledge of key mutations and an increasing understanding of the tumor microenvironment.  Until now, most clinical studies have not been biomarker driven in this highly immunosuppressive and heterogeneous cancer.  Ongoing basic and translational studies are better classifying the disease in hopes of identifying critical pathways that distinguish the unique PDAC subtypes, which will lead to personalized therapies.  In this review, we discuss the current treatment options for metastatic pancreatic cancer and highlight current ongoing clinical trials, which aim to target the stroma and the immune microenvironment either alone or in combination with standard chemotherapy.  Identifying biomarkers and key resistance pathways and targeting these pathways in a personalized manner in combination with chemotherapy are likely to yield a more immediate and durable clinical benefit.  Clin Cancer Res; 23(7); 1670-8. ©2017 AACRSee all articles in this CCR Focus section, "Pancreatic Cancer: Challenge and Inspiration."</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRS3gZgDC0xqLGbPKh4T9eAfW6udTcc2eYDUuG7O5S4Q7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvkt1aisA%253D%253D&md5=eeee384ae0ab37ff2afc92d33684869a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2319%26sid%3Dliteratum%253Aachs%26aulast%3DManji%26aufirst%3DG.%2BA.%26aulast%3DOlive%26aufirst%3DK.%2BP.%26aulast%3DSaenger%26aufirst%3DY.%2BM.%26aulast%3DOberstein%26aufirst%3DP.%26atitle%3DCurrent%2520and%2520Emerging%2520Therapies%2520in%2520Metastatic%2520Pancreatic%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D1670%26epage%3D1678%26doi%3D10.1158%2F1078-0432.CCR-16-2319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rahib, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aizenberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleshman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matrisian, L. M.</span></span> <span> </span><span class="NLM_article-title">Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">2913</span>– <span class="NLM_lpage">2921</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-0155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1158%2F0008-5472.CAN-14-0155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=24840647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovFalur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=2913-2921&author=L.+Rahibauthor=B.+D.+Smithauthor=R.+Aizenbergauthor=A.+B.+Rosenzweigauthor=J.+M.+Fleshmanauthor=L.+M.+Matrisian&title=Projecting+Cancer+Incidence+and+Deaths+to+2030%3A+The+Unexpected+Burden+of+Thyroid%2C+Liver%2C+and+Pancreas+Cancers+in+the+United+States&doi=10.1158%2F0008-5472.CAN-14-0155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States</span></div><div class="casAuthors">Rahib, Lola; Smith, Benjamin D.; Aizenberg, Rhonda; Rosenzweig, Allison B.; Fleshman, Julie M.; Matrisian, Lynn M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2913-2921</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cancer incidence and deaths in the United States were projected for the most common cancer types for the years 2020 and 2030 based on changing demographics and the av. annual percentage changes in incidence and death rates.  Breast, prostate, and lung cancers will remain the top cancer diagnoses throughout this time, but thyroid cancer will replace colorectal cancer as the fourth leading cancer diagnosis by 2030, and melanoma and uterine cancer will become the fifth and sixth most common cancers, resp.  Lung cancer is projected to remain the top cancer killer throughout this time period.  However, pancreas and liver cancers are projected to surpass breast, prostate, and colorectal cancers to become the second and third leading causes of cancer-related death by 2030, resp.  Advances in screening, prevention, and treatment can change cancer incidence and/or death rates, but it will require a concerted effort by the research and healthcare communities now to effect a substantial change for the future.  Cancer Res; 74(11); 2913-21. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHGt66quENkbVg90H21EOLACvtfcHk0ljyWkMVCV4ePQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovFalur0%253D&md5=893d688f1ccba88ee094b743f7e4f152</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-0155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-0155%26sid%3Dliteratum%253Aachs%26aulast%3DRahib%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DAizenberg%26aufirst%3DR.%26aulast%3DRosenzweig%26aufirst%3DA.%2BB.%26aulast%3DFleshman%26aufirst%3DJ.%2BM.%26aulast%3DMatrisian%26aufirst%3DL.%2BM.%26atitle%3DProjecting%2520Cancer%2520Incidence%2520and%2520Deaths%2520to%25202030%253A%2520The%2520Unexpected%2520Burden%2520of%2520Thyroid%252C%2520Liver%252C%2520and%2520Pancreas%2520Cancers%2520in%2520the%2520United%2520States%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D2913%26epage%3D2921%26doi%3D10.1158%2F0008-5472.CAN-14-0155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Cancer Statistics, 2016</span>. <i>CA—Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.3322/caac.21332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.3322%2Fcaac.21332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=26742998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A280%3ADC%252BC28rot1Kjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2016&pages=7-30&author=R.+L.+Siegelauthor=K.+D.+Millerauthor=A.+Jemal&title=Cancer+Statistics%2C+2016&doi=10.3322%2Fcaac.21332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2016</span></div><div class="casAuthors">Siegel Rebecca L; Miller Kimberly D; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival.  Incidence data were collected by the National Cancer Institute (Surveillance, Epidemiology, and End Results [SEER] Program), the Centers for Disease Control and Prevention (National Program of Cancer Registries), and the North American Association of Central Cancer Registries.  Mortality data were collected by the National Center for Health Statistics.  In 2016, 1,685,210 new cancer cases and 595,690 cancer deaths are projected to occur in the United States.  Overall cancer incidence trends (13 oldest SEER registries) are stable in women, but declining by 3.1% per year in men (from 2009-2012), much of which is because of recent rapid declines in prostate cancer diagnoses.  The cancer death rate has dropped by 23% since 1991, translating to more than 1.7 million deaths averted through 2012.  Despite this progress, death rates are increasing for cancers of the liver, pancreas, and uterine corpus, and cancer is now the leading cause of death in 21 states, primarily due to exceptionally large reductions in death from heart disease.  Among children and adolescents (aged birth-19 years), brain cancer has surpassed leukemia as the leading cause of cancer death because of the dramatic therapeutic advances against leukemia.  Accelerating progress against cancer requires both increased national investment in cancer research and the application of existing cancer control knowledge across all segments of the population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKAn5ROFAaRS86Js-BCLiifW6udTcc2ebh4Jh_nKursrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rot1Kjug%253D%253D&md5=2d4030a531945c5ebaaab181bfd80457</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21332%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520Statistics%252C%25202016%26jtitle%3DCA%25E2%2580%2594Cancer%2520J.%2520Clin.%26date%3D2016%26volume%3D66%26spage%3D7%26epage%3D30%26doi%3D10.3322%2Fcaac.21332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leary, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angenendt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mankoo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamiyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calhoun, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolskaya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolsky, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartigan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffee, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goggins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobuzio-Donahue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eshleman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruban, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karchin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmigiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velculescu, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzler, K. W.</span></span> <span> </span><span class="NLM_article-title">Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>321</i></span>,  <span class="NLM_fpage">1801</span>– <span class="NLM_lpage">1806</span>, <span class="refDoi"> DOI: 10.1126/science.1164368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1126%2Fscience.1164368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=18772397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFCrtLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2008&pages=1801-1806&author=S.+Jonesauthor=X.+Zhangauthor=D.+W.+Parsonsauthor=J.+C.+Linauthor=R.+J.+Learyauthor=P.+Angenendtauthor=P.+Mankooauthor=H.+Carterauthor=H.+Kamiyamaauthor=A.+Jimenoauthor=S.+M.+Hongauthor=B.+Fuauthor=M.+T.+Linauthor=E.+S.+Calhounauthor=M.+Kamiyamaauthor=K.+Walterauthor=T.+Nikolskayaauthor=Y.+Nikolskyauthor=J.+Hartiganauthor=D.+R.+Smithauthor=M.+Hidalgoauthor=S.+D.+Leachauthor=A.+P.+Kleinauthor=E.+M.+Jaffeeauthor=M.+Gogginsauthor=A.+Maitraauthor=C.+Iacobuzio-Donahueauthor=J.+R.+Eshlemanauthor=S.+E.+Kernauthor=R.+H.+Hrubanauthor=R.+Karchinauthor=N.+Papadopoulosauthor=G.+Parmigianiauthor=B.+Vogelsteinauthor=V.+E.+Velculescuauthor=K.+W.+Kinzler&title=Core+Signaling+Pathways+in+Human+Pancreatic+Cancers+Revealed+by+Global+Genomic+Analyses&doi=10.1126%2Fscience.1164368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses</span></div><div class="casAuthors">Jones, Sian; Zhang, Xiaosong; Parsons, D. Williams; Lin, Jimmy Cheng-Ho; Leary, Rebecca J.; Angenendt, Philipp; Mankoo, Parminder; Carter, Hannah; Kamiyama, Hirohiko; Jimeno, Antonio; Hong, Seung-Mo; Fu, Baojin; Lin, Ming-Tseh; Calhoun, Eric S.; Kamiyama, Mihoko; Walter, Kimberly; Nikolskaya, Tatiana; Nikolsky, Yuri; Hartigan, James; Smith, Douglas R.; Hidalgo, Manuel; Leach, Steven D.; Klein, Alison P.; Jaffee, Elizabeth M.; Goggins, Michael; Maitra, Anirban; Iacobuzio-Donahue, Christine; Eshleman, James R.; Kern, Scott E.; Hruban, Ralph H.; Karchin, Rachel; Papadopoulos, Nickolas; Parmigiani, Giovanni; Vogelstein, Bert; Velculescu, Victor E.; Kinzler, Kenneth W.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">5897</span>),
    <span class="NLM_cas:pages">1801-1806</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">There are currently few therapeutic options for patients with pancreatic cancer, and new insights into the pathogenesis of this lethal disease are urgently needed.  Toward this end, the authors performed a comprehensive genetic anal. of 24 pancreatic cancers.  The authors first detd. the sequences of 23,219 transcripts, representing 20,661 protein-coding genes, in these samples.  Then, the authors searched for homozygous deletions and amplifications in the tumor DNA by using microarrays contg. probes for ~106 single-nucleotide polymorphisms.  It was found that pancreatic cancers contain an av. of 63 genetic alterations, the majority of which are point mutations.  These alterations defined a core set of 12 cellular signaling pathways and processes that were each genetically altered in 67 to 100% of the tumors.  Anal. of these tumors' transcriptomes with next-generation sequencing-by-synthesis technologies provided independent evidence for the importance of these pathways and processes.  These data indicate that genetically altered core pathways and regulatory processes only become evident once the coding regions of the genome are analyzed in depth.  Dysregulation of these core pathways and processes through mutation can explain the major features of pancreatic tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopWEan4wZjSLVg90H21EOLACvtfcHk0ljhoepiYdPM1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFCrtLrL&md5=62aa344f0bd3ba335cf6a8263ebbf29a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.1164368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1164368%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DParsons%26aufirst%3DD.%2BW.%26aulast%3DLin%26aufirst%3DJ.%2BC.%26aulast%3DLeary%26aufirst%3DR.%2BJ.%26aulast%3DAngenendt%26aufirst%3DP.%26aulast%3DMankoo%26aufirst%3DP.%26aulast%3DCarter%26aufirst%3DH.%26aulast%3DKamiyama%26aufirst%3DH.%26aulast%3DJimeno%26aufirst%3DA.%26aulast%3DHong%26aufirst%3DS.%2BM.%26aulast%3DFu%26aufirst%3DB.%26aulast%3DLin%26aufirst%3DM.%2BT.%26aulast%3DCalhoun%26aufirst%3DE.%2BS.%26aulast%3DKamiyama%26aufirst%3DM.%26aulast%3DWalter%26aufirst%3DK.%26aulast%3DNikolskaya%26aufirst%3DT.%26aulast%3DNikolsky%26aufirst%3DY.%26aulast%3DHartigan%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DD.%2BR.%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DLeach%26aufirst%3DS.%2BD.%26aulast%3DKlein%26aufirst%3DA.%2BP.%26aulast%3DJaffee%26aufirst%3DE.%2BM.%26aulast%3DGoggins%26aufirst%3DM.%26aulast%3DMaitra%26aufirst%3DA.%26aulast%3DIacobuzio-Donahue%26aufirst%3DC.%26aulast%3DEshleman%26aufirst%3DJ.%2BR.%26aulast%3DKern%26aufirst%3DS.%2BE.%26aulast%3DHruban%26aufirst%3DR.%2BH.%26aulast%3DKarchin%26aufirst%3DR.%26aulast%3DPapadopoulos%26aufirst%3DN.%26aulast%3DParmigiani%26aufirst%3DG.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26atitle%3DCore%2520Signaling%2520Pathways%2520in%2520Human%2520Pancreatic%2520Cancers%2520Revealed%2520by%2520Global%2520Genomic%2520Analyses%26jtitle%3DScience%26date%3D2008%26volume%3D321%26spage%3D1801%26epage%3D1806%26doi%3D10.1126%2Fscience.1164368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biankin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waddell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassahn, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingras, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthuswamy, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patch, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardiner, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harliwong, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idrisoglu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nourse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nourbakhsh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gongora, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pajic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarlett, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinho, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nones, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christ, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruxner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloonan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolle, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mead, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colvin, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagrial, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chantrill, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mawson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samra, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kench, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrett, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, N. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeps, N.</span></span>; <span class="NLM_contrib-group">Australian Pancreatic Cancer Genome Initiative</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakkar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzny, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunicardi, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhay, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timms, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Borja, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denroche, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yung, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onetto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhopadhyay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, M.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruban, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobuzio-Donahue, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulick, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfgang, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawlor, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scardoni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortora, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempero, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Mancera, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Largaespada, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessels, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rust, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuveson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musgrove, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eshleman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPherson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimmond, S. M.</span></span> <span> </span><span class="NLM_article-title">Pancreatic Cancer Genomes Reveal Aberrations in Axon Guidance Pathway Genes</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>491</i></span>,  <span class="NLM_fpage">399</span>– <span class="NLM_lpage">405</span>, <span class="refDoi"> DOI: 10.1038/nature11547</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1038%2Fnature11547" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=23103869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOmt7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=491&publication_year=2012&pages=399-405&author=A.+V.+Biankinauthor=N.+Waddellauthor=K.+S.+Kassahnauthor=M.-C.+Gingrasauthor=L.+B.+Muthuswamyauthor=A.+L.+Johnsauthor=D.+K.+Millerauthor=P.+J.+Wilsonauthor=A.-M.+Patchauthor=J.+Wuauthor=D.+K.+Changauthor=M.+J.+Cowleyauthor=B.+B.+Gardinerauthor=S.+Songauthor=I.+Harliwongauthor=S.+Idrisogluauthor=C.+Nourseauthor=E.+Nourbakhshauthor=S.+Manningauthor=S.+Waniauthor=M.+Gongoraauthor=M.+Pajicauthor=C.+J.+Scarlettauthor=A.+J.+Gillauthor=A.+V.+Pinhoauthor=I.+Roomanauthor=M.+Andersonauthor=O.+Holmesauthor=C.+Leonardauthor=D.+Taylorauthor=S.+Woodauthor=Q.+Xuauthor=K.+Nonesauthor=J.+L.+Finkauthor=A.+Christauthor=T.+Bruxnerauthor=N.+Cloonanauthor=G.+Kolleauthor=F.+Newellauthor=M.+Pineseauthor=R.+S.+Meadauthor=J.+L.+Humphrisauthor=W.+Kaplanauthor=M.+D.+Jonesauthor=E.+K.+Colvinauthor=A.+M.+Nagrialauthor=E.+S.+Humphreyauthor=A.+Chouauthor=V.+T.+Chinauthor=L.+A.+Chantrillauthor=A.+Mawsonauthor=J.+S.+Samraauthor=J.+G.+Kenchauthor=J.+A.+Lovellauthor=R.+J.+Dalyauthor=N.+D.+Merrettauthor=C.+Toonauthor=K.+Epariauthor=N.+Q.+Nguyenauthor=A.+Barbourauthor=N.+Zepsauthor=Australian+Pancreatic+Cancer+Genome+Initiativeauthor=N.+Kakkarauthor=F.+Zhaoauthor=Y.+Q.+Wuauthor=M.+Wangauthor=D.+M.+Muznyauthor=W.+E.+Fisherauthor=F.+C.+Brunicardiauthor=S.+E.+Hodgesauthor=J.+G.+Reidauthor=J.+Drummondauthor=K.+Changauthor=Y.+Hanauthor=L.+R.+Lewisauthor=H.+Dinhauthor=C.+J.+Buhayauthor=T.+Beckauthor=L.+Timmsauthor=M.+Samauthor=K.+Begleyauthor=A.+Brownauthor=D.+Paiauthor=A.+Panchalauthor=N.+Buchnerauthor=R.+De+Borjaauthor=R.+E.+Denrocheauthor=C.+K.+Yungauthor=S.+Serraauthor=N.+Onettoauthor=D.+Mukhopadhyayauthor=M.-S.+Tsaoauthor=P.+A.+Shawauthor=G.+M.+Petersenauthor=S.+Gallingerauthor=R.+H.+Hrubanauthor=A.+Maitraauthor=C.+A.+Iacobuzio-Donahueauthor=R.+D.+Schulickauthor=C.+L.+Wolfgangauthor=R.+A.+Morganauthor=R.+T.+Lawlorauthor=P.+Capelliauthor=V.+Corboauthor=M.+Scardoniauthor=G.+Tortoraauthor=M.+A.+Temperoauthor=K.+M.+Mannauthor=N.+A.+Jenkinsauthor=P.+A.+Perez-Manceraauthor=D.+J.+Adamsauthor=D.+A.+Largaespadaauthor=L.+F.+Wesselsauthor=A.+G.+Rustauthor=L.+D.+Steinauthor=D.+A.+Tuvesonauthor=N.+G.+Copelandauthor=E.+A.+Musgroveauthor=A.+Scarpaauthor=J.+R.+Eshlemanauthor=T.+J.+Hudsonauthor=R.+L.+Sutherlandauthor=D.+A.+Wheelerauthor=J.+V.+Pearsonauthor=J.+D.+McPhersonauthor=R.+A.+Gibbsauthor=S.+M.+Grimmond&title=Pancreatic+Cancer+Genomes+Reveal+Aberrations+in+Axon+Guidance+Pathway+Genes&doi=10.1038%2Fnature11547"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes</span></div><div class="casAuthors">Biankin, Andrew V.; Waddell, Nicola; Kassahn, Karin S.; Gingras, Marie-Claude; Muthuswamy, Lakshmi B.; Johns, Amber L.; Miller, David K.; Wilson, Peter J.; Patch, Ann-Marie; Wu, Jianmin; Chang, David K.; Cowley, Mark J.; Gardiner, Brooke B.; Song, Sarah; Harliwong, Ivon; Idrisoglu, Senel; Nourse, Craig; Nourbakhsh, Ehsan; Manning, Suzanne; Wani, Shivangi; Gongora, Milena; Pajic, Marina; Scarlett, Christopher J.; Gill, Anthony J.; Pinho, Andreia V.; Rooman, Ilse; Anderson, Matthew; Holmes, Oliver; Leonard, Conrad; Taylor, Darrin; Wood, Scott; Xu, Christina; Nones, Katia; Lynn Fink, J.; Christ, Angelika; Bruxner, Tim; Cloonan, Nicole; Kolle, Gabriel; Newell, Felicity; Pinese, Mark; Scott Mead, R.; Humphris, Jeremy L.; Kaplan, Warren; Jones, Marc D.; Colvin, Emily K.; Nagrial, Adnan M.; Humphrey, Emily S.; Chou, Angela; Chin, Venessa T.; Chantrill, Lorraine A.; Mawson, Amanda; Samra, Jaswinder S.; Kench, James G.; Lovell, Jessica A.; Daly, Roger J.; Merrett, Neil D.; Toon, Christopher; Epari, Krishna P.; Nguyen, Nam Q.; Barbour, Andrew P.; Zeps, Nikolajs; Brancato, Mary-Anne L.; Rowe, Sarah J.; Simpson, Skye L.; Martyn-Smith, Mona; Thomas, Michelle T.; Pettit, Jessica; Tao, Jiang; DiPietro, Renee; Watson, Clare; Wong, Rachel; Giry-Laterriere, Marc; Musgrove, Elizabeth A.; Sutherland, Robert L.; Grimmond, Sean M.; Patch, Ann-Marie; Nourse, Craig; Anderson, Matthew; Pavlakis, Nick; Guminski, Alex; Asghari, Ray; Pavey, Darren A.; Das, Amitabha; Cosman, Peter H.; Ismail, Kasim; O'Connor, Chelsie; Lam, Vincent W.; McLeod, Duncan; Pleass, Henry C.; Richardson, Arthur; James, Virginia; Cooper, Caroline L.; Joseph, David; Sandroussi, Charbel; Crawford, Michael; Gallagher, James; Texler, Michael; Forrest, Cindy; Laycock, Andrew; Ballal, Mo; Fletcher, David R.; Mukhedkar, Sanjay; Spry, Nigel A.; DeBoer, Bastiaan; Chai, Ming; Beilin, Maria; Feeney, Kynan; Ruszkiewicz, Andrew R.; Worthley, Chris; Tan, Chuan P.; Debrencini, Tamara; Chen, John; Brooke-Smith, Mark E.; Papangelis, Virginia; Tang, Henry; Clouston, Andrew D.; Martin, Patrick; O'Rourke, Thomas J.; Chiang, Amy; Fawcett, Jonathan W.; Slater, Kellee; Yeung, Shinn; Hatzifotis, Michael; Hodgkinson, Peter; Christophi, Christopher; Nikfarjam, Mehrdad; Eshleman, James R.; Hruban, Ralph H.; Maitra, Anirban; Iacobuzio-Donahue, Christine A.; Schulick, Richard D.; Wolfgang, Christopher L.; Morgan, Richard A.; Hodgin, Mary B.; Scarpa, Aldo; Lawlor, Rita T.; Capelli, Paola; Beghelli, Stefania; Corbo, Vincenzo; Scardoni, Maria; Pederzoli, Paolo; Tortora, Giampaolo; Bassi, Claudio; Tempero, Margaret A.; Kakkar, Nipun; Zhao, Fengmei; Wu, Yuan Qing; Wang, Min; Muzny, Donna M.; Fisher, William E.; Charles Brunicardi, F.; Hodges, Sally E.; Reid, Jeffrey G.; Drummond, Jennifer; Chang, Kyle; Han, Yi; Lewis, Lora R.; Dinh, Huyen; Buhay, Christian J.; Beck, Timothy; Timms, Lee; Sam, Michelle; Begley, Kimberly; Brown, Andrew; Pai, Deepa; Panchal, Ami; Buchner, Nicholas; De Borja, Richard; Denroche, Robert E.; Yung, Christina K.; Serra, Stefano; Onetto, Nicole; Mukhopadhyay, Debabrata; Tsao, Ming-Sound; Shaw, Patricia A.; Petersen, Gloria M.; Gallinger, Steven; Iacobuzio-Donahue, Christine A.; Mann, Karen M.; Jenkins, Nancy A.; Perez-Mancera, Pedro A.; Adams, David J.; Largaespada, David A.; Wessels, Lodewyk F. A.; Rust, Alistair G.; Stein, Lincoln D.; Tuveson, David A.; Copeland, Neal G.; Hudson, Thomas J.; Wheeler, David A.; McPherson, John D.; Gibbs, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">491</span>
        (<span class="NLM_cas:issue">7424</span>),
    <span class="NLM_cas:pages">399-405</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pancreatic cancer is a highly lethal malignancy with few effective therapies.  We performed exome sequencing and copy no. anal. to define genomic aberrations in a prospectively accrued clin. cohort (n = 142) of early (stage I and II) sporadic pancreatic ductal adenocarcinoma.  Detailed anal. of 99 informative tumors identified substantial heterogeneity with 2,016 non-silent mutations and 1,628 copy-no. variations.  We define 16 significantly mutated genes, reaffirming known mutations (KRAS, TP53, CDKN2A, SMAD4, MLL3, TGFBR2, ARID1A and SF3B1), and uncover novel mutated genes including addnl. genes involved in chromatin modification (EPC1 and ARID2), DNA damage repair (ATM) and other mechanisms (ZIM2, MAP2K4, NALCN, SLC16A4 and MAGEA6).  Integrative anal. with in vitro functional data and animal models provided supportive evidence for potential roles for these genetic aberrations in carcinogenesis.  Pathway-based anal. of recurrently mutated genes recapitulated clustering in core signalling pathways in pancreatic ductal adenocarcinoma, and identified new mutated genes in each pathway.  We also identified frequent and diverse somatic aberrations in genes described traditionally as embryonic regulators of axon guidance, particularly SLIT/ROBO signalling, which was also evident in murine Sleeping Beauty transposon-mediated somatic mutagenesis models of pancreatic cancer, providing further supportive evidence for the potential involvement of axon guidance genes in pancreatic carcinogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6I8TIAplbi7Vg90H21EOLACvtfcHk0ljOtoFPWXxLtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOmt7jN&md5=482b61e2d2caec25b5b68aa955f2fb74</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature11547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11547%26sid%3Dliteratum%253Aachs%26aulast%3DBiankin%26aufirst%3DA.%2BV.%26aulast%3DWaddell%26aufirst%3DN.%26aulast%3DKassahn%26aufirst%3DK.%2BS.%26aulast%3DGingras%26aufirst%3DM.-C.%26aulast%3DMuthuswamy%26aufirst%3DL.%2BB.%26aulast%3DJohns%26aufirst%3DA.%2BL.%26aulast%3DMiller%26aufirst%3DD.%2BK.%26aulast%3DWilson%26aufirst%3DP.%2BJ.%26aulast%3DPatch%26aufirst%3DA.-M.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DD.%2BK.%26aulast%3DCowley%26aufirst%3DM.%2BJ.%26aulast%3DGardiner%26aufirst%3DB.%2BB.%26aulast%3DSong%26aufirst%3DS.%26aulast%3DHarliwong%26aufirst%3DI.%26aulast%3DIdrisoglu%26aufirst%3DS.%26aulast%3DNourse%26aufirst%3DC.%26aulast%3DNourbakhsh%26aufirst%3DE.%26aulast%3DManning%26aufirst%3DS.%26aulast%3DWani%26aufirst%3DS.%26aulast%3DGongora%26aufirst%3DM.%26aulast%3DPajic%26aufirst%3DM.%26aulast%3DScarlett%26aufirst%3DC.%2BJ.%26aulast%3DGill%26aufirst%3DA.%2BJ.%26aulast%3DPinho%26aufirst%3DA.%2BV.%26aulast%3DRooman%26aufirst%3DI.%26aulast%3DAnderson%26aufirst%3DM.%26aulast%3DHolmes%26aufirst%3DO.%26aulast%3DLeonard%26aufirst%3DC.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DNones%26aufirst%3DK.%26aulast%3DFink%26aufirst%3DJ.%2BL.%26aulast%3DChrist%26aufirst%3DA.%26aulast%3DBruxner%26aufirst%3DT.%26aulast%3DCloonan%26aufirst%3DN.%26aulast%3DKolle%26aufirst%3DG.%26aulast%3DNewell%26aufirst%3DF.%26aulast%3DPinese%26aufirst%3DM.%26aulast%3DMead%26aufirst%3DR.%2BS.%26aulast%3DHumphris%26aufirst%3DJ.%2BL.%26aulast%3DKaplan%26aufirst%3DW.%26aulast%3DJones%26aufirst%3DM.%2BD.%26aulast%3DColvin%26aufirst%3DE.%2BK.%26aulast%3DNagrial%26aufirst%3DA.%2BM.%26aulast%3DHumphrey%26aufirst%3DE.%2BS.%26aulast%3DChou%26aufirst%3DA.%26aulast%3DChin%26aufirst%3DV.%2BT.%26aulast%3DChantrill%26aufirst%3DL.%2BA.%26aulast%3DMawson%26aufirst%3DA.%26aulast%3DSamra%26aufirst%3DJ.%2BS.%26aulast%3DKench%26aufirst%3DJ.%2BG.%26aulast%3DLovell%26aufirst%3DJ.%2BA.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26aulast%3DMerrett%26aufirst%3DN.%2BD.%26aulast%3DToon%26aufirst%3DC.%26aulast%3DEpari%26aufirst%3DK.%26aulast%3DNguyen%26aufirst%3DN.%2BQ.%26aulast%3DBarbour%26aufirst%3DA.%26aulast%3DZeps%26aufirst%3DN.%26aulast%3D%26aulast%3DKakkar%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DY.%2BQ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DMuzny%26aufirst%3DD.%2BM.%26aulast%3DFisher%26aufirst%3DW.%2BE.%26aulast%3DBrunicardi%26aufirst%3DF.%2BC.%26aulast%3DHodges%26aufirst%3DS.%2BE.%26aulast%3DReid%26aufirst%3DJ.%2BG.%26aulast%3DDrummond%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DK.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DLewis%26aufirst%3DL.%2BR.%26aulast%3DDinh%26aufirst%3DH.%26aulast%3DBuhay%26aufirst%3DC.%2BJ.%26aulast%3DBeck%26aufirst%3DT.%26aulast%3DTimms%26aufirst%3DL.%26aulast%3DSam%26aufirst%3DM.%26aulast%3DBegley%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DPai%26aufirst%3DD.%26aulast%3DPanchal%26aufirst%3DA.%26aulast%3DBuchner%26aufirst%3DN.%26aulast%3DDe%2BBorja%26aufirst%3DR.%26aulast%3DDenroche%26aufirst%3DR.%2BE.%26aulast%3DYung%26aufirst%3DC.%2BK.%26aulast%3DSerra%26aufirst%3DS.%26aulast%3DOnetto%26aufirst%3DN.%26aulast%3DMukhopadhyay%26aufirst%3DD.%26aulast%3DTsao%26aufirst%3DM.-S.%26aulast%3DShaw%26aufirst%3DP.%2BA.%26aulast%3DPetersen%26aufirst%3DG.%2BM.%26aulast%3DGallinger%26aufirst%3DS.%26aulast%3DHruban%26aufirst%3DR.%2BH.%26aulast%3DMaitra%26aufirst%3DA.%26aulast%3DIacobuzio-Donahue%26aufirst%3DC.%2BA.%26aulast%3DSchulick%26aufirst%3DR.%2BD.%26aulast%3DWolfgang%26aufirst%3DC.%2BL.%26aulast%3DMorgan%26aufirst%3DR.%2BA.%26aulast%3DLawlor%26aufirst%3DR.%2BT.%26aulast%3DCapelli%26aufirst%3DP.%26aulast%3DCorbo%26aufirst%3DV.%26aulast%3DScardoni%26aufirst%3DM.%26aulast%3DTortora%26aufirst%3DG.%26aulast%3DTempero%26aufirst%3DM.%2BA.%26aulast%3DMann%26aufirst%3DK.%2BM.%26aulast%3DJenkins%26aufirst%3DN.%2BA.%26aulast%3DPerez-Mancera%26aufirst%3DP.%2BA.%26aulast%3DAdams%26aufirst%3DD.%2BJ.%26aulast%3DLargaespada%26aufirst%3DD.%2BA.%26aulast%3DWessels%26aufirst%3DL.%2BF.%26aulast%3DRust%26aufirst%3DA.%2BG.%26aulast%3DStein%26aufirst%3DL.%2BD.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DCopeland%26aufirst%3DN.%2BG.%26aulast%3DMusgrove%26aufirst%3DE.%2BA.%26aulast%3DScarpa%26aufirst%3DA.%26aulast%3DEshleman%26aufirst%3DJ.%2BR.%26aulast%3DHudson%26aufirst%3DT.%2BJ.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26aulast%3DWheeler%26aufirst%3DD.%2BA.%26aulast%3DPearson%26aufirst%3DJ.%2BV.%26aulast%3DMcPherson%26aufirst%3DJ.%2BD.%26aulast%3DGibbs%26aufirst%3DR.%2BA.%26aulast%3DGrimmond%26aufirst%3DS.%2BM.%26atitle%3DPancreatic%2520Cancer%2520Genomes%2520Reveal%2520Aberrations%2520in%2520Axon%2520Guidance%2520Pathway%2520Genes%26jtitle%3DNature%26date%3D2012%26volume%3D491%26spage%3D399%26epage%3D405%26doi%3D10.1038%2Fnature11547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rucki, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleponis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eyk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffee, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span> <span> </span><span class="NLM_article-title">Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-1383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1158%2F0008-5472.CAN-16-1383" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=41-52&author=A.+A.+Ruckiauthor=K.+Foleyauthor=P.+Zhangauthor=Q.+Xiaoauthor=J.+Kleponisauthor=A.+A.+Wuauthor=R.+Sharmaauthor=G.+Moauthor=A.+Liuauthor=J.+Van+Eykauthor=E.+M.+Jaffeeauthor=L.+Zheng&title=Heterogeneous+Stromal+Signaling+within+the+Tumor+Microenvironment+Controls+the+Metastasis+of+Pancreatic+Cancer&doi=10.1158%2F0008-5472.CAN-16-1383"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-1383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-1383%26sid%3Dliteratum%253Aachs%26aulast%3DRucki%26aufirst%3DA.%2BA.%26aulast%3DFoley%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DXiao%26aufirst%3DQ.%26aulast%3DKleponis%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DA.%2BA.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DMo%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DVan%2BEyk%26aufirst%3DJ.%26aulast%3DJaffee%26aufirst%3DE.%2BM.%26aulast%3DZheng%26aufirst%3DL.%26atitle%3DHeterogeneous%2520Stromal%2520Signaling%2520within%2520the%2520Tumor%2520Microenvironment%2520Controls%2520the%2520Metastasis%2520of%2520Pancreatic%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D41%26epage%3D52%26doi%3D10.1158%2F0008-5472.CAN-16-1383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurisica, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedley, D. W.</span></span> <span> </span><span class="NLM_article-title">Hypoxia Predicts Aggressive Growth and Spontaneous Metastasis Formation from Orthotopically Grown Primary Xenografts of Human Pancreatic Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">3110</span>– <span class="NLM_lpage">3120</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-4049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1158%2F0008-5472.CAN-10-4049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=21343390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslWjsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=3110-3120&author=Q.+Changauthor=I.+Jurisicaauthor=T.+Doauthor=D.+W.+Hedley&title=Hypoxia+Predicts+Aggressive+Growth+and+Spontaneous+Metastasis+Formation+from+Orthotopically+Grown+Primary+Xenografts+of+Human+Pancreatic+Cancer&doi=10.1158%2F0008-5472.CAN-10-4049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Hypoxia Predicts Aggressive Growth and Spontaneous Metastasis Formation from Orthotopically Grown Primary Xenografts of Human Pancreatic Cancer</span></div><div class="casAuthors">Chang, Qing; Jurisica, Igor; Do, Trevor; Hedley, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3110-3120</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Hypoxia in solid tumors is assocd. with treatment resistance and increased metastatic potential.  Although hypoxia has been reported in pancreatic cancer patients, there is little direct evidence that this contributes to their overall poor prognosis.  To address this, we examd. the assocns. between hypoxia and biol. aggression in a series of patient-derived xenografts grown orthotopically.  Early passage xenografts were established from 16 patients undergoing surgery for pancreatic cancer and maintained in the pancreas of immune-deprived mice.  Hypoxic cells were labeled using the 2-nitroimidazole probe EF5 and stained for immunofluorescence microscopy of tissue sections or as cell suspensions for flow cytometry.  Bromodeoxyuridine (BrdUrd) uptake, microvessel d., cleaved caspase-3, and the differentiation markers E-cadherin, cytokeratin 19, and vimentin were analyzed in relation to hypoxia.  Orthotopic implants closely resembled the histol. of the original surgical samples.  The 16 primary xenografts showed a wide range in their growth rates and metastatic potential, reminiscent of the spectrum of behavior seen in the clinic.  EF5 labeling, tumor growth rates, and metastatic patterns were highly consistent within replicates, indicating a significant transmissible (genetic or epigenetic) component.  Hypoxia was highly correlated with rapid tumor growth, increased BrdUrd uptake, and with spontaneous metastasis formation. mRNA expression anal. showed increased expression of genes involved in cell survival and proliferation in the hypoxic models.  The results suggest that hypoxia is a major adverse prognostic factor in pancreatic cancer patients and support the introduction of techniques to measure hypoxia directly in patients and the development of treatment protocols to target hypoxia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps-ZtGnk6qlbVg90H21EOLACvtfcHk0lhAHMAu4TsbmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslWjsb8%253D&md5=0be38da5f5489bc0b4501241f791c3ea</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-4049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-4049%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DQ.%26aulast%3DJurisica%26aufirst%3DI.%26aulast%3DDo%26aufirst%3DT.%26aulast%3DHedley%26aufirst%3DD.%2BW.%26atitle%3DHypoxia%2520Predicts%2520Aggressive%2520Growth%2520and%2520Spontaneous%2520Metastasis%2520Formation%2520from%2520Orthotopically%2520Grown%2520Primary%2520Xenografts%2520of%2520Human%2520Pancreatic%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D3110%26epage%3D3120%26doi%3D10.1158%2F0008-5472.CAN-10-4049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ceccacci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minucci, S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Histone Deacetylases in Cancer Therapy: Lessons from Leukaemia</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">611</span>, <span class="refDoi"> DOI: 10.1038/bjc.2016.36</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1038%2Fbjc.2016.36" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=26908329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsFehsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2016&pages=605-611&author=E.+Ceccacciauthor=S.+Minucci&title=Inhibition+of+Histone+Deacetylases+in+Cancer+Therapy%3A+Lessons+from+Leukaemia&doi=10.1038%2Fbjc.2016.36"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia</span></div><div class="casAuthors">Ceccacci, Elena; Minucci, Saverio</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">605-611</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are a key component of the epigenetic machinery regulating gene expression, and behave as oncogenes in several cancer types, spurring the development of HDAC inhibitors (HDACi) as anticancer drugs.  This review discusses new results regarding the role of HDACs in cancer and the effect of HDACi on tumor cells, focusing on haematol. malignancies, particularly acute myeloid leukemia.  Histone deacetylases may have opposite roles at different stages of tumor progression and in different tumor cell sub-populations (cancer stem cells), highlighting the importance of investigating these aspects for further improving the clin. use of HDACi in treating cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAMwt4F3whRbVg90H21EOLACvtfcHk0lhAHMAu4TsbmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsFehsLg%253D&md5=ed5746bf4f87e8047aff7db3c747ebd6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2016.36&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2016.36%26sid%3Dliteratum%253Aachs%26aulast%3DCeccacci%26aufirst%3DE.%26aulast%3DMinucci%26aufirst%3DS.%26atitle%3DInhibition%2520of%2520Histone%2520Deacetylases%2520in%2520Cancer%2520Therapy%253A%2520Lessons%2520from%2520Leukaemia%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2016%26volume%3D114%26spage%3D605%26epage%3D611%26doi%3D10.1038%2Fbjc.2016.36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barneda-Zahonero, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parra, M.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases and Cancer</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">579</span>– <span class="NLM_lpage">589</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2012.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1016%2Fj.molonc.2012.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=22963873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs12gt7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=579-589&author=B.+Barneda-Zahoneroauthor=M.+Parra&title=Histone+Deacetylases+and+Cancer&doi=10.1016%2Fj.molonc.2012.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and cancer</span></div><div class="casAuthors">Barneda-Zahonero, Bruna; Parra, Maribel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">579-589</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Reversible acetylation of histone and non-histone proteins is one of the most abundant post-translational modifications in eukaryotic cells.  Protein acetylation and deacetylation are achieved by the antagonistic actions of two families of enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs).  Aberrant protein acetylation, particularly on histones, has been related to cancer while abnormal expression of HDACs has been found in a broad range of cancer types.  Therefore, HDACs have emerged as promising targets in cancer therapeutics, and the development of HDAC inhibitors (HDIs), a rapidly evolving area of clin. research.  However, the contributions of specific HDACs to a given cancer type remain incompletely understood.  The aim of this review is to summarize the current knowledge concerning the role of HDACs in cancer with special emphasis on what we have learned from the anal. of patient samples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOl-qXEsP2IrVg90H21EOLACvtfcHk0lhXr3DT3cKFSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs12gt7%252FK&md5=7c294b40669bf079b1319391ee456642</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2012.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2012.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DBarneda-Zahonero%26aufirst%3DB.%26aulast%3DParra%26aufirst%3DM.%26atitle%3DHistone%2520Deacetylases%2520and%2520Cancer%26jtitle%3DMol.%2520Oncol.%26date%3D2012%26volume%3D6%26spage%3D579%26epage%3D589%26doi%3D10.1016%2Fj.molonc.2012.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structure, Mechanism, and Inhibition of Histone Deacetylases and Related Metalloenzymes</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">743</span>, <span class="refDoi"> DOI: 10.1016/j.sbi.2011.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1016%2Fj.sbi.2011.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=21872466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFOhurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=735-743&author=P.+M.+Lombardiauthor=K.+E.+Coleauthor=D.+P.+Dowlingauthor=D.+W.+Christianson&title=Structure%2C+Mechanism%2C+and+Inhibition+of+Histone+Deacetylases+and+Related+Metalloenzymes&doi=10.1016%2Fj.sbi.2011.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes</span></div><div class="casAuthors">Lombardi, Patrick M.; Cole, Kathryn E.; Dowling, Daniel P.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">735-743</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Metal-dependent histone deacetylases (HDACs) catalyze the hydrolysis of acetyl-L-lysine side-chains in histone and nonhistone proteins to yield L-lysine and acetate.  This chem. plays a crit. role in the regulation of numerous biol. processes.  Aberrant HDAC activity is implicated in various diseases, and HDACs are validated targets for drug design.  Two HDAC inhibitors are currently approved for cancer chemotherapy, and other inhibitors are in clin. trials.  To date, x-ray crystal structures are available for 4 human HDACs (2, 4, 7, and 8) and 3 HDAC-related deacetylases from bacteria [histone deacetylase-like protein (HDLP), histone deacetylase-like amidohydrolase (HDAH), and acetylpolyamine amidohydrolase (APAH)].  Structural comparisons among these enzymes reveal a conserved constellation of active site residues, suggesting a common mechanism for the metal-dependent hydrolysis of acetylated substrates.  Structural analyses of HDACs and HDAC-related deacetylases guide the design of tight-binding inhibitors, and future prospects for developing isoenzyme-specific inhibitors are quite promising.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2SnZUQ2FtTrVg90H21EOLACvtfcHk0lieyZDMiDbtdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFOhurrJ&md5=edab41900a9f233d7ff30c507cfcce66</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2011.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2011.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DLombardi%26aufirst%3DP.%2BM.%26aulast%3DCole%26aufirst%3DK.%2BE.%26aulast%3DDowling%26aufirst%3DD.%2BP.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructure%252C%2520Mechanism%252C%2520and%2520Inhibition%2520of%2520Histone%2520Deacetylases%2520and%2520Related%2520Metalloenzymes%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2011%26volume%3D21%26spage%3D735%26epage%3D743%26doi%3D10.1016%2Fj.sbi.2011.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verdin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span> <span> </span><span class="NLM_article-title">50 Years of Protein Acetylation: from Gene Regulation to Epigenetics, Metabolism and Beyond</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">258</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1038/nrm3931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1038%2Fnrm3931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=25549891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC2MXks1alsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=258-264&author=E.+Verdinauthor=M.+Ott&title=50+Years+of+Protein+Acetylation%3A+from+Gene+Regulation+to+Epigenetics%2C+Metabolism+and+Beyond&doi=10.1038%2Fnrm3931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond</span></div><div class="casAuthors">Verdin, Eric; Ott, Melanie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">258-264</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In 1964, Vincent Allfrey and colleagues reported the identification of histone acetylation and with deep insight proposed a regulatory role for this protein modification in transcription regulation.  Subsequently, histone acetyltransferases (HATs), histone deacetylases (HDACs) and acetyl-Lys-binding proteins were identified as transcription regulators, thereby providing compelling evidence for his daring hypothesis.  During the past 15 years, reversible protein acetylation and its modifying enzymes have been implicated in many cellular functions beyond transcription regulation.  Here, we review the progress accomplished during the past 50 years and discuss the future of protein acetylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCxnSTZh7_tLVg90H21EOLACvtfcHk0lieyZDMiDbtdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXks1alsLc%253D&md5=87196dc230d495b5e8fed093acf5254b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrm3931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3931%26sid%3Dliteratum%253Aachs%26aulast%3DVerdin%26aufirst%3DE.%26aulast%3DOtt%26aufirst%3DM.%26atitle%3D50%2520Years%2520of%2520Protein%2520Acetylation%253A%2520from%2520Gene%2520Regulation%2520to%2520Epigenetics%252C%2520Metabolism%2520and%2520Beyond%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2015%26volume%3D16%26spage%3D258%26epage%3D264%26doi%3D10.1038%2Fnrm3931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Ruijter, A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gennip, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kuilenburg, B. P.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases (HDACs): Characterization of the Classical HDAC Family</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1042/bj20021321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1042%2Fbj20021321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=12429021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvFKiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2003&pages=737-749&author=A.+J.+M.+de%0ARuijterauthor=A.+H.+van+Gennipauthor=H.+N.+Caronauthor=S.+Kempauthor=B.+P.+van+Kuilenburg&title=Histone+Deacetylases+%28HDACs%29%3A+Characterization+of+the+Classical+HDAC+Family&doi=10.1042%2Fbj20021321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases (HDACs): characterization of the classical HDAC family</span></div><div class="casAuthors">de Ruijter, Annemieke J. M.; van Gennip, Albert H.; Caron, Huib N.; Kemp, Stephan; van Kuilenburg, Andre B. P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">737-749</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review, with refs.  Transcriptional regulation in eukaryotes occurs within a chromatin setting, and is strongly influenced by the post-translational modification of histones, the building blocks of chromatin, such as methylation, phosphorylation and acetylation.  Acetylation is probably the best understood of these modifications: hyperacetylation leads to an increase in the expression of particular genes, and hypoacetylation has the opposite effect.  Many studies have identified several large, multisubunit enzyme complexes that are responsible for the targeted deacetylation of histones.  The aim of this review is to give a comprehensive overview of the structure, function and tissue distribution of members of the classical histone deacetylase (HDAC) family, in order to gain insight into the regulation of gene expression through HDAC activity.  SAGE (serial anal. of gene expression) data show that HDACs are generally expressed in almost all tissues investigated.  Surprisingly, no major differences were obsd. between the expression pattern in normal and malignant tissues.  However, significant variation in HDAC expression was obsd. within tissue types.  HDAC inhibitors have been shown to induce specific changes in gene expression and to influence a variety of other processes, including growth arrest, differentiation, cytotoxicity and induction of apoptosis.  This challenging field has generated many fascinating results which will ultimately lead to a better understanding of the mechanism of gene transcription as a whole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN1-6ct5EQtrVg90H21EOLACvtfcHk0lieyZDMiDbtdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvFKiu7o%253D&md5=8a521cd3ddcf046b4b806ebf9f1476b4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1042%2Fbj20021321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj20021321%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BRuijter%26aufirst%3DA.%2BJ.%2BM.%26aulast%3Dvan%2BGennip%26aufirst%3DA.%2BH.%26aulast%3DCaron%26aufirst%3DH.%2BN.%26aulast%3DKemp%26aufirst%3DS.%26aulast%3Dvan%2BKuilenburg%26aufirst%3DB.%2BP.%26atitle%3DHistone%2520Deacetylases%2520%2528HDACs%2529%253A%2520Characterization%2520of%2520the%2520Classical%2520HDAC%2520Family%26jtitle%3DBiochem.%2520J.%26date%3D2003%26volume%3D370%26spage%3D737%26epage%3D749%26doi%3D10.1042%2Fbj20021321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falkenberg, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases and their Inhibitors in Cancer, Neurological Diseases and Immune Disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1038/nrd4360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1038%2Fnrd4360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=25131830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=673-691&author=K.+J.+Falkenbergauthor=R.+W.+Johnstone&title=Histone+Deacetylases+and+their+Inhibitors+in+Cancer%2C+Neurological+Diseases+and+Immune+Disorders&doi=10.1038%2Fnrd4360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</span></div><div class="casAuthors">Falkenberg, Katrina J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">673-691</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters.  Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small mols.  This Review discusses the role of altered expression and/or function of one class of epigenetic regulators - histone deacetylases (HDACs) - and their role in cancer, neurol. diseases and immune disorders.  We highlight the development of small-mol. HDAC inhibitors and their use in the lab., in preclin. models and in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXiWEG49LhebVg90H21EOLACvtfcHk0lhB3XhlDe4vYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI&md5=ccfb68fa3fd4685e2305cdf8a6a9c81a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrd4360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4360%26sid%3Dliteratum%253Aachs%26aulast%3DFalkenberg%26aufirst%3DK.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DHistone%2520Deacetylases%2520and%2520their%2520Inhibitors%2520in%2520Cancer%252C%2520Neurological%2520Diseases%2520and%2520Immune%2520Disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D673%26epage%3D691%26doi%3D10.1038%2Fnrd4360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furdas, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kannan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Inhibitors of Histone Acetyltransferases as Epigenetic Tools and Drug Candidates</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>345</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1002/ardp.201100209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1002%2Fardp.201100209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=22234972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlOnu7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2012&pages=7-21&author=S.+D.+Furdasauthor=S.+Kannanauthor=W.+Sipplauthor=M.+Jung&title=Small+Molecule+Inhibitors+of+Histone+Acetyltransferases+as+Epigenetic+Tools+and+Drug+Candidates&doi=10.1002%2Fardp.201100209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors of Histone Acetyltransferases as Epigenetic Tools and Drug Candidates</span></div><div class="casAuthors">Furdas, Silviya D.; Kannan, Srinivasaraghavan; Sippl, Wolfgang; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-21</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Alteration of the acetylation state of histone proteins contributes to transcriptional regulation and epigenetic inheritance.  Dysregulation of these processes may lead to human diseases, esp. cancer.  One of the major chromatin modifications is histone acetylation and this review gives an overview of the role of histone acetyltransferases, their structural aspects, as well as of chem. modulators targeting their enzymic activities.  Inhibitors and activators of histone acetyltransferases are presented and their capability to influence histone and non-histone protein acetylation levels is discussed.  Development of small mols. as epigenetic tools that alter histone acetyltransferase activity will be helpful to better understand the consequences of histone and generally protein acetylation and potentially offer novel therapeutic approaches for the treatment of cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphwDWjySoJrrVg90H21EOLACvtfcHk0lhB3XhlDe4vYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlOnu7%252FK&md5=6a71f3f6cfcfb6e1a84b2761e0d61b11</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fardp.201100209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201100209%26sid%3Dliteratum%253Aachs%26aulast%3DFurdas%26aufirst%3DS.%2BD.%26aulast%3DKannan%26aufirst%3DS.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DSmall%2520Molecule%2520Inhibitors%2520of%2520Histone%2520Acetyltransferases%2520as%2520Epigenetic%2520Tools%2520and%2520Drug%2520Candidates%26jtitle%3DArch.%2520Pharm.%26date%3D2012%26volume%3D345%26spage%3D7%26epage%3D21%26doi%3D10.1002%2Fardp.201100209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mariño-Ramírez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kann, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landsman, D.</span></span> <span> </span><span class="NLM_article-title">Histone Structure and Nucleosome Stability</span>. <i>Expert Rev. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">729</span>, <span class="refDoi"> DOI: 10.1586/14789450.2.5.719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1586%2F14789450.2.5.719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=16209651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1SlsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=719-729&author=L.+Mari%C3%B1o-Ram%C3%ADrezauthor=M.+G.+Kannauthor=B.+A.+Shoemakerauthor=D.+Landsman&title=Histone+Structure+and+Nucleosome+Stability&doi=10.1586%2F14789450.2.5.719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Histone structure and nucleosome stability</span></div><div class="casAuthors">Marino-Ramirez, Leonardo; Kann, Maricel G.; Shoemaker, Benjamin A.; Landsman, David</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Proteomics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">719-729</span>CODEN:
                <span class="NLM_cas:coden">ERPXA3</span>;
        ISSN:<span class="NLM_cas:issn">1478-9450</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone proteins play essential structural and functional roles in the transition between active and inactive chromatin states.  Although histones have a high degree of conservation due to constraints to maintain the overall structure of the nucleosomal octameric core, variants have evolved to assume diverse roles in gene regulation and epigenetic silencing.  Histone variants, post-translational modifications and interactions with chromatin remodeling complexes influence DNA replication, transcription, repair and recombination.  The authors review recent findings on the structure of chromatin that confirm previous interparticle interactions obsd. in crystal structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopDcjUqe2LZrVg90H21EOLACvtfcHk0lhB3XhlDe4vYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1SlsrbF&md5=949ac0323e0d4b05c8f2fe5b951ae829</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1586%2F14789450.2.5.719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14789450.2.5.719%26sid%3Dliteratum%253Aachs%26aulast%3DMari%25C3%25B1o-Ram%25C3%25ADrez%26aufirst%3DL.%26aulast%3DKann%26aufirst%3DM.%2BG.%26aulast%3DShoemaker%26aufirst%3DB.%2BA.%26aulast%3DLandsman%26aufirst%3DD.%26atitle%3DHistone%2520Structure%2520and%2520Nucleosome%2520Stability%26jtitle%3DExpert%2520Rev.%2520Proteomics%26date%3D2005%26volume%3D2%26spage%3D719%26epage%3D729%26doi%3D10.1586%2F14789450.2.5.719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumagai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakimoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gery, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chumakov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeffler, H. P.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid (Vorinostat, SAHA) Profoundly Inhibits the Growth of Human Pancreatic Cancer Cells</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">656</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1002/ijc.22558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1002%2Fijc.22558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=17417771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnt1Crsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2007&pages=656-665&author=T.+Kumagaiauthor=N.+Wakimotoauthor=D.+Yinauthor=S.+Geryauthor=N.+Kawamataauthor=N.+Takaiauthor=N.+Komatsuauthor=A.+Chumakovauthor=Y.+Imaiauthor=H.+P.+Koeffler&title=Histone+Deacetylase+Inhibitor%2C+Suberoylanilide+Hydroxamic+Acid+%28Vorinostat%2C+SAHA%29+Profoundly+Inhibits+the+Growth+of+Human+Pancreatic+Cancer+Cells&doi=10.1002%2Fijc.22558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells</span></div><div class="casAuthors">Kumagai, Takashi; Wakimoto, Naoki; Yin, Dong; Gery, Sigal; Kawamata, Norihiko; Takai, Noriyuki; Komatsu, Naoki; Chumakov, Alexy; Imai, Yasufumi; Koeffler, H. Phillip</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">656-665</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Tumor suppressor genes are often silenced in human cancer; this can occur by transcriptional repression by deacetylation in the promoter regions, mediated by histone deacetylase (HDAC).  HDAC inhibitors can block cancer cell growth by restoring expression of tumor suppressor genes.  In this study, we investigated the effects of a HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA) on pancreatic cancer cells.  SAHA inhibited the growth of 6 pancreatic cancer cell lines in a dose-dependent manner as measured by MTT and clonogenic assays (ED50 ≈10-6 M) assocd. with induction of apoptosis, G2 cell cycle arrest and also induced differentiation as indicated by morphol. and increased expression of cytokeratin 7.  It increased expression of p21WAF1 (independent of the mutational status of p53), C/EBPα, RARα and E-cadherin; these genes have been assocd. with decreased proliferation in other cancers.  SAHA decreased cyclin B1 expression; this cyclin normally promotes progression through G2 of the cell cycle.  SAHA mediated acetylation of histone H3 globally, as well as, assocd. with the p21WAF1 promoter, as measured by chromatin immunopptn.  SAHA also decreased levels of c-myc and cyclin D1, independent of an active β-catenin pathway.  In further studies, the combination of SAHA and an inhibitor of DNA methylation, 5-Aza-2'-deoxycytidine, had an enhanced antiproliferative effect on pancreatic cancer cells.  In summary, SAHA inhibited the growth of human pancreatic cancer cells by inducing apoptosis, differentiation and cell cycle arrest, as well as increase in the expression of several tumor suppressor genes.  SAHA is a novel, promising therapeutic agent for human pancreatic cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVgeJjEzQr77Vg90H21EOLACvtfcHk0lhB3XhlDe4vYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnt1Crsrs%253D&md5=4c7224c82f75d160b934fb0560f73eb5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fijc.22558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.22558%26sid%3Dliteratum%253Aachs%26aulast%3DKumagai%26aufirst%3DT.%26aulast%3DWakimoto%26aufirst%3DN.%26aulast%3DYin%26aufirst%3DD.%26aulast%3DGery%26aufirst%3DS.%26aulast%3DKawamata%26aufirst%3DN.%26aulast%3DTakai%26aufirst%3DN.%26aulast%3DKomatsu%26aufirst%3DN.%26aulast%3DChumakov%26aufirst%3DA.%26aulast%3DImai%26aufirst%3DY.%26aulast%3DKoeffler%26aufirst%3DH.%2BP.%26atitle%3DHistone%2520Deacetylase%2520Inhibitor%252C%2520Suberoylanilide%2520Hydroxamic%2520Acid%2520%2528Vorinostat%252C%2520SAHA%2529%2520Profoundly%2520Inhibits%2520the%2520Growth%2520of%2520Human%2520Pancreatic%2520Cancer%2520Cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2007%26volume%3D121%26spage%3D656%26epage%3D665%26doi%3D10.1002%2Fijc.22558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piekarz, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschbaum, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prince, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geskin, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joske, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figg, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffe, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetler-Stevenson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lade, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span> <span> </span><span class="NLM_article-title">Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">5410</span>– <span class="NLM_lpage">5417</span>, <span class="refDoi"> DOI: 10.1200/JCO.2008.21.6150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1200%2FJCO.2008.21.6150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=19826128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFKkt7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=5410-5417&author=R.+L.+Piekarzauthor=R.+Fryeauthor=M.+Turnerauthor=J.+J.+Wrightauthor=S.+L.+Allenauthor=M.+H.+Kirschbaumauthor=J.+Zainauthor=H.+M.+Princeauthor=J.+P.+Leonardauthor=L.+J.+Geskinauthor=C.+Reederauthor=D.+Joskeauthor=W.+D.+Figgauthor=E.+R.+Gardnerauthor=S.+M.+Steinbergauthor=E.+S.+Jaffeauthor=M.+Stetler-Stevensonauthor=S.+Ladeauthor=A.+T.+Fojoauthor=S.+E.+Bates&title=Phase+II+Multi-Institutional+Trial+of+the+Histone+Deacetylase+Inhibitor+Romidepsin+As+Monotherapy+for+Patients+With+Cutaneous+T-Cell+Lymphoma&doi=10.1200%2FJCO.2008.21.6150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma</span></div><div class="casAuthors">Piekarz, Richard L.; Frye, Robin; Turner, Maria; Wright, John J.; Allen, Steven L.; Kirschbaum, Mark H.; Zain, Jasmine; Prince, H. Miles; Leonard, John P.; Geskin, Larisa J.; Reeder, Craig; Joske, David; Figg, William D.; Gardner, Erin R.; Steinberg, Seth M.; Jaffe, Elaine S.; Stetler-Stevenson, Maryalice; Lade, Stephen; Fojo, A. Tito; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">5410-5417</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Romidepsin (depsipeptide or FK228) is a member of a new class of antineoplastic agents active in T-cell lymphoma, the histone deacetylase inhibitors.  On the basis of obsd. responses in a phase I trial, a phase II trial of romidepsin in patients with T-cell lymphoma was initiated.  The initial cohort was limited to patients with cutaneous T-cell lymphoma (CTCL), or subtypes mycosis fungoides or Sezary syndrome, who had received no more than two prior cytotoxic regimens.  There were no limits on other types of therapy.  Subsequently, the protocol was expanded to enroll patients who had received more than two prior cytotoxic regimens.  Twenty-seven patients were enrolled onto the first cohort, and a total of 71 patients are included in this anal.  These patients had undergone a median of four prior treatments, and 62 patients (87%) had advanced-stage disease (stage IIB, n = 15; stage III, n= 6; or stage IV, n = 41).  Toxicities included nausea, vomiting, fatigue, and transient thrombocytopenia and granulocytopenia.  Pharmacokinetics were evaluated with the first administration of romidepsin.  Complete responses were obsd. in four patients, and partial responses were obsd. in 20 patients for an overall response rate of 34% (95% CI, 23% to 46%).  The median duration of response was 13.7 mo.  The histone deacetylase inhibitor romidepsin has single-agent clin. activity with significant and durable responses in patients with CTCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUzt-4ptTta7Vg90H21EOLACvtfcHk0lilf8HtmeI1Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFKkt7vO&md5=e99b3bf6b987b6cb5ed3d2cbefcbd259</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.21.6150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.21.6150%26sid%3Dliteratum%253Aachs%26aulast%3DPiekarz%26aufirst%3DR.%2BL.%26aulast%3DFrye%26aufirst%3DR.%26aulast%3DTurner%26aufirst%3DM.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DAllen%26aufirst%3DS.%2BL.%26aulast%3DKirschbaum%26aufirst%3DM.%2BH.%26aulast%3DZain%26aufirst%3DJ.%26aulast%3DPrince%26aufirst%3DH.%2BM.%26aulast%3DLeonard%26aufirst%3DJ.%2BP.%26aulast%3DGeskin%26aufirst%3DL.%2BJ.%26aulast%3DReeder%26aufirst%3DC.%26aulast%3DJoske%26aufirst%3DD.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DGardner%26aufirst%3DE.%2BR.%26aulast%3DSteinberg%26aufirst%3DS.%2BM.%26aulast%3DJaffe%26aufirst%3DE.%2BS.%26aulast%3DStetler-Stevenson%26aufirst%3DM.%26aulast%3DLade%26aufirst%3DS.%26aulast%3DFojo%26aufirst%3DA.%2BT.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DPhase%2520II%2520Multi-Institutional%2520Trial%2520of%2520the%2520Histone%2520Deacetylase%2520Inhibitor%2520Romidepsin%2520As%2520Monotherapy%2520for%2520Patients%2520With%2520Cutaneous%2520T-Cell%2520Lymphoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D5410%26epage%3D5417%26doi%3D10.1200%2FJCO.2008.21.6150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ara, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaRochelle, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichenstein, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffers, M.</span></span> <span> </span><span class="NLM_article-title">Activity of the Histone Deacetylase Inhibitor Belinostat (PXD101) in Preclinical Models of Prostate Cancer</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">1400</span>– <span class="NLM_lpage">1410</span>, <span class="refDoi"> DOI: 10.1002/ijc.23243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1002%2Fijc.23243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=18027850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BD1cXit1yht7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2008&pages=1400-1410&author=X.+Qianauthor=G.+Araauthor=E.+Millsauthor=W.+J.+LaRochelleauthor=H.+S.+Lichensteinauthor=M.+Jeffers&title=Activity+of+the+Histone+Deacetylase+Inhibitor+Belinostat+%28PXD101%29+in+Preclinical+Models+of+Prostate+Cancer&doi=10.1002%2Fijc.23243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer</span></div><div class="casAuthors">Qian, Xiaozhong; Ara, Gulshan; Mills, Evan; La Rochelle, William J.; Lichenstein, Henri S.; Jeffers, Michael</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1400-1410</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACi) represent a promising new class of anticancer agents.  In the current investigation, we examd. the activity of the HDACi belinostat in preclin. models of prostate cancer.  In vitro proliferation assays demonstrated that belinostat potently inhibited the growth of prostate cancer cell lines (IC50 < 1.0 μM) and was cytotoxic to these cells.  Washout expts. indicated that exposure to belinostat for relatively short periods of time (<12 h) induced suboptimal growth-inhibition and that cells exposed to 1.0 μM belinostat for 48 h retained the capacity for regrowth following drug withdrawal, while cells exposed to 4.0 μM belinostat were irreversibly growth-inhibited.  Cell cycle analyses demonstrated that belinostat induced G2/M arrest and increased the percentage of cells with subG1 DNA content, thus confirming the growth-inhibitory and cytotoxic effects of this compd.  Normal prostate epithelial cells were generally less susceptible to the effects of belinostat than were prostate cancer cells.  In an orthotopic prostate cancer tumor model, belinostat inhibited tumor growth by up to 43%.  Moreover, metastatic lung lesions were present in 47% of vehicle-treated animals but in none of the animals administered belinostat.  Consistent with its obsd. antimetastatic activity, belinostat inhibited the migration of prostate tumor cells and increased the prodn. of tissue inhibitor of metalloproteinase-1 (TIMP-1) by these cells, the latter effect being replicated by siRNA knockdown of HDAC3.  Belinostat also increased the expression of p21 and decreased the expression of potentially oncogenic proteins (mutant p53 and ERG).  These results support the clin. evaluation of belinostat for the treatment of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHxA5gtazFvLVg90H21EOLACvtfcHk0lilf8HtmeI1Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXit1yht7w%253D&md5=7db206329bf3ad0655a420b33243a3c2</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fijc.23243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.23243%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DX.%26aulast%3DAra%26aufirst%3DG.%26aulast%3DMills%26aufirst%3DE.%26aulast%3DLaRochelle%26aufirst%3DW.%2BJ.%26aulast%3DLichenstein%26aufirst%3DH.%2BS.%26aulast%3DJeffers%26aufirst%3DM.%26atitle%3DActivity%2520of%2520the%2520Histone%2520Deacetylase%2520Inhibitor%2520Belinostat%2520%2528PXD101%2529%2520in%2520Preclinical%2520Models%2520of%2520Prostate%2520Cancer%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2008%26volume%3D122%26spage%3D1400%26epage%3D1410%26doi%3D10.1002%2Fijc.23243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams-Truax, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterfoss, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culver, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prince, H. M.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">4500</span>– <span class="NLM_lpage">4510</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-4262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1158%2F1078-0432.CCR-07-4262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=18628465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFGitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=4500-4510&author=L.+Ellisauthor=Y.+Panauthor=G.+K.+Smythauthor=D.+J.+Georgeauthor=C.+McCormackauthor=R.+Williams-Truaxauthor=M.+Mitaauthor=J.+Beckauthor=H.+Burrisauthor=G.+Ryanauthor=P.+Atadjaauthor=D.+Butterfossauthor=M.+Duganauthor=K.+Culverauthor=R.+W.+Johnstoneauthor=H.+M.+Prince&title=Histone+Deacetylase+Inhibitor+Panobinostat+Induces+Clinical+Responses+with+Associated+Alterations+in+Gene+Expression+Profiles+in+Cutaneous+T-Cell+Lymphoma&doi=10.1158%2F1078-0432.CCR-07-4262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma</span></div><div class="casAuthors">Ellis, Leigh; Pan, Yan; Smyth, Gordon K.; George, Daniel J.; McCormack, Chris; Williams-Truax, Roxanne; Mita, Monica; Beck, Joachim; Burris, Howard; Ryan, Gail; Atadja, Peter; Butterfoss, Dale; Dugan, Margaret; Culver, Kenneth; Johnstone, Ricky W.; Prince, H. Miles</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4500-4510</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors can alter gene expression and mediate diverse antitumor activities.  Herein, we report the safety and activity of the histone deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma (CTCL) and identify genes commonly regulated by panobinostat.  Panobinostat was administered orally to patients with CTCL on Monday, Wednesday, and Friday of each week on a 28-day cycle.  A dose of 30 mg was considered excessively toxic, and subsequent patients were treated at the expanded max. tolerated dose of 20 mg.  Biopsies from six patients taken 0, 4, 8, and 24 h after administration were subjected to microarray gene expression profiling and real-time quant. PCR of selected genes.  Patients attained a complete response (n = 2), attained a partial response (n = 4), achieved stable disease with ongoing improvement (n = 1), and progressed on treatment (n = 2).  Microarray data showed distinct gene expression response profiles over time following panobinostat treatment, with the majority of genes being repressed.  Twenty-three genes were commonly regulated by panobinostat in all patients tested.  Panobinostat is well tolerated and induces clin. responses in CTCL patients.  Microarray analyses of tumor samples indicate that panobinostat induces rapid changes in gene expression, and surprisingly more genes are repressed than are activated.  A unique set of genes that can mediate biol. responses such as apoptosis, immune regulation, and angiogenesis were commonly regulated in response to panobinostat.  These genes are potential mol. biomarkers for panobinostat activity and are strong candidates for the future assessment of their functional role(s) in mediating the antitumor responses of panobinostat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKdLh4qldQ37Vg90H21EOLACvtfcHk0lhi9OILTHdhjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFGitL0%253D&md5=0b53d3b837c0f89a700287855ffcc961</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-4262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-4262%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DL.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DSmyth%26aufirst%3DG.%2BK.%26aulast%3DGeorge%26aufirst%3DD.%2BJ.%26aulast%3DMcCormack%26aufirst%3DC.%26aulast%3DWilliams-Truax%26aufirst%3DR.%26aulast%3DMita%26aufirst%3DM.%26aulast%3DBeck%26aufirst%3DJ.%26aulast%3DBurris%26aufirst%3DH.%26aulast%3DRyan%26aufirst%3DG.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DButterfoss%26aufirst%3DD.%26aulast%3DDugan%26aufirst%3DM.%26aulast%3DCulver%26aufirst%3DK.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DPrince%26aufirst%3DH.%2BM.%26atitle%3DHistone%2520Deacetylase%2520Inhibitor%2520Panobinostat%2520Induces%2520Clinical%2520Responses%2520with%2520Associated%2520Alterations%2520in%2520Gene%2520Expression%2520Profiles%2520in%2520Cutaneous%2520T-Cell%2520Lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D4500%26epage%3D4510%26doi%3D10.1158%2F1078-0432.CCR-07-4262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span>NPI-0052 and
Vorinostat in Patients
with Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma.
ClinicalTrials.gov; Identifier NCT00667082, <span class="NLM_year">2016</span> (accessed
Aug 16, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NPI-0052+and%0AVorinostat+in+Patients%0Awith+Non-small+Cell+Lung+Cancer%2C+Pancreatic+Cancer%2C+Melanoma+or+Lymphoma.%0AClinicalTrials.gov%3B+Identifier+NCT00667082%2C+2016+%28accessed%0AAug+16%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span>Vorinostat Plus Radiation Therapy
in Pancreatic Cancer. ClinicalTrials.gov; Identifier NCT00831493, <span class="NLM_year">2012</span> (accessed Aug 16, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Vorinostat+Plus+Radiation+Therapy%0Ain+Pancreatic+Cancer.+ClinicalTrials.gov%3B+Identifier+NCT00831493%2C+2012+%28accessed+Aug+16%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span>Vorinostat With XRT and 5-FU
for Locally Advanced Adenocarcinoma of the Pancreas. ClinicalTrials.gov;
Identifier NCT00948688, <span class="NLM_year">2017</span> (accessed Aug 16, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Vorinostat+With+XRT+and+5-FU%0Afor+Locally+Advanced+Adenocarcinoma+of+the+Pancreas.+ClinicalTrials.gov%3B%0AIdentifier+NCT00948688%2C+2017+%28accessed+Aug+16%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span>Capecitabine, Vorinostat,
and
Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic
Cancer. ClinicalTrials.gov; Identifier NCT00983268, <span class="NLM_year">2015</span> (accessed Aug 16, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Capecitabine%2C+Vorinostat%2C%0Aand%0ARadiation+Therapy+in+Treating+Patients+With+Nonmetastatic+Pancreatic%0ACancer.+ClinicalTrials.gov%3B+Identifier+NCT00983268%2C+2015+%28accessed+Aug+16%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span>Neoadjuvant Chemotherapy Followed
by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic
Cancer. ClinicalTrials.gov; Identifier NCT02349867, <span class="NLM_year">2017</span> (accessed Aug 16, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Neoadjuvant+Chemotherapy+Followed%0Aby+Radiation+Therapy+and+Gemcitabine%2FSorafenib%2FVorinostat+in+Pancreatic%0ACancer.+ClinicalTrials.gov%3B+Identifier+NCT02349867%2C+2017+%28accessed+Aug+16%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span>MS-275 in Treating Patients With
Advanced Solid Tumors or Lymphoma. ClinicalTrials.gov; Identifier
NCT00020579, <span class="NLM_year">2012</span> (accessed Aug 16, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=MS-275+in+Treating+Patients+With%0AAdvanced+Solid+Tumors+or+Lymphoma.+ClinicalTrials.gov%3B+Identifier%0ANCT00020579%2C+2012+%28accessed+Aug+16%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span>Panobinostat & Bortezomib
in Pancreatic Cancer Progressing on Gemcitabine Therapy. ClinicalTrials.gov;
Identifier NCT01056601, <span class="NLM_year">2012</span> (accessed Aug 16, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Panobinostat+%26+Bortezomib%0Ain+Pancreatic+Cancer+Progressing+on+Gemcitabine+Therapy.+ClinicalTrials.gov%3B%0AIdentifier+NCT01056601%2C+2012+%28accessed+Aug+16%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdelfatah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerner, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, N.</span></span> <span> </span><span class="NLM_article-title">Epigenetic Therapy in Gastrointestinal Cancer: the Right Combination</span>. <i>Ther. Adv. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">579</span>, <span class="refDoi"> DOI: 10.1177/1756283X16644247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1177%2F1756283X16644247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=27366224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFOrsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=560-579&author=E.+Abdelfatahauthor=Z.+Kernerauthor=N.+Nandaauthor=N.+Ahuja&title=Epigenetic+Therapy+in+Gastrointestinal+Cancer%3A+the+Right+Combination&doi=10.1177%2F1756283X16644247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic therapy in gastrointestinal cancer: the right combination</span></div><div class="casAuthors">Abdelfatah, Eihab; Kerner, Zachary; Nanda, Nainika; Ahuja, Nita</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Gastroenterology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">560-579</span>CODEN:
                <span class="NLM_cas:coden">TAGHAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-283X</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Epigenetics is a relatively recent field of mol. biol. that has arisen over the past 25 years.  Cancer is now understood to be a disease of widespread epigenetic dysregulation that interacts extensively with underlying genetic mutations.  The development of drugs targeting these processes has rapidly progressed; with several drugs already FDA approved as first-line therapy in hematol. malignancies.  Gastrointestinal (GI) cancers possess high degrees of epigenetic dysregulation, exemplified by subtypes such as CpG island methylator phenotype (CIMP), and the potential benefit of epigenetic therapy in these cancers is evident.  The application of epigenetic drugs in solid tumors, including GI cancers, is just emerging, with increased understanding of the cancer epigenome.  In this review, we provide a brief overview of cancer epigenetics and the epigenetic targets of therapy including DNA (DNA) methylation, histone modifications, and chromatin remodeling.  We discuss the epigenetic drugs currently in use, with a focus on DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibitors, and explain the pharmacokinetic and mechanistic challenges in their application.  We present the strategies employed in incorporating these drugs into the treatment of GI cancers, and explain the concept of the cancer stem cell in epigenetic reprogramming and reversal of chemo resistance.  We discuss the most promising combination strategies in GI cancers including: (1) epigenetic sensitization to radiotherapy, (2) epigenetic sensitization to cytotoxic chemotherapy, and (3) epigenetic immune modulation and priming for immune therapy.  Finally, we present preclin. and clin. trial data employing these strategies thus far in various GI cancers including colorectal, esophageal, gastric, and pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkime7zHEKY7Vg90H21EOLACvtfcHk0lhi9OILTHdhjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFOrsLw%253D&md5=864e758f0ac272f12cc5669630aac928</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1177%2F1756283X16644247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1756283X16644247%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelfatah%26aufirst%3DE.%26aulast%3DKerner%26aufirst%3DZ.%26aulast%3DNanda%26aufirst%3DN.%26aulast%3DAhuja%26aufirst%3DN.%26atitle%3DEpigenetic%2520Therapy%2520in%2520Gastrointestinal%2520Cancer%253A%2520the%2520Right%2520Combination%26jtitle%3DTher.%2520Adv.%2520Gastroenterol.%26date%3D2016%26volume%3D9%26spage%3D560%26epage%3D579%26doi%3D10.1177%2F1756283X16644247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentze, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">The Oral HDAC Inhibitor Pracinostat (SB939) is Efficacious and Synergistic with the JAK2 Inhibitor Pacritinib (SB1518) in Preclinical Models of AML</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e69</span> <span class="refDoi"> DOI: 10.1038/bcj.2012.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1038%2Fbcj.2012.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=22829971" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&author=V.+Novotny-Diermayrauthor=S.+Hartauthor=K.+C.+Gohauthor=A.+Cheongauthor=L.-C.+Ongauthor=H.+Hentzeauthor=M.+K.+Pashaauthor=R.+Jayaramanauthor=K.+Ethirajuluauthor=J.+M.+Wood&title=The+Oral+HDAC+Inhibitor+Pracinostat+%28SB939%29+is+Efficacious+and+Synergistic+with+the+JAK2+Inhibitor+Pacritinib+%28SB1518%29+in+Preclinical+Models+of+AML&doi=10.1038%2Fbcj.2012.14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2012.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2012.14%26sid%3Dliteratum%253Aachs%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DOng%26aufirst%3DL.-C.%26aulast%3DHentze%26aufirst%3DH.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520Oral%2520HDAC%2520Inhibitor%2520Pracinostat%2520%2528SB939%2529%2520is%2520Efficacious%2520and%2520Synergistic%2520with%2520the%2520JAK2%2520Inhibitor%2520Pacritinib%2520%2528SB1518%2529%2520in%2520Preclinical%2520Models%2520of%2520AML%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2012%26volume%3D2%26doi%3D10.1038%2Fbcj.2012.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venugopal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristeleit, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourneau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellemans, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsayed, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcclue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forslund, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelps, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, T. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de
Bono, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span> <span> </span><span class="NLM_article-title">A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4262</span>– <span class="NLM_lpage">4272</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1158%2F1078-0432.CCR-13-0312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=23741066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4262-4272&author=B.+Venugopalauthor=R.+Bairdauthor=R.+S.+Kristeleitauthor=R.+Plummerauthor=R.+Cowanauthor=A.+Stewartauthor=N.+Fourneauauthor=P.+Hellemansauthor=Y.+Elsayedauthor=S.+Mcclueauthor=J.+W.+Smitauthor=A.+Forslundauthor=C.+Phelpsauthor=J.+Cammauthor=T.+R.+J.+Evansauthor=J.+S.+de%0ABonoauthor=U.+Banerji&title=A+Phase+I+Study+of+Quisinostat+%28JNJ-26481585%29%2C+an+Oral+Hydroxamate+Histone+Deacetylase+Inhibitor+with+Evidence+of+Target+Modulation+and+Antitumor+Activity%2C+in+Patients+with+Advanced+Solid+Tumors&doi=10.1158%2F1078-0432.CCR-13-0312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Venugopal, Balaji; Baird, Richard; Kristeleit, Rebecca S.; Plummer, Ruth; Cowan, Richard; Stewart, Adam; Fourneau, Nele; Hellemans, Peter; Elsayed, Yusri; McClue, Steve; Smit, Johan W.; Forslund, Ann; Phelps, Charles; Camm, John; Evans, T. R. Jeffry; de Bono, Johann S.; Banerji, Udai</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4262-4272</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To det. the max.-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic and pharmacodynamic profile of quisinostat, a novel hydroxamate, pan-histone deacetylase inhibitor (HDACi).  Exptl. Design: In this first-in-human phase I study, quisinostat was administered orally, once daily in three weekly cycles to patients with advanced malignancies, using a two-stage accelerated titrn. design.  Three intermittent schedules were subsequently explored: four days on/three days off; every Monday, Wednesday, Friday (MWF); and every Monday and Thursday (M-Th).  Toxicity, pharmacokinetics, pharmacodynamics, and clin. efficacy were evaluated at each schedule.  Results: Ninety-two patients were treated in continuous daily (2-12 mg) and three intermittent dosing schedules (6-19 mg).  Treatment-emergent adverse events included: fatigue, nausea, decreased appetite, lethargy, and vomiting.  DLTs obsd. were predominantly cardiovascular, including nonsustained ventricular tachycardia, ST/T-wave abnormalities, and other tachyarhythmias.  Noncardiac DLTs were fatigue and abnormal liver function tests.  The max. plasma concn. (Cmax) and area under the plasma concn.-time curve (AUC) of quisinostat increased proportionally with dose.  Pharmacodynamic evaluation showed increased acetylated histone 3 in hair follicles, skin and tumor biopsies, and in peripheral blood mononuclear cells as well as decreased Ki67 in skin and tumor biopsies.  A partial response lasting five months was seen in one patient with melanoma.  Stable disease was seen in eight patients (duration 4-10.5 mo).  Conclusions: The adverse event profile of quisinostat was comparable with that of other HDACi.  Intermittent schedules were better tolerated than continuous schedules.  On the basis of tolerability, pharmacokinetic predictions, and pharmacodynamic effects, the recommended dose for phase II studies is 12 mg on the MWF schedule.  Clin Cancer Res; 19(15); 4262-72. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZhELE0VMCPbVg90H21EOLACvtfcHk0ljQU2zBFdjFiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zP&md5=f4db895a7878fddce61ea9640e427d4d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0312%26sid%3Dliteratum%253Aachs%26aulast%3DVenugopal%26aufirst%3DB.%26aulast%3DBaird%26aufirst%3DR.%26aulast%3DKristeleit%26aufirst%3DR.%2BS.%26aulast%3DPlummer%26aufirst%3DR.%26aulast%3DCowan%26aufirst%3DR.%26aulast%3DStewart%26aufirst%3DA.%26aulast%3DFourneau%26aufirst%3DN.%26aulast%3DHellemans%26aufirst%3DP.%26aulast%3DElsayed%26aufirst%3DY.%26aulast%3DMcclue%26aufirst%3DS.%26aulast%3DSmit%26aufirst%3DJ.%2BW.%26aulast%3DForslund%26aufirst%3DA.%26aulast%3DPhelps%26aufirst%3DC.%26aulast%3DCamm%26aufirst%3DJ.%26aulast%3DEvans%26aufirst%3DT.%2BR.%2BJ.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DBanerji%26aufirst%3DU.%26atitle%3DA%2520Phase%2520I%2520Study%2520of%2520Quisinostat%2520%2528JNJ-26481585%2529%252C%2520an%2520Oral%2520Hydroxamate%2520Histone%2520Deacetylase%2520Inhibitor%2520with%2520Evidence%2520of%2520Target%2520Modulation%2520and%2520Antitumor%2520Activity%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D4262%26epage%3D4272%26doi%3D10.1158%2F1078-0432.CCR-13-0312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knipstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gore, L.</span></span> <span> </span><span class="NLM_article-title">Entinostat for Treatment of Solid Tumors and Hematologic Malignancies</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1455</span>– <span class="NLM_lpage">1467</span>, <span class="refDoi"> DOI: 10.1517/13543784.2011.613822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1517%2F13543784.2011.613822" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=1455-1467&author=J.+Knipsteinauthor=L.+Gore&title=Entinostat+for+Treatment+of+Solid+Tumors+and+Hematologic+Malignancies&doi=10.1517%2F13543784.2011.613822"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1517%2F13543784.2011.613822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2011.613822%26sid%3Dliteratum%253Aachs%26aulast%3DKnipstein%26aufirst%3DJ.%26aulast%3DGore%26aufirst%3DL.%26atitle%3DEntinostat%2520for%2520Treatment%2520of%2520Solid%2520Tumors%2520and%2520Hematologic%2520Malignancies%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D1455%26epage%3D1467%26doi%3D10.1517%2F13543784.2011.613822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, O. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahboobi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellmer, A.</span></span> <span> </span><span class="NLM_article-title">Drugging the HDAC6–HSP90 Interplay in Malignant Cells</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2014.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1016%2Fj.tips.2014.08.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=501-509&author=O.+H.+Kr%C3%A4merauthor=S.+Mahboobiauthor=A.+Sellmer&title=Drugging+the+HDAC6%E2%80%93HSP90+Interplay+in+Malignant+Cells&doi=10.1016%2Fj.tips.2014.08.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2014.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2014.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DKr%25C3%25A4mer%26aufirst%3DO.%2BH.%26aulast%3DMahboobi%26aufirst%3DS.%26aulast%3DSellmer%26aufirst%3DA.%26atitle%3DDrugging%2520the%2520HDAC6%25E2%2580%2593HSP90%2520Interplay%2520in%2520Malignant%2520Cells%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2014%26volume%3D35%26spage%3D501%26epage%3D509%26doi%3D10.1016%2Fj.tips.2014.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kroesen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gielen, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brok, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armandari, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoogerbrugge, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adema, G. J.</span></span> <span> </span><span class="NLM_article-title">HDAC Inhibitors and Immunotherapy; a Double Edged Sword?</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">6558</span>– <span class="NLM_lpage">6572</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.18632%2Foncotarget.2289" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=6558-6572&author=M.+Kroesenauthor=P.+R.+Gielenauthor=I.+C.+Brokauthor=I.+Armandariauthor=P.+M.+Hoogerbruggeauthor=G.+J.+Adema&title=HDAC+Inhibitors+and+Immunotherapy%3B+a+Double+Edged+Sword%3F&doi=10.18632%2Foncotarget.2289"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2289%26sid%3Dliteratum%253Aachs%26aulast%3DKroesen%26aufirst%3DM.%26aulast%3DGielen%26aufirst%3DP.%2BR.%26aulast%3DBrok%26aufirst%3DI.%2BC.%26aulast%3DArmandari%26aufirst%3DI.%26aulast%3DHoogerbrugge%26aufirst%3DP.%2BM.%26aulast%3DAdema%26aufirst%3DG.%2BJ.%26atitle%3DHDAC%2520Inhibitors%2520and%2520Immunotherapy%253B%2520a%2520Double%2520Edged%2520Sword%253F%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D6558%26epage%3D6572%26doi%3D10.18632%2Foncotarget.2289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haftchenary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luchman, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouk, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veloso, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, B. D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinshtein, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahani, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-awar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span> <span> </span><span class="NLM_article-title">Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1102</span>– <span class="NLM_lpage">1107</span>, <span class="refDoi"> DOI: 10.1021/ml4003138</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4003138" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSls7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1102-1107&author=S.+Haftchenaryauthor=H.+A.+Luchmanauthor=A.+O.+Joukauthor=A.+J.+Velosoauthor=B.+D.+G.+Pageauthor=X.+R.+Chengauthor=S.+S.+Dawsonauthor=N.+Grinshteinauthor=V.+M.+Shahaniauthor=K.+Kermanauthor=D.+R.+Kaplanauthor=C.+Griffinauthor=A.+M.+Amanauthor=R.+Al-awarauthor=S.+Weissauthor=P.+T.+Gunning&title=Potent+Targeting+of+the+STAT3+Protein+in+Brain+Cancer+Stem+Cells%3A+A+Promising+Route+for+Treating+Glioblastoma&doi=10.1021%2Fml4003138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma</span></div><div class="casAuthors">Haftchenary, Sina; Luchman, H. Artee; Jouk, Andriana O.; Veloso, Anthony J.; Page, Brent D. G.; Cheng, Xin Ran; Dawson, Sean S.; Grinshtein, Natalie; Shahani, Vijay M.; Kerman, Kagan; Kaplan, David R.; Griffin, Carly; Aman, Ahmed M.; Al-awar, Rima; Weiss, Samuel; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1102-1107</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The STAT3 gene is abnormally active in glioblastoma (GBM) and is a critically important mediator of tumor growth and therapeutic resistance in GBM.  Thus, for poorly treated brain cancers such as gliomas, astrocytomas, and glioblastomas, which harbor constitutively activated STAT3, a STAT3-targeting therapeutic will be of significant importance.  Herein, we report a most potent, small mol., nonphosphorylated STAT3 inhibitor, I (SH-4-54) that strongly binds to STAT3 protein (KD = 300 nM).  Inhibitor I potently kills glioblastoma brain cancer stem cells (BTSCs) and effectively suppresses STAT3 phosphorylation and its downstream transcriptional targets at low nM concns.  Moreover, in vivo, I exhibited blood-brain barrier permeability, potently controlled glioma tumor growth, and inhibited pSTAT3 in vivo.  This work, for the first time, demonstrates the power of STAT3 inhibitors for the treatment of BTSCs and validates the therapeutic efficacy of a STAT3 inhibitor for GBM clin. application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8sxT0MMrOY7Vg90H21EOLACvtfcHk0lixkCk82iJfDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSls7rK&md5=34a07baae61cd1b90eef1d9eae3d2ea9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fml4003138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4003138%26sid%3Dliteratum%253Aachs%26aulast%3DHaftchenary%26aufirst%3DS.%26aulast%3DLuchman%26aufirst%3DH.%2BA.%26aulast%3DJouk%26aufirst%3DA.%2BO.%26aulast%3DVeloso%26aufirst%3DA.%2BJ.%26aulast%3DPage%26aufirst%3DB.%2BD.%2BG.%26aulast%3DCheng%26aufirst%3DX.%2BR.%26aulast%3DDawson%26aufirst%3DS.%2BS.%26aulast%3DGrinshtein%26aufirst%3DN.%26aulast%3DShahani%26aufirst%3DV.%2BM.%26aulast%3DKerman%26aufirst%3DK.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DGriffin%26aufirst%3DC.%26aulast%3DAman%26aufirst%3DA.%2BM.%26aulast%3DAl-awar%26aufirst%3DR.%26aulast%3DWeiss%26aufirst%3DS.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DPotent%2520Targeting%2520of%2520the%2520STAT3%2520Protein%2520in%2520Brain%2520Cancer%2520Stem%2520Cells%253A%2520A%2520Promising%2520Route%2520for%2520Treating%2520Glioblastoma%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D1102%26epage%3D1107%26doi%3D10.1021%2Fml4003138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haftchenary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croucher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudel, S.</span></span> <span> </span><span class="NLM_article-title">Abstract C246: SH-4-54, a Novel Small-Molecule Inhibitor of STAT3, Demonstrates Significant Anti-Tumor Activity Against Multiple Myeloma</span>. <i>Mol. Cancer. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">C246</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.TARG-13-C246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1158%2F1535-7163.TARG-13-C246" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=C246&author=Z.+H.+Liauthor=S.+Haftchenaryauthor=D.+Croucherauthor=P.+T.+Gunningauthor=S.+Trudel&title=Abstract+C246%3A+SH-4-54%2C+a+Novel+Small-Molecule+Inhibitor+of+STAT3%2C+Demonstrates+Significant+Anti-Tumor+Activity+Against+Multiple+Myeloma&doi=10.1158%2F1535-7163.TARG-13-C246"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.TARG-13-C246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.TARG-13-C246%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%2BH.%26aulast%3DHaftchenary%26aufirst%3DS.%26aulast%3DCroucher%26aufirst%3DD.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26aulast%3DTrudel%26aufirst%3DS.%26atitle%3DAbstract%2520C246%253A%2520SH-4-54%252C%2520a%2520Novel%2520Small-Molecule%2520Inhibitor%2520of%2520STAT3%252C%2520Demonstrates%2520Significant%2520Anti-Tumor%2520Activity%2520Against%2520Multiple%2520Myeloma%26jtitle%3DMol.%2520Cancer.%2520Ther.%26date%3D2013%26volume%3D12%26spage%3DC246%26doi%3D10.1158%2F1535-7163.TARG-13-C246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ali, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Biagi, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, P.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaton, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiring, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellore, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Araujo, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shouksmith, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span> <span> </span><span class="NLM_article-title">Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">850</span>– <span class="NLM_lpage">861</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1002%2Fcmdc.201600021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=27028877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC28XltVOitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=850-861&author=A.+M.+Aliauthor=R.+F.+Gomez-Biagiauthor=D.+A.+Rosaauthor=P.-S.+Laiauthor=W.+L.+Heatonauthor=J.+S.+Parkauthor=A.+M.+Eiringauthor=N.+A.+Velloreauthor=E.+D.+de+Araujoauthor=D.+P.+Ballauthor=A.+E.+Shouksmithauthor=A.+B.+Patelauthor=M.+W.+Deiningerauthor=T.+O%E2%80%99Hareauthor=P.+T.+Gunning&title=Disarming+an+Electrophilic+Warhead%3A+Retaining+Potency+in+Tyrosine+Kinase+Inhibitor+%28TKI%29-Resistant+CML+Lines+While+Circumventing+Pharmacokinetic+Liabilities&doi=10.1002%2Fcmdc.201600021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities</span></div><div class="casAuthors">Ali, Ahmed M.; Gomez-Biagi, Rodolfo F.; Rosa, David A.; Lai, Ping-Shan; Heaton, William L.; Park, Ji Sung; Eiring, Anna M.; Vellore, Nadeem A.; de Araujo, Elvin D.; Ball, Dan P.; Shouksmith, Andrew E.; Patel, Ami B.; Deininger, Michael W.; O'Hare, Thomas; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">850-861</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Pharmacol. blockade of the activation of signal transducer and activator of transcription 3 (STAT3) in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia (CML) cell lines characterized by kinase-independent resistance was shown to re-sensitize CML cells to TKI therapy, suggesting that STAT3 inhibitors in combination with TKIs are an effective combinatorial therapeutic for the treatment of CML.  Benzoic acid- and hydroxamic acid-based STAT3 inhibitors SH-4-054 and SH-5-007, developed previously in our lab., demonstrated promising activity against these resistant CML cell lines.  However, pharmacokinetic studies in murine models (CD-1 mice) revealed that both SH-4-054 and SH-5-007 are susceptible to glutathione conjugation at the para position of the pentafluorophenyl group via nucleophilic arom. substitution (SNAr).  To det. whether the electrophilicity of the pentafluorophenyl sulfonamide could be tempered, an in-depth structure-activity relationship (SAR) study of the SH-4-054 scaffold was conducted.  These studies revealed that AM-1-124, possessing a 2,3,5,6-tetrafluorophenylsulfonamide group, retained STAT3 protein affinity (Ki=15 μm), as well as selectivity over STAT1 (Ki>250 μm).  Moreover, in both hepatocytes and in in vivo pharmacokinetic studies (CD-1 mice), AM-1-124 was found to be dramatically more stable than SH-4-054 (t1/2=1.42 h cf. 10 min, resp.).  AM-1-124 is a promising STAT3-targeting inhibitor with demonstrated bioavailability, suitable for evaluation in preclin. cancer models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS38duOD8NmLVg90H21EOLACvtfcHk0lixkCk82iJfDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltVOitL4%253D&md5=f356ee9c2078e878e2756c885f099d55</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600021%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DA.%2BM.%26aulast%3DGomez-Biagi%26aufirst%3DR.%2BF.%26aulast%3DRosa%26aufirst%3DD.%2BA.%26aulast%3DLai%26aufirst%3DP.-S.%26aulast%3DHeaton%26aufirst%3DW.%2BL.%26aulast%3DPark%26aufirst%3DJ.%2BS.%26aulast%3DEiring%26aufirst%3DA.%2BM.%26aulast%3DVellore%26aufirst%3DN.%2BA.%26aulast%3Dde%2BAraujo%26aufirst%3DE.%2BD.%26aulast%3DBall%26aufirst%3DD.%2BP.%26aulast%3DShouksmith%26aufirst%3DA.%2BE.%26aulast%3DPatel%26aufirst%3DA.%2BB.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DDisarming%2520an%2520Electrophilic%2520Warhead%253A%2520Retaining%2520Potency%2520in%2520Tyrosine%2520Kinase%2520Inhibitor%2520%2528TKI%2529-Resistant%2520CML%2520Lines%2520While%2520Circumventing%2520Pharmacokinetic%2520Liabilities%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D850%26epage%3D861%26doi%3D10.1002%2Fcmdc.201600021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cumaraswamy, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geletu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laister, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muench, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimes, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minden, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span> <span> </span><span class="NLM_article-title">Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1202</span>– <span class="NLM_lpage">1206</span>, <span class="refDoi"> DOI: 10.1021/ml500165r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500165r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1202-1206&author=A.+A.+Cumaraswamyauthor=A.+M.+Lewisauthor=M.+Geletuauthor=A.+Todicauthor=D.+B.+Diazauthor=X.+R.+Chengauthor=C.+E.+Brownauthor=R.+C.+Laisterauthor=D.+Muenchauthor=K.+Kermanauthor=H.+L.+Grimesauthor=M.+D.+Mindenauthor=P.+T.+Gunning&title=Nanomolar-Potency+Small+Molecule+Inhibitor+of+STAT5+Protein&doi=10.1021%2Fml500165r"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fml500165r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500165r%26sid%3Dliteratum%253Aachs%26aulast%3DCumaraswamy%26aufirst%3DA.%2BA.%26aulast%3DLewis%26aufirst%3DA.%2BM.%26aulast%3DGeletu%26aufirst%3DM.%26aulast%3DTodic%26aufirst%3DA.%26aulast%3DDiaz%26aufirst%3DD.%2BB.%26aulast%3DCheng%26aufirst%3DX.%2BR.%26aulast%3DBrown%26aufirst%3DC.%2BE.%26aulast%3DLaister%26aufirst%3DR.%2BC.%26aulast%3DMuench%26aufirst%3DD.%26aulast%3DKerman%26aufirst%3DK.%26aulast%3DGrimes%26aufirst%3DH.%2BL.%26aulast%3DMinden%26aufirst%3DM.%2BD.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DNanomolar-Potency%2520Small%2520Molecule%2520Inhibitor%2520of%2520STAT5%2520Protein%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D1202%26epage%3D1206%26doi%3D10.1021%2Fml500165r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Page, B. D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croucher, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haftchenary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Zepeda, V. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spagnuolo, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colaguori, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span> <span> </span><span class="NLM_article-title">Inhibiting Aberrant Signal Transducer and Activator of Transcription Protein Activation with Tetrapodal, Small Molecule Src Homology 2 Domain Binders: Promising Agents Against Multiple Myeloma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7190</span>– <span class="NLM_lpage">7200</span>, <span class="refDoi"> DOI: 10.1021/jm3017255</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3017255" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlWltbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7190-7200&author=B.+D.+G.+Pageauthor=D.+C.+Croucherauthor=Z.+H.+Liauthor=S.+Haftchenaryauthor=V.+H.+Jimenez-Zepedaauthor=J.+Atkinsonauthor=P.+A.+Spagnuoloauthor=Y.+L.+Wongauthor=R.+Colaguoriauthor=A.+M.+Lewisauthor=A.+D.+Schimmerauthor=S.+Trudelauthor=P.+T.+Gunning&title=Inhibiting+Aberrant+Signal+Transducer+and+Activator+of+Transcription+Protein+Activation+with+Tetrapodal%2C+Small+Molecule+Src+Homology+2+Domain+Binders%3A+Promising+Agents+Against+Multiple+Myeloma&doi=10.1021%2Fjm3017255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting Aberrant Signal Transducer and Activator of Transcription Protein Activation with Tetrapodal, Small Molecule Src Homology 2 Domain Binders: Promising Agents against Multiple Myeloma</span></div><div class="casAuthors">Page, Brent D. G.; Croucher, Danielle C.; Li, Zhi Hua; Haftchenary, Sina; Jimenez-Zepeda, Victor H.; Atkinson, Jennifer; Spagnuolo, Paul A.; Wong, Yoong Lim; Colaguori, Robert; Lewis, Andrew M.; Schimmer, Aaron D.; Trudel, Suzanne; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7190-7200</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">[(Arylsulfonyl)glycinyl](cyclohexylbenzyl)aminosalicylic acids such as I (R = 4-MeC6H4, F5C6; R1 = 2-F3CC6H4) were prepd. as inhibitors of the signal transducer and activator of transcription (STAT) protein Stat3 for potential use as treatments for multiple myeloma.  The hydrophobicities of I and their inhibition of Stat3 were detd.; mol. docking of selected compds. to the SH2 domain of Stat3 and inhibition of Stat3 phosphorylation under various conditions were detd. for selected compds., and the activity of I (R = 4-MeC6H4; R1 = 2-F3CC6H4) against human multiple myeloma cells and human hematopoietic cells and its induction of apoptosis in multiple myeloma cells was detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9RTVwhgsvE7Vg90H21EOLACvtfcHk0ljwqCzwTZ74Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlWltbrL&md5=9cce9797681eccfcf43b0f8b1a813914</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm3017255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3017255%26sid%3Dliteratum%253Aachs%26aulast%3DPage%26aufirst%3DB.%2BD.%2BG.%26aulast%3DCroucher%26aufirst%3DD.%2BC.%26aulast%3DLi%26aufirst%3DZ.%2BH.%26aulast%3DHaftchenary%26aufirst%3DS.%26aulast%3DJimenez-Zepeda%26aufirst%3DV.%2BH.%26aulast%3DAtkinson%26aufirst%3DJ.%26aulast%3DSpagnuolo%26aufirst%3DP.%2BA.%26aulast%3DWong%26aufirst%3DY.%2BL.%26aulast%3DColaguori%26aufirst%3DR.%26aulast%3DLewis%26aufirst%3DA.%2BM.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DTrudel%26aufirst%3DS.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DInhibiting%2520Aberrant%2520Signal%2520Transducer%2520and%2520Activator%2520of%2520Transcription%2520Protein%2520Activation%2520with%2520Tetrapodal%252C%2520Small%2520Molecule%2520Src%2520Homology%25202%2520Domain%2520Binders%253A%2520Promising%2520Agents%2520Against%2520Multiple%2520Myeloma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7190%26epage%3D7200%26doi%3D10.1021%2Fjm3017255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helquist, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiech, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiest, O.</span></span> <span> </span><span class="NLM_article-title">Toward Selective Histone Deacetylase Inhibitor Design: Homology Modeling, Docking Studies, and Molecular Dynamics Simulations of Human Class I Histone Deacetylases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6936</span>– <span class="NLM_lpage">6947</span>, <span class="refDoi"> DOI: 10.1021/jm0505011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0505011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtV2jsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6936-6947&author=D.-F.+Wangauthor=P.+Helquistauthor=N.+L.+Wiechauthor=O.+Wiest&title=Toward+Selective+Histone+Deacetylase+Inhibitor+Design%3A+Homology+Modeling%2C+Docking+Studies%2C+and+Molecular+Dynamics+Simulations+of+Human+Class+I+Histone+Deacetylases&doi=10.1021%2Fjm0505011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Selective Histone Deacetylase Inhibitor Design: Homology Modeling, Docking Studies, and Molecular Dynamics Simulations of Human Class I Histone Deacetylases</span></div><div class="casAuthors">Wang, Di-Fei; Helquist, Paul; Wiech, Norbert L.; Wiest, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6936-6947</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) play an important role in gene transcription.  Inhibitors of HDACs induce cell differentiation and suppress cell proliferation in tumor cells.  Although many HDAC inhibitors have been designed and synthesized, selective inhibition for class I HDAC isoforms is a goal that has yet to be achieved.  To understand the difference between class I HDAC isoforms that could be exploited for the design of isoform-specific HDAC inhibitors, the authors have built three-dimensional models of four class I histone deacetylases, HDAC1, HDAC2, HDAC3, and HDAC8.  Comparison of the homol. model of HDAC8 with the recently published x-ray structure shows excellent agreement and validates the approach.  A series of HDAC inhibitors were docked to the homol. models to understand the similarities and differences between the binding modes.  Mol. dynamic simulations of these HDAC-inhibitor complexes indicate that the interaction between the protein surface and inhibitor is playing an important role; also some active site residues show some flexibility, which is usually not included in routine docking protocols.  The implications of these results for the design of isoform-selective HDAC inhibitors are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb6SYJC1ObVLVg90H21EOLACvtfcHk0ljwqCzwTZ74Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtV2jsLnL&md5=0b59815173df7f16feb9ba66c8b4da83</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm0505011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0505011%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.-F.%26aulast%3DHelquist%26aufirst%3DP.%26aulast%3DWiech%26aufirst%3DN.%2BL.%26aulast%3DWiest%26aufirst%3DO.%26atitle%3DToward%2520Selective%2520Histone%2520Deacetylase%2520Inhibitor%2520Design%253A%2520Homology%2520Modeling%252C%2520Docking%2520Studies%252C%2520and%2520Molecular%2520Dynamics%2520Simulations%2520of%2520Human%2520Class%2520I%2520Histone%2520Deacetylases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6936%26epage%3D6947%26doi%3D10.1021%2Fjm0505011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giannini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battistuzzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunetti, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabri, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vesci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisano, C.</span></span> <span> </span><span class="NLM_article-title">Exploring Bis-(Indolyl)Methane Moiety as an Alternative and Innovative CAP Group in the Design of Histone Deacetylase (HDAC) Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2840</span>– <span class="NLM_lpage">2843</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.03.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1016%2Fj.bmcl.2009.03.101" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2840-2843&author=G.+Gianniniauthor=M.+Marziauthor=M.+D.+Marzoauthor=G.+Battistuzziauthor=R.+Pezziauthor=T.+Brunettiauthor=W.+Cabriauthor=L.+Vesciauthor=C.+Pisano&title=Exploring+Bis-%28Indolyl%29Methane+Moiety+as+an+Alternative+and+Innovative+CAP+Group+in+the+Design+of+Histone+Deacetylase+%28HDAC%29+Inhibitors&doi=10.1016%2Fj.bmcl.2009.03.101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.03.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.03.101%26sid%3Dliteratum%253Aachs%26aulast%3DGiannini%26aufirst%3DG.%26aulast%3DMarzi%26aufirst%3DM.%26aulast%3DMarzo%26aufirst%3DM.%2BD.%26aulast%3DBattistuzzi%26aufirst%3DG.%26aulast%3DPezzi%26aufirst%3DR.%26aulast%3DBrunetti%26aufirst%3DT.%26aulast%3DCabri%26aufirst%3DW.%26aulast%3DVesci%26aufirst%3DL.%26aulast%3DPisano%26aufirst%3DC.%26atitle%3DExploring%2520Bis-%2528Indolyl%2529Methane%2520Moiety%2520as%2520an%2520Alternative%2520and%2520Innovative%2520CAP%2520Group%2520in%2520the%2520Design%2520of%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2840%26epage%3D2843%26doi%3D10.1016%2Fj.bmcl.2009.03.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salmi-Smail, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dequiedt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Restouin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morelli, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collette, Y.</span></span> <span> </span><span class="NLM_article-title">Modified Cap Group Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitor Derivatives Reveal Improved Selective Antileukemic Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3038</span>– <span class="NLM_lpage">3047</span>, <span class="refDoi"> DOI: 10.1021/jm901358y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901358y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtVOqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3038-3047&author=C.+Salmi-Smailauthor=A.+Fabreauthor=F.+Dequiedtauthor=A.+Restouinauthor=R.+Castellanoauthor=S.+Garbitauthor=P.+Rocheauthor=X.+Morelliauthor=J.+M.+Brunelauthor=Y.+Collette&title=Modified+Cap+Group+Suberoylanilide+Hydroxamic+Acid+Histone+Deacetylase+Inhibitor+Derivatives+Reveal+Improved+Selective+Antileukemic+Activity&doi=10.1021%2Fjm901358y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Modified Cap Group Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitor Derivatives Reveal Improved Selective Antileukemic Activity</span></div><div class="casAuthors">Salmi-Smail, Chanaz; Fabre, Aurelie; Dequiedt, Franck; Restouin, Audrey; Castellano, Remy; Garbit, Slaveia; Roche, Philippe; Morelli, Xavier; Brunel, Jean Michel; Collette, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3038-3047</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of SAHA cap derivs. RNHCO(CH2)6CONHOH (R = Ph, 4-H2NC6H4, 2-BrC6H4, 2-naphthyl, 8-quinolinyl, etc.) was designed and prepd. in good-to-excellent yields that varied from 49% to 95%.  These derivs. were evaluated for their antiproliferative activity in several human cancer cell lines.  Antiproliferative activity was obsd. for concns. varying from 0.12 to >100 μM, and a mol. modeling approach of selected SAHA derivs., based on available structural information of human HDAC8 in complex with SAHA, was performed.  Strikingly, two compds. displayed up to 10-fold improved antileukemic activity with respect to SAHA; however, these compds. displayed antiproliferative activity similar to SAHA when assayed against solid tumor-derived cell lines.  A 10-fold improvement in the leukemic vs peripheral blood mononuclear cell therapeutic ratio, with no evident in vivo toxicity toward blood cells, was also obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjnbACulcCkrVg90H21EOLACvtfcHk0liA5hdl_F5F7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtVOqtrY%253D&md5=70cf706e641add7d1ee6d410b501e075</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm901358y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901358y%26sid%3Dliteratum%253Aachs%26aulast%3DSalmi-Smail%26aufirst%3DC.%26aulast%3DFabre%26aufirst%3DA.%26aulast%3DDequiedt%26aufirst%3DF.%26aulast%3DRestouin%26aufirst%3DA.%26aulast%3DCastellano%26aufirst%3DR.%26aulast%3DGarbit%26aufirst%3DS.%26aulast%3DRoche%26aufirst%3DP.%26aulast%3DMorelli%26aufirst%3DX.%26aulast%3DBrunel%26aufirst%3DJ.%2BM.%26aulast%3DCollette%26aufirst%3DY.%26atitle%3DModified%2520Cap%2520Group%2520Suberoylanilide%2520Hydroxamic%2520Acid%2520Histone%2520Deacetylase%2520Inhibitor%2520Derivatives%2520Reveal%2520Improved%2520Selective%2520Antileukemic%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3038%26epage%3D3047%26doi%3D10.1021%2Fjm901358y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitarresi, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuitino, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kladney, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woelke, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sizemore, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egriboz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweickert, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trela, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schilling, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halloran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosol, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesinski, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konieczny, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrowski, M. C.</span></span> <span> </span><span class="NLM_article-title">Genetic Ablation of Smoothened in Pancreatic Fibroblasts Increases Acinar-Ductal Metaplasia</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1943</span>– <span class="NLM_lpage">1955</span>, <span class="refDoi"> DOI: 10.1101/gad.283499.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1101%2Fgad.283499.116" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=1943-1955&author=X.+Liuauthor=J.+R.+Pitarresiauthor=M.+C.+Cuitinoauthor=R.+D.+Kladneyauthor=S.+A.+Woelkeauthor=G.+M.+Sizemoreauthor=S.+G.+Nayakauthor=O.+Egribozauthor=P.+G.+Schweickertauthor=L.+Yuauthor=S.+Trelaauthor=D.+J.+Schillingauthor=S.+K.+Halloranauthor=M.+Liauthor=S.+Duttaauthor=S.+A.+Fernandezauthor=T.+J.+Rosolauthor=G.+B.+Lesinskiauthor=R.+Shakyaauthor=T.+Ludwigauthor=S.+F.+Koniecznyauthor=G.+Leoneauthor=J.+Wuauthor=M.+C.+Ostrowski&title=Genetic+Ablation+of+Smoothened+in+Pancreatic+Fibroblasts+Increases+Acinar-Ductal+Metaplasia&doi=10.1101%2Fgad.283499.116"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1101%2Fgad.283499.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.283499.116%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DPitarresi%26aufirst%3DJ.%2BR.%26aulast%3DCuitino%26aufirst%3DM.%2BC.%26aulast%3DKladney%26aufirst%3DR.%2BD.%26aulast%3DWoelke%26aufirst%3DS.%2BA.%26aulast%3DSizemore%26aufirst%3DG.%2BM.%26aulast%3DNayak%26aufirst%3DS.%2BG.%26aulast%3DEgriboz%26aufirst%3DO.%26aulast%3DSchweickert%26aufirst%3DP.%2BG.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DTrela%26aufirst%3DS.%26aulast%3DSchilling%26aufirst%3DD.%2BJ.%26aulast%3DHalloran%26aufirst%3DS.%2BK.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DDutta%26aufirst%3DS.%26aulast%3DFernandez%26aufirst%3DS.%2BA.%26aulast%3DRosol%26aufirst%3DT.%2BJ.%26aulast%3DLesinski%26aufirst%3DG.%2BB.%26aulast%3DShakya%26aufirst%3DR.%26aulast%3DLudwig%26aufirst%3DT.%26aulast%3DKonieczny%26aufirst%3DS.%2BF.%26aulast%3DLeone%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DOstrowski%26aufirst%3DM.%2BC.%26atitle%3DGenetic%2520Ablation%2520of%2520Smoothened%2520in%2520Pancreatic%2520Fibroblasts%2520Increases%2520Acinar-Ductal%2520Metaplasia%26jtitle%3DGenes%2520Dev.%26date%3D2016%26volume%3D30%26spage%3D1943%26epage%3D1955%26doi%3D10.1101%2Fgad.283499.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hingorani, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multani, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deramaudt, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruban, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustgi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuveson, D. A.</span></span> <span> </span><span class="NLM_article-title">Trp53R172H and KrasG12D Cooperate to Promote Chromosomal Instability and Widely Metastatic Pancreatic Ductal Adenocarcinoma in Mice</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">483</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2005.04.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1016%2Fj.ccr.2005.04.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=15894267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslyitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=469-483&author=S.+R.+Hingoraniauthor=L.+Wangauthor=A.+S.+Multaniauthor=C.+Combsauthor=T.+B.+Deramaudtauthor=R.+H.+Hrubanauthor=A.+K.+Rustgiauthor=S.+Changauthor=D.+A.+Tuveson&title=Trp53R172H+and+KrasG12D+Cooperate+to+Promote+Chromosomal+Instability+and+Widely+Metastatic+Pancreatic+Ductal+Adenocarcinoma+in+Mice&doi=10.1016%2Fj.ccr.2005.04.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice</span></div><div class="casAuthors">Hingorani, Sunil R.; Wang, Lifu; Multani, Asha S.; Combs, Chelsea; Deramaudt, Therese B.; Hruban, Ralph H.; Rustgi, Anil K.; Chang, Sandy; Tuveson, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">469-483</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To define the genetic requirements for pancreatic ductal adenocarcinoma (PDA), we have targeted concomitant endogenous expression of Trp53R172H and KrasG12D to the mouse pancreas, revealing the cooperative development of invasive and widely metastatic carcinoma that recapitulates the human disease.  The primary carcinomas and metastases demonstrate a high degree of genomic instability manifested by nonreciprocal translocations without obvious telomere erosion-hallmarks of human carcinomas not typically obsd. in mice.  No mutations were discovered in other cardinal tumor suppressor gene pathways, which, together with previous results, suggests that there are distinct genetic pathways to PDA with different biol. behaviors.  These findings have clear implications for understanding mechanisms of disease pathogenesis, and for the development of detection and targeted treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUqdYCBqe-vrVg90H21EOLACvtfcHk0liA5hdl_F5F7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslyitLk%253D&md5=fef745f04506e9e64bbc760a1d6f8cf6</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.04.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.04.023%26sid%3Dliteratum%253Aachs%26aulast%3DHingorani%26aufirst%3DS.%2BR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMultani%26aufirst%3DA.%2BS.%26aulast%3DCombs%26aufirst%3DC.%26aulast%3DDeramaudt%26aufirst%3DT.%2BB.%26aulast%3DHruban%26aufirst%3DR.%2BH.%26aulast%3DRustgi%26aufirst%3DA.%2BK.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26atitle%3DTrp53R172H%2520and%2520KrasG12D%2520Cooperate%2520to%2520Promote%2520Chromosomal%2520Instability%2520and%2520Widely%2520Metastatic%2520Pancreatic%2520Ductal%2520Adenocarcinoma%2520in%2520Mice%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D469%26epage%3D483%26doi%3D10.1016%2Fj.ccr.2005.04.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olive, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobetz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopinathan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldgraben, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frese, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeNicola, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ireland-Zecchini, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichelt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howat, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruckert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grutzmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilarsky, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izeradjene, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hingorani, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plunkett, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egorin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruban, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGovern, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobuzio-Donahue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuveson, D. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">1457</span>– <span class="NLM_lpage">1461</span>, <span class="refDoi"> DOI: 10.1126/science.1171362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1126%2Fscience.1171362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=19460966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVSiu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2009&pages=1457-1461&author=K.+P.+Oliveauthor=M.+A.+Jacobetzauthor=C.+J.+Davidsonauthor=A.+Gopinathanauthor=D.+McIntyreauthor=D.+Honessauthor=B.+Madhuauthor=M.+A.+Goldgrabenauthor=M.+E.+Caldwellauthor=D.+Allardauthor=K.+K.+Freseauthor=G.+DeNicolaauthor=C.+Feigauthor=C.+Combsauthor=S.+P.+Winterauthor=H.+Ireland-Zecchiniauthor=S.+Reicheltauthor=W.+J.+Howatauthor=A.+Changauthor=M.+Dharaauthor=L.+F.+Wangauthor=F.+Ruckertauthor=R.+Grutzmannauthor=C.+Pilarskyauthor=K.+Izeradjeneauthor=S.+R.+Hingoraniauthor=P.+Huangauthor=S.+E.+Daviesauthor=W.+Plunkettauthor=M.+Egorinauthor=R.+H.+Hrubanauthor=N.+Whitebreadauthor=K.+McGovernauthor=J.+Adamsauthor=C.+Iacobuzio-Donahueauthor=J.+Griffithsauthor=D.+A.+Tuveson&title=Inhibition+of+Hedgehog+Signaling+Enhances+Delivery+of+Chemotherapy+in+a+Mouse+Model+of+Pancreatic+Cancer&doi=10.1126%2Fscience.1171362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer</span></div><div class="casAuthors">Olive, Kenneth P.; Jacobetz, Michael A.; Davidson, Christian J.; Gopinathan, Aarthi; McIntyre, Dominick; Honess, Davina; Madhu, Basetti; Goldgraben, Mae A.; Caldwell, Meredith E.; Allard, David; Frese, Kristopher K.; DeNicola, Gina; Feig, Christine; Combs, Chelsea; Winter, Stephen P.; Ireland-Zecchini, Heather; Reichelt, Stefanie; Howat, William J.; Chang, Alex; Dhara, Mousumi; Wang, Lifu; Rueckert, Felix; Gruetzmann, Robert; Pilarsky, Christian; Izeradjene, Kamel; Hingorani, Sunil R.; Huang, Pearl; Davies, Susan E.; Plunkett, William; Egorin, Merrill; Hruban, Ralph H.; Whitebread, Nigel; McGovern, Karen; Adams, Julian; Iacobuzio-Donahue, Christine; Griffiths, John; Tuveson, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">5933</span>),
    <span class="NLM_cas:pages">1457-1461</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDA) is among the most lethal human cancers in part because it is insensitive to many chemotherapeutic drugs.  Studying a mouse model of PDA that is refractory to the clin. used drug gemcitabine, we found that the tumors in this model were poorly perfused and poorly vascularized, properties that are shared with human PDA.  We tested whether the delivery and efficacy of gemcitabine in the mice could be improved by coadministration of IPI-926, a drug that depletes tumor-assocd. stromal tissue by inhibition of the Hedgehog cellular signaling pathway.  The combination therapy produced a transient increase in intratumoral vascular d. and intratumoral concn. of gemcitabine, leading to transient stabilization of disease.  Thus, inefficient drug delivery may be an important contributor to chemoresistance in pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_XYqveCF3BLVg90H21EOLACvtfcHk0lia0pPLk952-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVSiu7Y%253D&md5=930e5843af03a3b1bb15cab8dcb4e3fe</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1126%2Fscience.1171362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1171362%26sid%3Dliteratum%253Aachs%26aulast%3DOlive%26aufirst%3DK.%2BP.%26aulast%3DJacobetz%26aufirst%3DM.%2BA.%26aulast%3DDavidson%26aufirst%3DC.%2BJ.%26aulast%3DGopinathan%26aufirst%3DA.%26aulast%3DMcIntyre%26aufirst%3DD.%26aulast%3DHoness%26aufirst%3DD.%26aulast%3DMadhu%26aufirst%3DB.%26aulast%3DGoldgraben%26aufirst%3DM.%2BA.%26aulast%3DCaldwell%26aufirst%3DM.%2BE.%26aulast%3DAllard%26aufirst%3DD.%26aulast%3DFrese%26aufirst%3DK.%2BK.%26aulast%3DDeNicola%26aufirst%3DG.%26aulast%3DFeig%26aufirst%3DC.%26aulast%3DCombs%26aufirst%3DC.%26aulast%3DWinter%26aufirst%3DS.%2BP.%26aulast%3DIreland-Zecchini%26aufirst%3DH.%26aulast%3DReichelt%26aufirst%3DS.%26aulast%3DHowat%26aufirst%3DW.%2BJ.%26aulast%3DChang%26aufirst%3DA.%26aulast%3DDhara%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%2BF.%26aulast%3DRuckert%26aufirst%3DF.%26aulast%3DGrutzmann%26aufirst%3DR.%26aulast%3DPilarsky%26aufirst%3DC.%26aulast%3DIzeradjene%26aufirst%3DK.%26aulast%3DHingorani%26aufirst%3DS.%2BR.%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DDavies%26aufirst%3DS.%2BE.%26aulast%3DPlunkett%26aufirst%3DW.%26aulast%3DEgorin%26aufirst%3DM.%26aulast%3DHruban%26aufirst%3DR.%2BH.%26aulast%3DWhitebread%26aufirst%3DN.%26aulast%3DMcGovern%26aufirst%3DK.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DIacobuzio-Donahue%26aufirst%3DC.%26aulast%3DGriffiths%26aufirst%3DJ.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26atitle%3DInhibition%2520of%2520Hedgehog%2520Signaling%2520Enhances%2520Delivery%2520of%2520Chemotherapy%2520in%2520a%2520Mouse%2520Model%2520of%2520Pancreatic%2520Cancer%26jtitle%3DScience%26date%3D2009%26volume%3D324%26spage%3D1457%26epage%3D1461%26doi%3D10.1126%2Fscience.1171362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Licciardi, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ververis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Osta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karagiannis, T. C.</span></span> <span> </span><span class="NLM_article-title">Immunomodulatory Effects of Histone Deacetylase Inhibitors</span>. <i>Curr. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">640</span>– <span class="NLM_lpage">647</span>, <span class="refDoi"> DOI: 10.2174/1566524011313040013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.2174%2F1566524011313040013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=23061676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFahtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=640-647&author=P.+V.+Licciardiauthor=K.+Ververisauthor=M.+L.+Tangauthor=A.+El-Ostaauthor=T.+C.+Karagiannis&title=Immunomodulatory+Effects+of+Histone+Deacetylase+Inhibitors&doi=10.2174%2F1566524011313040013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Immunomodulatory effects of histone deacetylase inhibitors</span></div><div class="casAuthors">Licciardi, P. V.; Ververis, K.; Tang, M. L.; El-Osta, A.; Karagiannis, T. C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Molecular Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">640-647</span>CODEN:
                <span class="NLM_cas:coden">CMMUBP</span>;
        ISSN:<span class="NLM_cas:issn">1566-5240</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors (HDACi) have emerged as a new generation of anticancer therapeutics.  The classical broad-spectrum HDACi typically alter the cell cycle distribution and induce cell-death, apoptosis and differentiation in malignant and transformed cells.  This provides the basis for the clin. potential of HDACi in cancer therapy.  Currently two compds., suberoylanilide hydroxamic acid (SAHA, Vorinostat, Zolinza) and depsipeptide (Romidepsin, Istodax) have been approved for by the US Food and Drug Administration for the treatment of refractory cutaneous T-cell lymphoma.  Apart from clin. application in oncol., HDACi have also been investigated as potential therapeutics for various pathologies including those of the central nervous system (such as Huntington's disease and multiple sclerosis), cardiac conditions (particularly hypertrophy), arthritis and malaria.  Further, evidence is accumulating for potent immunomodulatory effects of classical HDACi which is the focus of this review.  We review the anti-inflammatory effects of HDACi and in particular findings implicating regulation of the innate and adaptive immune systems by HDAC enzymes.  The recent findings highlighting the immunomodulatory function of HDAC11 which relates to balancing immune activation vs. tolerance are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCwr7rAQ9baLVg90H21EOLACvtfcHk0lia0pPLk952-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFahtLw%253D&md5=feabae7b0d27b18f38da335e6da10804</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.2174%2F1566524011313040013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1566524011313040013%26sid%3Dliteratum%253Aachs%26aulast%3DLicciardi%26aufirst%3DP.%2BV.%26aulast%3DVerveris%26aufirst%3DK.%26aulast%3DTang%26aufirst%3DM.%2BL.%26aulast%3DEl-Osta%26aufirst%3DA.%26aulast%3DKaragiannis%26aufirst%3DT.%2BC.%26atitle%3DImmunomodulatory%2520Effects%2520of%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DCurr.%2520Mol.%2520Med.%26date%3D2013%26volume%3D13%26spage%3D640%26epage%3D647%26doi%3D10.2174%2F1566524011313040013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orillion, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damayanti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adelaiye-Ogala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arisa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chintala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ordentlich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elzey, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrilovich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pili, R.</span></span> <span> </span><span class="NLM_article-title">Entinostat Neutralizes Myeloid Derived Suppressor Cells and Enhances the Anti-Tumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5187</span>– <span class="NLM_lpage">5201</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-0741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1158%2F1078-0432.CCR-17-0741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=28698201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVCit7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=5187-5201&author=A.+Orillionauthor=A.+Hashimotoauthor=N.+Damayantiauthor=L.+Shenauthor=R.+Adelaiye-Ogalaauthor=S.+Arisaauthor=S.+Chintalaauthor=P.+Ordentlichauthor=C.+Kaoauthor=B.+Elzeyauthor=D.+Gabrilovichauthor=R.+Pili&title=Entinostat+Neutralizes+Myeloid+Derived+Suppressor+Cells+and+Enhances+the+Anti-Tumor+Effect+of+PD-1+Inhibition+in+Murine+Models+of+Lung+and+Renal+Cell+Carcinoma&doi=10.1158%2F1078-0432.CCR-17-0741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma</span></div><div class="casAuthors">Orillion, Ashley; Hashimoto, Ayumi; Damayanti, Nur; Shen, Li; Adelaiye-Ogala, Remi; Arisa, Sreevani; Chintala, Sreenivasulu; Ordentlich, Peter; Kao, Chingai; Elzey, Bennett; Gabrilovich, Dmitry; Pili, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5187-5201</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Recent advances in immunotherapy highlight the antitumor effects of immune checkpoint inhibition despite a relatively limited subset of patients receiving clin. benefit.  The selective class I histone deacetylase inhibitor entinostat has been reported to have immunomodulatory activity including targeting of immune suppressor cells in the tumor microenvironment.  Thus, we decided to assess whether entinostat could enhance anti-PD-1 treatment and investigate those alterations in the immunosuppressive tumor microenvironment that contribute to the combined antitumor activity.  Exptl. Design: We utilized syngeneic mouse models of lung (LLC) and renal cell (RENCA) carcinoma and assessed immune correlates, tumor growth, and survival following treatment with entinostat (5 or 10 mg/kg, p.o.) and a PD-1 inhibitor (10 and 20 mg/kg, s.c.).  Results: Entinostat enhanced the antitumor effect of PD-1 inhibition in two syngeneic mouse tumor models by reducing tumor growth and increasing survival.  Entinostat inhibited the immunosuppressive function of both polymorphonuclear (PMN)- and monocytic-myeloid derived suppressor cell (M-MDSC) populations.  Anal. of MDSC response to entinostat revealed significantly reduced arginase-1, iNOS, and COX-2 levels, suggesting potential mechanisms for the altered function.  We also obsd. significant alterations in cytokine/chemokine release in vivo with a shift toward a tumor-suppressive microenvironment.  Conclusions: Our results demonstrate that entinostat enhances the antitumor effect of PD-1 targeting through functional inhibition of MDSCs and a transition away from an immune-suppressive tumor microenvironment.  These data provide a mechanistic rationale for the clin. testing and potential markers of response of this novel combination in solid tumor patients.  Clin Cancer Res; 23(17); 5187-201. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfjJgfVBKo5rVg90H21EOLACvtfcHk0ljT11PZGq_OpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVCit7jM&md5=b4461a1641c69b820bc7f6c5f1fcbba8</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-0741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-0741%26sid%3Dliteratum%253Aachs%26aulast%3DOrillion%26aufirst%3DA.%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DDamayanti%26aufirst%3DN.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DAdelaiye-Ogala%26aufirst%3DR.%26aulast%3DArisa%26aufirst%3DS.%26aulast%3DChintala%26aufirst%3DS.%26aulast%3DOrdentlich%26aufirst%3DP.%26aulast%3DKao%26aufirst%3DC.%26aulast%3DElzey%26aufirst%3DB.%26aulast%3DGabrilovich%26aufirst%3DD.%26aulast%3DPili%26aufirst%3DR.%26atitle%3DEntinostat%2520Neutralizes%2520Myeloid%2520Derived%2520Suppressor%2520Cells%2520and%2520Enhances%2520the%2520Anti-Tumor%2520Effect%2520of%2520PD-1%2520Inhibition%2520in%2520Murine%2520Models%2520of%2520Lung%2520and%2520Renal%2520Cell%2520Carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D5187%26epage%3D5201%26doi%3D10.1158%2F1078-0432.CCR-17-0741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markowitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedke, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesinski, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundy-Bosse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekaii-Saab, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, W. E.</span></span> <span> </span><span class="NLM_article-title">Patients with Pancreatic Adenocarcinoma Exhibit Elevated Levels of Myeloid-Derived Suppressor Cells upon Progression of Disease</span>. <i>Cancer Immunol. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1007/s00262-014-1618-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1007%2Fs00262-014-1618-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=25305035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslCisLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=149-159&author=J.+Markowitzauthor=T.+R.+Brooksauthor=M.+C.+Dugganauthor=B.+K.+Paulauthor=X.+Panauthor=L.+Weiauthor=Z.+Abramsauthor=E.+Luedkeauthor=G.+B.+Lesinskiauthor=B.+Mundy-Bosseauthor=T.+Bekaii-Saabauthor=W.+E.+Carson&title=Patients+with+Pancreatic+Adenocarcinoma+Exhibit+Elevated+Levels+of+Myeloid-Derived+Suppressor+Cells+upon+Progression+of+Disease&doi=10.1007%2Fs00262-014-1618-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease</span></div><div class="casAuthors">Markowitz, Joseph; Brooks, Taylor R.; Duggan, Megan C.; Paul, Bonnie K.; Pan, Xueliang; Wei, Lai; Abrams, Zachary; Luedke, Eric; Lesinski, Gregory B.; Mundy-Bosse, Bethany; Bekaii-Saab, Tanios; Carson, William E., III</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">149-159</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Elevated levels of myeloid-derived suppressor cells (MDSCs) induced by tumor-derived factors are assocd. with inhibition of immune responses in patients with gastrointestinal malignancies.  We hypothesized that pro-MDSC cytokines and levels of MDSC in the peripheral blood would be elevated in pancreatic adenocarcinoma patients with progressive disease.  Peripheral blood mononuclear cells (PBMCs) were isolated from 16 pancreatic cancer patients undergoing chemotherapy and phenotyped for MDSC using a five antigen panel (CD33, HLA-DR, CD11b, CD14, CD15).  Patients with stable disease had significantly lower MDSC levels in the peripheral blood than those with progressive disease (1.41 ± 1.12 vs. 5.14 ± 4.58 %, p = 0.013, Wilcoxon test).  A cutoff of 2.5 % MDSC identified patients with progressive disease.  Patients with ECOG performance status ≥2 had a weaker assocn. with increased levels of MDSC.  Plasma was obtained from 15 chemonaive patients, 13 patients undergoing chemotherapy and 9 normal donors.  Increases in the levels of pro-MDSC cytokines were obsd. for pancreatic cancer patients vs. controls, and the pro-MDSC cytokine IL-6 was increased in those patients undergoing chemotherapy.  This study suggests that MDSC in peripheral blood may be a predictive biomarker of chemotherapy failure in pancreatic cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqllxDB5kBbBrVg90H21EOLACvtfcHk0ljT11PZGq_OpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslCisLfJ&md5=4eef6d9ee81dc20b52de58bc19c11384</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1007%2Fs00262-014-1618-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00262-014-1618-8%26sid%3Dliteratum%253Aachs%26aulast%3DMarkowitz%26aufirst%3DJ.%26aulast%3DBrooks%26aufirst%3DT.%2BR.%26aulast%3DDuggan%26aufirst%3DM.%2BC.%26aulast%3DPaul%26aufirst%3DB.%2BK.%26aulast%3DPan%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DAbrams%26aufirst%3DZ.%26aulast%3DLuedke%26aufirst%3DE.%26aulast%3DLesinski%26aufirst%3DG.%2BB.%26aulast%3DMundy-Bosse%26aufirst%3DB.%26aulast%3DBekaii-Saab%26aufirst%3DT.%26aulast%3DCarson%26aufirst%3DW.%2BE.%26atitle%3DPatients%2520with%2520Pancreatic%2520Adenocarcinoma%2520Exhibit%2520Elevated%2520Levels%2520of%2520Myeloid-Derived%2520Suppressor%2520Cells%2520upon%2520Progression%2520of%2520Disease%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D2015%26volume%3D64%26spage%3D149%26epage%3D159%26doi%3D10.1007%2Fs00262-014-1618-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W. W.</span></span> <span> </span><span class="NLM_article-title">Targeting Stromal Microenvironment in Pancreatic Ductal Adenocarcinoma: Controversies and Promises</span>. <i>J. Gastrointest. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">494</span>, <span class="refDoi"> DOI: 10.21037/jgo.2016.03.03</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.21037%2Fjgo.2016.03.03" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=27284483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FovVSrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=487-494&author=L.+Meiauthor=W.+Duauthor=W.+W.+Ma&title=Targeting+Stromal+Microenvironment+in+Pancreatic+Ductal+Adenocarcinoma%3A+Controversies+and+Promises&doi=10.21037%2Fjgo.2016.03.03"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises</span></div><div class="casAuthors">Mei Lin; Du Wei; Ma Wen Wee</div><div class="citationInfo"><span class="NLM_cas:title">Journal of gastrointestinal oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">487-94</span>
        ISSN:<span class="NLM_cas:issn">2078-6891</span>.
    </div><div class="casAbstract">Pancreatic cancer is a highly lethal disease.  Conventional therapeutics targeting pancreas cancer cell compartment using cytotoxics improved patient survival but at the expense of significant toxicity.  Microscopically, the tumor is characterized by thick desmoplastic stroma that surrounds islands of pancreatic cancer cells.  The tumor microenvironment has been found to play important roles in carcinogenesis, the development of drug resistance, and mediating immunosuppression.  The understanding the tumor-stromal interaction has led to the development of novel therapeutic approaches.  Here, we review the strategies that are currently in (or, near to) clinical evaluation and the underlying preclinical rationales.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQqR636AWNzbgwxfk_AGB-EfW6udTcc2eaQEYRAQCLIFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FovVSrug%253D%253D&md5=a4cde6407249c5c8e5277291c456f39f</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.21037%2Fjgo.2016.03.03&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Fjgo.2016.03.03%26sid%3Dliteratum%253Aachs%26aulast%3DMei%26aufirst%3DL.%26aulast%3DDu%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DW.%2BW.%26atitle%3DTargeting%2520Stromal%2520Microenvironment%2520in%2520Pancreatic%2520Ductal%2520Adenocarcinoma%253A%2520Controversies%2520and%2520Promises%26jtitle%3DJ.%2520Gastrointest.%2520Oncol.%26date%3D2016%26volume%3D7%26spage%3D487%26epage%3D494%26doi%3D10.21037%2Fjgo.2016.03.03" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, O. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsche, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saur, D.</span></span> <span> </span><span class="NLM_article-title">Targeting Histone Deacetylases in Pancreatic Ductal Adenocarcinoma</span>. <i>J. Cell. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1255</span>– <span class="NLM_lpage">1263</span>, <span class="refDoi"> DOI: 10.1111/j.1582-4934.2009.00974.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1111%2Fj.1582-4934.2009.00974.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=19929947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGksLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=1255-1263&author=G.+Schneiderauthor=O.+H.+Kramerauthor=P.+Fritscheauthor=S.+Schulerauthor=R.+M.+Schmidauthor=D.+Saur&title=Targeting+Histone+Deacetylases+in+Pancreatic+Ductal+Adenocarcinoma&doi=10.1111%2Fj.1582-4934.2009.00974.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting histone deacetylases in pancreatic ductal adenocarcinoma</span></div><div class="casAuthors">Schneider, Guenter; Kraemer, Oliver H.; Fritsche, Petra; Schueler, Susanne; Schmid, Roland M.; Saur, Dieter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6A</span>),
    <span class="NLM_cas:pages">1255-1263</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-1838</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease with a median survival below 6 mo and a 5-yr survival rate below 1%.  Effective therapies for locally advanced or metastatic tumors are missing and curatively resected patients relapse in over 80% of the cases.  Although histone deacetylases (HDACs) are involved in the control of proliferation, apoptosis, differentiation, migration and angiogenesis of cancer cells, knowledge about the expression patterns and functions of individual HDAC isoenzymes in pancreatic cancer is sparse.  This review summarizes the roles of HDACs as novel therapeutic targets and the mol. mode of action of HDAC-inhibitors (HDACI) in PDACs.  Success of HDACI in clin. settings will depend on an increased knowledge of HDAC functions as well as on a better understanding of the mode of action of HDACI.  Pre-clin. exptl. data that constitute the basis for rational therapeutic strategies to treat PDAC are described here.  Translating these rational-based therapies into the clinic will finally increase our chance to establish an effective HDACI-contg. combination therapy effective against PDAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs7iIdLdruy7Vg90H21EOLACvtfcHk0ljV6OcRsgLjsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGksLvM&md5=ba3952fdf36be24a94657aedf82d7c05</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1111%2Fj.1582-4934.2009.00974.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1582-4934.2009.00974.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DG.%26aulast%3DKramer%26aufirst%3DO.%2BH.%26aulast%3DFritsche%26aufirst%3DP.%26aulast%3DSchuler%26aufirst%3DS.%26aulast%3DSchmid%26aufirst%3DR.%2BM.%26aulast%3DSaur%26aufirst%3DD.%26atitle%3DTargeting%2520Histone%2520Deacetylases%2520in%2520Pancreatic%2520Ductal%2520Adenocarcinoma%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2010%26volume%3D14%26spage%3D1255%26epage%3D1263%26doi%3D10.1111%2Fj.1582-4934.2009.00974.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koutsounas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaginis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patsouris, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theocharis, S.</span></span> <span> </span><span class="NLM_article-title">Current Evidence for Histone Deacetylase Inhibitors in Pancreatic Cancer</span>. <i>World J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">813</span>– <span class="NLM_lpage">828</span>, <span class="refDoi"> DOI: 10.3748/wjg.v19.i6.813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.3748%2Fwjg.v19.i6.813" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=23430136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFKhsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=813-828&author=I.+Koutsounasauthor=C.+Giaginisauthor=E.+Patsourisauthor=S.+Theocharis&title=Current+Evidence+for+Histone+Deacetylase+Inhibitors+in+Pancreatic+Cancer&doi=10.3748%2Fwjg.v19.i6.813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Current evidence for histone deacetylase inhibitors in pancreatic cancer</span></div><div class="casAuthors">Koutsounas, Ioannis; Giaginis, Constantinos; Patsouris, Efstratios; Theocharis, Stamatios</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">813-828</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">Baishideng Publishing Group Co., Ltd.</span>)
        </div><div class="casAbstract">A review.  Pancreatic cancer is one of the most aggressive human cancers, with more than 200 000 deaths worldwide every year.  Despite recent efforts, conventional treatment approaches, such as surgery and classic chemotherapy, have only slightly improved patient outcomes.  More effective and well-tolerated therapies are required to reverse the current poor prognosis of this type of neoplasm.  Among new agents, histone deacetylase inhibitors (HDACIs) are now being tested.  HDACIs have multiple biol. effects related to acetylation of histones and many non-histone proteins that are involved in regulation of gene expression, apoptosis, cell cycle progression and angiogenesis.  HDACIs induce cell cycle arrest and can activate the extrinsic and intrinsic pathways of apoptosis in different cancer cell lines.  In the present review, the main mechanisms by which HDACIs act in pancreatic cancer cells in vitro, as well as their antiproliferative effects in animal models are presented.  HDACIs constitute a promising treatment for pancreatic cancer with encouraging anti-tumor effects, at well-tolerated doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5vOqCZoSOYbVg90H21EOLACvtfcHk0ljV6OcRsgLjsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFKhsbY%253D&md5=9356d261d3a3d684e1b4997236383485</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v19.i6.813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v19.i6.813%26sid%3Dliteratum%253Aachs%26aulast%3DKoutsounas%26aufirst%3DI.%26aulast%3DGiaginis%26aufirst%3DC.%26aulast%3DPatsouris%26aufirst%3DE.%26aulast%3DTheocharis%26aufirst%3DS.%26atitle%3DCurrent%2520Evidence%2520for%2520Histone%2520Deacetylase%2520Inhibitors%2520in%2520Pancreatic%2520Cancer%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2013%26volume%3D19%26spage%3D813%26epage%3D828%26doi%3D10.3748%2Fwjg.v19.i6.813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, X.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of Histone Deacetylase Inhibitors in Pancreatic Cancer</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2014.02.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1016%2Fj.canlet.2014.02.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=24534202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjsVWkurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2014&pages=183-190&author=W.+Fengauthor=B.+Zhangauthor=D.+Caiauthor=X.+Zou&title=Therapeutic+Potential+of+Histone+Deacetylase+Inhibitors+in+Pancreatic+Cancer&doi=10.1016%2Fj.canlet.2014.02.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer</span></div><div class="casAuthors">Feng, Wan; Zhang, Bin; Cai, Dawei; Zou, Xiaoping</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">183-190</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Pancreatic cancer is a devastating disease with a dismal prognosis.  Surgical resection is the only curative option but is heavily hampered by delayed diagnosis.  Due to few therapeutic treatments available, novel and efficacious therapy is urgently needed.  Histone deacetylase inhibitors (HDACIs) are emerging as a prominent class of therapeutic agents for pancreatic cancer and have exhibited significant anticancer potential with negligible toxicity in preclin. studies.  Clin. evaluations of HDACIs are currently underway.  HDACIs as monotherapy in solid tumors have proven less effective than hematol. malignancies, the combination of HDACIs with other anticancer agents have been assessed for advanced pancreatic cancer.  In this review, we describe the mol. mechanism underpin the anticancer effect of HDACIs in pancreatic cancer and summarize the recent advances in the rationale for the combination strategies incorporating HDACIs.  In addn., we discuss the importance of identifying predictors of response to HDACI-based therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEYTC6UbSLT7Vg90H21EOLACvtfcHk0ljV6OcRsgLjsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjsVWkurw%253D&md5=a2c52370fdf987aa6f565f459562292d</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2014.02.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2014.02.012%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DCai%26aufirst%3DD.%26aulast%3DZou%26aufirst%3DX.%26atitle%3DTherapeutic%2520Potential%2520of%2520Histone%2520Deacetylase%2520Inhibitors%2520in%2520Pancreatic%2520Cancer%26jtitle%3DCancer%2520Lett.%26date%3D2014%26volume%3D347%26spage%3D183%26epage%3D190%26doi%3D10.1016%2Fj.canlet.2014.02.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, Y.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases Function as Novel Potential Therapeutic Targets for Cancer</span>. <i>Hepatol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1111/hepr.12757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=10.1111%2Fhepr.12757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=27457249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFWmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2017&pages=149-159&author=H.+Zhangauthor=Y.-P.+Shangauthor=H.-Y.+Chenauthor=J.+Li&title=Histone+Deacetylases+Function+as+Novel+Potential+Therapeutic+Targets+for+Cancer&doi=10.1111%2Fhepr.12757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases function as novel potential therapeutic targets for cancer</span></div><div class="casAuthors">Zhang, Hui; Shang, Yu-Ping; Chen, Hong-ying; Li, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">149-159</span>CODEN:
                <span class="NLM_cas:coden">HPRSFM</span>;
        ISSN:<span class="NLM_cas:issn">1386-6346</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Diverse cellular functions, including tumor suppressor gene expression, DNA repair, cell proliferation and apoptosis, are regulated by histone acetylation and deacetylation.  Histone deacetylases (HDACs) are enzymes involved in remodeling of chromatin by deacetylating the lysine residues.  They play a pivotal role in epigenetic regulation of gene expression.  Dysregulation of HDACs and aberrant chromatin acetylation and deacetylation have been implicated in the pathogenesis of various diseases, including cancer.  Histone deacetylases have become a target for the development of drugs for treating cancer because of their major contribution to oncogenic cell transformation.  Overexpression of HDACs correlates with tumorigenesis.  Previous work showed that inhibition of HDACs results in apoptosis and the inhibition of cell proliferation in multiple cells.  A significant no. of HDAC inhibitors have been developed in the past decade.  These inhibitors have strong anticancer effects in vitro and in vivo, inducing growth arrest, differentiation, and programmed cell death, inhibiting cell migration, invasion, and metastasis, and suppressing angiogenesis.  In addn., HDAC-mediated deacetylation alters the transcriptional activity of nuclear transcription factors, including p53, E2F, c-Myc, and nuclear factor-κB, as well as the extracellular signal-regulated kinase1/2, phosphatidylinositol 3-kinase, Notch, and Wnt signaling pathways.  This review highlights the role of HDACs in cancer pathogenesis and, more importantly, that HDACs are potential novel therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJSNAFKpT4ErVg90H21EOLACvtfcHk0ljk2_3P6piugw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFWmtbg%253D&md5=c39207521f57c2c8b48dc3f8924bebf2</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1111%2Fhepr.12757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fhepr.12757%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DShang%26aufirst%3DY.-P.%26aulast%3DChen%26aufirst%3DH.-Y.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DHistone%2520Deacetylases%2520Function%2520as%2520Novel%2520Potential%2520Therapeutic%2520Targets%2520for%2520Cancer%26jtitle%3DHepatol.%2520Res.%26date%3D2017%26volume%3D47%26spage%3D149%26epage%3D159%26doi%3D10.1111%2Fhepr.12757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4A69" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4A69','PDB','4A69'); return false;">PDB: 4A69</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EDU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EDU','PDB','5EDU'); return false;">PDB: 5EDU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T64" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T64','PDB','1T64'); return false;">PDB: 1T64</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i52"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01957">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_32553"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b01957">10.1021/acs.jmedchem.8b01957</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Chemicals and solvents, analytical techniques and chromatography methods; cytotoxicity results of top compounds in breast, AML, CML, MDB, and pancreatic cancer cell lines, GBM BTSCs, and noncancerous human lung fibroblasts; glutathione stability data by HPLC and <sup>19</sup>F NMR; western blots in breast cancer cells, AML cells, and GBM BTSCs; in vitro half-life and intrinsic clearance rates of top compounds in mouse hepatocytes; mouse plasma protein binding assay data; determination of experimental Log <i>D</i><sub>7.4</sub>; PAMPA and Caco-2 permeability data; in vivo PK data and orthotopic tumor treatment data; HDAC inhibition assay data; in silico modeling/docking data; chemical synthesis procedures for all compounds with NMR, LRMS, HRMS, and HPLC data; <sup>1</sup>H NMR spectra for all final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings for final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_001.pdf">jm8b01957_si_001.pdf (2.75 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01957/suppl_file/jm8b01957_si_002.csv">jm8b01957_si_002.csv (1.92 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01957%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-5%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01957" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0cb213f5f24eb","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
